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ABSTRACT
The Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus that is implicated in the 
aetiology of African Burkitt’s lymphoma (BL) and several other cancers of 
lymphoid/epithelial origin In vitro, expression of all of the eleven EBV latent proteins or 
just the oncogenic Latent Membrane Protein 1 (LMP1) can protect BL cells from apoptosis 
by several stimuli including growth factor deprivation and this is related to the ability to 
upregulate the expression of several anti-apoptotic 6c/-2-related genes In this study, it is 
shown that EBV latent gene expression and in particular LMP1 can induce the upregulation 
of expression of the anti-apoptotic gene bfl-1 in addition to bcl-2 in BL cells and also that Bfl- 
1 expression can not onlt protect BL cells from serum-deprivation-induced apoptosis but also 
exert a proliferative effect under these culture conditions Bfl-1 has been shown by others to 
suppress apoptosis and exhibits proliferative and potent cooperative transforming properties 
Both increased mRNA stability and increased promoter activity were found to contribute to 
the effect of LMP1 on bfl-1 expression The transcription factor NF-kB was shown to 
mediate the effect of LMP1 on bfl-1 promoter activity in both BL and T cells however, cell- 
type-dependent differences in the regions of the promoter targeted by LMP1 were observed 
CD40, which engages similar signaling proteins (TRAFs) as LMP1, also stimulates bfl-1 
mRNA expression, however, mechanistic similarities and differences were found between the 
two TNFR family members in this effect LMP1 could also be demonstrated to contribute to 
activation of the bfl-1 promoter in EBV-immortahsed B lymphoblastoid cell lines (LCLs), 
however, NF-kB activation may not be the only mechanism regulating bfl-1 promoter 
activity in different LCLs A minor but significant finding in this study is that both 
transcriptional and translational mechanisms are involved in the LMPl-mediated 
upregulation of bcl-2 expression, with the latter exerting a stronger effect The upregulation 
o f bfl-1 expression by LMP1 represents the first example of regulation of expression of this 
anti-apoptotic gene by a viral protein and extends the list of anti-apoptotic proteins whose 
expression is controlled by LMP1 Protection against apoptosis constitutes an important part 
of the latent phase of the EBV life cycle, in that it provides a mechanism to ensure life-long 
viral persistence in the host by mimicking the natural process of selection of B cells into the 
memory compartment The regulation of expression of bcl-2-related genes by LMP1 provides 
an important link between EBV and its cellular survival and growth transforming properties
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CHAPTER 1
INTRODUCTION
1.0 EPSTEIN BARR VIRUS
1.1 DISCOVERY AND CLASSIFICATION
The Epstein-Barr virus (EBV) was discovered in cultured lymphoblasts from samples of 
African Burkitt’s lymphoma by Epstein et a l , (1964) Since its discovery as the virus 
associated with African Burkitt’s lymphoma, EBV has also been found to be associated 
with many other malignant diseases including Hodgkin’s lymphoma, T-cell lymphomas, 
nasopharyngeal carcinoma, post-transplant lymphoprohferative diseases, and gastric 
carcinomas as well as non-malignant diseases such as infectious mononucleosis 
(reviewed by Klein, 1994, K ieff 1996, Dillner and Kallin, 1988, Chen et a l , 1993, Imai 
et a l , 1994) EBV is a ubiquitous human herpes virus, for which humans are the 
exclusive natural host, infecting between 90-95% of the population (Kieff, 1996) The 
herpesviruses are a family o f DNA viruses found commonly in humans and animals 
Herpes viruses are biologically classified into three subfamilies, alpha, beta and gamma 
with EBV belonging to the gammaherpesvirus subfamily and the genera 
Lymphocryptovirus Viruses o f this subfamily are characterised by their tropism for 
lymphoid cells and their capacity to induce cell proliferation in vivo resulting in transient 
or chronic lymphoprohferative disorders and in vitro where they can immortalize the 
infected cell Taxonomists have renamed EBV as human herpesvirus 4 (HHV4) but EBV 
is still its commonly used name (IARC Monographs, 1997) Like other herpesviruses, a 
mature EBV virion has a toroid-shaped protein core that is wrapped with double-stranded 
DNA and this is surrounded by an icosahedral capsid with 162 capsomers (Figure 1 1) 
The capsid is surrounded by an amorphous material, the tegument, composed o f globular 
proteins The envelope o f herpesviruses have numerous glycoprotein spikes (Kieff, 
1996)
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Figure 1 1 Schematic representation o f herpes virus structure 
1.2 EBV GENOME STRUCTURE
The EBV genome is a linear, double stranded 172 Kb DNA with a guanine/cytosine 
content o f 60% (Kieff, 1996) The genome encodes an estimated 100 genes, but like 
many viruses there is complicated differential splicing o f RNA transcripts and hence, the 
number o f proteins encoded by the genome may be greater (Kieff, 1996) The EBV 
genome was completely sequenced from the EBV strain B95-8, initially cloned as a Bam  
H I fragment library Therefore, open reading frames (ORF), genes, sites for transcription 
or RNA processing are frequently referred to as specific Bam  H I fragments (Baer et a l ,
1984) For example, the BARF1 ORF is found in the Bam  HI fragment (BA) and it is the 
first ORF (F I) extending in a rightward ® direction A simplified schematic 
representation o f the EBV genome is outlined in figure 1 2
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Fig 1 2 A schem atic representation o f the EBV genome The genome contains repeat regions, 0 5 Kb 
terminal direct repeats (TR) and 3 0 Kb internal direct repeats (IR) that divides the genome into short and 
long largely unique sequence domains (US and UL) The Bam H l fragments are represented by the letters 
(N, C, W etc ) The B am H l fragment location o f  the EBV latent genes are indicated below the fragments 
EBER, EBV encoded RNA, EBNA, EBV nuclear antigen, LMP, latent membrane protein, LP, leader 
protein A dapted  fro m  IARC M onographs (1997)
Two EBV types circulate in most human populations (Gerber et a l , 1976, Young et a l , 
1987, Rowe et a l , 1989) These genomes formerly known as type A and type B are now 
referred to as type-1 and type-2 The genomes are almost identical except for the genes 
that encode some o f the Epstein-Barr nuclear antigens (EBNAs) such as EBNA2, 
EBNA3A, 3B, 3C and EBNALP, in latently infected cells (Nanoyama and Pagano, 1973, 
Bornkamm et a l , 1980) The differences in type-1 and type-2 EBV genomes are reflected 
in type-specific and type-common epitopes for antibodies (Young et a l , 1987) and T-cell 
recognition (Moss et a l , 1988) As type-1 EBV is more common in developed societies, 
most EBV immune human sera from these countries react preferentially or exclusively 
with type-1 LMP1, EBNA2, EBNA3A, 3B, 3C and EBNALP African sera are almost 
evenly split in their serological reactivity However, the recovery o f type-2 virus from 
blood is unusual (Young et a l , 1987, Rowe et a l , 1989) In culture, EBV type-2 infected
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lymphocytes grow less efficiently in vitro than their type-1 infected counterparts 
(Rickinson et a l , 1987)
1.3 EBV STRATEGY OF INFECTION
1.3.1 Reservoir o f EBV
Two forms o f EBV-cellular infection are recognised latent and replicative (or lytic) The 
virus exhibits a tropism for lymphocytes and epithelial cells and both cell compartments 
have been alternately considered the mam virus-reservoir (reviewed in Power and Walls,
1993) As long as B-cells were regarded as the only EBV-infectable cells in vitro, they or 
their precursors were regarded as the most probable carriers o f the latent virus The 
regular in vitro outgrowth o f permanent B-lymphoblastoid cell lines (LCLs) from the 
peripheral blood or lymphoid tissues o f all seropositive persons was often quoted in 
support o f this view (reviewed in Power and Walls, 1993) With the discovery that the 
proliferative and cytotoxic T-cell (CTL) responses to autologous EBV-transformed LCLs 
are as strong as the corresponding T-cell responses against allogeneic targets, the 
hypothesis was put forward that EBV-carrying B-cells are continuously destroyed by the 
immune response and must be newly generated by repeated infection from the epithelial 
cell compartment The detection o f EBV genomes in oropharyngeal epithelia where lytic 
infection is observed support this view (reviewed in Farrell, 1995)
The predominant role o f the epithelial cell compartment in virus-persistence was 
challenged by findings in bone marrow transplant recipients (reviewed in Power and 
Walls, 1993) In one case, where the marrow donor was seropositive, the virus o f the 
recipient was totally replaced by the strain o f the donor The eradication o f the resident 
virus by the combined irradiation and drug treatment suggested that the latent virus is 
harboured in a tissue compartment that has been destroyed by the treatment and replaced 
by the graft These observations have led to the suggestion that the reservoir responsible 
for EBV-persistence is in the hematopoietic compartment, and the long-lived memory B- 
cell pool was suggested as the most likely reservoir for latent EBV genomes Affirmative
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proof for the reservoir o f EBV infection residing in the B-cell compartment was provided 
by the finding o f the virus in resting memory B cells o f the peripheral blood o f healthy 
carriers (Decker et al., 1996; Miyashita et al., 1997).
Entry into the memory pool is normally restricted to a very small proportion o f B-cells in 
vivo and depends on positive selection by antigen in germinal centres (GCs) (Liu et 
a l ,  1989). The mechanism o f positive selection is based on the receipt o f  signals which 
protect against apoptotic death, since unselected GC B-cells (centrocytes) die by 
apoptosis (Liu et al., 1991). EBV is thought to be able to ensure persistence in the host 
by protecting infected B-cells from apoptotic death in the GC, thereby 
mimicking/bypassing the selection mechanism and ensuring entry o f the infected cell into 
the memory pool.
1.3.2 Early events in EBV-infection of B-lymhocytes
EBV infection o f primary B-lymphocytes in vitro involves binding o f CD21 on the B- 
lymphocyte plasma membrane which is expressed by approximately 10% o f all B cells 
(Kieff, 1996). CD21 (also known as CR2) is the receptor for the C3d component o f 
complement. After binding, aggregation o f CD21 in the plasma membrane, the co­
aggregation o f surface immunoglobulins (slg) and internalization o f EBV into 
cytoplasmic vesicles occur (Nemerow and Cooper, 1984; Carel et a l ,  1990). The virus 
envelope then fuses with the vesicle membrane, releasing the nucleocapsid and tegument 
into the cytoplasm. Penetration is usually complete within l-2h. Superinfection o f 
established BL cell lines is somewhat different in that EBV binding does not result in as 
significant a patching o f CD21 and slg and the envelope fuses with the plasma 
membrane, releasing the nucleocapsid and tegument into the plasma membrane. The 
observed differences in mode o f infection between primary B-lymphocytes and BL cells 
are likely to be due to the cytoskeletal abnormalities o f the tumour cells (Kieff, 1996). 
The EBV outer envelope glycoproteins gp350 and gp220 constitute the CD21 ligand. 
The interaction o f CD21, gp350 and gp220 mediates EBV absorption (Kieff, 1996; 
Nemerow et a l ,  1987; 1989). Another EBV gylcoprotein, gp85, has also been implicated
6
in the fusion o f the EBV envelope with the vesicle membrane (Miller and Fletcher,
1988) Little is known about EBV capsid dissolution, genome transport to the cell 
nucleus or DNA circularisation
Circularisation (as a result o f fusion o f the terminal repeats) o f the viral genome appears 
to be required for successful immortalisation o f B-cells and is associated with latent 
infection in vivo and in vitro The circular or episomal configuration o f the viral DNA is 
generally retained following immortalisation, with subsequent increases in rates of 
replication generating multiple episome copies (reviewed in Kieff, 1996, Joske and 
Knecht, 1993) Replicative infection by EBV is associated with linearised viral genome 
and is thought to require cellular RAG gene expression (RAG gene products are a part o f 
the cellular immunoglobulin recombination machinery and is upregulated by EBV 
infection) in addition to viral gene expression A homolog o f the RAG protein, BALF-2, 
encoded by the viral genome has been identified and is also implicated in the process of 
the mterconversion o f the genome (Dreyfus et a l , 1996)
Much less is known about epithelial cell factors that facilitate viral entry, though viral 
entry is not likely to involve CD21 since this molecule is either not expressed or 
expressed at very low levels by epithelial cells One in vitro epithelial cell system 
developed has been based on the usage o f antibody to EBV to assist viral entry (reviewed 
in Sugden, 1992) In this system, addition o f specific anti-EBV gp350 polymeric IgA 
(plgA) molecules in culture was shown to assist entry o f EBV into a human epithelial cell 
line that expresses the receptor for plgA Moreover, this study revealed that the infected 
cells expressed viral genes characteristic o f the lytic phase More recently, an efficient 
system o f infection based on coculturmg epithelial cells with an EBV producing BL cell 
line was developed and the requirement o f cell-cell contact for efficient infection was 
demonstrated (Imai et a l , 1998) In this system, the EBV-infected epithelial cell lines 
exhibited the pattern o f latent gene expression characteristic o f EBV-associated gastric 
cancers or LMP-1-negative NPC (table 1 3) The epithelial cell factor that is responsible 
for facilitating virus entry in this system is still unknown
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1.4 LYMPHOBLASTOID CELL LINES AS A MODEL FOR STUDYING
LATENT INFECTION OF B-LYMPHOCYTES BY EBV
Most human peripheral blood B-lymphocytes are susceptible to EBV infection and 
infection leads to the establishment o f immortalised cell lines called lymphoblastoid cell 
lines (LCLs) (reviewed in Farrell, 1995) The virus does not usually replicate m recently 
infected B-lymphocytes, instead they become stably latently infected However 2-3% of 
the cells in cultures o f LCLs exhibit lytic infection In latently infected B-lymphocytes, 
EBV expresses six different nuclear proteins or EBNAs (EBNA-1, -2, -3A, -3B, -3C, - 
LP), three integral membrane proteins or LMPs (LMP-1, -2A, 2B) and two small non 
polyadenalated RNAs or EBERs (EBER -1 , -2) These viral gene products maintain the 
latent infection and cause the previously resting B-lymphocytes to continuously 
proliferate (Mark and Sugden, 1982) Recombinant genetic analyses o f the EBV genome 
have demonstrated that o f the 11 latent gene products, five are absolutely required for B 
cell immortalisation EBNA-1, 2, 3a, 3c and LMP-1, while EBNA-LP and LMP-2A 
appear to improve the efficiency o f immortalisation (Hammerschmidt and Sugden, 1989, 
Cohen et a l , 1989, Kaye et a l , 1993, Tomkinson et a l , 1993, Kieff, 1996) The EBV 
infected proliferating B-lymphocytes are similar to activated B-lymphocytes in their 
secretion o f immunoglobulin and their adherence to each other (Klein, 1987, Zhang et a l , 
1991) Approximately 1 in every 105'106 o f the B-lymphocytes purified from the 
peripheral blood o f previously infected people are latently infected with EBV (Sixbey 
andPagano, 1985)
While the growth transformation o f human B-cells from the resting state to the 
continuously proliferating LCL is always associated with the expression o f the full 
spectrum o f 11 EBV latent proteins, the mechanisms through which the virus subverts 
normal B-cell growth regulation are not fully understood A key issue in this regard is 
the observation that all LCLs display a consistent array o f activation/differentiation 
antigens on their surface (reviewed in Gregory, 1995) irrespective o f the B-cell 
maturation stage at the moment o f EBV infection (Table 1 1) These antigens, whose 
functions include those o f autocrine growth and survival signaling (e g , CD23 or CD40)
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\as well as intercellular adhesion [e g , leukocyte function antigen-1 (LFA-1), intercellular 
adhesion molecule-1 (ICAM-1) or LFA-3], are typically induced or up-regulated 
transiently on the B-cell surface following physiological activation by cognate antigen 
and T-cell factors Their strong expression by all LCLs strongly suggests that at least 
some o f them are required to mediate the growth-transforming properties o f the virus
TABLE 1 1 Cell surface molecules modulated following EBV infection o f B-lym phocytes
(adaptedfrom Gregory, 1995)
Molecule Structure/F unction
EBV- 
Induced change 
( Î  or
CD10 Neutral endopeptidase
CD 11 a/CD 18 (LFA-1) Intercellular adhesion t
CD21 C3d/EBV receptor, CD23-hgand t
CD23 Autocrine growth, adhesion Î
CD30 Neuronal growth factor receptor
family member t
CD39 Function unknown t
CD40 Growth signaling, inhibition o f
apoptosis t
CD44 Intercellular adhesion t
CD54 (ICAM-1) Intercellular adhesion t
CD58 (LFA-3) Intercellular adhesion t
CD70 CD27-ligand Î
CD77 Neutral glycosphmgohpid
CD95 (Fas) Induction o f apoptosis t
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1.5 BURKITT’S LYMPHOMA AS A MODEL FOR STUDYING LATENT
INFECTION OF B LYMPHOCYTES BY EBV
Most non-EBV infected continuous B-lymphocyte cell lines are derived from 
sporadically occurring EBV-negative Burkitt’s lymphomas (BL) and many can be 
infected with EBV in vitro (Calendar et a l ,  1987; 1990). The growth o f BL cells in vitro 
is attributed to deregulated c-myc expression resulting from a specific translocation in 
which c-myc is juxtaposed to a heavy or light-chain Ig locus (Dallas-Favara et a l ,  1983) 
and to less characterised changes in chromosome 1 (Berger and Bernheim, 1985). A 
fundamental feature o f BL tumour lines which has imposed restrictions on models o f BL 
pathogenesis is the marked phenotypic heterogeneity that is observed between different 
lines (reviewed in Gregory, 1995). However, a limited rationale for some o f the 
phenotypes assumed by BL cells, at least in cases o f EBV-positive tumours, has been 
achieved.
Broadly speaking, successful discrimination o f BL lines into phenotypic groups has been 
based upon the expression o f two categories o f antigens which may be loosely termed (1) 
“BL specific” antigens and (2) “activation” antigens (reviewed by Gregory, 1995). The 
first category constitutes CD77 (a glycolipid antigen, also called BL-associated antigen) 
and CD 10 (CALLA-common acute lymphoblastic leukemia-associated antigen); the 
second category includes cell-surface molecules such as CD23, CD30, CD39 and CD70 
that are found to be constitutively up-regulated on EBV-LCLs. EBV-positive BL lines 
have been categorised into four groups: group I cell populations coexpressed only CD 10 
and CD77 o f the panel o f markers tested; group I/II cells additionally expressed CD70; 
groupll populations expressed the surface markers, CD 10, CD77, CD23, CD30, CD39, 
and CD70 and group III cells expressed CD23, CD30, CD39 and CD70 but not CD10 or 
CD77 (Rowe et al., 1987). The importance o f the group I to III categorisation scheme 
lay in its ability not only to identify heterogeneity among BL lines, but also to pick up 
changes that occurred within individual EBV-positive BL lines shortly after their 
establishment in vitro (Table 1.2). In particular, in studies o f freshly isolated BL tumour 
populations and cell lines from cases o f EBV-positive African BL, the tumour biopsy
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cells were found, in all cases, to display the group I phenotype In some lines following 
their establishment in vitro the group I phenotype was either retained or the cell 
populations fluctuated between group I and its subcategory group I/II, during continuous 
culture for several months Other lines, however, underwent a rapid process o f 
phenotypic drift from group I, through the transient group II stage to group III This 
propensity for phenotypic change was found to be a feature o f EBV-positive, rather than 
o f EBV-negative, cases o f BL, whether o f sporadic or endemic origin (reviewed by 
Gregory, 1995)
TABLE 1 2 Phenotypic grouping o f Burkitt’s Lymphoma cell lines
(adapted from  Gregory, 1995)
Phenotype Group I GroupIII
Cell growth pattern Dispersed single cells Multicellular clumps
Cell surface antigens CD10+, CD77+, CD23', 
CD39',CD30',CD70‘, 
LF A -1 L0,IC A M -1', 
LFA-3'
CD 10',CD77-,CD23+, 
CD39+,CD30+,CD70+, 
LFA-1hi, i c a m + 
LFA-3+
EBV latent genes EBNA-1 E B N A -1,-2, -3A,B,C, 
-LP,LMP-1,-2A, -2B, EBERs
Bcl-2 protein expression Negative or low High
Apoptosis rate High Low
Overall phenotype Resembles parental tumour Resembles EBV-transformed 
LCL
The cell surface changes that characterise the groupl group III phenotypic drift are 
accompanied by changes in morphology (Rowe et a l , 1987,Gregory et a l , 1990) Thus, 
whereas group I lines grow as a dispersed, single-cell suspension, the cells o f group III
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lines acquire a motile morphological appearance and cluster together m large 
multicellular aggregates, reminiscent o f the constituent cells o f normal EBV-LCLs The 
molecular basis for the observed homotypic adhesion o f group III cells was found to be 
via LFA-l/ICAM -1 interactions on closely apposed cells In terms o f cell surface 
expression, LFA-1 was found to be present at low levels on group I cells, whereas 
ICAM-1 was absent, on group III cells, both antigens are present, as on EBV-LCL, 
expressed at high levels (Gregory et a l , 1990)
Analysis o f changes in EBV latent protein expression during the groupl —> group III 
phenotypic drift led to the suggestion that this drift is EBV-dnven (Gregory et a l , 1990) 
Thus, whereas group I BL cells express only EBNA-1 and the EBERs (Rymo, 1979, 
Howe and Shue, 1989), cells in latency II resemble latency I cells as they express 
EBNA1 and the EBER RNAs but also express LMP1, LMP2A and LMP2B (Rowe et a l , 
1987) The classic features o f latency I are exhibited in endemic BL biopsies and in early 
passage cell lines derived from these tumours (Rowe et a l , 1987) Two EBV-related 
clinical conditions exhibit the latency II program nasopharyngeal carcinoma (NPC) and 
Hodgkin’s disease (HD) (Table 1 3) Group III cells were found to resemble EBV-LCLs 
in that they express the full complement o f EBV latent proteins - all six EBNAs, the three 
LMPs and the two EBERs (Gregory et a l , 1990) Two EBV-associated diseases best 
exemplify the latency III program, infectious mononucleosis and posttransplantation 
lymphoprohferative disorder (PTLD) which is a potentially fatal immunoblastic 
lymphoma in transplant patients The EBV-specific cytotoxic T-cell response is 
considered to be the most important factor in controlling EBV-induced B-cell 
proliferation in vivo All o f the latent proteins except for EBNA1 elicit a strong 
immunogenic response and this explains why expression o f latent proteins in EBV- 
associated BL is restricted to EBNA1 and also why EBV-associated B-lymphocyte 
malignancies (such as PTLD) in immuno- suppressed patients exhibit a wider panel o f 
latent gene expression (Liebowitz, 1994)
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TABLE 1 3 Pattern o f EBV latent gene expression 
adapted in part from  the I  ARC monograph ,1997
Type of 
Latency
Gene Product Examples Reference
I EBERs, EBNA1 Burkitt’s lymphoma 
Gastric Carcinoma
Rowe et a l , (1987) 
Imai et a l , (1994)
II EBERs, EBNA1, 
LMP1, 2A, 2B, 
BARFO
Hodgkin’s disease
Nasopharyngeal
carcinoma
Deacon et a l , (1993) 
Hitt et a l , (1989) 
Brooks et a l , (1992)
III All EBV latent genes PTLD, IM Young et a l , (1989) 
Tirney et a l , (1994)
Other EBNA-1,-2, LMP-1 T-cell lymphomas Harabuchi et a l , 
(1990)
Other EBERs, EBNA-1, -2 Smooth muscle tumours Lee et a l , (1995)
Other EBNA-l,-2,-LP
,LMP1
Oral hairy leukoplakia W ebster-Cynaque et al 
(2000)
PTLD Post-transplant lymphoprohferative disorder, IM infectious mononucleosis
1.6 EBV LATENT GENES
The binding o f EBV to C D 21 and the subsequent infection o f the cell triggers a cascade 
o f events leading ultimately to the immortalization of the cell The immortalization o f 
the primary B cell requires the expression o f several viral genes (Allday et a l , 1989, 
Rooney et a l , 1989, Alfieri, et a l , 1991) The first viral proteins to be expressed in B
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cells upon EBV infection are EBNA2 and EBNA-LP and are detected by 12 h o f 
infection. By 48 h post-infection, expression o f EBNA-1, EBNA3s and LMP-1 is 
induced and is later followed by the expression o f EBERs and LMP-2 (Alfieri et al., 
1991). Transcription o f nuclear protein is initiated at RNA polymerase II-dependent 
promoters in the Bam  HI C (Cp) and Bam HI W (Wp) regions o f the viral genome 
(Rogers et al., 1992) (Figure 1.3). EBNA2 and EBNALP are initially transcribed from 
the very strong promoter Wp, which is present in multiple copies in the major internal 
repeat. Once immortalization is established, Wp activity declines and transcription o f the 
EBNA genes switches to using the Cp promoter (W oisetschlaeger et al., 1990). All 
EBNA coding mRNAs are derived from the same transcriptional unit by alternative 
splicing and alternative polyadenylation (Figure 1.3). The coding exons for most o f the 
EBNAs are towards the 3’ end o f the mRNAs and are preceded by the highly spliced 
leader exons, which are encoded within the major internal repeat o f the genome (Farrell, 
1995).
0 20 40 60 80 100 120 140 160 172kb
LMP1
Figure 1.3 A simplified outline o f the splicing o f the EBV nuclear antigen coding mRNAs.
Transcription initiation is shown to arise from the Cp promoter. The EBNA mRNAs all derive from the 
same transcription unit by alternative splicing and alternative polyadenylation.
1.6.1 EBNA1
EBV nuclear antigen 1 is the only EBV latent gene that is detectable in all EBV infected 
cells. The 73 kDa protein consists o f a short amino-terminal region, a 20-40 kDa 
glycine-alanine repetitive sequence flanked by arginine-rich sequences and a highly
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charged acidic carboxy terminal sequence (Hennessy and Kieff, 1983) (figure 1 4) The 
primary role o f EBNA-1 is in the maintenance o f viral replication During latent infection 
o f human host cells, EBV genomes are maintained as double-stranded DNA episomes 
that replicate once every cell cycle (Adams, 1987, Yates and Guan, 1991) The carboxy 
terminus o f EBNA1 determines its nuclear localisation by interacting with a specific 
protein that is homogeneously distributed on chromosomes (Harris et a l , 1985, Petti et 
a l ,  1990) This property is likely to be important for segregation o f episomes into 
progeny nuclei during mitosis EBNA1 is the only EBNA that continues to be made 
during lytic infection (IARC Monograph, 1997)
EBNA1 is a sequence-specific DNA binding protein that binds as a dimer to the sequence 
TGGATAGCATATGCTATCCA present in the latent cycle origin o f replication ori P  
(Ring, 1994) Regions o f the protein important for DNA binding and transactivation o f 
ori P  are located in the carboxy-terminal third o f the protein (Ambinder et a l , 1991) 
(Figure 1 4) Furthermore, ori P  acts as an EBNA 1-dependent enhancer and plays a 
crucial role in the regulation o f viral transcription from both the C and the LMP1 
promoter in growth-transformed cells (Sugden and Warren, 1989, Gahn and Sugden
1995)
Gly - Ala
98 327 641
DNA binding
D im érisation
42 76 450 641
— N uclear localisation
Transcriptional
activation
379 387
F ig u re  1 4 F unctional dom ains o f EB V  n u clear an tigen  1 (EBNA1) The Gly-Ala box is a repetitive 
region composed entirely o f  glycine and alanine, it varies in length between viral strains A dapted  from  
Farrell, 1995
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The promoter from which the EBNA1 gene is transcribed differs between cell types. In 
EBV transformed LCLs, all the EBNA genes are derived from a highly spliced transcript 
that is generated by transcription from the C or W promoters located on the Bam  HI C 
and W fragments respectively (Middleton et al., 1991). In the absence o f a stimulus to 
induce virus replication, RNA transcripts from latently infected early passage type-I BL 
cells, is initiated from a promoter located in the Bam  H I-Q fragment (Nonkwelo et a l ,
1995). This promoter is designated Qp. Following the switch from latent to lytic 
infection, EBNA1 transcription is controlled by Fp upstream o f Q (Lear et a l ,  1992).
EBNA1 can bind RNA in vitro through arginine/glycine motifs (Snudden et a l ,  1994). 
EBNA1 also activates expression o f the lymphoid recombinase genes (RAGs) through an 
as yet unindentified mechanism (Srinivas and Sixbey, 1995). Activation o f the RAGs 
could promote chromosomal rearangements and translocations and possibly also facilitate 
viral integration. Expression o f EBNA 1 in EBV negative cell lines has no obvious effect 
upon cellular growth characteristics. However, the expression o f EBNA 1 in the B cells 
o f transgenic mice has been shown to be associated with the development o f lymphocytic 
lymphoma and leukemia suggesting that EBNA1 predisposes the mouse lymphocytes to 
oncogenic change (W ilson and Levine, 1992).
1.6.2 EBNA2
The EBV nuclear antigen 2 (EBNA2) is one o f the first EBV-encoded proteins expressed 
after primary infection o f B-lymphocytes. EBNA2 differs extensively between type-1 
and type-2 EBV isolates (Aitken et al, 1994) and is the primary determinant o f the 
biological difference that enables the type-1 strains to transform B lymphocytes with 
greater efficiency (Rickinson et a l ,  1987). In nuclear fractions, EBNA2 is associated 
with nucleoplasmic chromatin and nuclear matrix fraction (Petti et a l ,  1993). EBNA2 is 
an 83 kDa protein containing a polyproline region, a glycine arginine repeat and a highly 
acidic carboxy terminus and is phosphorylated on serine and threonine residues 
(Dambaugh et a l ,  1984). EBNA2 is a trans-activator o f cellular and viral gene expression 
including CD21, CD23, the c-fgr oncogene, cyclin D2, TNF-a  and viral genes including
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LMP1 and LMP2 (Knutson, 1990; Abbot et a l ,  1990; Ghosh and Keiff, 1990; Peng and 
Lundgren, 1992; Wang et a l ,  1987; 1990a;1990b; Tsang et a l ,  1991; Fahraeus et a l ,  
1993; Spender et a l ,  2001). EBNA2 has also been shown to play an important role in the 
maintenance o f proliferation o f LCLs and this effect is mediated by its ability to regulate 
the expression o f the cell cycle-related proteins cyclin D2, cdk 4 (drive cell cycle 
progression in early G l) and c-Myc (Kempkes et a l ,  1995; Zimber-Strobl et a l ,  1996, 
Kaiser et al., 1999). However, in the context o f BL cells, expression o f EBNA2 exerts 
growth-inhibitory effects most likely due to a downregulation o f c-Myc expression 
(Jochner et a l , 1996).
Three regions within EBNA-2 have been identified which appear to be stringently 
required for transformation and the ¿ram-activating activity o f EBNA2 and these are 
located between amino acid residues 95 andllO , 280 and 337 and 425 and 462 (Figure 
1.5). The exact role o f the 95-110 region is unclear, the 425-462 region is essential due 
to its acidic /ram'-activating properties and the 280-337 region mediates the interaction 
with sequence-specific DNA binding proteins that bring EBNA2 to its responsive 
elements as EBNA2 does not interact directly with DNA (IARC Monographs, 1997). 
Many o f the promoters activated by EBNA2 share the core sequence GTGGGAA 
(W altzer et a l ,  1994, Tun et a l ,  1994). Through studies o f its responsive elements a 28 
amino acid polypeptide corresponding to residues 310-336 of EBNA2 (Figure 1.5) was 
used to purify a nuclear protein p63. The sequence o f p63 revealed it to be the previously 
characterised recombination signal sequence binding protein RBP-Jk or CBF-1, a widely 
expressed and highly conserved protein that acts as a key adapter for transcription o f 
regulatory factors o f cellular genes. CBF-1 acts as a transcription repressor and 
repression is exerted in part by tethering a histone deacetylase (HDAC) corepressor 
complex to the promoter (Henkel et al., 1999; Hsieh and Hayward, 1995; W altzer et a l ,  
1995; Kao et al., 1998). Repression is believed to be a consequence o f histone 
deacetylation which leads to chromatin remodeling and loss o f transcription factor access 
to the nucleosome-associated promoter sequences. EBNA2 activates transcription by 
binding to the repression domain o f CBF1 to relieve repression and bringing a 
transcriptional activation/acidic domain to the promoter (Hsieh et al., 1995). The acidic
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domain o f EBNA2 interacts with the basal transcriptional machinery including TFIIB, 
TAF-40 and RPA70 (Tong et a l , 1995a, 1995b) Recently, interaction with both CBF-1 
and SKIP (Ski-interacting protein) were shown to be required for transactivation by 
EBNA-2 (Zhou et a l , 2000)
Fig 1 5 Functional domains o f EBV nuclear antigen 2 (EBNA2) The pro box is a region composed
Pro
1 59 100 483
■■■ < Transcriptional 
4-26 462 activation
Regions not required-* EJ
for immortalization 200 234 463 483
I  I   w ^ — M B  1 B H B H  + Region not
379 required for
1 243 nuclear
Binding o f  RBP-Jk " + 3 1^ * 3 3 6 localization
entirely o f prolm e, it varies in length between viral strains A dapted from  Farrell 1995
EBNA2 regulates expression o f the EBV latency Cp promoter that drives expression o f 
the EBNA family o f nuclear proteins in type III latency and also contributes to the 
positive regulation o f the LMP2A, LMP2B, and LMP1 promoters (Jin and Speck, 1992, 
Sung et a l , 1991, Tsang et a l , 1991, Zimber-Strobl et a l , 1993) Targeting through Pu 1 
(S pil) has been described for the LMP1 promoter (Johanssen et a l , 1995, Laux et a l ,
1994), while CBF-1 has been identified as the targeting partner for the viral Cp, LMP2A, 
and divergent LMP1 and LMP2B  promoters (Grossman et a l , 1994, Henkel et a l , 1994, 
W altzer et a l , 1995, Zimber-Strobl et a l , 1994) EBNA2 regulates its own expression, 
and deletion o f the region containing the CBF1 binding site from Cp biases promoter 
usage toward Wp (Yoo et a l , 1997) Although the regulation o f many o f the EBNA-2- 
target genes such as those encoding CD23, interleukins and beta interferon have been 
shown to be mediated by CBF1 (Kanda et a l , 1999, Krauer et a l , 1998, Ling et a l , 
1994; W ang et a l , 1991), there are some responsive genes, such as the eye I in D2 gene
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(Kempkes et a l ,  1995; Sinclair et al., 1994) which lack CBF-1 binding sites in their 
promoter regions (Spender et al., 2001). These genes may be activated as part o f a 
downstream response cascade, or additional EBNA2 targeting mechanisms may exist.
The EBNA2-responsive elements in the promoters o f several EBNA-2-regulated genes 
have a large complex structure and although the CBF-1 binding sites are essential, 
optimal activation by EBNA2 also requires cooperation with other transcription factors. 
The Cp EBNA2-responsive element contains a CBF2 binding site adjacent to the CBF1 
binding site, and the CBF2 site contributes to EBNA2 responsiveness (Fuentes-Panana 
and Ling, 1998; Jin and Speck, 1992, Ling et al., 1993a, Robertson et al., 1995). The 
LMP1 promoter is complexly regulated with both CBF1 and PU .l targeting sites and 
multiple transcription factor binding sites that enhance responsiveness (Johannsen et al., 
1995; Laux et al., 1994, Sjoblom et al., 1998).
The effects o f EBNA-2 on CBF-1-mediated transactivation o f its target genes can be 
modulated by EBV latent proteins including EBNA3s and the BamHI-A rightward 
transcripts (BARTs) (W altzer et al., 1996, Smith et al., 2000; Zhang et al., 2001). EBNA- 
3A and EBNA-3C have been reported to stably interact with RBP-Jk (Bain et al., 1996; 
Robertson et al., 1995; Zhao et a l ,  1996) and repress EBNA-2-activated transcription by 
destabilising the binding o f RBP-Jk to DNA (Johannsen et al., 1996; W altzer et al.,
1996). One o f the BART family transcripts contains an open reading frame, R PM S1, that 
encodes a nuclear protein called RPMS. RPMS interacts with both CBF-1 and 
components o f the CBF1-associated corepressor complex to negatively regulate the 
activity o f EBNA2 (Zhang et a l ,  2001; Smith et al., 2000).
1.6.2.1 EBNA2 and the Notch signaling pathway
CBF-1/RBP-Jk is highly conserved in evolution from nematodes to humans (Artavanis- 
Tsakonas, 1995). CBF-1 acts downstream o f the receptor Notch. Activation o f the Notch 
receptor by binding o f its ligand Delta, Jagged or Serrate (in Drosophila) leads to 
proteolytic cleavage o f the receptor at the inner side o f the membrane (Schroeter et al.,
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1998) The intracellular domain (Notch-IC) is then translocated to the nucleus where it 
activates genes by interacting with CBF-1 (Struhl and Adachi, 1998, Lecourtois and 
Schweisguth, 1995) Four Notch receptors have been cloned in humans and mice N otchl 
(Tanl), Notch2, Notch3 and Notch4 (int3) In vertebrates, the Notch signal transduction 
pathway has an essential function during embryogenesis and is involved in the 
differentiation processes o f neuronal precursors, myoblasts and Malphigan tubules 
(Artavams-Tsakonas et a l , 1995, Kopan et a l , 1994, Nye et a l , 1994) Notch signalling 
is also involved in the renewal and differentiation o f hematopoietic cells For example, 
Notch influences the choice between CD4 and CD8 as well as the choice between the 
alpha-beta versus gamma-delta T-cell lineage (Robey et a l , 1996, Washburn et a l ,
1997) Also, constitutive Notch activation is a characteristic feature o f a subset o f T-cell 
leukemias and lymphomas in humans (Ellisen et a l , 1991) EBNA-2 has been regarded 
as a functional homolog o f the activated Notch protein by virtue o f the association o f 
both o f these proteins with the CBF-1 repression domain to relieve repression and 
consequently stimulate activation o f genes via an endogenous transactivation domain 
(Hsieh et a l , 1996, 1997) Consequently, both proteins show a certain degree o f overlap 
in modulation o f expression o f genes including CD21, Ig ^ i , LMP-1 and LMP-2A  (Strobl 
et a l , 2000, Hofelmayer et a l , 1999, Sakai et a l , 1998, Strobl et a l , 1997) These 
observations have raised the question as to whether Notch may play a physiological role 
during B-cell activation CD23, whose expression is upregulated by EBNA-2 in BL cells, 
is not activated by murine N otchl- IC, suggesting that the functions encompassed by 
EBNA-2 may extend beyond that o f Notch-IC Activated Notch 1 can also transiently 
substitute for EBNA2 m the maintenance o f proliferation o f LMP-1-expressing 
immortalised B cells (Hofelmayr et a l , 2001) However, in this study it was shown that, 
unlike EBNA2, murme N otchl-IC  is unable to upregulate the expression o f  c-myc in 
these cells The commonality o f the EBNA2 and NotchIC interactions with CBF1 
suggests that the early steps in EBV immortalization o f B cells may mimic an aspect of 
Notch signaling Furthermore, the similarity in their functions may provide insights into 
the role o f EBNA-2 in tumours with which it is known to be associated such as smooth 
muscle tumours (Lee et a l , 1995) In this regard it is interesting to note that both EBNA-
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2 and Notch-IC have been shown to block muscle cell differentiation (Sakai et a l , 1998, 
Hofelmayr et a l , 1999)
1.6.3 EBNA3A, 3B, 3C.
EBNA3A, 3B and 3C are encoded by 3 genes located m tandem in the EBV genome 
Each is encoded by a short and a long exon (Hennessy et a l , 1985, Kalhn et a l , 1986, 
Petti and Kieff, 1988, Rickstein et a l , 1988) The mRNAs that encode these proteins are 
the least abundant EBNA mRNAs, with only a few molecules occurring in each latently 
infected cell The proteins are located in large nuclear clumps m the nuclear matrix, 
chromatin and nucleoplasmid fractions but not in the nucleolus (Petti et a l , 1990) Type- 
1 and 2 strains o f EBV exhibit 84%, 80% and 72% amino acid identity in their EBNA3 A, 
3B and 3C sequences respectively (Sample and Kieff, 1990) EBNA3A and 3C are 
required for B-cell transformation whereas EBNA3B is not (Tomkinson and Kieff, 
1992a, Tomkinson et a l , 1993) EBNA3A, 3B and 3C proteins have been shown to 
inhibit the transcriptional activation o f several EBNA2-responsive promoters (such as 
TP1 and LMP1 promoters) by destabilizing RBP-Jk and RBP-Jk complexes from binding 
to their cognate RBP-Jk binding sites (Le Roux et a l , 1994) (Figure 1 6) EBNA3 
proteins are thus believed to counter balance and finely tune the action o f EBNA2 
(W altzer et a l , 1996, Robertson et a l , 1995,1996, Zhao et a l , 1996) Also, by inhibiting 
EBNA2-mediated transactivation o f the Cp promoter, a feedback loop o f inhibition by 
EBNA 3 proteins o f their own synthesis is created-(Waltzer et a l , 1996, Robertson et a l ,
1995) (Figure 1 6)
There is increasing evidence that EBNA3C, like EBNA2, functions as a trans-activator 
o f both cellular and viral genes Transfection o f an EBNA3C expression construct into 
an EBV negative BL cell has been shown to result in the upregulation o f the EBV 
receptor CD21 (Wang et a l , 1990) Furthermore, expression o f EBNA3C in the Raji cell 
line (in which the EBV genome is deleted for most o f the EBNA3C open reading frame) 
induces an up-regulation o f LMP1 and the cellular proteins CD23 and vimentin (Allday 
et a l , 1993, Ring, 1994)
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Figure 1 6 A schematic model o f the mechanism by which EBNA3C counteracts EBNA2-m ediated 
activation EBNA3C destabilises the interaction o f RBP-Jk and RBP-Jk/EBNA2 complexes binding DNA  
A dapted from  Robertson et a l , 1995
Recently, EBNA3C but not EBNA3A or EBNA3B was demonstrated to possess 
transactivation properties independent o f CBF-1 (Zhao and Sample, 2000) In this study 
EBNA3C was shown to activate the LMP-1 promoter in conjunction with EBNA2, and 
this effect was mediated by a Spi-l/Spi-B binding site in the promoter Like EBNA2, 
EBNA3C could also bind directly to Spi-1 and Spi-B in vitro Binding to the Spi-bmdmg 
site by both EBNA2 and EBNA3C via the Spi proteins is thought to form a stable 
complex that can effectively bring about transcription from the LMP-1 promoter
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1.6.4 EBNALP
EBNA leader protein (EBNA LP) is so designated because it is encoded by the 5 ’ leader 
sequence o f bicistronic mRNAs specifying the other EBNAs The translation initiation 
codon for EBNALP is created by a splicing event that occurs near the 5 ’ end o f the 
message (Sample et a l , 1986, Speck et a l , 1986, Rogers et a l , 1990) The EBNA-LP 
protein is composed o f amino-terminal repetitive segments followed by a unique 
carboxy-terminal sequence EBNA-LP is frequently observed as a ladder o f proteins in 
gel electrophoresis which differ in the number o f ammo-termmal repeats due to the fact 
that the repetitive part o f the protein is derived from exons m the major internal repeat o f 
the virus, which varies in copy number in any EBV population (Hammerschmidt and 
Sugden, 1989) The protein is strongly associated with the nuclear matrix (Petti et a l , 
1990, Jiang et a l , 1991) Association o f EBNALP with pRb and p53 has been suggested 
based on in vitro biochemical interaction and colocahsation o f EBNALP with pRb in 
cells, the in vivo relevance o f this is unknown (Jiang et a l , 1991, Szekely et a l , 1993) 
EBNALP localises to PML (promyelocytic leukemia) nuclear bodies and associates with 
hsp (heat-shock protein)-70 (Szekely et a l , 1996, Kitay and Rowe, 1996) Transient 
transfection o f EBNA-LP and EBNA2 into primary B-lymphocytes co-stimulated with 
gp350 demonstrated that the two proteins co-operate in the induction o f Go to Gi 
transition as marked by an increase o f cychn D2 transcription, however, the mechanism 
o f action remains unclear (Sinclair et a l , 1994) EBNA-LP stimulates EBNA-2-mediated 
activation o f the LMP-1 promoter and o f the LMP1/LMP2B bidirectional transcriptional 
regulatory element (Harada and Kieff, 1997) EBNA-LP alone exerts a negative effect 
Like EBNA2, EBNALP can also bind CBF-1 However, coactivation by EBNA-LP 
requires only the EBNA-2 acidic domain to be localised near a promoter as evidenced by 
transient transfection studies with a fusion protein o f the EBNA2 acidic domain and Gal4 
DNA binding domain and a reporter plasmid having Gal4 DNA binding sites upstream o f 
a minimal promoter (Harada and Kieff, 1997) The coactivation function o f EBNALP 
was shown in this study to reside in the repeating domains while the carboxy terminal 
unique domain has a regulatory role on this coactivation function The acidic domain o f 
EBNA2 associates with the nuclear protein p i 00 and can interact with basal and activated
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transcription factors (Tong et al., 1995a; 1995b). EBNALP is thought to act by enhancing 
these interactions o f the EBNA2 acidic domain which compensates for the relative 
weakness o f the acidic domain in transactivation.
1.6.5 LMP1
Latent membrane protein 1 (LMP1) mRNA is the second abundant viral transcript in 
latently infected cells (Fennewald et al., 1984; Sample and Kieff, 1990). The product, 
encoded by three exons, is an integral membrane protein consisting o f a short 23 amino 
acid N-terminal cytoplasmic domain, six hydrophobic transmembrane domains separated 
by short reverse turns and a 200 aminoacid carboxy-terminal cytoplasmic domain (Figure 
1.7). LMP1 forms patches in the cell membrane, to which the intermediate filament 
protein vimentin colocalizes, however, patch formation does not require vimentin or 
other EBV proteins (Liebowitz et al., 1986; Moorthy and Thorley-Lawson, 1990, 1993a). 
LMP1 oligomerises in the plasma membrane in the absence o f ligand binding and 
oligomerisation is crucial to its activity (Floettmann and Rowe, 1997; Gires et al., 1997). 
LMP1 is palmitoylated and the transmembrane domains facilitate its association with 
lipid rafts (Higuchi et al., 2001). LMP1 is the only known EBV gene that can 
independently transform rodent fibroblasts and render them tumorigenic (Wang et al., 
1985). Transgenic mice carrying an Ig heavy chain promoter/enhancer-driven LMP-1 
gene develop lymphomas with high incidence in vivo (Kulwichit et al., 1998), 
demonstrating that LMP1 alone is a transforming gene even in situations lacking an EBV 
background. LMP1 is highly toxic if  expressed at high levels (Hammerschmidt et al.,
1989).
At least half o f  the LMP1 protein expressed is associated with the cytoskeleton as defined 
by resistance to extraction with non-ionic detergents and co-localization with vimentin. 
In various cell types, nascent, non-ionic detergent-soluble LMP1 has a half-life o f less 
than 2 hours and is converted to an insoluble, cytoskeleton associated form, with a half- 
life o f 2-15h, that is phosphorylated on serine and threonine residues in the carboxy 
terminal domain (Baichwal and Sugden, 1987; Martin and Sugden, 1991; Mann and
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Thorley-Lawson, 1987, Moorthy and Thorley-Lawson, 1990, 1993a) Phosphorylation 
appears to be important for the function of LMP1 In LCLs, LMP1 is made at a steady 
rate and within 30 minutes o f being made localises to the plasma membrane in the 
phosphorylated form (Baichwal and Sugden, 1987, Martin and Sugden, 1991, Mann and 
Thorley-Lawson, 1987, Moorthy and Thorley-Lawson, 1993) This fraction o f LMP1 is 
associated with the cytoskeleton and forms patches in the membrane (Liebowitz et a l , 
1986, Mann and Thorley-Lawson, 1987) LMP1 is then turned over and inactivated by a 
specific cleavage with a half-life o f less than 2 hours (Moorthy and Thorley-Lawson, 
1990, 1993a) LMP1 migrates on SDS-PAGE between 58 and 63 kDa depending on the 
EBV strain (Liebowitz et a l , 1986, Thorley-Lawson and Israelsohn, 1987) An amino- 
terminal truncated form o f LMP-1 is expressed during lytic infection and migrates with a 
molecular weight o f 45 kDa in SDS -PA G E (Baichwal and Sugden, 1997, Hudson et a l ,
1985) The lytic form o f LMP-1, lyLMP-1, which is also found associated with the EBV 
virion can negatively modulate full-length LMP-1 function but not by affecting LMP1 
oligomerisation (Erickson and Martin, 2000)
LMP1 also alters the growth o f EBV-negative BL lines when expressed stably or by 
transient transfection at an appropriate level In fact, LMP1 induces many o f the changes 
usually associated with EBV infection o f primary B-lymphocytes or with antigen 
activation o f primary B-lymphocytes, including cell clumping, increased cell size, 
increased villous projections and increased vimentin expression (Gregory, 1995) 
Furthermore, such LMP-1 expressing cells exhibit increased cell surface expression o f 
CD23, CD39, CD40, CD44, LFA-1, ICAM-1 and LFA-3 and class II major 
histocompatability complex (MHC) and decreased expression o f CD 10 (Wang et a l , 
1988b, Birkenbach et a l , 1989, Wang et a l , 1990a, Liebowitz et a l , 1992, Peng and 
Lundgren, 1992, Zhang et a l , 1994a, K ieff 1996) LMP1 was also shown to increase 
certain cytokines with B-cell promoting activity, such as IL-10 (Nakagomi et a l , 1994) 
Another important biological consequence o f LMP-1 expression is its ability to protect B- 
lymphocytes from apoptosis by inducing the expression o f anti-apoptotic proteins 
including Bcl-2, Mcl-1 and A20 (Henderson et a l , 1991, Rowe et a l , 1994, Wang et a l , 
1996, Martin et a l , 1993, Laherty et a l , 1992) Raised steady-state levels o f intracellular
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calcium, but not inositol triphosphate, have been reported in LMP-1 transfectants o f a B 
lymphoma cell line and LMP-1 has also been shown to induce a calcium/calmodulin- 
dependent kinase in the same line (Wang et al., 1988b; Mosialos et al., 1994). LMP-1 
has also been shown to upregulate the expression o f matrix metalloproteinase 9 (MMP-9) 
and CD44, two proteins which are associated with increased invasiveness/ metastatis o f 
tumours (Yoshizaki et al., 1998; Gregory, 1995; Sneath and Mangham, 1998).
Constitutive LMP1 expression in EBV-immortalised B cells carrying a conditional 
(estrogen-regulatable) EBNA-2 gene has provided evidence that LM P1 in the absence o f 
functional EBNA2 was incapable o f sustaining B-cell proliferation (at levels o f 
expression similar to that observed in LCLs) but induced a phenotype consistent with 
prolonged cell viability (Zimber-Strobl et a l ,  1996). Proliferation o f these transfectants 
resumed only in the presence o f functional EBNA-2. Studies involving conditional 
expression o f LMP-1 in EBV-immortalised B cells (expressing all o f the other latent 
genes) have revealed that LMP-1 expression was required for continuous proliferation. 
In the absence o f LMP-1 expression, these cells remained in a resting state (Kilger et al.,
1998). Although expression o f LMP-1 as the sole EBV gene can induce DNA synthesis 
in primary B-cells (Peng and Lundgren, 1992, Zimber-Strobl et al., 1996), the inability to 
sustain proliferation was shown to be due to the inabiltiy o f the cells to progress through 
S phase (Zimber-Strobl et a l ,  1996). In studies with established EBV-negative BL cell 
lines in which expression o f LMP-1 was regulated by tetracycline, induction o f LMP-1 
expression resulted in a transient cytostatic effect due to an accumulation o f cells at the 
G2/M phase o f the cell cycle and a decrease in c-Myc expression (Floettmann et a l ,
1996).
Transfection studies with LMP-1 deletion mutants indicate that the cytoplasmic amino 
terminus is not responsible for the activating effects, the transmembrane domains are 
critical, due to their importance for LMP1 aggregation in the plasma membrane, and the 
carboxy-terminal domain is essential (Wang et al., 1988b; Martin and Sugden, 1991; 
Moorthy and Thorley-Lawson, 1993a; 1993b). As expected, EBV recombinants lacking 
LMP1 were unable to induce growth transformation o f primary B cells (Kaye et al.,
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1993). Further experiments with EBV recombinants carrying deletion mutants o f LMP-1 
have shown that the transmembrane domain and the membrane proximal carboxy- 
terminal region are the principal LMP-1 components that mediate primary B-lymphocyte 
growth transformation while the distal region (last 155 amino acids) o f the carboxy 
terminal region is critical for LCL outgrowth (Izumi et a l 1994; 1997; Izumi and Kieff, 
1997; Kaye et a l ,  1993; 1995; 1999).
Genetic and biochemical data indicate that LMP-1 is equivalent to a constitutively 
activated receptor o f the tumour necrosis Factor receptor (TNFR) family requiring 
oligomerisation for its activity in the absence o f ligand (Floettmann and Rowe, 1997; 
Hatzivassiliou et al., 1998; Izumi and Kieff, 1997; Kilger et al., 1998; Mosialos et al., 
1995, Gires et al., 1997). Members o f the TNFR superfamily including TNFR, IL-1R, 
CD40, CD30, LMP-1 and lymphotoxin-p receptor exert a number o f effects including 
regulation o f apoptosis and stress responses via signaling pathways that involve 
recruitment o f adapter proteins called TNF receptor associated factors or TRAFs (Arch et 
al., 1998; Baker and Reddy, 1996). Mutational analysis has identified two functional 
domains in the carboxy terminus o f LMP-1: CTAR (carboxy-terminal activation region)- 
1 or TES (Transformation effector site)-1 (residues 187-231) and CTAR-2/TES-2 
(residues 351-386) (Huen et al., 1995; Mitchell and Sugden, 1995) (Figure 1.7). CTAR-1 
engages the tumour necrosis factor receptor family-associated factors (TRAFs) through a 
TRAF interaction domain located within this region (Kaye et al., 1996; Devergne et a l ,  
1996; 1998; Eliopoulos et a l ,  1997; Miller et a l ,  1997; 1998; Brodeur et al., 1997; 
Sandberg et al., 1997). In EBV-transformed B cells or transiently transfected BL cells, 
TRAF-1, -2, -3, and -5  are associated with LMP-1 with engagement o f TRAF-2 
occurring largely via TRAF1 as TRAF1-TRAF2 heterodimers. However, in epithelial 
cells, very little TRAF-1 is expressed and only TRAF-2, -3 and -5  are significantly 
complexed with LMP-1. Critical to the association o f TRAFs with LMP1 is a 
P204xQ206xT208 m otif located within CTAR-1. Unlike CTAR-1, CTAR-2 does not 
directly interact with TRAFs. However, LMP-1 associates with the tumour necrosis 
factor receptor adaptor protein TRADD (Izumi and Kieff, 1997) as well as receptor 
interacting protein RIP (Izumi et al., 1999) and it is via these adaptor proteins that
27
CTAR-2 is thought to recruit TRAF proteins In contrast to TNFR1, LMP1 does not 
associate with the death domain (carboxy-terminus) o f TRADD but with the N-terminus 
(Kieser et a l , 1999)
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Figure 1 7 Schematic diagram of LMP-1 LMP1 consists o f  a 24-aminoacid N-terminal cytoplasmic 
domain, six transmembrane domains and a 200 ammo acid C-terminal cytoplasmic tail LMP-1 
constitutively aggregates in the plasm a membrane and associates with TRAFs via the P204xQ206xT208 
m otif in TES (Transformation Effector S ite)-1 or CTAR (Carboxy terminal activation region)-l (residues 
187 -  231) and with TRADD and RIP via the y 384Y385D386 m otif in TES-2 or CTAR-2 (residues 352 -  
386) The region between aminoacids 275 and 307 o f LMP-1 is responsible for activation o f  JAK3 
A dapted from  Izumi et a l , 1999
One o f the first signaling functions assigned to LMP-1 is activation o f the transcription 
factor, NF-kB and this function could be demonstrated in both B and T-lymphocytes and 
epithelial cells (Hammarskjöld and Simurda, 1992, Huen et a l , 1995, Mitchell and 
Sugden, 1995) With the discovery that LMP-1 associates with the TRAF signaling 
molecules and exhibits similar functions to members o f the TNF-superfamily, deeper 
insight into the mechanism o f activation o f NF-kB by this EBV protein have been 
realised Thus, CTAR1 was demonstrated to mediate 20-40% o f the total activation o f 
NF-kB by LMP-1 while CTAR-2 makes a greater contribution (60-80%) m this effect in 
different cell types Furthermore, TRAF-2 has been shown to be an important mediator 
o f NF-kB activation by both domains TRAF-3 on the other hand has been shown to act
28
as a negative modulator o f N F - k B  activation by LMP-1 by displacing TRAF-1 and 
TRAF-2 (Kaye et a l , 1996, Devergne et a l , 1996) Although the association o f CTAR-2 
with TRADD is required for N F - k B  activation by this region, the association with RIP is 
not (Izumi et a l , 1999) The residues between positions 384 to 386 (YYD) o f LMP-1 are 
critical to the association o f TRADD and RIP to CTAR2 as well as N F - k B  activation and 
LCL outgrowth (Izumi et a l , 1997, 1999) Constitutive association o f TRAFs and 
TRADD with the carboxy-terminal region o f LMP-1 and N F - k B  activation is dependent 
on ligand-independent aggregation o f LMP-1 (Gires et a l , 1997, Devergne et a l , 1996, 
Izumi and Kieff, 1997) TRAF3 has been shown to mediate the effect o f LMP-1 on 
growth inhibition o f epithelial cells (Eliopoulos et a l , 1996) and is implicated in 
association o f LMP1 with the cytoskeleton (Higuchi et a l , 2001)
The pathway downstream o f TRAF-binding to CTAR-1 and TRADD binding to CTAR-2 
leading to NF-kB activation has been partially deciphered and is similar to the TNFR 
signaling pathway (Sylla et a l , 1998) (Figure 1 8) Aggregation o f TRAF-2 recruited to 
activated LMP-1 somehow leads to activation o f the NF-KB-inducing kinase (NIK) 
which in turn activates IKK (iKBa-kinase)- a  and *P IK K a and IKK(3 then 
phosphorylate IkBoi which is then ubiqumated and degraded releasing active NF-kB 
The N IK-IKK a -IKK -P association is thought to occur in a complex separate but 
neighbouring to that o f LMP-1 -TRAF-TRADD (Sylla et a l , 1998)
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Figure 1 8 Schematic diagram o f aggregated LMP1 m the cell plasma membrane showing the 
pathway involved in activation o f NF-kB downstream of TRAF2 TRAF1, TRAF2 and TRAF3 
constitutively associate with the LMP-1-proximal NF-KB-activating region, CTAR-1 TRADD 
constitutively associates with the LMP-1 distal and m ajor NF-KB-activating region, CTAR2 Aggregation 
o f TRAF2 most likely activates NIK which in turn phosphorylates and activates IK K a and IKK(3 IK K a 
and 1KKP then phosphorylate iKBa, leading to its ubiquitination and degradation and N F-kB activation 
A dapted from  Sylla et a l , 1998
CTAR-2 but not CTAR-1 is also responsible for the activation o f the JNK (c-jun N-
terminal km ase)-l pathway by LMP-1 which leads to activation o f the c-Jun-N-terminus
component o f the transcription factor AP-1 (Kieser et a l , 1997, 1999, Ehopoulos and
Young, 1998) While SEK (stress enhanced kinase)-1 has been shown to mediate
activation o f JNK1 by LMP-1 (Kieser et a l , 1997, Ehopoulos and Young, 1998), the
components o f the pathway upstream o f SEK1 are unknown and does not include MEK
kinase (a mitogen activated protein kinase kinase kinase) (Kieser et a l , 1997) However,
there is controversy over the involvement o f TRADD/TRAF2 in the signaling pathway
from the CTAR2 domain o f LMP1 to JNK1 Thus, while Ehopoulos et al (1999), have
demonstrated the involvement o f TRADD/TRAF2 in LMP1-mediated signaling to the
JNK pathway, the study o f Kieser et al (1999) demonstrates otherwise It is likely that
this discrepancy is due to the differences in the methodology used (different TRAF2
dominant negative mutants and usage o f a TRADD mutant in one case and not in the
other) The activation o f AP-1 has been shown to also be required for the effect o f LMP-1
expression on upregulatmg MMP-9 (Takeshita et a l , 1999) LMP-1 can also activate the
p38 M APK (mitogen-activated protein kinase) pathway and both CTAR-1 and CTAR-2
are responsible for mediating this effect in a TRAF2-dependent manner (Ehopoulos et
a l , 1999) This pathway is responsible for the upregulation o f IL-6 and IL-8 production
by LMP-1 in epithelial cells A third functional domain o f LMP-1, CTAR3, has recently
been identified which localises to a region o f the carboxy terminus o f LMP-1 (aa 275-
307) between CTAR-1 and CTAR-2 (Figure 1 7) This domain is responsible for the
interaction o f LMP-1 with Janus kinase (JAK)-3 which in turn activates STAT (signal
transducers and activators o f transcription) proteins (Gires et a l , 1999) However,
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activation o f JAK 3 may also require interaction between CTAR1 or CTAR2 and CTAR3 
(Brennan et a l , 2001) Activation o f the p21-Rho-like GTP-ase cdc-42 in fibroblasts has 
been identified as yet another signaling function o f LMP-1, however, this function maps 
to the transmembrane domains o f LMP-1 and unlike the TNFR1 signaling pathway is not 
responsible for mediating LMP-1 signaling to JNK (Gires et a l , 1999) LMP-1 has also 
been shown to mediate activation o f a Ras-MAPK-dependent pathway and this activity is 
required for cellular transformation (Roberts and Cooper, 1998)
There appear to be cell-type-specific differences in the effects o f induction o f LMP-1 
For instance, upregulation o f Bcl-2 expression by LMP-1 appears to be a B-cell 
dependent effect and that too in a Bcl-2-negative context (Henderson et a l , 1991, Martin 
et a l , 1993) Thus, whilst LMP-1 has been shown to upregulate Bcl-2 expression in 
EBV-negative BL lines which express low to negligible levels o f Bcl-2 protein, such an 
effect is not evident in epithelial cells Also, the observation that EBV infection or LMP- 
1 expression in peripheral B lymphocytes (which constitutively express Bcl-2) does not 
lead to significant upregulation o f Bcl-2 has led to the suggestion that the function o f 
LMP-1 in this cellular context may be to maintain rather than induce Bcl-2 levels (Martin 
et a l , 1993) LMP-1 has also been shown to upregulate IL-6 and IL-8 expression m 
epithelial cells in an NF-kB- and p38MAPK- dependent manner (Ehopoulos et a l , 1997,
1999) Expression o f LMP-1 has been shown to block morphological differentiation of 
epithelial cells suggesting that the expression o f this EBV protein may participate in the 
development o f EBV-associated epithelial malignancy such as NPC via a mechanism 
different from that observed m B-cell or fibroblast transformation, that o f  deregulation o f 
morphological differentiation (Dawson et a l , 1990) LMP1 can also induce expression o f 
the epidermal growth factor receptor (EGFR) in epithelial cells and although this function 
maps to CTAR1 it is independent o f NF-kB activation (Miller et a l , 1995) Also, the 
ability o f LMP-1 to upregulate the expression o f proteins CD44 and MMP-9 suggests that 
this EBV protein may not only be involved in transformation but also promoting tumour 
spread (Gregory, 1995, Yoshizaki et a l , 1998)
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Transcription o f LMP1 can be regulated by EBV gene products including EBNA2, 
EBNALP and BARFO (Harada and Kieff, 1997; Kusano and Raab-Traub, 2001) through 
elements present within its promoter region and each o f these may serve as an alternative 
route to inducing LMP1 expression. Thus, many o f the effects o f these gene products 
may be indirect and mediated by regulation o f the expression o f LM P1.
1.6.6 LMP2A AND 2B
The genes encoding LMP2A and 2B have also been named terminal protein 1 and 
terminal protein 2 (TP1, TP2), because they are transcribed across the terminal repeat 
sequences o f the linear viral genome of which are fused together upon infection to 
generate the intracellular episomal form of the viral genome (Laux et a l ,  1988; Sample et 
al., 1989). The two messages consist o f different 5’ exons and eight common exons and 
are predicted to encode nearly identical proteins differing only in the length o f their 
hydrophilic amino termini (Ring, 1994). Transcription o f the LMP2A starts 3 kb. 
downstream o f the LMP1 transcription start site (Laux et al., 1988; Sample et al., 1989). 
The LMP2B and LMP1 promoters form bi-directional transcription units containing a 
common EBNA2 responsive element, while a separate EBNA2 response element 
regulates LMP2A transcription (Zimber-Strobl, et al., 1993). LMP2A and 2B are 54 and 
40 kDa in size respectively. Both proteins are predicted to encode twelve highly 
hydrophobic membrane spanning domains and are localized to patches in the plasma 
membrane o f infected cells, in close association with LMP1 (Longnecker and Kieff,
1990). LMP2A and 2B are not required for EBV mediated immortalization, but LMP 2A 
appears to be important for maintaining viral latency (Longnecker et al., 1992; Brielmeir 
et al., 1996; Freuhling et al., 1998, Longnecker and Miller, 1996). The LMP2 proteins 
are phosphorylated on serine, threonine and tyrosine residues (Longnecker et al., 1991) 
and have been shown to interact with ¿rc-family tyrosine kinases in EBV-infected B cells 
(Burkhardt et al., 1992). However, in epithelial cells, LMP2A does not appear to be 
phosphorylated by src kinases but by Csk (Scholle et a l ,  1999). The LMP2s are also 
associated with another stably phosphorylated tyrosine kinase sky. These interactions 
suggest that the LMP2s play a role in transmembrane signal transduction (Kieff, 1996).
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LMP2A has been shown to inhibit anti-immunoglobulm-mediated Ca2+ mobilization, 
PLCy2 activation and anti-immunoglobulm-induced reactivation o f the lytic cycle, which 
can be bypassed by TPA and calcium íonophores (Miller et a l , 1994, 1995a) These data 
are consistent with a model in which LMP2A sequesters the B-cell receptor-associated 
tyrosine kinase, blocking its autophosphorylation and downstream signalling events 
(Miller et a l , 1995a) LMP2A and LMP2B singly or LMP1/LMP2A coexpressed are 
capable o f altering keratinocyte cell adhesion molecule expression (Farwell et a l , 1999) 
In vivo studies indicate that LMP2A allows B-cell survival in the absence o f normal B- 
cell receptor signals (Merchant et a l , 2000) Although LMP2A can activate the protein 
kinase Akt in a phosphatidyl-inositol-3-kinase (PI3-K)-dependent pathway in an EBV- 
negative BL line, this well known regulator o f cell survival in B lymphocytes does not 
appear to mediate the cell survival effect o f LMP 2A (Swart et a l , 2000) The activation 
o f the PI3-kinase-Akt pathway by LMP2A has been demonstrated to contribute to the 
ability o f this latent protein to transform epithelial cells and inhibit differentiation 
(Scholle et a l , 2000)
1.6.7 EBV ENCODED RNAS (EBERS)
The two EBV-encoded, small nonpolyadenylated RNAs, EBER1 and EBER2, are by far 
the most abundant EBV RNAs in latently infected cells (Kieff, 1996) They are usually 
transcribed by RNA polymerase III although polymerase II may also be involved Most 
EBERs are located m the nucleus and are associated at the 3 ’ terminus with the cellular 
La antigen (Howe and Steiz, 1986, Howe and Shu, 1989) EBER 1 and 2 have extensive 
sequence similarity to adenovirus VA1 and VA2 and cell U6 small RNAs, both o f which 
form similar secondary structures and complex with La protein (Rosa et a l , 1981, 
Ghckman et a l , 1988) Stable expression o f EBERs m the EBV-negative BL cell line, 
Akata, at levels comparable to those in EBV-positive cells, was found to confer enhanced 
tum ongem c potential (Komano et a l , 1999, R uf et a l , 2000) The function o f the 
EBERs is unclear but by analogy to the VA and U6 RNAs two alternative roles have 
been proposed for the EBERs In adenovirus infection VA1 RNA acts in the cytoplasm 
to directly inhibit activation o f an interferon-induced protein kinase, which blocks
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transcription by phosphorylating the protein-synthesis initiator factor eIF-2a EBER1 
and 2 can partially complement the replication o f an adenovirus with null mutation in 
VAI and VAII, but their effect on eIF-2a, kinase activity is significantly less and they are 
not found in the cytoplasm (Kieff, 1996) Both o f the proposed functions o f EBERs are 
somewhat incompatible with the observation that their expression is delayed until after 
EBNA and LMP gene expression and initiation o f DNA synthesis (A lfien et a l , 1991) 
Nevertheless, the earlier events in primary B-cell infection are sensitive to interferon 
(IFN) and EBERs may play a role in blocking eIF-2 kinase (Thorley-Lawson,1980, 
1981)
1.7 GENES OF THE LYTIC VIRAL CYCLE
Only a small fraction o f latently infected B-lymphocytes spontaneously enter the 
productive cycle and in these cells the viral DNA is amplified several hundred fold by a 
lytic origin o f DNA replication, ori Lyt (Hammerschmidt and Sugden, 1988) EBV lytic 
infection is usually induced in vitro by chemicals (Luka et a l , 1979, Saemundsen et a l , 
1980) Phorbol esters are among the most reproducible and most broadly applicable 
inducers, their effect is probably mediated by protein kinase C activation o f Jun-Fos 
interactions with AP-1 sites upstream o f the immediate early virus genes (Farell et a l , 
1983, 1989, Farell 1992, Laux et a l , 1988) The Akata cell line which carries an 
LMP2A-deleted virus can be induced by cross-linking o f surface immumoglobulms (slg) 
to the extent that more than 50% o f the cells enter the lytic cycle (Takada, 1984, Takada 
and Ono, 1989) A second approach to investigating viral replication is to induce the 
lytic cycle by supermfection o f Raji cells with defective EBV from the P3HR-1 cell line 
(Mueller-Lantzch et a l , 1980) Raji is an EBV-positive BL cell with an unusually high 
EBV episome copy number This cell line is defective for DNA replication and late gene 
expression and infection is thus tightly latent (Polack et a l , 1984) Defective virions 
from P3HR-1 contain rearranged DNA molecules in which the intermediate early trans- 
activator o f lytic cycle are expressed after supermfection (Cho et a l , 1984, Miller et a l , 
1984) Studies with such cell lines has allowed the division o f EBV replicative proteins 
into early antigens (EA), membrane antigens (MA) and virus capsid antigens (VCA)
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(Figure 1.9). Early antigens are further subdivided into EA-D (diffuse) and EA-R 
(restricted) due to a different sensitivity to methanol fixation (Henle et al., 1971a; 1971b). 
After induction, cells that have become permissive to viral replication undergo cytopathic 
changes characteristic o f herpesviruses, including migration o f nuclear chromatin, 
synthesis o f viral DNA, assembly o f nucleocapsids, envelopment o f the virus by budding 
through the inner nuclear membrane and inhibition o f host macromolecular synthesis 
(IARC Monograph, 1997).
OR 1-
F.BV DNA polymerase BALF5
Thym idine Kinase BXLF1
Ribonucleotide reductase B O R F2 & BARF1
Alkaline Dnase B G LF5
DNA binding protein pi 88 BALF2
MA OKI7
gp3 50/220 B LLFI
KP 150 BDLF3
gpl 10 BALF4
gp85 BXLF2
gp78 B ILF2
gp42 BZLF2
BP25 BKR.F2
Figure 1.9 A schematic representation o f early and late EBV gene expression. The VCA, the MA and
the EA are illustrated and their open reading frames are written in bold.
Virus gene expression follows a temporal and sequential order (Farrell, 1992; Takada and 
Ono, 1989). Some virus genes are expressed independently o f new protein synthesis; 
early after induction and are classified as immediate early genes. Early lytic virus genes
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are expressed slightly later and their expression is not affected by inhibition o f viral DNA 
synthesis (Kieff, 1996).
1.7.1 Immediate early genes
After P3HR-1 superinfection o f Raji or slg cross-linking o f Akata cells in the presence o f 
protein synthesis inhibitors, three leftward mRNAs are transcribed. The BZLF1, BRLF1 
and BL’LF4 encoded proteins are potent transactivators o f early EBV lytic gene 
expression (Takada and Ono, 1989; Marschall et a l ,  1991; Kieff, 1996). B Z L Fl’s 
functional and physical interaction with NFkB is an important regulator o f LMP1- 
mediated effects in latent infection. BZLF1 can also downregulate the EBNA Cp 
promoter perhaps facilitating the transition from latent to lytic infection (Kenney et al., 
1989; Sinclair et a l ,  1992).
1.7.2 Early genes
The early genes are expressed when lytic cycle is induced in the presence o f inhibitors o f 
DNA synthesis. By this criterion at least 30 EBV mRNAs are early gene products 
(Hummel and Kieff, 1982; Baer et a l ,  1984). Two very abundant early proteins have 
been mapped to specific DNA sequences. The BALF2 protein is homologous to a HSV 
DNA binding protein and is important in DNA replication (Hummel and Kieff, 1982; 
Kieff, 1996). The BHRF1 protein which is expressed in moderate abundance, has 
extensive collinear homology with bcl-2 (Pearson et a l ,  1983; Austin et a l ,  1988). 
BHRF1 can protect EBV negative BL cells from apoptosis (Me Carthy et al., 1996). 
However, EBV recombinants lacking the BHRF1 ORF are fully capable o f initiating and 
maintain cell growth transformation and they can also enter the lytic cycle and produce 
virus (Lee and Yates, 1992; Marchini et a l ,  1991). Several o f the early genes are linked 
to DNA replication as indicated in Figure 1.9. Transfection experiments indicate that 
some o f these genes are activated in the process o f cell differentiation in the absence o f 
other viral gene products, suggesting a possible role o f cellular factors in regulating the 
productive cycle, at least in certain cell types (Marschall et a l ,  1991).
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1.7.3 LATE GENES
The late genes code for structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress (IARC Monograph, 1997) Among the 
non-glycoproteins the major nucleocapsid protein is encoded by BCLF1, BNRF1 encodes 
the major external nonglycoprotein o f the virion and BXRF1 is likely to encode a basic 
core protein The BFRF3 ORF encodes the tegument protein, (Figure 1 1) and VCA p i 8, 
which is strongly immunogenic in humans (Kieff, 1996) The genes encoding the EBV 
glycoproteins are illustrated in bold figure 1 9 The late BCRF1 gene which is located in 
the middle o f the EBNA regulatory domain between ori-P  and Cp, is a close homolog o f 
the human IL-10 gene, with nearly 90% collinear identity in amino-acid sequence (Moore 
et a l , 1990, Vieira et a l , 1991, Touitou et a l , 1996) BCRF1 has most o f the activity o f 
human IL-10, including negative regulation o f macrophages and NK cell functions and 
inhibition o f IFN y production Thus, virally expressed IL-10 may have a local effect on 
these responses to reactivate infection (IARC Monograph, 1997)
1.8 ROLE OF APOPTOSIS IN EBV BIOLOGY
While the process o f apoptosis is a genetically controlled pre-programmed event o f cell 
death that eliminates cells during development when they have become redundant, it also 
functions as an emergency response to various agents including radiation damage, 
aberrant growth induced by the activation o f oncogenes and viral infection In the case o f 
virus-infected cells, the induction o f early cell death would severely limit virus 
production and severely reduce or eliminate spread o f progeny virus in the host (Shen and 
Shenk, 1995) Thus, many viruses have evolved strategies to evade or delay early 
apoptosis to allow persistence in the host and production o f high yields o f progeny virus 
W ithin the last few years, both the biochemical basis o f apoptosis and its regulation by 
some viral products have become clearer For example, part o f  the apoptotic program 
includes the induction o f cellular endonucleases which could target replicating viral DNA 
and prevent virus production at a very early stage In order to combat such host cell
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responses to infection many viruses have evolved genes that either themselves encode 
proteins or effect the expression of host cell apoptosis-related proteins that efficiently 
suppress the apoptotic program. In addition, many viruses are now known to induce 
apoptosis actively at late stages o f infection. This process may represent a final and 
important step in the spread o f progeny to neighbouring cells while also evading host 
immune inflammatory responses and protecting progeny virus from host enzymes and 
antibodies. Such virally-induced apoptosis may also contribute to some clinical 
manifestations and cytotoxicity associated with many human diseases o f viral origin 
(Shen and Shenk, 1995).
EBV is unique in that it uses both pro- and anti-apoptotic properties to its advantage in its 
life cycle. This virus is able to effectively utilise these properties by either regulating the 
host cell apoptotic death machinery or encoding gene products that function similarly to 
anti-apoptotic proteins o f the host cell. In the life cycle o f EBV, protection against 
apoptosis serves two purposes. Firstly, as a mechanism that ensures its persistence in the 
host in the memory B-cell compartment by mimicking the normal process o f B- 
lymphocyte selection in germinal centers. Secondly, the expression o f particular virally 
encoded proteins in the lytic phase delays/suppresses cell death until sufficient progeny 
virions are made.
1.8.1 EBV induces the expression of anti-apoptotic proteins
EBV-negative BL cells and type I BL cell lines phenotypically resemble germinal center 
B-lymphocytes (Gregory, 1995). This resemblance includes their ability to undergo 
apoptosis in the face o f diverse stimuli including serum deprivation and calcium 
ionophore. On the other hand, type III EBV-positive BL lines that express the entire 
complement o f latent proteins, display increased resistance to apoptosis (Gregory et al., 
1991). These observations prompted further studies aimed at understanding the molecular 
basis o f the protection from apoptosis conferred by EBV to the BL cell lines. Thus, it 
was found that the apoptosis-sensitive EBV-positive group I BL lines (and primary BL 
cells) also have little or no detectable Bcl-2 expression, while the apoptosis resistant
38
group III BL lines were found to be Bcl-2-positive (Henderson et a l , 1991) 
Identification o f a candidate latent protein encoded by the EBV genome that may be 
responsible for the upregulation o f Bcl-2 observed in the group III BL cells was achieved 
when clear correlations were found between LMP-1 expression and protection from 
apoptosis on the one hand and on the other hand between LMP-1 expression and 
upregulation o f Bcl-2 expression in LMP-1- (but not EBNA-1-, EBNA-2-, EBNA-LP- or 
LMP-2-) transfectants derived from EBV-negative BL cell lines (Henderson et a l , 1991) 
This study also reported that EBNA-2 can augment the effect o f LMP-1 expression on 
induction o f Bcl-2 in dual transfection experiments o f BJAB-cells (Henderson et a l ,
1991) In another study, Martin et al (1993) reported the effect o f ectopic expression o f 
EBNA-2 on induction o f Bcl-2 protein in transient transfection experiments o f BJAB- 
cells, however, coexpression o f the LMP-1 and EBNA-2 genes did not result in 
significantly higher levels o f Bcl-2 expression than did either gene alone in these cells 
The induction o f Bcl-2 expression by LMP-1 has been shown to be a delayed response 
relative to its effects on NF-kB activation and upregulation o f several adhesion molecules 
Studies w ith cell lines in which LMP-1 is under inducible control or expressed transiently 
have shown that maximum upregulation o f Bcl-2 occurs 48-72 h post-induction o f LMP- 
1 (Rowe et a l , 1994, Wang et a l , 1996) There is also evidence that EBNA3B (EBNA4) 
can upregulate Bcl-2 expression in an EBV-negative cell line (Silins and Sculley, 1995)
While expression o f LMP-1 can induce Bcl-2 expression in group I BL lines and protect 
them from apoptosis, EBV infection o f primary B-cells does not significantly increase 
Bcl-2 levels despite the fact that LMP-1 is expressed in the infected cells (Martin et a l , 
1993) Compared to EBV-negative or group I BL lines, primary B lymphocytes express 
significant amount o f  Bcl-2 and it has therefore been suggested that induction o f Bcl-2 
expression by EBV (or LMP-1) may not be relevant in a Bcl-2-positive cellular context 
such as exists in peripheral B-lymphocytes Furthermore, it is possible that there is some 
cellular control on the levels o f expression o f Bcl-2 in peripheral B-lymphocytes, perhaps 
a negative feedback mechanism as occurs in the case o f the A20 protein (Song et a l ,
1996) The role o f LMP-1 in LCLs, therefore, may not be to induce, but rather to 
maintain, the high constitutive level o f Bcl-2 that is found in the uninfected peripheral B-
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cells. The observation that LMP-1 -  mediated upregulation o f Bcl-2 expression may be 
more relevant in a Bcl-2-negative cellular context also applies to epithelial and T cell 
lines since studies have shown that ectopic expression o f LMP-1 in these cell lines does 
not further upregulate the constitutive Bcl-2 levels (Rowe et a l ,  1994; Kawanishi, 1997).
Overexpression o f Bcl-2 in group I BL cell lines following bcl-2 gene transfer results in a 
change in the behaviour o f the cells in apoptosis assays towards that o f group III lines 
(Henderson et al., 1991; Milner et a l ,  1992). These 6c7-2-transfectants display reduced 
apoptotic responses following serum starvation, calcium ionophore treatment or anti- 
smlg stimulation; the inhibition o f cell death being proportional to the amount o f Bcl-2 
protein (Milner et a l ,  1992). Interestingly, in a panel o f group I, group I/bcl-2 (bcl-2 
transfectants o f group I cell lines), and group III sublines from the same BL parental line, 
it was found that, for the three different apoptosis triggers, the degree o f protection 
imparted by the group III phenotype far outweighed that apparent from the levels o f Bcl- 
2 protein measured in the group III cells. Since there were no gross differences observed 
between the distribution o f Bcl-2 in the group I transfectants and the group III 
transfectants, these observations were interpreted to mean that either, in a group I cell, 
Bcl-2 function is antagonised or one or more additional Bcl-2-independent survival- 
pathways are operational in group III cells. In so far as the first possibility is concerned, 
bcl-2 homologs, bax and bcl-xS, which can suppress Bcl-2 function have been identified 
(reviewed in Allday, 1996 and Korsmeyer, 1995). It is therefore conceivable that 
antagonism of Bcl-2 function by such homologous proteins occurs in the groupl, but not 
in the group III environment. In so far as protein levels are concerned, there does not 
appear to be consistent differences in the levels o f these Bcl-2 antagonists between type I 
and type III BL cells (Spender et al., 1999). In support o f the second possibility, it is 
plausible that additional EBV-induced apoptosis-suppressor proteins, such as the Bcl-2 
homo logs Bcl-xL, Mcl-1 or the A20 protein act in concert with Bcl-2 in group III cells to 
promote survival. In this regard, LMP-1 has been shown to upregulate the expression o f 
several other anti-apoptotic proteins including Mcl-1 and A20 (Wang et al., 1996; 
Laherty et al., 1992), the former serving as a rapid and short-term effector o f cell viability 
prior to the up-regulation o f Bcl-2 (Wang et al., 1996).
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The upregulation o f the anti-apoptotic zinc-finger protein, A20, by LMP-1 has been 
demonstrated in B- lymphocytes as well as epithelial cells and this effect is NF-kB 
dependent mapping to both CTAR1 and CTAR2 (Laherty et a l , 1992, Fries el a l , 1996, 
M iller et a l , 1995, 1997) A20 is also constitutively expressed in EBV-immortalised B- 
cells (Spender et a l , 1999) LMP-1-mediated protection o f epithelial cells from p53- 
mediated apoptosis has been shown to involve A20 (Fries et a l , 1996) A20 can also 
contribute to the antiapoptotic effect o f LMP-1 expression in BL cell lines (Laherty et a l ,
1992) More recently, A20 was demonstrated to function in a negative feedback loop by 
inhibiting activation o f NF-kB from both CTAR1 and CTAR2 domains o f LMP-1 
(Eliopoulos et a l , 1999) This effect was mediated by the binding o f A20 to TRAF2 and 
this effect by A20 has also been demonstrated in the case o f signaling from some o f the 
other members o f the TNFR-family including CD40 which can also induce A20 
expression in BL cells (Sarma et a l , 1995)
1.8.2 EBV regulates components o f the cell cycle machinery to protect against 
apoptosis
In addition to regulating apoptosis by inducing the expression o f anti-apoptotic proteins, 
EBV and in particular LMP-1 can also control apoptosis by regulating the cell cycle, 
since the processes o f apoptosis and cell cycle progression (proliferation) are coupled 
through the use and control o f shared molecular machinery (Evan et a l , 1995)
Many oncogenes that promote cell cycle progression also induce apoptosis This duality 
in function is exemplified by c-Myc which is a sequence-specific DNA-binding 
phosphoprotein that serves as a transcriptional activator and whose expression is required 
for passage through G1 and entry into the S-phase o f the cell cycle (Gregory, 1995) In 
order to explain the ability o f c-Myc to promote such opposed cellular functions as 
proliferation and death, a model has been proposed according to which c-Myc necessarily 
drives both processes, proliferation being favoured under appropriate conditions o f 
availability o f nutrients, space, growth and survival factors (Evan et a l , 1995) Thus, this
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model predicts that the activity o f Myc in promoting proliferation is dependent on the 
route to its apoptosis-promoting activity being blocked Accordingly, even normally 
proliferating cells may be regarded as being “primed” for apoptosis This model can 
explain why c-Myc, being a potent inducer o f cell death is strongly favoured during the 
carcinogenic process Thus, it has been suggested that as soon as the affected cell 
acquires some form o f apoptosis-suppressing mutation, the advantage afforded by c-Myc- 
mduced proliferation outweighs any disadvantage conferred by c-Myc-induced apoptosis 
Until that point, however, most cells with deregulated c-Myc are thought to delete 
themselves (by apoptosis) This theory gains support from observations made in 
transgenic animals expressing deregulated c-Myc Lymphocytes from these animals 
were found to exhibit elevated levels o f spontaneous apoptosis and an increased 
sensitivity to induction o f apoptosis in lymphoid organs was also observed (Evan et al, 
1995, Levine 1997) That cell death is an important restraint during carcinogenesis 
induced by c-Myc in the absence o f an ‘anti-death factor’, is best exemplified by the 
occurrence m these animals o f tumours displaying oncogenic synergy between c-myc and 
the anti-apoptotic gene bcl-2 (reviewed in Allday, 1996) Further studies have shown that 
Bcl-2 suppresses only the apoptotic actions o f c-Myc, leaving its ability to promote cell 
proliferation unaffected, thus leading to the suggestion that the proliferative and apoptotic 
arms o f the c-Myc pathway must be distinct at the point at which Bcl-2 acts
Further support for the theory that apoptosis and cell proliferation coincide comes from 
the observation that key tumour suppressor proteins such as pRb and p53 exert direct 
effects on cell viability and on cell cycle progression (reviewed in Allday, 1996, Levine, 
1997, Hunter, 1993) Phosphorylation o f pRb (the product o f the retinoblastoma gene rb) 
inactivates the protein during late G1 at a point in the cell cycle that appears to be 
coincident with the late G1 restriction point (after which cells no longer require 
mitogemc signals to complete their cell cycle) pRb is the principal target for inactivation 
by several DNA tumour virus oncoproteins including Simian virus (SY) 40 large T 
antigen (Tag), human papilloma virus (HPV) E7 protein and adenoviral E l A This 
suggests that active pRb acts as a restraint to the mitogemc actions o f these virus proteins 
(Taya, 1997).
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One o f the functions o f pRb is to suppress the action o f the G1-specific E2F-DP 
transcription factors which coordinate expression o f the late G1 phase and early S phase 
genes required for cell cycle progression The activity o f pRb is regulated by 
phosphorylation in the pl6-cyclinD l-cdk4-rb  pathway (Taya, 1996, Levine, 1997) 
(Figure 110) p i 6 is a negative regulator o f cyclin D l-cdk4 and the gene is shut off in 
many cancer cells or mutated in others Cyclm-Dl-cdk4 complexes target pRb for cell 
cycle regulation by phosphorylating it E2F-DP transcription factor complexes (E2F-l,-2 
and -3 and D P -1,-2 and -3) whose activity is regulated by pRb, in turn regulate a number 
o f genes [including those encoding cyclin E, cyclin A, dihydrofolate reductase and 
proliferating cell nuclear antigen (PCNA)] required to initiate or propagate the S phase o f 
the cell cycle Phosphorylation o f pRb by cyclmDl-cdk4 releases E2F-DP proteins (E2F- 
DP proteins are bound by dephosphorylated pRb ) from the pRb complex, relieving 
repression o f these genes or activating their transcription
p l6
cdk 4 “  cyclin D
M yc— ►
E2F1
BAX
MDM-2 
(—  BCL-2
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Figure 1 10 The p53-Rb pathway Inter-relationships among a number o f  oncogenes (Myc, MDM-2, 
BCL-2) and tum our suppressor genes (p l6 , Rb, p53) that regulate the G l-S  phase restriction point, its 
relation to a DNA damage checkpoint mediated by p53, and the choice by p53 whether to initiate a G1 
arrest (via p 2 1) or apoptosis Available evidence suggests an important role for Rb and its two related gene 
products, p 107 and p 130 (along with E2F-4 and -5 ) , in p53-mediated G l-S  phase regulation Shown are 
the p53-M DM 2 autoregulatory loop that reverses this checkpoint control and the gene products that 
positively or negatively act on the probability o f  entering apoptosis (Key - -| inhibits activity , —> induces 
activity) A dapted  from  Levine, 1997
By binding and inactivating pRb, thereby liberating active E2F, the viral oncoproteins 
E l A (adenovirus) and E7 (HPV) promote cell cycle progression (Levine, 1997) 
Consistent with this, is data showing that deregulated expression o f E2F transcription 
factors induces both proliferation and apoptosis c-Myc can also override the growth- 
suppressive effects o f pRb, however, there is some doubt as to whether c-Myc can 
interact with pRb in vivo Not only does a lack o f functional pRb lead to apoptosis, but 
restoration o f functional pRb to rb ' cells directly inhibits it, under conditions where 
apoptosis is induced by radiation (i e p5 3-dependent) or even by dominant oncogenes 
This indicates that the effects o f pRb must be exerted downstream of p53
p53 plays a key role in limiting the further expansion o f cells containing damaged 
genomes and it achieves this by either enforcing cell cycle arrest or triggering apoptosis 
(reviewed in Levine, 1997 and Bates and Vousden, 1996) Which o f these two alternate 
fates occurs in any particular instance appears to depend on a number o f undefined 
factors, such as cell type, nature and intensity o f insult and cytokine status The high 
frequency with which p53 is functionally inactivated in human tumours attests to the 
critical role that p53 plays in limiting neoplastic progression By transducing genome 
damage into growth arrest and/or apoptosis, p53 prevents the progression o f potentially 
mutant cells together with the neoplastic risk they present Levels o f p53 rapidly increase 
following DNA damage, mainly because the normally short-lived p53 protein is 
stabilised, and this appears to be an important component o f the G1 arrest and apoptosis 
that follow DNA damage Tumour cells that have lost functional p53 exhibit resistance 
to induction o f apoptosis by a range o f genotoxic agents Moreover, because such cells
44
fail to arrest or die following DNA damage, they enter S phase with unrepaired DNA and 
sustain substantially elevated risks o f further mutation.
p53 can act as a transcription factor, and most evidence suggests that it induces growth- 
arrest by the modulation o f specific target genes (reviewed in Levine, 1997). Most 
prominent among these is the gene encoding the cyclin-dependent kinase (cdk) inhibitor 
p21/W A F-l/C ip-l, whose action arrests cells in late G l. p21 binds to a number o f cyclin 
and cdk complexes: cyclinDl-cdk4, cyclin E-cdk2, cyclin A-cdk2 and cyclin A-cdc2 
(Figures 1.10, 1.11). One molecule o f p21 per complex appears to permit cdk activity, 
while any more inhibits kinase activity and cell cycle progression. p21 also binds to 
PCNA, and formation o f p21-PCNA complexes blocks the role o f PCNA in DNA 
replication (but not its role in DNA repair). Thus, p21 can act on cyclin-cdk complexes 
and PCNA to block DNA replication. p21-independent pathways may also contribute to 
p53-mediated growth arrest. In this respect, GADD45, which is encoded by a p53- 
responsive gene, can also bind PCNA.
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responsible for G l/S  transition), MDM2 (negatively controls p53 expresion), GADD45 (DNA replication), 
Bax (pro-apoptotic) and cyclin G] Two modes o f signaling for cellular apoptosis are possible one 
requiring transcription and one involving direct signaling with no transcription o f  downstream genes 
required A dapted  fro m  Levine, 1997
It is less certain how p53 regulates apoptosis or what factors coordinate its actions as a 
cytostatic- versus a cytotoxic- agent Some evidence indicates that induction o f apoptosis 
by p53 may not require transcriptional activation o f genes, although transrepression has 
not been excluded (reviewed in Levine, 1997, Evan, 1995) Other data implicate p53- 
dependent transactivation o f the bax gene, which encodes a member o f the Bcl-2 family 
that can induce apoptosis It is well estabhsed that overexpression o f Bcl-2 can block 
p53-mediated apoptosis Bax binds to Bcl-2 and antagonises its ability to block 
apoptosis, so a p53-dependent bax synthesis can tip the scales towards apoptosis A 
second p53-regulated gene product that could affect growth regulation is the insulin-like 
growth factor-binding protein-3 (IGF-BP3) IGF-BP3 blocks the IGF mitotic signaling 
pathway by binding to IGF and preventing its interaction with its receptor Thus, the 
blocking o f IGF activity could enhance apoptosis or lower the mitogemc response of 
cells
p53 also acts to induce apoptosis in cells with oncogenic lesions such as loss o f 
functional pRb or the expression o f viral proteins such as E l A or deregulated c-Myc 
(reviewed by Evan et a l , 1995) Mice in which pRb inactivation is targeted to the lens or 
photoreceptors o f the developing eye exhibit the characteristic excessive proliferation and 
apoptosis which are associated with the inactivation o f pRb Such apoptosis is inhibited 
m a -negative background and in this case, the animals develop tumours instead The 
expression o f the adenovirus E l A protein in rat embryo fibroblasts stabilises and 
activates p53, the resulting cells die o f apoptosis Adenoviruses normally express the 
E1B-55 kD protein, which binds to p53 and blocks its transcription factor activity, and 
the E lB-19kD  protein, which acts like Bcl-2 to block apoptosis downstream o f p53  
activation
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EBV-negative BL cells which exhibit deregulated c-Myc expression as a result o f the t 
(8; 14) translocation proliferate rapidly in culture but readily undergo apoptosis under 
inappropriate conditions such as serum deprivation (Gregory, 1995). Expression o f 
LMP-1 or EBNA2 in these cell lines has been shown to have growth inhibitory and anti- 
apoptotic effects which may at least in part be a consequence o f downregulation o f c-Myc 
expression as a result o f downregulation o f transcription o f the adjacent translocated Ig-p. 
locus (Floettmann et al., 1996; Jochner et al., 1996). LMP-1 has also been demonstrated 
to protect Jurkat T cells from apoptosis induced by serum deprivation by downregulating 
the expression o f c-Myc (Kawanishi, 1997).
TGFp peptides belong to a family o f structurally related molecules with a variety o f 
biological functions including differentiation and apoptosis on a variety o f cell and tissue 
types including human B and T lymphocytes (reviewed in Aravanitakis et al., 1995). 
EBV-negative BL lines and EBV-positive BL lines with a group I phenotype are 
generally sensitive to the growth inhibitory effects o f TGF-p and this results from cells 
accumulating in G1 and undergoing apoptosis. However, EBV immortalised LCLs and 
EBV-positive BL lines that express all the latent viral proteins are resistant to the growth- 
inhibitory effects o f TGF-P (Altiok et al., 1993; MacDonald et al., 1996). Aravanitakis et 
al. (1995) were able to demonstrate that LMP-1 expression could independently 
reproduce the ability o f EBV to confer TGF-P-resistance on infected B-lymphocytes and 
group III BL lines by gene transfer into the EBV-negative BL cell line BL41. TGF-P is 
known to arrest cells in the mid- to late- G1 phase o f cell cycle in not only mitogen- 
activated human B-cells but also in non-lymphoid cell systems (reviewed in MacDonald 
et al., 1995; Chaouchi et al., 1995). This G1 arrest has been linked to an upregulation of 
at least three inhibitors o f cyclin-dependent kinases (cdks) namely, p l5 INK4B, p27KIP1 and 
p21WAF1 and in some cells to a downregulation o f cdk4 (reviewed in MacDonald et al., 
1996 and Hunter, 1993). Binding o f these inhibitors to cdk inhibits the formation o f cdk- 
cyclin complexes that are required for progression through the cell cycle. The inhibition 
o f cyclin D function leads to a block in phosphorylation o f the retinoblastoma gene 
product, pRb, and this in turn represses the activity o f the E2F family o f transcription 
factors, thus preventing cells from making the transition from G l- to S- phase o f the cell
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cycle The protection against TGF-P-induced G1 arrest afforded by LMP-1 was shown to 
be related to the induction o f cyclin D2 expression by LMP-1 leading to the maintenance 
o f pRb in the hyperphosphorylated state In the early G1 phase o f the cell cycle, the 
presence o f hypophosphorylated pRb is associated with transcriptional activation of 
cyclin D expression in normal cells (Taya et a l , 1997) D-type cyclins form complexes 
with cdk4 which then proceed to phosphorylate pRb and shut down cyclin D 
transcription, thus completing the feedback loop regulating progression from the G1 
phase to the S phase o f the cell cycle The maintenance o f pRb in the 
hyperphosphorylated state by LMP-1-thus leads to cell cycle progression regardless o f 
the negative growth regulatory signal imposed by TGF-P
Mutations and elevated expression o f p53 are two factors that can play a role in 
malignant transformation or tumour cell growth o f Burkitt’s lymphoma Mutations in p53 
have been found in approximately 33% o f BL biopsies and in at least 63% o f BL lines 
(Farrell et a l , 1991) In 65% of BL lines studies the wild-type allele is lost and the cells 
express the mutant p53 allele at elevated levels In general, single nucleotide 
substitutions which result in aminoacid changes are found BL cells with p53 lesions 
have been shown to be relatively resistant to DNA-damaging drugs such as cisplatin 
compared to those cell lines harbouring wild-type p53 (Allday et a l , 1995) Expression o f 
LMP-1 can however protect against wild-type p53-mediated apoptosis and this has been 
demonstrated in both the BL and epithelial cell contexts based on the usage o f cell lines 
expressing temperature-sensitive p53 In BL cells, protection by LMP-1 is most likely 
due to the induction o f Bcl-2 expression (Okan et a l , 1995) However, in the epithelial 
cells examined, protection against p53-mediated apoptosis was shown to be due to the 
induction o f A20 expression (Fries et a l , 1996) In both cases, protection by LMP-1 did 
not involve an effect on the transactivation function o f p53
1.8.2.1 EBV primes LCLs for apoptosis
c-Myc
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Activated peripheral blood B-cells ( IL-4 + anti-CD40 antibodies) cultured in 
vitro in the absence o f serum exhibit little DNA synthesis, accumulate in the Go/Gl 
phase o f the cell cycle and have a lower level o f c-myc expression compared to when 
grown in the continuous presence o f serum (reviewed in Chemey et al., 1994). However, 
EBV-immortalised lymphoblastoid cell lines grown under autocrine growth factor- 
deprived conditions (cultured under low-density conditions) exhibit apoptosis by day 3 o f 
growth (Allday, 1996). In fact, under such culture conditions, these cells continue to 
proliferate until apoptotic death and this change in growth properties is not accompanied 
by a change in the levels o f c-Myc protein (or even p53 or Bcl-2). These observations led 
to the suggestion that deregulation o f c-myc may mediate the apoptotic response o f the 
growth factor-deprived LCLs. Indeed, it was demonstrated that antisense 
oligonucleotides to c-myc specifically inhibited apoptosis in the growth factor-deprived 
LCLs but suppressed growth o f undeprived LCLs. These studies indicated that EBV 
latent gene expression must deregulate c-myc in B lymphocytes and this promotes both 
proliferation and apoptosis when there is a depletion o f autocrine growth factors 
(Chemey et al., 1994).
Studies based on the usage o f an LCL established with a recombinant EBV conditional 
for the expression o f EBNA-2, have shown that EBNA-2 is the likely EBV latent gene 
product responsible for deregulating c-Myc in LCLs. In this study by Kempkes et al. 
(1995), primary B-lymphocytes were infected with the recombinant virus such that in the 
presence o f estrogen, growth transformation o f the infected B-cells was achieved leading 
to the formation o f estrogen-dependent LCLs expressing EBNA2 (as a fusion protein 
with the hormone binding domain o f the estrogen receptor) in addition to the other EBV 
latent proteins. Removal o f estrogen resulted in about half o f the cells entering a 
quiescent non-proliferative state whereas the others underwent apoptotic death. Growth 
arrest occurred at both the G1 and G2 phases o f the cell cycle which is indicative o f a 
requirement o f EBNA-2 function at both o f these stages o f the cell cycle. However, only 
those cells arrested in G1 could be rescued into cell cycle on induction o f EBNA2, and 
this was shown to correlate with the induction o f c-Myc and LMP-1 expression, followed 
by the induction o f cyclin D2 (G1-specific cyclin) and cdk4 and then the phosphorylated
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form o f pRb Concomitant with the appearance o f the phosphorylated form o f pRb, the 
E2F transcription factor, (which is maintained inactive by binding to the 
hypophosphorylated form o f Rb and is required for DNA synthesis) became detectable 
This study therefore demonstrated that in LCLs, functional EBNA-2 is responsible not 
only for the induction and maintenance o f c-Myc in a deregulated state but also for 
proliferation In order to investigate if  this effect o f EBNA2 was due to an indirect effect 
on expression o f LMP-1, Zimber-Strobl et al (1996) have analysed the growth 
characteristics o f primary B-cell transfectants that constitutively expressed LMP-1 from a 
hetrologous promoter that was carried on a plasmid vector containing a conditional 
(estrogen-dependent) EBNA-2 allele in addition to the other wild-type latent EBV genes 
(Zimber-Strobl et a l , 1996) In the absence o f functional EBNA-2, it was found that 
LMP-1 was incapable o f sustaining B-cell proliferation (at levels o f expression similar to 
that observed in LCLs) but induced a phenotype consistent with prolonged cell viability 
Proliferation o f these transfectants resumed only in the presence o f functional EBNA-2 
Thus, it was demonstrated that LMP-1 is not sufficient to maintain proliferation o f B- 
cells in the absence o f EBNA-2 and that EBNA-2 acts beyond the upregulation o f LMP-1 
to maintain proliferation o f EBV-immortahsed B-cells perhaps by cooperating with other 
cellular and viral genes Studies in EBV-immortahsed B lymphocytes expressing a 
conditional LMP-1 have shown that the continuous expression o f LMP-1 is essential for 
proliferation (Kilger et a l , 1998)
A likely viral latent gene that may serve in the role o f cooperating with EBNA-2 in 
initiating and maintaining B-cells in cycle is EBNA-LP Resting B-cells, primed by 
CD21 cross-linking with the gp350 virus envelope protein to mimic virus infection and 
transfected with EBNA-2 and EBNA-LP expression vectors, enter and progress through 
the cell cycle and this ability o f EBNA-2 and EBNA-LP is correlated with their ability to 
induce the synthesis o f cyclin D2 (Sinclair et al, 1994) Expression o f both EBNA-2 and 
EBNA-LP were required for this effect Thus, by inducing cychnD2 synthesis, EBNA-2 
and EBNA-LP cooperate to induce a GO to G1 transition In this relation it is interesting 
to note that following EBV infection o f resting primary B-cells, EBNA-2 and EBNA-LP 
are the first viral latent proteins to be expressed and that too in a coordinate fashion
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Studies by Kitay and Rowe have shown that EBNA-LP is phosphorylated throughout the 
cell cycle, but the extent o f phosphorylation is increased during G2 phase and is maximal 
at the G2/M transition (Kitay and Rowe, 1996). Moreover, in vitro studies have shown 
that EBNA-LP can interact with p53 and pRb, two proteins known to play important 
roles in cell-cycle regulation. The significance o f these latter observations are not known 
since EBNA-LP does not alter the function o f these molecules when bound (Szekely et 
a l ,  1993).
Investigations aimed at assessing the integrity o f the p53/p21w af-l/ pRb/E2F 
pathway in B-cells immortalised by EBV have led to the same conclusion as that o f the 
influence o f EBV infection on c-myc expression in B-cells: EBV infection o f B-cells 
primes the cells for apoptosis. Resting primary B-cells are essentially p53-negative 
(Allday et al., 1995). Some o f these cells spontaneously undergo apoptosis when placed 
in culture, through a p53-independent pathway. Normal peripheral B-cells treated with 
IL-4 and anti-CD40 are activated into proliferation and accumulate p53. EBV infection o f 
resting B-cells similarly rescues them from spontaneous cell death and this process is also 
accompanied by an acumulation o f p53 (Allday et al., 1995). In the case o f EBV- 
infected B-cells, accumulation o f p53 requires viral gene expresssion (infection with UV 
-inactivated virus did not result in p53 accumulation) and it has been shown by Chen and 
Cooper (1996) that EBNA-2 and LMP-1 can independently transactivate p53. While IL- 
4/anti-CD40-activated B-cells respond to the DNA-damaging agent cisplatin by ceasing 
DNA synthesis (growth arrest), LCLs, respond with apoptosis (Allday et al., 1995). 
Cisplatin-treatment o f either IL-4/anti-CD40 activated B-cells or LCLs led to an 
elevation o f p53 levels with similar kinetics. p53 accumulation in cisplatin-treated LCLs 
was shown to be due to post-translational modification leading to enhanced stability. 
Also, cisplatin-treatment o f the LCLs did not alter Bcl-2 expression or the heterodimeric 
partner o f Bcl-2, Bax (which is also known to be transcriptionally activated by p53 in 
some cell types). Ectopic expression o f p53 in LCLs results in spontaneous apoptosis, 
indicating that the cisplatin-induced apoptosis observed in the LCLs is likely to be due to 
the increased accumulation o f p53. Furthermore, in the latter experiment, in the cells
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proceeding towards apoptosis, transcriptional activation o f ^ 2 \ WAF''  by p53 correlated 
with the presence o f dephosphorylated pRb In normal fibroblasts, cisplatin-treatment 
correlates with the presence o f hypophosphorylated pRb and G1-arrest since the cells are 
unable to proceed into S-phase (reviewed in Allday, 1995) However, the observation 
that the presence o f hypophosphorylated pRb correlates with apoptosis in LCLs suggests 
that EBV must encode a function which enables the G l/S  restriction point to be 
overcome and thus allow progression through the cell cycle, converting the p53 arrest 
response to apoptosis (Levine, 1997) Candidate mechanisms by which EBV may 
overcome the G l/S  restriction point include deregulation o f c-myc or utility o f a virally- 
encoded E l A-like function which generates high levels o f transcriptionally active E2F
1.8.3 EBV lytic proteins encode anti-apoptotic functions
Unlike most viruses, EBV maintains a very stable persistent infection in vivo (Rowe el 
a l , 1992) Another state in which EBV may be found is in the process o f active 
replication and the production o f progeny virions, this is the lytic cycle Virus production 
is generally accepted to preceed replication o f viral DNA (Allday, 1996) This may be 
sensed by the host cell as damaged DNA and the p53 checkpoint response could then be 
activated If the cells are driven to proliferate by EBV (as in type III latency) then 
apoptosis will be the most likely outcome In this situation additional repressors o f 
apoptosis can provide a selective advantage Consistent with this model, there are at least 
two known virally encoded proteins, BHRF-1 and BZLF-1, that are synthesised during 
the lytic cycle that can provide a survival advantage to the infected cell (Allday, 1996) 
These lytic gene products can therefore delay apoptosis in order to maximise viral 
production Expression o f BHRF-1 in epithelial cells has been shown to confer enhanced 
resistance to cisplatin-induced apoptosis and can also inhibit differentiation (Dawson el 
a l , 1990, 1995) In lymphoid cells, BZLF-1 has been shown to interact with p53 and 
inhibit its transactivating function, thereby providing a mechanism for preventing p53- 
mediated apoptosis (Zhang et a l , 1994b) However, in epithelial cells, expression o f this 
EBV protein was shown to result in growth arrest without inhibiting the transactivating 
function o f p53 (Cayrol and Flemmington, 1996)
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calcium, but not inositol triphosphate, have been reported in LM P-1 transfectants o f a B 
lymphoma cell line and LMP-1 has also been shown to induce a calcium/calmodulin- 
dependent kinase in the same line (Wang et al., 1988b; Mosialos et al., 1994). LMP-1 
has also been shown to upregulate the expression o f matrix metalloproteinase 9 (MMP-9) 
and CD44, two proteins which are associated with increased invasiveness/ metastatis o f 
tumours (Yoshizaki et al., 1998; Gregory, 1995; Sneath and Mangham, 1998).
Constitutive LMP1 expression in EBV-immortalised B cells carrying a conditional 
(estrogen-regulatable) EBNA-2 gene has provided evidence that LMP1 in the absence o f 
functional EBNA2 was incapable o f sustaining B-cell proliferation (at levels o f 
expression similar to that observed in LCLs) but induced a phenotype consistent with 
prolonged cell viability (Zimber-Strobl et al., 1996). Proliferation o f these transfectants 
resumed only in the presence o f functional EBNA-2. Studies involving conditional 
expression o f LMP-1 in EBV-immortalised B cells (expressing all o f the other latent 
genes) have revealed that LMP-1 expression was required for continuous proliferation. 
In the absence o f LMP-1 expression, these cells remained in a resting state (Kilger et al.,
1998). Although expression o f LMP-1 as the sole EBV gene can induce DNA synthesis 
in primary B-cells (Peng and Lundgren, 1992, Zimber-Strobl et al., 1996), the inability to 
sustain proliferation was shown to be due to the inabiltiy o f the cells to progress through 
S phase (Zimber-Strobl et al., 1996). In studies with established EBV-negative BL cell 
lines in which expression o f LMP-1 was regulated by tetracycline, induction o f LMP-1 
expression resulted in a transient cytostatic effect due to an accumulation o f cells at the 
G2/M phase o f the cell cycle and a decrease in c-Myc expression (Floettmann et al., 
1996).
Transfection studies with LMP-1 deletion mutants indicate that the cytoplasmic amino 
terminus is not responsible for the activating effects, the transmembrane domains are 
critical, due to their importance for LMP1 aggregation in the plasma membrane, and the 
carboxy-terminal domain is essential (Wang et al., 1988b; Martin and Sugden, 1991; 
Moorthy and Thorley-Lawson, 1993a; 1993b). As expected, EBV recombinants lacking 
LMP1 were unable to induce growth transformation o f primary B cells (Kaye et a l ,
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1993) Further experiments with EBV recombinants carrying deletion mutants o f LMP-1 
have shown that the transmembrane domain and the membrane proximal carboxy- 
termmal region are the principal LMP-1 components that mediate primary B-lymphocyte 
growth transformation while the distal region (last 155 ammo acids) o f the carboxy 
terminal region is critical for LCL outgrowth (Izumi et a l , 1994, 1997, Izumi and Kieff, 
1997, Kaye et a l , 1993, 1995, 1999)
Genetic and biochemical data indicate that LMP-1 is equivalent to a constitutively 
activated receptor o f the tumour necrosis Factor receptor (TNFR) family requiring 
oligomerisation for its activity in the absence o f ligand (Floettmann and Rowe, 1997, 
Hatzivassiliou et a l , 1998, Izumi and Kieff, 1997, Kilger et a l , 1998, Mosialos et a l ,
1995, Gires et a l , 1997) Members o f the TNFR superfamily including TNFR, IL-1R, 
CD40, CD30, LMP-1 and lymphotoxin-P receptor exert a number o f effects including 
regulation o f apoptosis and stress responses via signaling pathways that involve 
recruitment o f adapter proteins called TNF receptor associated factors or TRAFs (Arch et 
a l , 1998, Baker and Reddy, 1996) Mutational analysis has identified two functional 
domains in the carboxy terminus o f LMP-1 CTAR (carboxy-terminal activation region)- 
1 or TES (Transformation effector site)-1 (residues 187-231) and CTAR-2/TES-2 
(residues 351-386) (Huen et a l , 1995, Mitchell and Sugden, 1995) (Figure 1 7) CTAR-1 
engages the tumour necrosis factor receptor family-associated factors (TRAFs) through a 
TRAF interaction domain located within this region (Kaye et a l , 1996, Devergne et a l ,
1996, 1998, Ehopoulos et a l , 1997, Miller et a l , 1997, 1998, Brodeur et a l , 1997, 
Sandberg et a l , 1997) In EBV-transformed B cells or transiently transfected BL cells, 
TRAF-1, -2, -3, and -5  are associated with LMP-1 with engagement o f TRAF-2 
occurring largely via TRAF1 as TRAF1-TRAF2 heterodimers However, in epithelial 
cells, very little TRAF-1 is expressed and only TRAF-2, -3 and -5  are significantly 
complexed with LMP-1 Critical to the association o f TRAFs with LMP1 is a 
P204xQ206xT208 m otif located within CTAR-1 Unlike CTAR-1, CTAR-2 does not 
directly interact with TRAFs However, LMP-1 associates with the tumour necrosis 
factor receptor adaptor protein TRADD (Izumi and Kieff, 1997) as well as receptor 
interacting protein RIP (Izumi et a l , 1999) and it is via these adaptor proteins that
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CTAR-2 is thought to recruit TRAF proteins In contrast to TNFR1, LMP1 does not 
associate with the death domain (carboxy-terminus) o f TRADD but with the N-terminus 
(Kieser et a l , 1999)
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Figure 1 7 Schem atic diagram o f LM P-1 LMP1 consists o f a 24-aminoacid N-terminal cytoplasmic 
domain, six transmembrane domains and a 200 ammo acid C-terminal cytoplasmic tail LMP-1 
constitutively aggregates in the plasma membrane and associates with TRAFs via the P204xQ206xT208 
m otif in TES (Transformation Effector S ite)-1 or CTAR (Carboxy terminal activation region)-l (residues 
187 -  231) and with TRADD and RIP via the y 384Y385D386 m otif in TES-2 or CTAR-2 (residues 352 -  
386) The region between ammoacids 275 and 307 o f  LMP-1 is responsible for activation o f  JAK3 
A dapted from  Izumi et a l , 1999
One o f the first signaling functions assigned to LMP-1 is activation o f the transcription 
factor, NF-kB and this function could be demonstrated in both B and T-lymphocytes and 
epithelial cells (Hammarskjöld and Simurda, 1992, Huen et a l , 1995, Mitchell and 
Sugden, 1995) With the discovery that LMP-1 associates with the TRAF signaling 
molecules and exhibits similar functions to members o f the TNF-superfamily, deeper 
insight into the mechanism o f activation o f NF-kB by this EBV protein have been 
realised Thus, CTAR1 was demonstrated to mediate 20-40% o f the total activation o f 
NF-kB by LMP-1 while CTAR-2 makes a greater contribution (60-80%) in this effect in 
different cell types Furthermore, TRAF-2 has been shown to be an important mediator 
o f NF-kB activation by both domains TRAF-3 on the other hand has been shown to act
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as a negative modulator o f NF-kB activation by LMP-1 by displacing TRAF-1 and 
TRAF-2 (Kaye et a l , 1996, Devergne et a l , 1996) Although the association o f CTAR-2 
with TRADD is required for NF-kB activation by this region, the association with RIP is 
not (Izumi et a l , 1999) The residues between positions 384 to 386 (YYD) o f LMP-1 are 
critical to the association o f TRADD and RIP to CTAR2 as well as NF-kB activation and 
LCL outgrowth (Izumi et a l , 1997, 1999) Constitutive association o f TRAFs and 
TRADD with the carboxy-terminal region o f LMP-1 and NF-kB activation is dependent 
on ligand-independent aggregation o f LMP-1 (Gires et a l , 1997, Devergne et a l , 1996, 
Izumi and Kieff, 1997) TRAF3 has been shown to mediate the effect o f LMP-1 on 
growth inhibition o f epithelial cells (Ehopoulos et a l , 1996) and is implicated in 
association o f LMP1 with the cytoskeleton (Higuchi et a l , 2001)
The pathway downstream o f TRAF-binding to CTAR-1 and TRADD binding to CTAR-2 
leading to NF-kB activation has been partially deciphered and is similar to the TNFR 
signaling pathway (Sylla et a l , 1998) (Figure 1 8) Aggregation o f TRAF-2 recruited to 
activated LMP-1 somehow leads to activation o f the NF-KB-inducing kinase (NIK) 
which in turn activates IKK (iKBa-kinase)- a  and -p IK K a and IKKp then 
phosphorylate Ik B cc which is then ubiquinated and degraded releasing active NF-kB 
The NIK-IKKa -IKK -P association is thought to occur in a complex separate but 
neighbouring to that o f LMP-1-TRAF-TRADD (Sylla et a l , 1998)
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Figure 1 8 Schem atic diagram of aggregated LMP1 m the cell plasma membrane showing the 
pathway involved in activation o f NF-kB downstream o f TRAF2 TRAF1, TRAF2 and TRAF3 
constitutively associate with the LMP-1-proximal NF-KB-activating region, CTAR-1 TRADD 
constitutively associates with the LMP-1 distal and major NF-xB-activating region, CTAR2 Aggregation 
o f  TRAF2 most likely activates N IK  which in turn phosphorylates and activates IK K a and IKKp IK K a 
and IKK(3 then phosphorylate IkB cc, leading to its ubiquitination and degradation and N F-kB  activation 
Adaptedfrom Sylla et al, 1998
CTAR-2 but not CTAR-1 is also responsible for the activation o f the JNK (c-jun N-
termmal kinase)-l pathway by LMP-1 which leads to activation o f the c-Jun-N-terminus
component o f the transcription factor AP-1 (Kieser et a l , 1997, 1999, Ehopoulos and
Young, 1998) While SEK (stress enhanced kinase)-1 has been shown to mediate
activation o f JNK1 by LMP-1 (Kieser et a l , 1997, Ehopoulos and Young, 1998), the
components o f the pathway upstream of SEK1 are unknown and does not include MEK
kinase (a mitogen activated protein kinase kinase kinase) (Kieser et a l , 1997) However,
there is controversy over the involvement o f TRADD/TRAF2 in the signaling pathway
from the CTAR2 domain o f LMP1 to JNK1 Thus, while Ehopoulos et al (1999), have
demonstrated the involvement o f TRADD/TRAF2 in LMP1-mediated signaling to the
JNK pathway, the study o f Kieser et al (1999) demonstrates otherwise It is likely that
this discrepancy is due to the differences in the methodology used (different TRAF2
dominant negative mutants and usage o f a TRADD mutant in one case and not in the
other) The activation o f AP-1 has been shown to also be required for the effect o f LMP-1
expression on upregulating MMP-9 (Takeshita el a l , 1999) LMP-1 can also activate the
p38 M APK (mitogen-activated protein kinase) pathway and both CTAR-1 and CTAR-2
are responsible for mediating this effect in a TRAF2-dependent manner (Ehopoulos et
a l , 1999) This pathway is responsible for the upregulation o f IL-6 and IL-8 production
by LMP-1 in epithelial cells A third functional domain o f LMP-1, CTAR3, has recently
been identified which localises to a region o f the carboxy terminus o f LMP-1 (aa 275-
307) between CTAR-1 and CTAR-2 (Figure 1 7) This domain is responsible for the
interaction o f LMP-1 with Janus kinase (JAK)-3 which in turn activates STAT (signal
transducers and activators o f transcription) proteins (Gires et a l , 1999) However,
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activation o f JAK 3 may also require interaction between CTAR1 or CTAR2 and CTAR3 
(Brennan et a l , 2001) Activation o f the p21-Rho-hke GTP-ase cdc-42 in fibroblasts has 
been identified as yet another signaling function o f LMP-1, however, this function maps 
to the transmembrane domains o f LMP-1 and unlike the TNFR1 signaling pathway is not 
responsible for mediating LMP-1 signaling to JNK (Gires et a l , 1999) LMP-1 has also 
been shown to mediate activation o f a Ras-MAPK-dependent pathway and this activity is 
required for cellular transformation (Roberts and Cooper, 1998)
There appear to be cell-type-specific differences in the effects o f induction o f LMP-1 
For instance, upregulation o f Bcl-2 expression by LMP-1 appears to be a B-cell 
dependent effect and that too in a Bcl-2-negative context (Henderson et a l , 1991, Martin 
et a l , 1993) Thus, whilst LMP-1 has been shown to upregulate Bcl-2 expression in 
EBV-negative BL lines which express low to negligible levels o f Bcl-2 protein, such an 
effect is not evident in epithelial cells Also, the observation that EBV infection or LMP- 
1 expression in peripheral B lymphocytes (which constitutively express Bcl-2) does not 
lead to significant upregulation o f Bcl-2 has led to the suggestion that the function o f 
LMP-1 in this cellular context may be to maintain rather than induce Bcl-2 levels (Martin 
et a l , 1993) LMP-1 has also been shown to upregulate IL-6 and IL-8 expression in 
epithelial cells in an NF-kB- and p38MAPK- dependent manner (Ehopoulos et a l , 1997,
1999) Expression o f LMP-1 has been shown to block morphological differentiation o f 
epithelial cells suggesting that the expression o f this EBV protein may participate in the 
development o f EBV-associated epithelial malignancy such as NPC via a mechanism 
different from that observed in B-cell or fibroblast transformation, that o f deregulation o f 
morphological differentiation (Dawson et a l , 1990) LMP1 can also induce expression o f 
the epidermal growth factor receptor (EGFR) in epithelial cells and although this function 
maps to CTAR1 it is independent o f NF-kB activation (Miller et a l , 1995) Also, the 
ability o f LMP-1 to upregulate the expression o f proteins CD44 and MMP-9 suggests that 
this EBV protein may not only be involved in transformation but also promoting tumour 
spread (Gregory, 1995, Yoshizaki et a l , 1998)
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Transcription o f LMP1 can be regulated by EBV gene products including EBNA2, 
EBNALP and BARFO (Harada and Kieff, 1997; Kusano and Raab-Traub, 2001) through 
elements present within its promoter region and each o f these may serve as an alternative 
route to inducing LMP1 expression. Thus, many o f the effects o f  these gene products 
may be indirect and mediated by regulation o f the expression o f LMP1.
1.6.6 LM P2A  AND 2B
The genes encoding LMP2A and 2B have also been named terminal protein 1 and 
terminal protein 2 (TP1, TP2), because they are transcribed across the terminal repeat 
sequences o f the linear viral genome o f which are fused together upon infection to 
generate the intracellular episomal form o f the viral genome (Laux et al., 1988; Sample et 
al., 1989). The two messages consist o f different 5’ exons and eight common exons and 
are predicted to encode nearly identical proteins differing only in the length o f their 
hydrophilic amino termini (Ring, 1994). Transcription o f the LMP2A starts 3 kb. 
downstream o f the LMP1 transcription start site (Laux et al., 1988; Sample et al., 1989). 
The LMP2B and LMP1 promoters form bi-directional transcription units containing a 
common EBNA2 responsive element, while a separate EBNA2 response element 
regulates LMP2A transcription (Zimber-Strobl, et al., 1993). LMP2A and 2B are 54 and 
40 kDa in size respectively. Both proteins are predicted to encode twelve highly 
hydrophobic membrane spanning domains and are localized to patches in the plasma 
membrane o f infected cells, in close association with LMP1 (Longnecker and Kieff,
1990). LMP2A and 2B are not required for EBV mediated immortalization, but LMP 2A 
appears to be important for maintaining viral latency (Longnecker et al., 1992; Brielmeir 
et al., 1996; Freuhling et al., 1998, Longnecker and Miller, 1996). The LMP2 proteins 
are phosphorylated on serine, threonine and tyrosine residues (Longnecker et al., 1991) 
and have been shown to interact with src-family tyrosine kinases in EBV-infected B cells 
(Burkhardt et al., 1992). However, in epithelial cells, LMP2A does not appear to be 
phosphorylated by src kinases but by Csk (Scholle et al., 1999). The LMP2s are also 
associated with another stably phosphorylated tyrosine kinase sky. These interactions 
suggest that the LMP2s play a role in transmembrane signal transduction (Kieff, 1996).
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LMP2A has been shown to inhibit anti-immunoglobuhn-mediated Ca2+ mobilization, 
PLCy2 activation and anti-immunoglobuhn-mduced reactivation o f the lytic cycle, which 
can be bypassed by TPA and calcium íonophores (Miller et a l , 1994, 1995a) These data 
are consistent with a model in which LMP2A sequesters the B-cell receptor-associated 
tyrosine kinase, blocking its autophosphorylation and downstream signalling events 
(Miller et a l , 1995a) LMP2A and LMP2B singly or LMP1/LMP2A coexpressed are 
capable o f altering keratinocyte cell adhesion molecule expression (Farwell et a l , 1999) 
In vivo studies indicate that LMP2A allows B-cell survival m the absence o f normal B- 
cell receptor signals (Merchant et a l , 2000) Although LMP2A can activate the protein 
kmase Akt in a phosphatidyl-mositol-3-kinase (PI3-K)-dependent pathway in an EBV- 
negative BL line, this well known regulator o f cell survival in B lymphocytes does not 
appear to mediate the cell survival effect o f LMP 2A (Swart et a l , 2000) The activation 
o f the PI3-kmase-Akt pathway by LMP2A has been demonstrated to contribute to the 
ability o f this latent protein to transform epithelial cells and inhibit differentiation 
(Scholle et a l , 2000)
1.6.7 EBV ENCODED RNAS (EBERS)
The two EBV-encoded, small nonpolyadenylated RNAs, EBER1 and EBER2, are by far 
the most abundant EBV RNAs in latently infected cells (Kieff, 1996) They are usually 
transcribed by RNA polymerase III although polymerase II may also be involved Most 
EBERs are located in the nucleus and are associated at the 3 ’ terminus with the cellular 
La antigen (Howe and Steiz, 1986, Howe and Shu, 1989) EBER 1 and 2 have extensive 
sequence similarity to adenovirus VA1 and VA2 and cell U6 small RNAs, both o f which 
form similar secondary structures and complex with La protein (Rosa et a l , 1981, 
Glickman et a l , 1988) Stable expression o f EBERs in the EBV-negative BL cell line, 
Akata, at levels comparable to those in EBV-positive cells, was found to confer enhanced 
tumorigemc potential (Komano et a l , 1999, R uf et a l , 2000) The function o f the 
EBERs is unclear but by analogy to the VA and U6 RNAs two alternative roles have 
been proposed for the EBERs In adenovirus infection VA1 RNA acts in the cytoplasm 
to directly inhibit activation o f an interferon-induced protein kinase, which blocks
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transcription by phosphorylating the protein-synthesis initiator factor eIF-2a. EBER1 
and 2 can partially complement the replication o f an adenovirus with null mutation in 
VAI and VAII, but their effect on eIF-2a, kinase activity is significantly less and they are 
not found in the cytoplasm (Kieff, 1996). Both o f the proposed functions o f EBERs are 
somewhat incompatible with the observation that their expression is delayed until after 
EBNA and LMP gene expression and initiation o f DNA synthesis (Alfieri et al., 1991). 
Nevertheless, the earlier events in primary B-cell infection are sensitive to interferon 
(IFN) and EBERs may play a role in blocking eIF-2 kinase (Thorley-Lawson,1980; 
1981).
1.7 GENES OF THE LYTIC VIRAL CYCLE
Only a small fraction o f latently infected B-lymphocytes spontaneously enter the 
productive cycle and in these cells the viral DNA is amplified several hundred fold by a 
lytic origin o f DNA replication, ori Lyt (Hammerschmidt and Sugden, 1988). EBV lytic 
infection is usually induced in vitro by chemicals (Luka et al., 1979; Saemundsen et al., 
1980). Phorbol esters are among the most reproducible and most broadly applicable 
inducers, their effect is probably mediated by protein kinase C activation o f Jun-Fos 
interactions with AP-1 sites upstream o f the immediate early virus genes (Farell et al., 
1983; 1989; Farell 1992; Laux et al., 1988). The Akata cell line which carries an 
LMP2A-deleted virus can be induced by cross-linking o f surface immumoglobulins (slg) 
to the extent that more than 50% o f the cells enter the lytic cycle (Takada, 1984; Takada 
and Ono; 1989). A second approach to investigating viral replication is to induce the 
lytic cycle by superinfection o f Raji cells with defective EBV from the P3HR-1 cell line 
(Mueller-Lantzch et al., 1980). Raji is an EBV-positive BL cell with an unusually high 
EBV episome copy number. This cell line is defective for DNA replication and late gene 
expression and infection is thus tightly latent (Polack et al., 1984). Defective virions 
from P3HR-1 contain rearranged DNA molecules in which the intermediate early trans­
activator o f lytic cycle are expressed after superinfection (Cho et al., 1984; Miller et al., 
1984). Studies with such cell lines has allowed the division o f EBV replicative proteins 
into early antigens (EA), membrane antigens (MA) and virus capsid antigens (VCA)
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(Figure 1 9) Early antigens are further subdivided into EA-D (diffuse) and EA-R 
(restricted) due to a different sensitivity to methanol fixation (Henle et a l , 1971a, 1971b) 
After induction, cells that have become permissive to viral replication undergo cytopathic 
changes characteristic o f herpesviruses, including migration o f nuclear chromatin, 
synthesis o f viral DNA, assembly o f nucleocapsids, envelopment o f the virus by budding 
through the inner nuclear membrane and inhibition o f host macromolecular synthesis 
(IARC Monograph, 1997)
CA ORT
HBV DNA polymerase BALF5
thym idine Kirust- BXLF1
Ribonuclcotide reductase BORF2 & BARF1
Alkaline Dnase BGLF5
DNA binding protein p i 88 BALF2
MA ORT
gp3 SO/220 BLLF1
BP 150 BDLF3
gpl 10 BALF4
gp85 BXLF2
gP78 BILF2
gp42 BZLF2
BP2< BKRF2
Figure 1 9 A schem atic representation o f early and late EBV gene expression The VCA, the MA and
the EA are illustrated and their open reading frames are written in bold
Virus gene expression follows a temporal and sequential order (Farrell, 1992, Takada and 
Ono, 1989) Some virus genes are expressed independently o f new protein synthesis, 
early after induction and are classified as immediate early genes Early lytic virus genes
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are expressed slightly later and their expression is not affected by inhibition o f viral DNA 
synthesis (Kieff, 1996)
1.7.1 Immediate early genes
After P3HR-1 superinfection o f Raji or slg cross-linking o f Akata cells in the presence o f 
protein synthesis inhibitors, three leftward mRNAs are transcribed The BZLF1, BRLF1 
and BL’LF4 encoded proteins are potent transactivators o f early EBV lytic gene 
expression (Takada and Ono, 1989, Marschall et a l , 1991, Kieff, 1996) B Z L F l’s 
functional and physical interaction with NFkB is an important regulator o f LMP1- 
mediated effects in latent infection BZLF1 can also downregulate the EBNA Cp 
promoter perhaps facilitating the transition from latent to lytic infection (Kenney et a l , 
1989, Sinclair et a l , 1992)
1.7.2 Early genes
The early genes are expressed when lytic cycle is induced in the presence o f inhibitors o f 
DNA synthesis By this criterion at least 30 EBV mRNAs are early gene products 
(Hummel and Kieff, 1982, Baer et a l , 1984) Two very abundant early proteins have 
been mapped to specific DNA sequences The BALF2 protein is homologous to a HSV 
DNA binding protein and is important in DNA replication (Hummel and Kieff, 1982, 
Kieff, 1996) The BHRF1 protein which is expressed in moderate abundance, has 
extensive colhnear homology with bcl-2 (Pearson et a l , 1983, Austin et a l , 1988) 
BHRF1 can protect EBV negative BL cells from apoptosis (Me Carthy et a l , 1996) 
However, EBV recombinants lacking the BHRF1 ORF are fully capable o f initiating and 
maintain cell growth transformation and they can also enter the lytic cycle and produce 
virus (Lee and Yates, 1992, Marchim et a l , 1991) Several o f the early genes are linked 
to DNA replication as indicated in Figure 1 9 Transfection experiments indicate that 
some o f these genes are activated in the process o f cell differentiation in the absence o f 
other viral gene products, suggesting a possible role o f cellular factors in regulating the 
productive cycle, at least in certain cell types (Marschall et a l , 1991).
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1.7.3 LATE GENES
The late genes code for structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress (IARC Monograph, 1997) Among the 
non-glycoproteins the major nucleocapsid protein is encoded by BCLF1, BNRF1 encodes 
the major external nonglycoprotein o f the virion and BXRF1 is likely to encode a basic 
core protein The BFRF3 ORF encodes the tegument protein, (Figure 1 1) and VC A p i 8, 
which is strongly immunogenic in humans (Kieff, 1996) The genes encoding the EBV 
glycoproteins are illustrated in bold figure 1 9 The late BCRF1 gene which is located in 
the middle o f the EBNA regulatory domain between on-P  and Cp, is a close homolog o f 
the human IL-10 gene, with nearly 90% colhnear identity in amino-acid sequence (Moore 
et a l , 1990, Vieira et a l , 1991, Touitou et a l , 1996) BCRF1 has most o f  the activity o f 
human IL-10, including negative regulation o f macrophages and NK cell functions and 
inhibition o f IFN y production Thus, virally expressed IL-10 may have a local effect on 
these responses to reactivate infection (IARC Monograph, 1997)
1.8 ROLE OF APOPTOSIS IN EBV BIOLOGY
While the process o f apoptosis is a genetically controlled pre-programmed event o f cell 
death that eliminates cells during development when they have become redundant, it also 
functions as an emergency response to various agents including radiation damage, 
aberrant growth induced by the activation o f oncogenes and viral infection In the case o f 
virus-infected cells, the induction o f early cell death would severely limit virus 
production and severely reduce or eliminate spread o f progeny virus in the host (Shen and 
Shenk, 1995) Thus, many viruses have evolved strategies to evade or delay early 
apoptosis to allow persistence in the host and production o f high yields o f progeny virus 
W ithin the last few years, both the biochemical basis o f apoptosis and its regulation by 
some viral products have become clearer For example, part o f the apoptotic program 
includes the induction o f cellular endonucleases which could target replicating viral DNA 
and prevent virus production at a very early stage In order to combat such host cell
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responses to infection many viruses have evolved genes that either themselves encode 
proteins or effect the expression o f host cell apoptosis-related proteins that efficiently 
suppress the apoptotic program In addition, many viruses are now known to induce 
apoptosis actively at late stages o f infection This process may represent a final and 
important step in the spread o f progeny to neighbouring cells while also evading host 
immune inflammatory responses and protecting progeny virus from host enzymes and 
antibodies Such virally-induced apoptosis may also contribute to some clinical 
manifestations and cytotoxicity associated with many human diseases o f viral origin 
(Shen and Shenk, 1995)
EBV is unique in that it uses both pro- and anti-apoptotic properties to its advantage in its 
life cycle This virus is able to effectively utilise these properties by either regulating the 
host cell apoptotic death machinery or encoding gene products that function similarly to 
anti-apoptotic proteins o f the host cell In the life cycle o f EBV, protection against 
apoptosis serves two purposes Firstly, as a mechanism that ensures its persistence in the 
host m the memory B-cell compartment by mimicking the normal process o f B- 
lymphocyte selection in germinal centers Secondly, the expression o f particular virally 
encoded proteins m the lytic phase delays/suppresses cell death until sufficient progeny 
virions are made
1.8.1 EBV induces the expression of anti-apoptotic proteins
EBV-negative BL cells and type I BL cell lines phenotypically resemble germinal center 
B-lymphocytes (Gregory, 1995) This resemblance includes their ability to undergo 
apoptosis in the face o f diverse stimuli including serum deprivation and calcium 
lonophore On the other hand, type III EBV-positive BL lines that express the entire 
complement o f latent proteins, display increased resistance to apoptosis (Gregory et a l , 
1991) These observations prompted further studies aimed at understanding the molecular 
basis o f the protection from apoptosis conferred by EBV to the BL cell lines Thus, it 
was found that the apoptosis-sensitive EBV-positive group I BL lines (and primary BL 
cells) also have little or no detectable Bcl-2 expression, while the apoptosis resistant
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group III BL lines were found to be Bcl-2-positive (Henderson et a l , 1991) 
Identification o f a candidate latent protein encoded by the EBV genome that may be 
responsible for the upregulation o f Bcl-2 observed in the group III BL cells was achieved 
when clear correlations were found between LMP-1 expression and protection from 
apoptosis on the one hand and on the other hand between LMP-1 expression and 
upregulation o f Bcl-2 expression in LMP-1- (but not EBNA-1-, EBNA-2-, EBNA-LP- or 
LMP-2-) transfectants derived from EBV-negative BL cell lines (Henderson et a l , 1991) 
This study also reported that EBNA-2 can augment the effect o f LMP-1 expression on 
induction o f Bcl-2 in dual transfection experiments o f BJAB-cells (Henderson et a l ,
1991) In another study, Martin et al (1993) reported the effect o f ectopic expression o f 
EBNA-2 on induction o f Bcl-2 protein in transient transfection experiments o f BJAB- 
cells, however, coexpression o f the LMP-1 and EBNA-2 genes did not result in 
significantly higher levels o f Bcl-2 expression than did either gene alone in these cells 
The induction o f Bcl-2 expression by LMP-1 has been shown to be a delayed response 
relative to its effects on NF-kB activation and upregulation o f several adhesion molecules 
Studies with cell lines in which LMP-1 is under inducible control or expressed transiently 
have shown that maximum upregulation o f Bcl-2 occurs 48-72 h post-induction o f LMP- 
1 (Rowe et a l , 1994, Wang et a l , 1996) There is also evidence that EBNA3B (EBNA4) 
can upregulate Bcl-2 expression in an EBV-negative cell line (Silins and Sculley, 1995)
W hile expression o f LMP-1 can induce Bcl-2 expression in group I BL lines and protect 
them from apoptosis, EBV infection o f primary B-cells does not significantly increase 
Bcl-2 levels despite the fact that LMP-1 is expressed in the infected cells (Martin et a l ,
1993) Compared to EBV-negative or group I BL lines, primary B lymphocytes express 
significant amount o f Bcl-2 and it has therefore been suggested that induction o f Bcl-2 
expression by EBV (or LMP-1) may not be relevant in a Bcl-2-positive cellular context 
such as exists m peripheral B-lymphocytes Furthermore, it is possible that there is some 
cellular control on the levels o f expression o f Bcl-2 in peripheral B-lymphocytes, perhaps 
a negative feedback mechanism as occurs in the case o f the A20 protein (Song et a l , 
1996) The role o f LMP-1 in LCLs, therefore, may not be to induce, but rather to 
maintain, the high constitutive level o f Bcl-2 that is found in the uninfected peripheral B-
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cells The observation that LM P-1 -  mediated upregulation o f Bcl-2 expression may be 
more relevant in a Bcl-2-negative cellular context also applies to epithelial and T cell 
lines since studies have shown that ectopic expression o f LM P-1 in these cell lines does 
not further upregulate the constitutive Bcl-2 levels (Rowe et a l , 1994, Kawanishi, 1997)
Overexpression o f Bcl-2 m group I BL cell lines following bcl-2 gene transfer results in a 
change in the behaviour o f the cells in apoptosis assays towards that o f group III lines 
(Henderson et a l , 1991, Milner et a l , 1992) These 6c/-2-transfectants display reduced 
apoptotic responses following serum starvation, calcium lonophore treatment or anti- 
smlg stimulation, the inhibition o f cell death being proportional to the amount o f Bcl-2 
protein (Milner et a l , 1992) Interestingly, in a panel o f group I, group l/bcl-2 (bcl-2 
transfectants o f group I cell lines), and group III sublines from the same BL parental line, 
it was found that, for the three different apoptosis triggers, the degree o f protection 
imparted by the group III phenotype far outweighed that apparent from the levels o f Bcl- 
2 protein measured in the group III cells Since there were no gross differences observed 
between the distribution o f Bcl-2 in the group I transfectants and the group III 
transfectants, these observations were interpreted to mean that either, in a group I cell, 
Bcl-2 function is antagonised or one or more additional Bcl-2-mdependent survival- 
pathways are operational in group III cells In so far as the first possibility is concerned, 
bcl-2 homologs, bax and bcl-xS, which can suppress Bcl-2 function have been identified 
(reviewed in Allday, 1996 and Korsmeyer, 1995) It is therefore conceivable that 
antagonism o f Bcl-2 function by such homologous proteins occurs in the groupl, but not 
in the group III environment In so far as protein levels are concerned, there does not 
appear to be consistent differences in the levels o f these Bcl-2 antagonists between type I 
and type III BL cells (Spender et a l , 1999) In support o f the second possibility, it is 
plausible that additional EBV-induced apoptosis-suppressor proteins, such as the Bcl-2 
homologs Bcl-xL, Mcl-1 or the A20 protein act in concert with Bcl-2 m group III cells to 
promote survival In this regard, LMP-1 has been shown to upregulate the expression o f 
several other anti-apoptotic proteins including Mcl-1 and A20 (Wang et a l , 1996, 
Laherty et a l , 1992), the former serving as a rapid and short-term effector o f cell viability 
prior to the up-regulation o f Bcl-2 (Wang et a l , 1996)
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The upregulation o f the anti-apoptotic zinc-finger protein, A20, by LMP-1 has been 
demonstrated in B- lymphocytes as well as epithelial cells and this effect is NF-kB 
dependent mapping to both CTAR1 and CTAR2 (Laherty et a l ,  1992; Fries et a l ,  1996, 
Miller et a l ,  1995; 1997). A20 is also constitutively expressed in EBV-immortalised B- 
cells (Spender et al., 1999). LMP-1-mediated protection o f epithelial cells from p53- 
mediated apoptosis has been shown to involve A20 (Fries et al., 1996). A20 can also 
contribute to the antiapoptotic effect o f LMP-1 expression in BL cell lines (Laherty et al.,
1992). More recently, A20 was demonstrated to function in a negative feedback loop by 
inhibiting activation o f NF-kB from both CTAR1 and CTAR2 domains o f LMP-1 
(Eliopoulos et a l ,  1999). This effect was mediated by the binding o f A20 to TRAF2 and 
this effect by A20 has also been demonstrated in the case o f signaling from some o f the 
other members o f  the TNFR-family including CD40 which can also induce A20 
expression in BL cells (Sarma et al., 1995).
1.8.2 EBV regulates components of the cell cycle machinery to protect against 
apoptosis
In addition to regulating apoptosis by inducing the expression o f anti-apoptotic proteins, 
EBV and in particular LMP-1 can also control apoptosis by regulating the cell cycle, 
since the processes o f apoptosis and cell cycle progression (proliferation) are coupled 
through the use and control o f shared molecular machinery (Evan et a l ,  1995).
Many oncogenes that promote cell cycle progression also induce apoptosis. This duality 
in function is exemplified by c-Myc which is a sequence-specific DNA-binding 
phosphoprotein that serves as a transcriptional activator and whose expression is required 
for passage through G1 and entry into the S-phase o f the cell cycle (Gregory, 1995). In 
order to explain the ability o f c-Myc to promote such opposed cellular functions as 
proliferation and death, a model has been proposed according to which c-Myc necessarily 
drives both processes, proliferation being favoured under appropriate conditions o f 
availability o f nutrients, space, growth and survival factors (Evan et a l ,  1995). Thus, this
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model predicts that the activity o f Myc in promoting proliferation is dependent on the 
route to its apoptosis-promoting activity being blocked Accordingly, even normally 
proliferating cells may be regarded as being “primed” for apoptosis This model can 
explain why c-Myc, being a potent inducer o f cell death is strongly favoured during the 
carcinogenic process Thus, it has been suggested that as soon as the affected cell 
acquires some form of apoptosis-suppressing mutation, the advantage afforded by c-Myc- 
mduced proliferation outweighs any disadvantage conferred by c-Myc-induced apoptosis 
Until that point, however, most cells with deregulated c-Myc are thought to delete 
themselves (by apoptosis) This theory gams support from observations made in 
transgenic animals expressing deregulated c-Myc Lymphocytes from these animals 
were found to exhibit elevated levels o f spontaneous apoptosis and an increased 
sensitivity to induction o f apoptosis in lymphoid organs was also observed (Evan et al, 
1995, Levine 1997) That cell death is an important restraint during carcinogenesis 
induced by c-Myc in the absence o f an ‘anti-death factor’, is best exemplified by the 
occurrence in these animals o f tumours displaying oncogenic synergy between c-myc and 
the anti-apoptotic gene bcl-2 (reviewed in Allday, 1996) Further studies have shown that 
Bcl-2 suppresses only the apoptotic actions o f c-Myc, leaving its ability to promote cell 
proliferation unaffected, thus leading to the suggestion that the proliferative and apoptotic 
arms o f the c-Myc pathway must be distinct at the point at which Bcl-2 acts
Further support for the theory that apoptosis and cell proliferation coincide comes from 
the observation that key tumour suppressor proteins such as pRb and p53 exert direct 
effects on cell viability and on cell cycle progression (reviewed in Allday, 1996, Levine, 
1997, Hunter, 1993) Phosphorylation o f pRb (the product o f the retinoblastoma gene rb) 
inactivates the protein during late G1 at a point in the cell cycle that appears to be 
coincident with the late G1 restriction point (after which cells no longer require 
mitogenic signals to complete their cell cycle) pRb is the principal target for inactivation 
by several DNA tumour virus oncoproteins including Simian virus (SV) 40 large T 
antigen (Tag), human papilloma virus (HPV) E7 protein and adenoviral E l A This 
suggests that active pRb acts as a restraint to the mitogenic actions o f these virus proteins 
(Taya, 1997)
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One o f the functions o f pRb is to suppress the action o f the G1-specific E2F-DP 
transcription factors which coordinate expression o f the late G1 phase and early S phase 
genes required for cell cycle progression The activity o f pRb is regulated by 
phosphorylation m the pl6-cyclm D l-cdk4-rb  pathway (Taya, 1996, Levine, 1997) 
(Figure 110) p i 6 is a negative regulator o f cyclin D l-cdk4 and the gene is shut off in 
many cancer cells or mutated in others Cyclin-Dl-cdk4 complexes target pRb for cell 
cycle regulation by phosphorylating it E2F-DP transcription factor complexes (E2F-l,-2 
and -3 and D P-1,-2 and -3) whose activity is regulated by pRb, m turn regulate a number 
o f genes [including those encoding cyclin E, cyclin A, dihydrofolate reductase and 
proliferating cell nuclear antigen (PCNA)] required to initiate or propagate the S phase of 
the cell cycle Phosphorylation o f pRb by cyclmDl-cdk4 releases E2F-DP proteins (E2F- 
DP proteins are bound by dephosphorylated pRb ) from the pRb complex, relieving 
repression o f these genes or activating their transcription
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F igu re  1.10 T he p53-R b pathw ay. Inter-relationships among a num ber o f  oncogenes (M yc, MDM-2, 
BCL-2) and tum our suppressor genes ( p i6, Rb, p53) that regulate the G l-S  phase restriction point, its 
relation to a DNA damage checkpoint mediated by p53, and the choice by p53 whether to initiate a G1 
arrest (via p21) or apoptosis. Available evidence suggests an important role for Rb and its two related gene 
products, p i 07 and p i 30 (along with E2F-4 and -5 ) , in p53-mediated G l-S  phase regulation. Shown are 
the p53-M DM 2 autoregulatory loop that reverses this checkpoint control and the gene products that 
positively or negatively act on the probability o f  entering apoptosis. (Key:- -j inhibits activity ; —» induces 
activity) A dapted from  Levine, 1997.
By binding and inactivating pRb, thereby liberating active E2F, the viral oncoproteins 
E l A (adenovirus) and E7 (HPV) promote cell cycle progression (Levine, 1997). 
Consistent with this, is data showing that deregulated expression o f E2F transcription 
factors induces both proliferation and apoptosis. c-Myc can also override the growth- 
suppressive effects o f pRb; however, there is some doubt as to whether c-Myc can 
interact with pRb in vivo . Not only does a lack o f functional pRb lead to apoptosis, but 
restoration o f functional pRb to rb ' cells directly inhibits it, under conditions where 
apoptosis is induced by radiation (i.e. p53-dependent) or even by dominant oncogenes. 
This indicates that the effects o f pRb must be exerted downstream o f p53.
p53 plays a key role in limiting the further expansion o f cells containing damaged 
genomes and it achieves this by either enforcing cell cycle arrest or triggering apoptosis 
(reviewed in Levine, 1997 and Bates and Vousden, 1996). Which o f these two alternate 
fates occurs in any particular instance appears to depend on a number o f undefined 
factors, such as cell type, nature and intensity o f insult and cytokine status. The high 
frequency with which p53 is functionally in a c t iv a te d  in human tumours attests to the 
critical role that p53 plays in limiting neoplastic progression. By transducing genome 
damage into growth arrest and/or apoptosis, p53 prevents the progression o f potentially 
mutant cells together with the neoplastic risk they present. Levels o f p53 rapidly increase 
following DNA damage, mainly because the normally short-lived p53 protein is 
stabilised, and this appears to be an important component o f the G1 arrest and apoptosis 
that follow DNA damage. Tumour cells that have lost functional p53 exhibit resistance 
to induction o f apoptosis by a range o f genotoxic agents. Moreover, because such cells
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fail to arrest or die following DNA damage, they enter S phase with unrepaired DNA and 
sustain substantially elevated risks o f further mutation.
p53 can act as a transcription factor, and most evidence suggests that it induces growth- 
arrest by the modulation o f specific target genes (reviewed in Levine, 1997). Most 
prominent among these is the gene encoding the cyclin-dependent kinase (cdk) inhibitor 
p21/W A F-l/C ip-l, whose action arrests cells in late G l. p21 binds to a number o f cyclin 
and cdk complexes: cyclinDl-cdk4, cyclin E-cdk2, cyclin A-cdk2 and cyclin A-cdc2 
(Figures 1.10, 1.11). One molecule o f p21 per complex appears to permit cdk activity, 
while any more inhibits kinase activity and cell cycle progression. p21 also binds to 
PCNA, and formation o f p21-PCNA complexes blocks the role o f PCNA in DNA 
replication (but not its role in DNA repair). Thus, p21 can act on cyclin-cdk complexes 
and PCNA to block DNA replication. p21-independent pathways may also contribute to 
p53-mediated growth arrest. In this respect, GADD45, which is encoded by a p53- 
responsive gene, can also bind PCNA.
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F igu re  1.11 T he E vents in p53 activation . DNA damage (indictaed by the break in the double line at the 
top) is recognised by a “sensor” molecule that identifies a specific type o f  lesion and possibly by the p53 
protein. The sensor modifies p53 (by phosphorylation) when both molecules correctly determine that there 
is damage. A modified p53 is more stable (increased half-life) and a steric or allosteric change in p53 
permits DNA binding to a specific DNA sequence regulating several downstream genes [p21 (inhibits cdks
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responsible for G l/S  transition), MDM2 (negatively controls p53 expresion), GADD45 (DNA replication), 
Bax (pro-apoptotic) and cyclin G] Two modes o f signaling for cellular apoptosis are possible one 
requiring transcription and one involving direct signaling with no transcription o f  downstream genes 
required A dapted  fro m  Levine, 1997
It is less certain how p53 regulates apoptosis or what factors coordinate its actions as a 
cytostatic- versus a cytotoxic- agent Some evidence indicates that induction o f apoptosis 
by p53 may not require transcriptional activation o f genes, although transrepression has 
not been excluded (reviewed in Levine, 1997, Evan, 1995) Other data implicate p53- 
dependent transactivation o f the bax gene, which encodes a member o f the Bcl-2 family 
that can induce apoptosis It is well estabhsed that overexpression o f Bcl-2 can block 
p5 3-mediated apoptosis Bax binds to Bcl-2 and antagonises its ability to block 
apoptosis, so a p5 3-dependent bax synthesis can tip the scales towards apoptosis A 
second p5 3-regulated gene product that could affect growth regulation is the insulin-like 
growth factor-binding protein-3 (IGF-BP3) IGF-BP3 blocks the IGF mitotic signaling 
pathway by binding to IGF and preventing its interaction with its receptor Thus, the 
blocking o f IGF activity could enhance apoptosis or lower the mitogenic response o f 
cells
p53 also acts to induce apoptosis in cells with oncogenic lesions such as loss o f 
functional pRb or the expression o f viral proteins such as E l A or deregulated c-Myc 
(reviewed by Evan et a l , 1995) Mice in which pRb inactivation is targeted to the lens or 
photoreceptors o f the developing eye exhibit the characteristic excessive proliferation and 
apoptosis which are associated with the inactivation o f pRb Such apoptosis is inhibited 
in a />53-negative background and in this case, the animals develop tumours instead The 
expression o f the adenovirus E l A protein in rat embryo fibroblasts stabilises and 
activates p53, the resulting cells die o f apoptosis Adenoviruses normally express the 
E1B-55 kD protein, which binds to p53 and blocks its transcription factor activity, and 
the E lB-19kD  protein, which acts like Bcl-2 to block apoptosis downstream o f p53  
activation
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EBV-negative BL cells which exhibit deregulated c-Myc expression as a result o f the t 
(8,14) translocation proliferate rapidly in culture but readily undergo apoptosis under 
inappropriate conditions such as serum deprivation (Gregory, 1995) Expression of 
LMP-1 or EBNA2 in these cell lines has been shown to have growth inhibitory and anti- 
apoptotic effects which may at least in part be a consequence o f downregulation o f c-Myc 
expression as a result o f downregulation o f transcription o f the adjacent translocated Ig-jj. 
locus (Floettmann et a l , 1996, Jochner et a l , 1996) LMP-1 has also been demonstrated 
to protect Jurkat T cells from apoptosis induced by serum deprivation by downregulating 
the expression o f c-Myc (Kawamshi, 1997)
TGF(3 peptides belong to a family o f structurally related molecules with a variety o f 
biological functions including differentiation and apoptosis on a variety o f cell and tissue 
types including human B and T lymphocytes (reviewed in Aravamtakis et a l , 1995) 
EBV-negative BL lines and EBV-positive BL lines with a group I phenotype are 
generally sensitive to the growth inhibitory effects o f TGF-|3 and this results from cells 
accumulating in G1 and undergoing apoptosis However, EBV immortalised LCLs and 
EBV-positive BL lines that express all the latent viral proteins are resistant to the growth- 
inhibitory effects o f TGF-P (Altiok et a l , 1993, MacDonald et a l , 1996) Aravamtakis et 
al (1995) were able to demonstrate that LMP-1 expression could independently 
reproduce the ability o f EBV to confer TGF-p-resistance on infected B-lymphocytes and 
group III BL lines by gene transfer into the EBV-negative BL cell line BL41 TGF-p is 
known to arrest cells m the mid- to late- G1 phase o f cell cycle in not only mitogen- 
activated human B-cells but also m non-lymphoid cell systems (reviewed in MacDonald 
et a l , 1995, Chaouchi et a l , 1995) This G1 arrest has been linked to an upregulation o f 
at least three inhibitors o f cyclm-dependent kinases (cdks) namely, p l5 INK4B, p27KIP1 and 
p2 j WAFi ancj m some ce]]s t0 a downregulation o f cdk4 (reviewed in MacDonald et a l , 
1996 and Hunter, 1993) Binding o f these inhibitors to cdk inhibits the formation o f cdk- 
cyclin complexes that are required for progression through the cell cycle The inhibition 
o f cyclin D function leads to a block in phosphorylation o f the retinoblastoma gene 
product, pRb, and this in turn represses the activity o f the E2F family o f transcription 
factors, thus preventing cells from making the transition from G l- to S- phase o f the cell
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cycle The protection against TGF-|3-induced G1 arrest afforded by LMP-1 was shown to 
be related to the induction o f cyclin D2 expression by LM P-1 leading to the maintenance 
o f pRb in the hyperphosphorylated state In the early G1 phase o f the cell cycle, the 
presence o f hypophosphorylated pRb is associated with transcriptional activation o f 
cyclin D expression in normal cells (Taya et a l , 1997) D-type cyclins form complexes 
with cdk4 which then proceed to phosphorylate pRb and shut down cyclin D 
transcription, thus completing the feedback loop regulating progression from the G1 
phase to the S phase o f the cell cycle The maintenance o f pRb in the 
hyperphosphorylated state by LMP-1-thus leads to cell cycle progression regardless o f 
the negative growth regulatory signal imposed by TGF-(3
Mutations and elevated expression o f p53 are two factors that can play a role in 
malignant transformation or tumour cell growth o f Burkitt’s lymphoma Mutations in p53 
have been found in approximately 33% o f BL biopsies and m at least 63% o f BL lines 
(Farrell et a l , 1991) In 65% of BL lines studies the wild-type allele is lost and the cells 
express the mutant p53 allele at elevated levels In general, single nucleotide 
substitutions which result in aminoacid changes are found BL cells with p53 lesions 
have been shown to be relatively resistant to DNA-damaging drugs such as cisplatin 
compared to those cell lines harbouring wild-type p53 (Allday et a l , 1995) Expression o f 
LMP-1 can however protect against wild-type p53-mediated apoptosis and this has been 
demonstrated in both the BL and epithelial cell contexts based on the usage o f cell lines 
expressing temperature-sensitive p53 In BL cells, protection by LMP-1 is most likely 
due to the induction o f Bcl-2 expression (Okan et a l , 1995) However, in the epithelial 
cells examined, protection against p5 3-mediated apoptosis was shown to be due to the 
induction o f A20 expression (Fries et a l , 1996) In both cases, protection by LMP-1 did 
not involve an effect on the transactivation function o f p53
1.8.2.1 EBV primes LCLs for apoptosis
c-Myc
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Activated peripheral blood B-cells ( IL-4 + anti-CD40 antibodies) cultured in 
vitro in the absence o f serum exhibit little DNA synthesis, accumulate in the Go/Gl 
phase o f the cell cycle and have a lower level o f c-myc expression compared to when 
grown in the continuous presence o f serum (reviewed in Chemey et a l , 1994) However, 
EBV-immortahsed lymphoblastoid cell lines grown under autocrine growth factor- 
deprived conditions (cultured under low-density conditions) exhibit apoptosis by day 3 o f 
growth (Allday, 1996) In fact, under such culture conditions, these cells continue to 
proliferate until apoptotic death and this change in growth properties is not accompanied 
by a change in the levels o f c-Myc protein (or even p53 or Bcl-2) These observations led 
to the suggestion that deregulation o f c-myc may mediate the apoptotic response o f the 
growth factor-deprived LCLs Indeed, it was demonstrated that antisense 
oligonucleotides to c-myc specifically inhibited apoptosis m the growth factor-deprived 
LCLs but suppressed growth o f undeprived LCLs These studies indicated that EBV 
latent gene expression must deregulate c-myc in B lymphocytes and this promotes both 
proliferation and apoptosis when there is a depletion o f autocrine growth factors 
(Cherney et a l , 1994)
Studies based on the usage o f an LCL established with a recombinant EBV conditional 
for the expression o f EBNA-2, have shown that EBNA-2 is the likely EBV latent gene 
product responsible for deregulating c-Myc in LCLs In this study by Kempkes et al 
(1995), primary B-lymphocytes were infected with the recombinant virus such that in the 
presence o f estrogen, growth transformation o f the infected B-cells was achieved leading 
to the formation o f estrogen-dependent LCLs expressing EBNA2 (as a fusion protein 
with the hormone binding domain o f the estrogen receptor) in addition to the other EBV 
latent proteins Removal o f estrogen resulted in about half o f the cells entering a 
quiescent non-proliferative state whereas the others underwent apoptotic death Growth 
arrest occurred at both the G1 and G2 phases o f  the cell cycle which is indicative o f a 
requirement o f EBNA-2 function at both o f these stages o f the cell cycle However, only 
those cells arrested in G1 could be rescued into cell cycle on induction o f EBNA2, and 
this was shown to correlate with the induction o f c-Myc and LMP-1 expression, followed 
by the induction o f cyclin D2 (G1 -specific cychn) and cdk4 and then the phosphorylated
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form o f pRb. Concomitant with the appearance o f the phosphorylated form o f pRb, the 
E2F transcription factor, (which is maintained inactive by binding to the 
hypophosphorylated form of Rb and is required for DNA synthesis) became detectable. 
This study therefore demonstrated that in LCLs, functional EBNA-2 is responsible not 
only for the induction and maintenance o f c-Myc in a deregulated state but also for 
proliferation. In order to investigate if this effect o f EBNA2 was due to an indirect effect 
on expression o f LMP-1, Zimber-Strobl et al. (1996) have analysed the growth 
characteristics o f primary B-cell transfectants that constitutively expressed LMP-1 from a 
hetrologous promoter that was carried on a plasmid vector containing a conditional 
(estrogen-dependent) EBNA-2 allele in addition to the other wild-type latent EBV genes 
(Zimber-Strobl et a l ,  1996). In the absence o f functional EBNA-2, it was found that 
LMP-1 was incapable o f sustaining B-cell proliferation (at levels o f expression similar to 
that observed in LCLs) but induced a phenotype consistent with prolonged cell viability. 
Proliferation o f these transfectants resumed only in the presence o f functional EBNA-2. 
Thus, it was demonstrated that LMP-1 is not sufficient to maintain proliferation o f B- 
cells in the absence o f EBNA-2 and that EBNA-2 acts beyond the upregulation o f LMP-1 
to maintain proliferation o f EBV-immortalised B-cells perhaps by cooperating with other 
cellular and viral genes. Studies in EBV-immortalised B lymphocytes expressing a 
conditional LMP-1 have shown that the continuous expression o f LMP-1 is essential for 
proliferation (Kilger et a l ,  1998).
A likely viral latent gene that may serve in the role o f cooperating with EBNA-2 in 
initiating and maintaining B-cells in cycle is EBNA-LP. Resting B-cells, primed by 
CD21 cross-linking with the gp350 virus envelope protein to mimic virus infection and 
transfected with EBNA-2 and EBNA-LP expression vectors, enter and progress through 
the cell cycle and this ability o f EBNA-2 and EBNA-LP is correlated with their ability to 
induce the synthesis o f cyclin D2 (Sinclair et al, 1994). Expression o f both EBNA-2 and 
EBNA-LP were required for this effect. Thus, by inducing cyclinD2 synthesis, EBNA-2 
and EBNA-LP cooperate to induce a GO to G1 transition. In this relation it is interesting 
to note that following EBV infection o f resting primary B-cells, EBNA-2 and EBNA-LP 
are the first viral latent proteins to be expressed and that too in a coordinate fashion.
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Studies by Kitay and Rowe have shown that EBNA-LP is phosphorylated throughout the 
cell cycle, but the extent o f phosphorylation is increased during G2 phase and is maximal 
at the G2/M transition (Kitay and Rowe, 1996) Moreover, in vitro studies have shown 
that EBNA-LP can interact with p53 and pRb, two proteins known to play important 
roles m cell-cycle regulation The significance o f these latter observations are not known 
since EBNA-LP does not alter the function o f these molecules when bound (Szekely et 
a l ,  1993)
p53
Investigations aimed at assessing the integrity o f the p53/p21w af-l/ pRb/E2F 
pathway in B-cells immortalised by EBV have led to the same conclusion as that o f the 
influence o f EBV infection on c-myc expression in B-cells EBV infection o f B-cells 
primes the cells for apoptosis Resting primary B-cells are essentially p53-negative 
(Allday et a l , 1995) Some o f these cells spontaneously undergo apoptosis when placed 
in culture, through a p5 3-independent pathway Normal peripheral B-cells treated with 
IL-4 and anti-CD40 are activated into proliferation and accumulate p53 EBV infection o f 
resting B-cells similarly rescues them from spontaneous cell death and this process is also 
accompanied by an acumulation o f p53 (Allday et a l , 1995) In the case o f EBV- 
mfected B-cells, accumulation o f p53 requires viral gene expresssion (infection with UV 
-inactivated virus did not result in p53 accumulation) and it has been shown by Chen and 
Cooper (1996) that EBNA-2 and LMP-1 can independently transactivate p53 While IL- 
4/anti-CD40-activated B-cells respond to the DNA-damaging agent cisplatin by ceasing 
DNA synthesis (growth arrest), LCLs, respond with apoptosis (Allday et a l , 1995) 
Cisplatin-treatment o f either IL-4/anti-CD40 activated B-cells or LCLs led to an 
elevation o f p53 levels with similar kinetics p53 accumulation in cisplatin-treated LCLs 
was shown to be due to post-translational modification leading to enhanced stability 
Also, cisplatin-treatment o f the LCLs did not alter Bcl-2 expression or the heterodimeric 
partner o f Bcl-2, Bax (which is also known to be transcriptionally activated by p53 in 
some cell types) Ectopic expression o f p53 in LCLs results in spontaneous apoptosis, 
indicating that the cisplatin-induced apoptosis observed in the LCLs is likely to be due to 
the increased accumulation o f p53 Furthermore, in the latter experiment, in the cells
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proceeding towards apoptosis, transcriptional activation o f p l \ WAF'' by p53 correlated 
with the presence o f dephosphorylated pRb. In normal fibroblasts, cisplatin-treatment 
correlates with the presence o f hypophosphorylated pRb and G1 -arrest since the cells are 
unable to proceed into S-phase (reviewed in Allday, 1995). However, the observation 
that the presence o f hypophosphorylated pRb correlates with apoptosis in LCLs suggests 
that EBV must encode a function which enables the G l/S  restriction point to be 
overcome and thus allow progression through the cell cycle, converting the p53 arrest 
response to apoptosis (Levine, 1997). Candidate mechanisms by which EBV may 
overcome the G l/S  restriction point include deregulation o f c-myc or utility o f a virally- 
encoded E lA -like function which generates high levels o f transcriptionally active E2F.
1.8.3 EBV lytic proteins encode anti-apoptotic functions
Unlike most viruses, EBV maintains a very stable persistent infection in vivo (Rowe et 
al., 1992). Another state in which EBV may be found is in the process o f active 
replication and the production o f progeny virions; this is the lytic cycle. Virus production 
is generally accepted to preceed replication o f viral DNA (Allday, 1996). This may be 
sensed by the host cell as damaged DNA and the p53 checkpoint response could then be 
activated. If  the cells are driven to proliferate by EBV (as in type III latency) then 
apoptosis will be the most likely outcome. In this situation additional repressors o f 
apoptosis can provide a selective advantage. Consistent with this model, there are at least 
two known virally encoded proteins, BHRF-1 and BZLF-1, that are synthesised during 
the lytic cycle that can provide a survival advantage to the infected cell (Allday, 1996). 
These lytic gene products can therefore delay apoptosis in order to maximise viral 
production. Expression o f BHRF-1 in epithelial cells has been shown to confer enhanced 
resistance to cisplatin-induced apoptosis and can also inhibit differentiation (Dawson et 
al., 1990; 1995). In lymphoid cells, BZLF-1 has been shown to interact with p53 and 
inhibit its transactivating function, thereby providing a mechanism for preventing p53- 
mediated apoptosis (Zhang et al., 1994b). However, in epithelial cells, expression o f this 
EBV protein was shown to result in growth arrest without inhibiting the transactivating 
function o f p53 (Cayrol and Flemmington, 1996).
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CHAPTER 2
MATERIALS AND METHODS
2.1 BIOLOGICAL MATERIALS 
2 11 Cell lines
Table 2 1 Cell lines used in this study
C ell L ine EB V
S ta tus
Cell
C lassification
D escrip tion
DG75 EBV negative BL Lymphoid B cell line derived from an Israeli 
Burkitt-hke lymphoma case (Ben-Bassat et 
a l,  1977)
DG75 tTA BL (stable 
transfectant)
Clonal derivative o f DG75 stably transfected 
with the tetracycline-regulated transactivator 
only (Floettmann et a l , 1997)
DG75 tTA 
LMP1
BL (Stable 
transfectant)
Tetracycline-regulated system established in 
DG75 whereby the expression o f  LMP1 can 
be induced by the removal o f  tetracycline 
from the growth m edia (Floettmann et a l , 
1997)
M utu 1 + Type I BL Early passage BL cell line expressing 
E B N A 1 as the sole viral latent gene (Gregory 
e ta l ,  1990)
Mutu 3 c95 + Type III BL A clone o f M utu I cells that have upon serial 
passage in culture, “drifted”  to express the 
entire complem ent o f  EBV latent genes 
(Gregory e t a l , 1990)
M utu 3 
(LM P1-)
+ Type III BL This is a partially characterised M utu 3 clone 
which no longer expresses LMP-1
BL41,
BL41-B95 8 
I ARC 171
+
+
EBV-negative BL 
Type III phenotype 
LCL
These cell lines are a matched set BL41- 
B95 8 was established by infection o f  BL41 
cells with the EBV strain B95 8 and 
expresses all o f  the EBV latent genes 
(Calendar et a l , 1987, Andersson et a l , 
1991)) IARC 171 is a LCL established by 
infection o f  B lymphocytes from the same 
patient from whom the BL41 cell line was
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derived with the B95 8 strain (Lenoir et a l , 
1985)
OKU BL + Type I These cells are a m atched pair OKU BL is a
OKU LCL + LCL group I BL cell line expressing only EBNA1 
OKU LCL was established by infection o f 
peripheral B lymphocytes from the same 
patient from whom OKU BL was derived 
with the EBV strain B95 8
IARC 290B + LCL A spontaneously transformed LCL (Lenoir et 
a l,  1985)
IB4 + LCL An LCL established by infection o f fetal cord 
blood lymphocytes with the EBV strain 
B95 8 (King et al, 1980)
X50-7 + LCL A spontaneously transform ed LCL (W ilson 
and Miller, 1979)
Ag876 + Type III BL Type III BL cell line expressing all o f  the 
EBV latent genes
Jurkat T cell Acute T-lymphocytic leukemic cell line 
(Brattsand et a l , 1990)
Jurkat tTA 
LMP-1
T cell (stable 
transfectant)
Tetracycline-regulated system established m 
Jurkat cells whereby the expression o f  LMP1 
can be induced by the removal o f  tetracycline 
from the growth medium
C33A,
C33A Neo, 
C33A LMP1 -
Epithelial cell These are cervical epithelial cell lines C33A 
is the parental cell line C33A N eo is the 
control transfectant expressing the neomycin- 
resistance gene only C33A LMP1 is stably 
transfected with a vector constitutively 
expressing LMP1 and the neomycm 
resistance gene (M iller et a l , 1995)
All BL cell lines, LCLs, the Jurkat and the Jurkat tTA LMP-1 cell lines were obtained 
from Professor Martin Rowe, University o f Wales, Cardiff The epithetial cell line C33A 
and its derivatives were a gift from Dr Nancy Raab-Traub, University o f North Carolina, 
USA
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2.1.2 Antibodies
The monoclonal antibodies against LMP-1, CS1-4, was a generous gift from Professor 
M artin Rowe, University o f Wales, Cardiff The monoclonal antibodies against Bcl-2, 
Bcl2 100/124 was a gift from Professor David Mason, John Radchffe Hospital, 
University o f Oxford, Oxford The rabbit polyclonal antibodies to HA was a gift from 
Professor Luke O ’Neill, Trinity College Dublin The monoclonal antibodies against the 
CD40 receptor, G28 5, was obtained from Professor Edward Clark, (affinity-purified 
antibodies) and Professor M artin Rowe (ascites) The monoclonal antibodies against 
phosphotyrosine, PT66, was a gift from Dr Deirdre Cooke, Dublin City University The 
alkaline-phosphatase (AP) conjugated anti-mouse antibodies was purchased from 
Promega and the alkaline-phosphatase (AP) conjugated anti-rabbit antibodies was 
purchased from Boehringer Mannheim The polyclonal antibodies against p65 and c-rel 
were purchased from Chemicon Int and the polyclonal antibodies against p50 was a gift 
from Dr Katherine Fitzgerald, Trinity College Dublin
2.1.3 Bacterial Strains
E  coli D H 5a, genotype F-, end  A l, hsdR17 (rk-,mk=), supEAA, thi rec A1 ,g y r  
A96, rel A l, <|) 80lac Z5M15
2.1.4 Plasmids
Table 2 2 Plasmids used m this study
PLASMID GIFT FROM DESCRIPTION
pEFCX 
pEFC X LM P-1 
PEFCXIkB ocDN
Dr Peter Brodm , Umea 
University, Sweden
pEFC X LM P-1 is an LMP-1 
expression plasmid in which the 
LMP-1 gene (from the B95 8 
virus) was cloned in front o f  the 
strong polypeptide chain 
elongation factor let promoter 
contained m pEFCX pEFCX 
IkBocDN expresses a dominant 
negative IkBoc in which serines 
32 and 36 were mutated to 
alanines (Liljeholm et a l , 1998)
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pSG5
pSG5 LMP-1 
pSG5 LMP AAA 
pSG5 LM P G 
pSG5 LM P AAAG
Professor M artin Rowe, 
University o f  Wales College o f 
M edicine, Cardiff, U K
pSG5 LMP-1 is an LMP-1 
expression plasm id in which the 
LMP-1 gene from the B95 8 virus 
was cloned in front o f  the SV40 
prom oter contained in pSG5 
(Stratagene) PSG5 LMP AAA 
expresses LMP-1 with ammo 
acids proline 204, glutamine 206 
and threonine 208 mutated to 
alanine PSG5 LMP G expresses 
LMP-1 with am inoacid 384 
changed from tyrosine to glycine 
PSG5 LMP AAAG expresses 
LMP-1 with the combination o f 
mutations present in LMP-1 AAA 
and LMP-1 G (Floettmann et a l , 
1998)
pSG5 TRAF2A(6-86) Professor Martin Rowe, 
University o f  Wales College o f 
M edicine, Cardiff, U K
Expresses a dominant-negative 
TRAF2 molecule that carries an 
N-terminal deletion o f 
am inoacids 6 to 86 (Eliopoulos et 
a l ,  1999)
pSG5 IxBotDN Professor M artin Rowe, 
University o f W ales College o f 
M edicine, Cardiff, U K
Expresses a dominant negative 
IkBoc in which serines 32 and 36 
were muatated to alanines
pSG5 A20 Professor Martin Rowe, 
University o f W ales College o f 
M edicine, Cardiff, U K
Expression plasmid for the full- 
length A20 protein (Eliopoulos et 
a l,  1999)
p-1374/+81B fl-l CAT 
p-1374/+81 Bfl-1 idkB CAT 
p -1240/+81 B fl-1 CAT 
P-367/+81BA-1 CAT 
p-129/+81Bfl-l CAT
D r Celine Gelinas, School o f 
M edicine and Dentistry, 
University o f New Jersey, New 
Jersey U S A
p-1374/+81B fl-l CAT contains 
the region -1 3 7 4  to +81 o f  the 
human bfl-1 gene cloned m the 
promoterless vector, pCAT-basic, 
expressing a CAT reporter gene 
P-1374/+81 Bfl-1 itikB CAT 
contains the -1 3 7 4  to +81 o f  the 
bfl-1 gene but with a mutated 
NF-kB site at position -833  
(GTTTATTTACC) p -1240/+81 
Bfl-1 CAT, p-367/+81 Bfl-1 CAT 
and p-129/+81 Bfl-1 CAT contain 
the regions -1 2 4 0  to +81, -367 to 
+81 and -1 2 9  to +81 o f  bfl-1 
cloned into pCAT-basic (Zong et 
a l,  1999)
3 x enh kB-1uc Professor M artin Rowe, 
University o f Wales College o f 
M edicine, C ardiff U K
Contains three kB elements 
upstream o f  a minimal 
conalbumin prom oter driving the 
expression o f  the firefly 
luciferase gene (Floettmann and 
Rowe, 1997)
pcDNA3 HABfl-1 Dr G Chinnadurai, Saint Louis 
University School o f  M edicine, 
M issouri U S A
Expresses Bfl-1 protein tagged to 
the influenza virus HA epitope 
(D ’Sa-Eipper et a l , 1996)
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2.1.5 Oligonucleotides
Sigma Genosys Ltd
-54/-41BA-1 NF-kB
Forward oligonucleotide 
5’ ACA GAA ATT CCA CC 3’ 
Reverse oligonucleotide 
5’ GGT GGA ATT TCT GT 3’
Promega
‘consensus’ NF-kB oligonucleotide
5’ AGT TGA GGG GAC TTT CCC AGG C 3’ 
3 ’ TCA ACT CCC CTG AAA GGG TCC G 5’
2.1.6 Commercial kits and restriction enzymes
Restriction enzymes Roche Biochemicals and New England Biolabs
In Vitro Transcription kit Pharmingen
BCA Protein assay kit Pierce
Qiagen T ip-100 Qiagen
RPA kit Pharmingen
Wizard PCR Preps DNA purification system Promega
2.2 CHEMICAL MATERIALS
Protein prestained markers NEB
a 32P labeled UTP Amersham
Y32P labeled ATP New England Biolabs
58
dNTPs 
Rnase A
Pharmacia Biotech
Pharmacia Biotech
Poly(dl-dC) Poly(dl-dC)
MicroSpin™  G-25 columns
Marvel
Chloroform
Isopropanol
Pharmacia Biotech
Pharmacia Biotech 
Premier Beverages 
ROMIL
ROMIL
Sigma-Aldrich-Fluka Chemical Co
Urea, Dithothreitol, Coomassie blue R, BCIP/NBT, Tetracycline, Liquid Phenol, 
Nitocellulose, Ampicillin, Potassium acetate, Tween-20, BSA, Sodium azide, Sigmacote, 
Ammonium phosphate, Mineral oil, a-Thiol-glycerol, PMSF, MOPS, BCS E  coll tRNA, 
Aprotimn, Formaldehyde, Micophenohc acid, BCS, DEAE-dextran, okadaic acid
Merck
Boric acid, Ammonium persulphate, Sodium acetate, Magnesium chloride, Glucose, 
Sodium chloride, Potassium chloride, Sodium hydroxide, Sodium dodecylsulphate, 
Calcium chloride, Glycine, Methanol
TEMED, Bromophenol blue, Potassium dihydrogen phosphate, Potassium hydrogen 
phosphate, Sodium phosphate, Glycerol, Tris (hydroxymethyl) methylamine, EDTA, 
Magnesium sulphate, Ethidium bromide, Isoamyl alcohol, Hydrochloric acid, Acetic 
acid, Methanol, Isopropanol, Nondent P40, Sucrose, Paraformaldehyde
Boehringer Mannheim
Agarose, Low melt agarose, IPTG, Hygromycin B, Geneticin (G418), Leupeptin
Calbiochem-Novobiochem 
Okadaic acid
BDH
Oxoid
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Agar technical, Bacto-Tryptone, Yeast extract
KODAK
X-ray film, X-ray film developer, X-ray film fixer
National diagnostics 
Acrylagel, Bis-acrylagel, Accugel
Gibco-BRL
RPMI 1640, DMEM-H, Trypsin EDTA, Fetal calf serum, Pencillin, Streptomycin, L- 
Glutamine, Hepes, Sodium Pyruvate, 1Kb DNA ladder
Promega
lOObp DNA ladder, T4 polynucleotide kinase, NF-kappaB oligonucleotide
2.3 DNA MANIPULATION
Preparation o f all solutions used m chapter two are outlined in the appendix
2.3.1 Storage o f DNA samples
DNA samples were stored in TE buffer pH 8 0 at 4°C EDTA was used to chelate heavy 
metal ions that are needed for DNase activity while storage at pH 8 0 minimises 
deamidation DNA was also stored in sterile distilled H 2O (dH20)
2.3.2 Equilibration of phenol
Before use, phenol was equilibrated to pH 8 0 with TnsCI pH 8 0 as DNA partitions into
the organic phase at <pH 7 8 Solid phenol was melted at 68°C, hydroxyquinolme was
added to a final concentration o f 0 1% (w/v) (acts as an antioxidant, a chelator o f metal
1 0 ns and an RNase inhibitor) An equal volume o f buffer (0 5 M TrisHCl pH 8 0) was
added to the liquified phenol and stirred for 15 mins The two phases were then allowed
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to equilibrate and as much as possible o f the upper aqueous phase was removed The 
extraction was repeated using equal volumes o f 0 1 M TrisHCl pH 8 0 until the pH o f the 
phenol was > 7 8  An equal volume o f 0 1M TrisHCl pH 8 0 and 0 2 %  (w/v) P- 
mercapthoethanol were added to the phenol, which was then stored at 4°C in the dark 
until required
2.3.3 Phenol/chloroform extraction and ethanol precipitation
Phenol/chloroform extraction and ethanol precipitation was carried out to concentrate 
nucleic acid samples or change the buffers in which a sample was dissolved An equal 
volume o f phenol/chloroform/isoamyl alcohol (25 24 1) was added to the DNA solution, 
mixed by vortexing and centrifuged for 10 mm at 13,000 x g The upper aqueous phase 
was removed, taking care not to take any material from the mterphase and this was placed 
in a fresh autoclaved eppendorf tube An equal volume o f chloroform/isoamyl alcohol 
(24 1) was added to the aqueous phase, vortexed as before and centrifuged for 5 mm at 
13,000 x g Again the upper aqueous phase was removed to a fresh tube One tenth 
volume o f 3 M sodium acetate (pH 5 2) was added to the solution o f DNA, mixed and 
then 2 and a half volumes o f 100% (v/v) ethanol was added This mixture was vortexed 
briefly and incubated at room temperature for 5 mm The DNA samples were then 
centrifuged for 30 mm at 12,000 x g at 4°C, the supernatant was removed and pellets 
were washed with 1 ml 70% (v/v) ethanol to remove excess salts The tube was 
centrifuged for 5 mm at 10,000 x g, the supernatant was removed and pellets were air 
dried for approximately 10 mm Pellets were resuspended in an appropriate volume o f 
sterile Tns-EDTA (TE) (pH 8 0) or dHaO
2.3.4 Restriction enzyme digestion o f DNA
Restriction enzymes bind specifically to and cleave double-stranded DNA at specific 
sites w ithin or adjacent to a particular sequence known as the recognition site The 
restriction enzymes used were supplied with incubation buffers at a concentration o f 10X 
(working concentration IX) DNA was digested with restriction endonucleases for
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identification purposes or to linearise or cut fragments from a plasmid DNA digests 
were performed by adding
200 ng -  1 |ag o f DNA (Final concentration o f <300 ng/|j.l)
1 jj.1 o f enzyme/fig o f DNA solution (10 U)
10 X buffer to a final concentration o f IX  
dF^O to the final volume required
The reaction was gently mixed, centrifuged, then incubated for 2 hr at the optimum 
enzyme temperature (37°C or 50°C, usually 37°C)
2.3.5 Ligation reactions
Two fragments o f DNA may be ligated in one o f two ways The majority o f restriction 
endonucleases digest DNA leaving either a 5 ’or a 3 ’ overhang If  the ends o f the linear 
DNA molecules to be ligated are compatible then they may be ligated by cohesive 
ligation If they are not, blunt-end ligation may be required During ligation, the ligase 
enzyme catalyses the formation o f a phosphodiester bond between adjacent nucleotides 
only if  one contains a 5’ phosphate group and the other contains a 3 ’ hydroxyl group 
Since recircularisation o f vector DNA can be a potential problem, it is necessary to carry 
out a dephosphorylation reaction on the vector DNA prior to including it in the ligation 
reaction Removal o f 5 ’ phosphate groups was carried out by treatment o f vector DNA 
with C alf Intestinal phosphatase (CIP) Digested vector DNAs (<100ng/|j.l) were 
dephosphorylated using CIP in a 1 OOju.1 volume (CIP was added at 1 umt/100 pmoles for 
cohesive termini and 1 umt/2 pmole for blunt termini) The solution was mixed gently 
and incubated for 30 min at 37°C This was followed by an enzyme denaturation step 
achieved by heating to 75°C for 10 mm DNA was then purified by phenol/chloroform 
extraction and ethanol precipitation (section 2 3 3)
Cohesive-end ligations o f equimolar amounts o f vector and insert DNA (< l^g ) were 
generally carried out overnight at 16°C in a commercial ligation buffer (5mM ATP) with 
10 units o f T4 DNA ligase /ml in a total reaction volume o f 10p.l After ligation, the
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samples were heated at 70°C for 10 mm to inactivate the ligase and stored on ice until 
required in transformation
Blunt-end ligations are usually less desirable than cohesive-end ligations due to their 
much lower efficiency Nonetheless, blunt-end ligations were required in cases where 
restriction enzymes generated blunt ended molecules Also, if  two compatible cohesive 
ends cannot be generated, it is necessary to ‘fill-in’ the unmatched bases at the 5 ’ or 3’ 
overhangs and then carry out a blunt-ended ligation reaction DNA repair was achieved 
by using the Klenow fragment o f E  coli DNA polymerase I (New England Biolabs) as 
follows The DNA was resuspended at a concentration o f 50 (ig/ml in IX  Eco Pol buffer 
(supplied with the Klenow), dNTPs were added to a final concentration o f 33 |jM  each, 1 
(j,l o f Klenow was added and the reaction was placed at 25°C for 15 mm The enzyme 
was inactivated by heating to 70°C for 10 mm This DNA was then purified by 
phenol/chloroform extraction and ethanol precipitation (see Section 2 3 3) Ligation 
reactions were then performed as for cohesive-end reactions except that a 1 3 to 1 5 
molar ratio o f vector insert DNA was used in the reactions to improve the efficiency o f 
ligation
2.3.6 Preparation o f competent cells
The Calcium chloride (CaCh) method was employed to prepare competent cells An 
E coli strain (D H5a) was streaked from a glycerol stock on to a LB agar plate and 
incubated at 37°C overnight An isolated colony was then picked using a sterile 
inoculating loop and used to inoculate 5 ml o f SOB (see Appendix) broth This culture 
was incubated in a shaking incubator at 200 rpm overnight 37°C An aliquot o f this 
starter culture (2 ml) was then used to inoculate 100 ml o f sterile SOB and incubated at 
37°C with shaking until the O D o f the culture at 640 nm was between 0 4 and 0 8 
(approximately 2 hr 15 mm) The cells were then transferred to two sterile 50 ml falcon 
tubes and incubated on ice for 10 mm followed by centrifugation at 4,000 x g, 4°C for 10 
mm The resulting pellets were resuspended in 25 ml o f 100 mM CaC^, mixed gently 
and incubated on ice for a further 20 mm Centrifugation was carried out as before
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(4,000 x g at 4°C for 10 min) followed by removal o f the supernatant and the pellet was 
then resuspended in a 1% (w/v) volume o f CaCl2 The competent cells were stored on ice 
and used within 24 hr
2.3.7 Transformations
Two hundred microliters o f competent cells were placed in a pre-chilled microcentifuge 
tube containing 10]a.L o f DNA at a concentration o f approximately 100ng/10(il The 
contents were mixed gently and incubated on ice for 30 mm, during which time an 
aliquot o f SOC (see Appendix) was pre-heated to 42°C After 30 mm on ice the cells 
were heat-pulsed at 42°C for 90 s followed by incubation on ice for a further 2 mm One 
milliliter o f preheated SOC was then added to the cells and incubated at 37°C in a 
shaking incubator for 1 hr 10 mm The cells were concentrated by centrifugation 
following which 800^.1 o f the supernatant was removed and discarded The cells were 
resuspended in the remaining supernatant and plated out with the appropriate controls on 
LB plates containing ampicillin and incubated overnight at 37°C Only bacteria that took 
up plasmid DNA encoding ampicilhn-resistance grew on the LB amp plates 
Recombinant colonies were thus used to inoculate 5 ml o f LB containing ampicillin, 
incubated overnight at 37°C and DNA mmipreparations were carried out as described in 
section 2 3 8 Glycerol stocks o f all bacterial cultures were prepared by the addition o f 
0 5 ml o f a 50% (v/v) glycerol solution to 0 5 ml o f an overnight bacterial culture o f 
interest and storing at -80°C
2.3.8 Small scale preparation o f plasmid DNA (miniprep)
This method is a modification o f a protocol from Sambrook et al (1989) A single
bacterial colony was used to inoculate 5 ml o f LB medium (with appropriate antibiotic)
and incubated overnight at 37°C An aliquot (1 5ml) o f this culture was added to a sterile
microfuge tube and centrifuged for 30 s at room temperature, the remainder was stored at
4°C The medium was removed from the tube, leaving the pellet as dry as possible The
pellet was resuspended thoroughly in 100 |j,l o f solution I by vigorous vortexmg To this,
64
V200 jj,1 o f freshly prepared solution II was added, the tube contents were mixed by 
inverting the tube rapidly a number o f times Ice-cold solution III (150 p.1) was added 
and the tubes were vortexed gently for 10 s
The lysate was centrifuged for 5 mm at 12,000 x g, the supernatant was transferred to a 
fresh tube, taking care not to carry over any o f the white precipitate An equal volume of 
phenol/chloroform/isoamyl alcohol (25 24 1) was added, mixed by vortexing and 
centrifuged for 5 mm at 12,000 x g The upper aqueous phase was removed to a fresh 
microfuge tube, to which 2 and a half volumes o f 100% (v/v) ethanol were added, the 
solution was vortexed and centrifuged for 5 min at 12,000 x g The supernatant was 
discarded and the pellet was washed with 1 ml 70% (v/v) ethanol, centrifuged as before 
and the supernatant removed The pellet was air-dried for 10-15 mm After resuspending 
in 50 |il o f TE (pH 8 0), 1 |_il o f DNase-free RNase A (20 (ag/ml) was added, the tubes 
vortexed, incubated at 37°C for 1 hr and then stored at 4°C
2.3.9 Qiagen™  plasmid DNA purification protocol
Plasmid DNA was purified using the QIAGEN-tip 100 solution system from Promega 
All buffers used are described in the Appendix A glycerol stock o f the bacteria o f 
interest was streaked out on LB-ampicillin agar and incubated overnight at 37°C, an 
isolated colony from this plate was used to inoculate a 5 ml LB-ampicillin starter culture 
and incubated in a shaking incubator at (-300rpm) 37°C for 8 hrs One millilitre o f the 
starter culture was used to inoculate 25 ml o f LB-ampicillin in a 250 ml sterile flask and 
incubated overnight in a shaking incubator at 37°C The O D o f the culture must read 1- 
1 5 at X = 600 nm The following centrifugation steps were carried out using a JA-20 
rotor in a Beckman centrifuge The bacterial culture was transferred to a centrifuge tube 
and subjected to centrifugation at 6,000 x g for 15 min at 4°C The supernatant was 
removed and the pellet was dried by inverting the tube on tissue paper and allowing any 
remainder o f the supernatant to dram off The bacterial pellet was resuspended 
completely in 4 ml o f ice-cold Buffer PI containing RNaseA (100|ng/ml) and then 4 ml o f 
freshly prepared Buffer P2 was added and incubated at room temperature for 5 mm
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Following incubation, 10 ml o f prechilled Buffer P3 was added, mixed by gentle 
inversion o f the tube (5-6 times) and then incubated on ice for 20 min. The mixture was 
then centrifuged for 1 hr at 20,000 x g at 4°C.
The Qiagen-tip 100 was equilibrated by applying 4 ml o f QBT buffer and allowing the 
column to empty by gravity. The column does not dry out at this stage as the flow of 
buffer will stop when the buffer reaches the upper filter. After the centrifugation step, the 
supernatant was removed immediately from the tube without disturbing the pelleted 
material and applied to the column after filtering through 1MM filter paper. The 
QIAGEN-tip was washed with 2 x 10 ml o f Buffer QC. DNA was then eluted with 5 ml 
o f Buffer QF. DNA as precipitated by adding 0.7 volumes o f room-temperature 
isopropanol and centrifuged immediately at 15,000 x g for 30 min at 4°C and the 
supernatant was carefully removed. The resulting pellet was washed with 70% (v/v) 
ethanol, allowed to air dry for 5 min and redissolved in a suitable volume o f TE or dF^O. 
DNA was then quantified by spectrophotometric analysis as described in section 2.3.13.
2.3.10 Agarose gel electrophoresis o f DNA
Electrophoresis through agarose gel is the standard method used to separate, identify, and 
purify DNA fragments. The technique is simple, rapid to perform and can be used for the 
isolation o f DNA fragments.
An appropriate quantity o f agarose or low melt agarose was added to 100 ml IX
TBE/TAE buffer based on the percentage agarose gel required. Increasing the percentage
agarose (1.8-2.0%) in thegel was generally used to improve resolution o f smaller DNA
fragments while separation o f larger DNA molecules was best achieved by using lower
percentage gels (0.7%-0.8%). The agarose was completely dissolved by boiling and after
sufficient cooling (~60°C) the gel was cast into the Hybaid horizontal gel electrophoresis
system and a comb was inserted for formation o f wells. The gel was allowed to set for at
least 1 hour before filling the chamber with IX  TBE/TAE and removing the comb.
Sample buffer containing bromophenol blue as a tracking marker was added to each
sample before loading up to a maximum volume o f 20fil per well. DNA sample buffer
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was also added to 500 ng o f a 1Kb or 100 bp DNA ladder which was loaded as a size 
marker The gel was run at constant voltage (5 V/cm), usually at 100V, for 1-2 hr 
W hen complete, the gel was stained in ethidium bromide (0 5 mg/ml) for 30 mm, placed 
in distilled water to destain for 15 min and viewed under UV illumination
2.3.11 Isolation o f DNA from agarose gels
Low melting point agarose solution was prepared in IX  TAE buffer (gel isolation is not 
carried out in TBE buffer as borate ions are difficult to remove from the resultant DNA 
solution) Ethidium bromide was added to the samples before electrophoresis so as to 
minimise manipulations with the fragile low melting point agarose gels After 
electrophoresis, the gels were viewed under 70% UV illumination The time o f  exposure 
to UV light was kept to a minimum, as overexposure would cause damage to the DNA 
The DNA band o f interest was excised from the gel using a clean scalpel, excess agarose 
was cut away to minimise the size o f the gel which was then placed in a sterile microfuge 
tube
2.3.12 Purification o f DNA from low melt agarose
All DNA fragments o f interest were purified from agarose using the Wizard PCR Preps 
DNA Purification System (Promega) as follows the agarose gel slice (300 mg) was 
placed in a sterile microcentifuge tube and heated to 70°C until the agarose had melted 
completely One millilitre o f the resin provided was added to the liquified solution and 
mixed gently but thoroughly for 20 s (not vortexed)
A 2 ml syringe (plunger removed) was attached to the Wizard minicolumn and the 
DNA/agarose/resin mix was added to the syringe The plunger was replaced and the mix 
was pushed gently through the column The column was washed with 2 ml o f 80% (v/v) 
isopropanol and then subjected to centrifugation at 10,000 x g for 2 mm to dry the resin 
The DNA was eluted from the resm by adding 50 (il o f TE or dH20  to the minicolumn ,
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incubating for 1 mm at room temperature followed by centrifugation at 10,000 x g for 
20s The purified DNA was stored at 4°C or at -20°C
2.3.13 Spectrophotometric analysis of nucleic acids
DNA and RNA concentration was determined by measuring the absorbance at 260 nm, 
which is the wavelength at which nucleic acids absorb maximally (X max) A 50 |ig/ml 
preparation o f pure DNA has an absorbance o f 1 unit at 260 nm while 40 |ig/ml o f pure 
RNA also has an absorbance reading o f 1 at this wavelength The purity o f an RNA or 
DNA preparation was determined by reading absorbance at 260 nm, the X max for nucleic 
acids and at 280 nm, the X max for proteins and obtaining the ratio for these absorbances 
Pure DNA and RNA have A 260/A280 ratios o f 1 8 and 2 0 respectively Lower ratios 
indicate the presence o f protein while higher ratios often indicate residues o f organic 
reagents
2.4 CELL CULTURE METHODS
All cell culture techniques were performed in a sterile environment using a Holten class 
II laminar air-flow cabinet Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope
2.4.1 Culture of cells in suspension
All media compositions and media supplements are given in the Appendix The cell lines 
DG75, DG75 tTA, DG75 tTA EBNA 2, DG75 tTA LMP1, BJABtTA, Mutu 1, Mutu 3 
c95, M utu 3 LMP1-, X50-7, BL41, BL41-B958, IARC 171, Rael BL, IARC 290B, 
Ag876 III, OKUBL, OKU LCL, Jurkat and Jurkat tTA LMP-1 were maintained in 
supplemented RPMI 1640 Additional supplements were added to some culture media
(see section 2 4 4) Cultures were seeded at a density o f 2 x 105 to 5 x 105 cells per ml in
2 2 25 cm flasks and expanded in 75 cm flasks Cells were sub-cultured two or three times
per week by harvesting into a sterile centrifuge tube and centrifuging at 1000 x g for 5
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min at room temperature The cell pellet was resuspended gently in an appropriate 
volume o f fresh media and replaced into the tissue culture flask All cell lines were 
incubated in a humidified 5% CO2 atmosphere at 37°C in a Heraeus cell culture 
incubator
2.4.2 Culture o f adherent cells
C33A, C33A Neo and C33A LMP1 were maintained in high glucose DMEM 
supplemented with 10% (v/v) FCS, penicillin (100 umts/ml) and streptomycin (1 |ag/ml) 
In addition, the growth medium for latter two cell lines was supplemented with 600 
)j.g/ml geneticin Cultures were seeded into 25 cm and 75 cm tissue culture flasks As 
the cells were strongly adherent trypsimsation was required for harvesting prior to sub- 
culturing For trypsimsation the medium was decanted and the cells were washed with 2 
ml o f sterile IX  PBS to remove any residual FCS which contains a trypsm-mhibitor 
activity (ct2 -m acroglobuhn) Two millilitres o f IX  trypsin EDTA solution was placed in 
each flask and the flasks incubated at 37°C for 5 mm or until all the cells could be 
visualised as having detached form the flask surface The cell suspension was then 
decanted into a sterile centrifuge tube containing 5 ml o f sterile supplemented media 
(FCS inhibits trypsin) and centrifuged at 1000 x g for 5 mm Cells were resuspended in
csupplemented medium at 2 to 5 x 10 cells/ml, using 5 ml per 25 cm flask and 15 ml per 
75 cm flask Cells were then incubated as in section 2 4 1
2.4.3 Preparation of conditioned medium
Conditioned medium was prepared by regrowing cells in exponential phase o f growth in 
fresh medium for 24 h After centrifugation o f the cell suspension at 1,000 x g for 5 mm 
at room temperature, the supernatant was filtered through a 0 45 (am filter (Gelman 
Sciences) and then used immediately for testing
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2.4.4 M edia supplements
Supplements were added to the growth media o f certain cell lines to (a) improve cellular 
proliferation or (b) to select cells containing transfected plasmids (all media supplements 
are outlined in the Appendix L-cysteine is required for the survival and proliferation o f 
many group I BL cell lines However, L-cysteine is rapidly oxidised under normal 
culture conditions To improve proliferation o f the group I Burkitt’s lymphoma cell line 
Mutu 1, a-thioglycerol was added to growth media as a stable substitute for L-cysteine 
The a-thioglycerol was dissolved in bathocuprine disulfomc acid (BCS) which 
effectively prevents auto-oxidation o f thiols in liquid solutions Sodium pyruvate was 
also added to protect against H2 O2 which may be generated HEPES was added to 
maintain an alkaline pH o f 7 4 The cell lines DG75 tTA LMP1 and Jurkat tTA LMP1 
are tetracycline-responsive cell lines in which the LMP-1 gene is cloned downstream if  a 
promoter containing a binding site for a hybrid tetracycline regulated transactivator (tTA) 
which is constitutively expressed from a second co-transfected plasmid (Floettmann et 
a l , 1996) Tetracycline binds the tTA and prevents it binding to the promoter which 
remains silent, but upon removal o f tetracycline from the growth medium the tTA binds 
the promoter sequence and activates transcription Theses cell lines were maintained in 
supplemented RPMI containing 1 |ig/ml o f tetraycline Every three weeks the 
transfectants were reselected by the addition o f 800 |_ig/ml o f hygromycin to DG75 tTA 
cultures, 800 |.ig/ml o f hygromycm and 2,000 |ag/ml o f geneticin (G418) to DG75 tTA 
LMP1 and 300 (ag/ml o f hygromycm and 2,000 jig/m 1 geneticin to Jurkat tTA LMP1 
cells
The stably transfected cell lines C33A Neo and C33A LMP1 were maintained in 
supplemented high-glucose DMEM containing 600 (ig/ml o f geneticin The parental cell 
line C33A was maintained in supplemented high glucose DMEM
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2 4.5 Cell counts
Cell counts were performed using an improved Neubauer haemocytometer slide Trypan 
blue exclusion dye was routinely used to determine cell viability Ten microlitres o f 
trypan blue was added to 90 jj,1 o f a cell suspension and mixed A sample o f this mixture 
was added to the counting chamber o f the haemocytometer and cells were visualised by 
light microscopy Viable cells exclude the dye and remained clear while dead cells 
stained blue Cell numbers were ascertained by multiplying the average cell count (of 
three individual counts) by the dilution factor (usually 1 1) and again by the volume of 
the haemocytometer chamber (1 x 104/ml) Thus, cell counts were expressed as number 
o f cells per ml
2.4.6 Cell storage and recovery
Cell stocks were prepared for long term storage as follows Suspension cells 1 x 107 cells 
in exponential phase were pelleted and resuspended in 800 pi o f supplemented RPMI to 
which 100 (0.1 o f  FCS was added, then placed on ice for 10 mm DMSO was added to a 
final concentration o f 10% (v/v), mixed gently and transferred to a sterile cryotube 
Adherent cells one confluent 75 cm2 flask o f adherent cells was used per cell stock 
Adherent cells were washed with IX  PBS followed by trypsimsation and resuspension in 
900 pi o f FCS and 100 |0,1 o f DMSO The cells were mixed gently and transferred to a 
sterile cryotube The cryotubes were slowly lowered into the gas phase o f liquid nitrogen 
and immersed in liquid nitrogen in a cryofreezer (Cooper Cryoservices Ltd) Cells were 
recovered form liquid nitrogen by thawing rapidly at 37°C and transferring to a sterile 
centrifuge tube containing 5 ml o f prewarmed supplemented media The cells were 
centrifuged at 1000 x g for 5 mm, the pellet was resuspended in 5-10 ml o f fresh 
supplemented medium, transferred to a culture flask and incubated at 37°C in 5% CO2
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2.4.7 Induction of gene expression m the tetracycline-regulated cell system
After counting cells, an appropriate volume was pelleted at 1,000 x g for 5 min and 
washed three times in sterile PBS Cells were then incubated in supplemented RPMI 
medium for 1 h at 37°C Cells were washed again once in sterile PBS and seeded at 
approximately 2-5 x 105 cells per ml m the presence or absence o f tetracycline 
Unmduced cells (Tet+) were washed as per induced cells (Tet -) but were constantly 
maintained in the presence o f tetracycline
2.4.8 Transient transfections
Transient transfection o f cells was performed by the DEAE-dextran protocol or by 
electroporation In both cases, cells were seeded at a density o f 5 x 105 per ml o f 
medium 24 h prior to transfection Total DNA for transfection was normally co- 
precipitated in 100% ethanol, then washed in 70% ethanol and resuspended in a final 
volume o f 30 pi TE buffer pH 7 4 (this pH is very important), using the same total 
quantity o f DNA per transfection
2.4.8.1 Electroporation of B lymphocytes
On the day o f transfection, cells were centrifuged at 1,000 x g for 5 mm, washed once in 
a small (one-fifth) volume of complete RPMI medium and resuspended in complete 
RPMI medium at a density o f 2 x 107 cells per ml For each transfection, a 60 mm culture 
dish with 5 ml complete medium (RPMI 1640/glutamine/10 %FCS) was preincubated at 
37°C for at least 1 h prior to transfection The DNA to be transfected (dissolved in 30 pi 
T E pH 7 4) was added to the bottom of labeled cuvettes (Biorad, 0 4 mm) placed on ice 
500(j,l o f the cell suspension (= 1 x 107 cells) was then dispensed into the cuvettes and 
mixed with the DNA Each cell/DNA mix was then pulsed at either 270 V in the case o f 
M utu I cells or 300 V in the case o f IARC 290B and IB4 cells with a capacitance o f 
960|iF in a Biorad electroporator with a capacitance extender, and the cuvettes returned 
to ice immediately after electroporation Cells must not stay longer than 10 mm on ice
72
before being transferred to media Contents o f cuvettes were transferred to culture dishes 
using a micropipette and yellow tip, treating the cells gently during the process Cuvettes 
were washed with media from the culture dish, and placed at 37°C in a 5% CO2 incubator 
for the required amount o f time
2.4.8.2 DEAE Dextran-mediated transfection
Details o f all solutions required for this protocol are given in the Appendix section The 
day before transfection, cells were seeded at 5 x 105 cells/ml After 24 h in culture, cells 
were counted again -  it was essential for cell numbers to have almost doubled before 
beginning the transfection, thus ensuring that cell growth is in logarithmic phase and that 
cells are at their optimum for the uptake o f DNA during transfection 1 4 x 107 cells were 
used for each transfection On the day o f transfection, cells were centrifuged at 1,000 x g 
for 5 mm, resuspended in sterile TBS and 1 4 x 107 cells dispensed into 25 ml stenlin 
tubes After centrifugation, all o f the supernatant was removed with any traces o f TBS 
carefully (without disturbing the cell pellet) removed using a pipette tip The DNA- 
DEAE dextran mixes were prepared in microfuge tubes as follows A total o f between 6 
and 16 0 pg o f DNA made up to a volume of 30 pi with TE buffer pH 7 4 was used per 
transfection and 570 pi TBS was then added to the DNA in a microfuge tube For any 
transfection set, the total amount o f DNA was kept constant with any deficiencies made 
up with the corresponding empty vector Then, 600 pi o f 1 mg/ml DEAE dextran 
solution made up in TBS was mixed with the DNA solution and the cell pellet gently 
resuspended in the DNA-DEAE dextran mix The transfection cocktails were incubated 
at room temperature for 30 mm (40 min in the case o f Jurkat T cells) with gentle swirling 
every 5-10 min to allow homogenisation Transfections were terminated by adding 10 ml 
o f warm (37°C) complete RPMI medium and the cells pelleted by centrifugation at 1,000 
x g for 5 mm The cells were then washed once more with 10 ml complete medium and 
then transferred m 10 ml o f medium to 25 cm2 cell culture flasks for incubation
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2.4.8.3 Luciferase assays
Cells for luciferase assay were normally harvested 24 or 48 h post-transfection Cells 
were pelleted by centrifugation at 1,000 x g for 5 mm at room temperature, washed once 
in sterile PBS and then transferred to a microfuge tube in 1 ml o f sterile PBS After 
centrifugation at 5,000 x g for 5 min at room temperature, the supernatant was completely 
removed and the cell pellet resuspended in 100 pi o f Reporter lysis buffer (1 X, 
Promega) The tubes were vortexed for 10-15 s and lysis allowed to proceed for 15 mm 
on ice The lysates were subjected to one freeze-thaw cycle and then clarified by 
centrifugation at 12,000 x g for 5 mm and the supernatant saved in a fresh tube Samples 
were stored at -80°C  until required, when 20 pi was taken for assay Samples are stable 
in lysis buffer over several freeze-thaw cycles At the time o f assay, it was important to 
allow sufficient time for the detection reagent (stored at - 80°C) to equilibrate to room 
temperature Subsequently, 100 pi o f detection reagent was added to the sample, mixed 
by repetitive pipetting (3 times) and light emission integrated over a period o f  60 s after 
lag period o f 10 s in a luminometer Luciferase activity levels were adjusted for 
transfection efficiencies, estimated using P-galactosidase activities expressed from 
pCMVlacZ construct (lp g ) included in the transfections (section 2 4 8 4) Normalised 
luciferase values were expressed as fold activation relative to control and the average 
from 2 independent experiments were usually plotted unless indicated otherwise
2.4.8.4 p-galactosidase assay
The P-galactosidase assay was performed using the same lysates as that used for 
measuring the luciferase activity Mock-transfected (lacking DNA) cells were included as 
a control to account for endogenous enzyme activity and these values used to calculate 
the activity due to transfection o f the lac Z  containing expression vector Cell extract (30 
pi) was added to 3 pi 100X Mg solution, 66 pi ONPG (0-mtrophenyl p-D 
galactopyranoside) and 201 pi 0 1 M sodium phosphate pH7 5 (Appendix, Sambrook et 
a l , 1989) and incubated at 37°C for 30 min or until a faint yellow colour developed. A 
reaction tube was included in which ONPG substrate was omitted in order to obtain a
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background reading Reactions were terminated by adding 500 pi 1 M Na2CC>3 Optical 
densities were read at 420nm over a linear range o f 0 2-0 8
2.4.9 Stable transfections
2.4.9.1 Establishment o f sensitivity o f cells to geneticin (G418)
Mutu I cells, in logarithmic phase o f growth, were seeded at a density o f 2 x 105 cells per 
ml in media containing 0, 200, 400, 600, 800, 1000, 1200, 1400, 1600, 1800 or 2000 pg 
o f active G418 per ml and grown for 12 days under standard conditions Media was 
changed every 4 days during this time and cell viability measured every 3 days by trypan 
blue exclusion The minimum concentration o f G418 which killed > 95% o f the cells 
after the 12 day period was determined and this concentration then used in subsequent 
selection procedures for the generation o f stable transfectants (section 2 4 9 2)
2.4.9.2 Generation of a pool o f transfectants o f Mutu I cells Expressing HA-Bfl-1
Stable transfectants o f Mutu I expressing HA-tagged Bfl-1 or HA were established by 
electroporation o f the cells with 10 pg o f pcDN A3 HA-Bfl-1 or pcDNA3HA as described 
in section 2 4 9 1 A mock transfection (without DNA) was also set up and the cells 
maintained under similar experimental conditions as the HA-Bfl-l -  or HA- transfected 
cells At 48 h post-electroporation, the media was replaced with selection medium 1 e 
normal growth medium but containing 1,400 pg active G418 per ml M edia containing 
antibiotic was changed every 3 - 4  days for the next 21 days by which time all o f the 
mock-transfected cells were killed The transfected population o f cells was then 
examined for the expression o f HABfl-1 and its functional consequence within the next 
14 days
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2.4.10 Apoptosis assays
2.4.10.1 DNA fragmentation analysis
For the DNA ladder assay, cells were washed once in PBS and then lysed in a buffer 
comprising 0 8 % sodium lauryl sarcosinate, 20 mM EDTA pH 8 0, 100 mM  Tns-HCl 
pH 8 0 and 0 5 mg/ml proteinase K for 12 h at 50°C followed by treatment with 0 5 
mg/ml RNase A for 4 h at 37°C The DNA was mixed with DNA loading dye 
(Appendix) and electrophoresed through a 2% agarose -  1 x TBE gel at 60 V for 3 h in 1 
x TBE buffer The gel was stained in an ethidium bromide bath before visualisation 
under UV light
2.4.10.2Acridine orange staining of cells
Ninety-five pi o f the cell suspension mixed with 5 pi o f a lOOpg/ml solution o f acndine 
orange was placed on a glass slide and then immediately visualised with a fluorescence 
microscope Non-apoptotic cells display a diffuse chromatin staining pattern while 
apoptotic cells display a characteristic condensed chromatin staining pattern (Gregory et 
a l , 1991) The percentage o f apoptotic cells was determined from counts on at least 150 
cells per individual culture
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2.5 RNA ANALYSIS
2.5.1 RNase-free environment
RNA is easily degraded by ubiquitous RNase enzymes and thus stringent measures were 
employed to avoid this potential hazard. All glassware and metal spatulas were baked 
prior to use at 180°C for 16 - 24 h in order to inactivate any RNases. Sterile disposable 
plasticware is generally considered RNase-free and thus did not require treatment. 
RNases are resistant to autoclaving but they can be deactivated by the chemical 
diethylpyrocarbonate (DEPC). DEPC was added to solutions at a final concentration o f 
0.1 % (v/v), incubated at room temperature for 18 hr and then autoclaved. Solutions 
which contain amines such as Tris cannot be DEPC-treated as the amines are inactivated 
by DEPC. Solutions containing these chemicals were prepared using DEPC-treated 
upFkO followed by autoclaving. Hands are a major source o f RNase contamination, 
thus, gloves were used at all times and changed frequently.
2.5.2 RNA extraction from cultured cells
Prior to RNA isolation, the cells were examined by phase contrast microscopy to 
determine the condition o f the cells. A cell count was performed as described in section 
2.4.5. RNA was extracted from cultured cells using the commercial reagent RNA 
ISOLATOR™  (Genosys). Cells grown in suspension were pelleted and then lysed in 
RNA ISOLATOR™ by repetitive pipetting. One millilitre o f RNA ISOLATOR™  was 
used per 1 x 107 cultured cells. Cells grown in monolayers were lysed directly in the cell 
culture plates as trypsin can lead to the introduction o f RNases. The lysate was collected 
by a sterile cell scraper and pipette and then homogenized as above. The homogenised 
sample was incubated at room temperature for 5-10 min to allow complete dissociation o f 
nuclear protein complexes (the procedure may be stopped at this point by storing samples 
at -70°C ). Phase separation was achieved by adding 0.2 ml o f chloroform per 1 ml o f 
RNA ISOLATOR. The samples were covered and shaken gently but thoroughly for 15 s 
or until completely emulsified. Samples were incubated at room temperature for 15 min.
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The resulting mixture was centrifuged at 12,000 x g for 15 mm at 4°C Following 
centrifugation the mixture separates into a lower red, phenol-chloroform phase, an 
mterphase and a colourless upper aqueous phase The aqueous phase, which contains the 
RNA, was removed to a fresh tube and RNA was precipitated by adding 0 5 ml o f 
isopropanol per ml o f RNA ISOLATOR used initially The samples were stored for 10 
mm at room temperature, then centrifuged at 12,000 x g for 10 mm at 4°C The resulting 
RNA pellet was washed using 1 ml o f 75% (v/v) ethanol by inverting the tube 5 times 
The pellets were then recentnfuged at 10,000 x g for 5 mm at 4°C and the 75% (v/v) 
ethanol was removed Pellets were air dried and dissolved in DEPC-treated upHiO The 
resulting RNA preparation was heated at 60°C and mixed gently to ensure a 
homogeneous solution prior to aliquoting An aliquot was removed for 
spectrophotometnc and gel electrophoretic analysis (sections 2 3 13, 2 5 3)
2.5.3 RNA analysis by gel electrophoresis
In order to check the integrity o f RNA, isolated samples were run on a 1 6 % (w/v) 
agarose -  1 x TAE gels These gels were prepared as outlined in section 2 3 10 The 
RNA samples (5 pi) were prepared for electrophoresis by adding 15 pi o f RNA sample 
buffer and 3 pi o f RNA loading buffer The samples were heated to 65°C for 10 mm 
prior to loading on the gel The gel was run in IX  TAE as described in section 2 3 10 
As ethidium bromide is included in the RNA loading buffer the gels did not require 
further staining and could be visualized directly on a UV transilluminator The presence 
o f two strongly staining bands represent the 28 S (approx 5 0 kb)and the 18 S (approx 
1 8 kb) ribosomal RNAs, which indicated intact RNA Degradation is observed by a 
smear running down the length o f the gel
2.5.4 Northern blotting
Northern blotting was carried out according to Sambrook et al, (1989) RNA samples 
were first size-fractionated on a formaldehyde gel
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2.5.4.1 Treatment o f electrophoresis apparatus
Prior to electrophoresis o f RNA through formaldehyde gels, the electrophoresis apparatus 
was treated to remove any RNase The tank, gel tray, comb and lid were washed in 
detergent, rinsed well in DEPC-treated H2 O and then air dried in 100% (v/v) ethanol 
The tank, gel tray and comb were then immersed in a 3% (v/v) solution o f Hydrogen 
peroxide for 15 minutes The apparatus was then rinsed thoroughly m DEPC-treated 
upHzO and allowed to air-dry
2.5.4.2 Electrophoresis o f RNA through gels containing formaldehyde
As formaldehyde vapours are toxic these gels were prepared m a fume hood The gel 
was prepared by melting the appropriate amount o f agarose m DEPC-treated water, 
cooling to 60°C and adding 5X formaldehyde gel running buffer and formaldehyde to 
give a final concentration o f 1 X and 2 2 M respectively (Appendix) The gel was 
allowed to set for at least 1 h The samples were prepared by mixing the following in a 
microcentrifuge tube
RNA (up to 30 pg) 4 5pl
5X formaldehyde gel running buffer 2 Opl
Formaldehyde 3 5 pi
Formamide 10 pi
The samples were incubated at 65°C for 15 mm, chilled on ice then centrifuged briefly to 
collect the sample Ethidium bromide was added to the samples (0 01 pg/sample) to 
enable examination o f the quality o f the RNA briefly under UV (70% strength) after 
electrophoresis Sterile DEPC-treated gel loading buffer (2 pi) was added to each sample 
and applied to the gel immediately after pre-running the gel for five minutes at 5V/cm 
Gels were run while submerged in IX formaldehyde gel running buffer for approximately 
3 hr or until the dye front had migrated two-thirds o f the way down the gel The gel was
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removed from the buffer and viewed under UV light The gel was then processed for 
blotting as described m section 2 5 4 3
2.5.4.3 Transfer o f denatured RNA to nitrocellulose filters
Gels containing formaldehyde were first washed in several changes o f DEPC-treated 
H2 O As the percentage agarose used to prepare the gel was greater than 1% (w/v), the 
gel was soaked in 0 05 M NaOH for 20 mm This treatment hydrolyses the RNA and 
improves the efficiency o f transfer The gel was then rinsed in DEPC-treated H 2O and 
soaked in 20X SSC for 45 mm (Sambrook et al, 1989) Unused areas o f the gel were 
trimmed away and the top left-hand com er was cut for orientation purposes in this and 
succeeding operations Capillary transfer was used to transfer the RNA onto the filter 
transfer was set up as illustrated m Figure 2 1
W eight 
Glass plate
Paper towels
F ig u re  2 1 C a p illa ry  tra n s fe r  o f nucleic acids from  agarose  gels to solid su p p o rts  A dapted  from  
Sam brook et a l , 1989
A solid support was placed m a bath o f 20X SSC A sheet o f 3MM W hatman paper was 
cut to cover the support and dip down either side into the buffer The washed gel was 
then placed (wells facing down) on to the Whatman and covered by a piece o f
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nitrocellulose membrane cut to the size o f the gel. This membrane was pre-wetted in 
deionised water and then soaked in 20X SSC for at least 5 min prior to placing it on the 
gel. The buffer chamber was then covered with cling film. Two pieces o f 3MM 
Whatman paper which had been soaked in 2X SSC were then placed on top o f the filter 
paper, care was taken at all times to ensure that no bubbles were trapped when preparing 
the transfer. A stack o f paper towels were then placed on top o f the gel and held in place 
by a weight. Transfer was allowed to proceed overnight. After transfer was completed, 
the saturated paper towels were removed as were the Whatman paper sheets. The gel and 
the filter paper were removed together and turned upside down on a clean piece o f towel. 
The position o f the wells were marked using a ball point pen and the gel was then 
discarded. The filter was washed briefly in 6X SSC to remove any remnants o f the gel 
that may have adhered to the membrane, then placed on a fresh sheet o f W hatman paper 
and allowed to dry for at least 30 min. The dried filter was then placed between two 
pieces o f 3MM Whatman paper and baked in an oven at 80°C for 2 hr. The filter was 
then used directly for prehybridisation or stored at room temperature wrapped in 
aluminium foil.
2.5.4.4 Purification of a  P-Iabelled riboprobes from denaturing polyacrylamide gels
Riboprobes generated by in vitro transcription o f the APO-2 template set (section 2.5.6.1) 
were size-fractionated on a 5% polyacrylamide-urea gel (section 2.5.6.4) and those 
corresponding to the genes o f interest (bcl-2, bfl-1, bcl-x and GAPDH) were excised from 
the gel by the ‘crush and soak’ method (Sambrook et al., 1989) for use in Northern 
analysis. After polyacrylamide gel electrophoresis o f the set o f in vitro transcribed 
fragments, the plates were disassembled. ‘Orientation’ markers were prepared by 
carefully streaking a 32P-UTP-containing loading dye (containing bromophenol blue) 
across a piece o f filter paper in a recognisable shape and wrapping the filter paper tightly 
with selotape. Two o f such ‘orientation’ markers were placed directly on the gel at 
positions away from the lanes containing the samples o f interest. The gel was then 
wrapped in cling film and exposed to X-ray film for a length o f time (usually 1-2 min) 
that permitted visualisation o f the bands o f interest and the orientation markers. Once the
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appropriate exposure o f  the gel was achieved, the X-ray film was placed on the gel and 
aligned using the ‘orientation’ markers The DNA fragments o f interest could thus be 
located in the gel and were excised using a clean sharp razor blade After excision o f the 
gel slices, the fragments were eluted by the crushing the gel slices in 2 volumes 
(approximately 300pl) o f elution buffer (see Appendix) in a microfuge tube After a short 
vortex, the tubes were centrifuged briefly and incubated at 37°C for 3-4 hours, with 
intermittent crushing and vortexing every 30-40 minutes The samples were then 
subjected to centrifugation at 13,000 x g for 20 mm and the supernatant saved A half­
volume (75 fj.1) o f elution buffer was added to the crushed gel slice, the sample vortexed 
briefly, and subjected to centrifugation as before and incubated at 37°C for an hour 
After centrifugation, the supernatant was saved and combined with the first eluant 
fraction The riboprobes were precipitated by the addition o f 2pg o f yeast tRNA and 2 
volumes o f ice-cold ethanol and incubated at -20°C for at least 2 hours After 
centrifugation at 13,000 x g for 30 mm at room temperature, the pellet was washed with 
75% ethanol, air dried and dissolved in 50pl o f DEPC-treated upHaO A one |_il sample 
o f the purified nboprobe was used to measure the level o f incorporation o f radiolabel 
using a scintillation counter
2.5.4.5 Prehybridization and hybridization protocol
The dried membrane was placed in a baked hybridization bottle, 10 ml o f hybridization 
buffer (see Appendix) was added and incubated in a Hybaid roller oven for 2 to 3 hours 
at 55°C The prehybridization buffer was then removed and fresh hybridisation buffer 
(preheated to 55°C) containing the nboprobe (1-2 x 106cpm/ml) was promptly added 
Hybridization was allowed to proceed for 16-24 hours at 55°C
2.5.4.6 Stringency washing
Following the overnight incubation the hybridization buffer was removed and the 
membrane was washed successively as follows
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Table 2 3 Northern blot stringency washes
Wash solution Temperature Time
IX SSC, 0 1% (w/v) SDS Room temperature 30 s
IX SSC, 0 1% (w/v) SDS 22°C 30 min
IX SSC, 0 1% (w/v) SDS 22°C 30 min
0 IX SSC, 0 1% (w/v) SDS 65°C 30 min
0 IX SSC, 0 1% (w/v) SDS 65°C 30 min
After washing the membrane was removed gently from the hybridization bottle and 
placed in a stomacher bag in a cassette The blot was kept moist at all times with 0 IX  
SSC, 0 1% (w/v) SDS The membrane was exposed to X-ray film for 24-96 hr at -80°C
2.5.5 Determination of b f l - 1  mRNA half-lives
The half-life o f bfl-1 mRNA in various cell lines was determined by monitoring the rate 
o f decay o f bfl-1 mRNA by Northern blotting (section 2 5 4) o f RNA extracted from cells 
(seeded at 106 cells per ml) at various times after treatment with an inhibitor o f RNA 
synthesis, actinomycin D (5|ag/ml) Bfl-1 mRNA levels in treated cells were determined 
by densitometnc analysis o f autoradiograms after Northern blotting using the LISCAP 
capture and image analysis program (Pharmacia), and values were corrected for 
variations due to loading after estimation o f the 18S rRNA levels in each lane (as 
determined by densitometnc analysis o f ethidium bromide -  stained gels) Values thus 
obtained were expressed as a percentage o f the bfl-1 mRNA level in untreated cells 
(taken as 100%) The half-life o f bfl-1 mRNA (i e the time taken for the mRNA to decay 
to 50% o f the level observed in untreated cells) was then determined from the best-fit 
semilogarithmic line o f the graph o f these values plotted against time (hours) o f exposure 
to actinomycin D
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2.5.6 RNase protection assay
The ribonuclease protection assay (RPA) is a highly sensitive and specific method for the 
detection and quantitation o f mRNA species. The RiboQuant® RNase protection assay 
system (PharMingen) was employed during this study. The procedure is outlined below:
Day 1: Probe Synthesis RNA preparation
1
Overnight Hybridization
I
Day 2: RNase treatment and Purification O f Protected Probes
Gel preparation
I I
Electrophoresis on Denaturing 
Polyacrylamide Gel
I
F igure  2.2 O verview  o f the  ribonuclease pro tection  assay protocol.
2.5.6.1 Probe synthesis
The [oc-32P]UTP, GACU nucleotide pool, DTT, 5X transcription buffer and the template 
DNA set was brought to room temperature prior to setting up the reactions. The 
following were added to a 1.5 ml microcentifuge tube for each probe Synthesis:
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Rnasm 
GACU pool 
DTT
5X transcription buffer 
Template DNA
[oc-32P]UTP(3000Ci/mmol, 10mCi/ml) 
T7 RNA polymerase
lp l
lp l
2pl
4pl
lp l
1 Opl
I [il
The contents o f the tube were mixed by gentle pipetting and centrifuged quickly followed 
by incubation at 37°C for 1 hour The reaction was terminated by adding 2 pi o f RNase - 
free DNase, mixing gently and incubating at 37°C for 30 min The following reagents 
were then added to the reactions
The contents were vortexed into an emulsion and centrifuged for 5 mm at room 
temperature The upper phase was transferred to a fresh tube containing 50pl o f 
chloroform isoamyl alcohol (50 1) , the contents o f the tube mixed by vortexing and the 
tube subjected to centrifugation (top speed) for 2 mm at room temperature The upper 
aqueous phase was transferred to a sterile 1 5 ml tube to which 50pl o f 4M ammonium 
acetate and 250pl o f ice cold 100% (v/v) ethanol was added The contents o f the tube 
were mixed by inversion and the tube incubated at -70°C for 30 mm followed by 
centrifugation at 4°C for 15 min The supernatant was removed and the pellet was 
washed with 1 OOpl o f ice cold 90% (v/v) ethanol after which the pellet was air-dried for 
5-10 mm The pellet was solubilized by the addition o f 50 pi o f hybridization buffer and 
gentle vortexing Duplicate one pi samples o f  the labelled probe were quantified in a 
scintillation counter. A maximum yield o f ~3 x 106 Cherenkov counts/pl with an
Tris saturated phenol
EDTA 20 mM 26pl
26pl
Chloroform isoamyl alcohol (50 1) 25pl
Yeast tRNA 2 pi
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acceptable lower limit o f -3  x 105 Cherenkov counts/pl was expected The probe was 
stored at -20°C until required Generally probe can only be used for two overnight
32hybridizations when labeled with [cc- P]UTP
2.5.6.2 RNA preparation and hybridization
RNA was prepared using the RNA isolation method outlined in section 2 5 2 Fifteen pg 
o f total RNA was used for each probe hybridization Each RNA sample was diluted to 
50 pi with DEPC-treated upFkO to which 50 pi o f 4 M ammonium acetate and 250 pi o f 
ice cold 100% (v/v) ethanol were added The samples were mixed by inverting and 
stored at -70°C for one hr or -20°C overnight The precipitated RNA was collected by 
centrifugation at 12,000 x g for 30 mm at 4°C and the pellet was washed with 90% (v/v) 
ice- cold ethanol After removal o f the supernatant and subsequent air-drying, the pellet 
was resuspended in 8 pi o f hybridization buffer by gently vortexing for 3-4 mm followed 
by a brief centrifugation step Two microlitres o f the probe was then added to each RNA 
sample and mixed by pipetting A drop o f mineral oil was added to each sample and the 
tubes were centrifuged briefly in the microfuge Samples were then placed in a heating 
block for 3 mm which had been preheated to 90°C, and then immediately turned down to 
56°C, allowing the temperature to ramp down slowly, and hybridisation allowed to 
proceed for 12-16 hr The temperature o f the heating block was then turned down to 
37°C prior to RNase treatment allowing it to ramp down slowly and the tubes maintained 
at 37°C for 15 mm
2.5.6.3 RNase treatments
An RNase mixture was prepared by adding 2 5 ml o f RNase buffer to 6 pi o f RNase A + 
T1 mix, per 20 RNA samples (RNase A 80ng/pl, RNase T1 250 U/pl) The RNA 
samples were removed from the heating block and 100 /pi o f  the RNase cocktail was 
added underneath the oil into the aqueous layer (bubble) The tubes were
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microcentrifuged for 10 s and incubated for 45 min at 30°C Before the RNase treatment 
was completed a Proteinase K mixture was prepared (per 20 samples),
Proteinase K buffer I X  390 pi
Proteinsase K (10 mg/ml) 30 pi
Yeast tRNA (2 mg/ml) 30 pi
The mixture was mixed together and 18 pi aliquots were added to a sterile 1 5 ml 
microcentifuge tubes The RNase-treated samples were extracted from underneath the oil 
and transferred to the tube containing the proteinsase K mixture (avoiding transfer o f oil) 
The RNase/Proteinase K mixture was vortexed briefly, subjected to brief centrifugation 
and incubated for 15 mm at 37°C Tns-saturated phenol pH 8 0 (65 pi) and 65 pi o f 
chloroform isoamyl alcohol (50 1) were added to the samples, vortexed into an emulsion 
then centrifuged for 5 mm at room temperature The upper aqueous phase was extracted, 
avoiding the mterphase, and transferred to a fresh tube to which 120 pi o f 4 M 
ammonium acetate and 650 pi o f ice cold 100% (v/v) ethanol was then added The 
contents o f the tubes were mixed by inversion and the tubes were subsequently incubated 
at -70°C for 30 mm Samples were subjected to centrifugation for 5 mm at 4°C and the 
pellet was then washed with ice cold 90% (v/v) ethanol and allowed to air-dry for 5-10 
mm The pellets were resuspended in 5 pi o f 1 X loading buffer (provided in the kit) 
Prior to loading onto the gel the samples were heated to 90°C for 3 mm and placed 
immediately in an ice bath
2.5.6.4 Denaturing polyacrylamide gel electrophoresis
Five percent (w/v) polyacrylamide-urea gels were prepared according to the formula 
given in the Appendix A Biorad gel electrophoresis system was used in this study The 
plates were washed with detergent, rinsed first with tap water and then with dHiO and 
finally wiped in one direction with tissue soaked with 100% (v/v) ethanol One plate was 
siliconsied using Sigmacote (Sigma) The apparatus was set up, the gel cast and the comb
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inserted as per manufacturer’s instructions Prior to loading o f the samples, the gel was 
pre-run m i x  TBE at a constant power o f 50 W for 45 mm -  lh  The wells were washed 
several times with electrophoresis buffer (1 x TBE) to remove unpolymerised acrylamide 
and urea that would otherwise interfere with loading and/or electrophoresis o f the sample 
After loading the samples, the gel was electrophoresed at 50 W for approximately 3 h 
After electrophoresis, the gel was carefully removed, placed on two sheets o f 3MM 
W hatmann paper cut to the size o f the gel, covered with Saran Wrap and vacuum dried at 
80°C for l-2h  The dried gel was then exposed to X-ray film in a cassette with two 
intensifying screens was exposed at -70°C for an appropriate length o f time
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2.6 W ESTERN BLOT ANALYSIS
2.6.1 Preparation of cellular protein extracts
Prior to protein isolation the viability o f the cells was examined and the viable cell count 
determined as described in Section 2 4 5 Four different methods were employed to 
isolate cellular protein with the method used depending on the ability to extract the 
protein o f interest
2.6.1.1 Preparation of cellular protein - Method A
This method was employed to isolate total cellular protein (l e cytoplasmic and nuclear 
proteins) and was used for the extraction o f LMP-1 and Bcl-2 proteins Cells were 
pelleted at 1,000 x g for 5 mm and washed with 5 ml o f ice-cold PBS The cells were 
then transferred to a microfuge tube m 1 ml o f ice-cold PBS, pelleted at 3,000 x g for 5 
mm and all o f the supernatant removed Adherent cells were washed twice with 5ml o f 
ice-cold PBS, scraped into 1 ml o f PBS and then pelleted by centrifugation at 3,000 x g 
for 5 mm The cell pellet was resuspended in ice-cold suspension buffer (0 1M NaCl, 
0 01M Tns-H Cl pH 7 6, 0 001M EDTA pH 8 0, lpg/m l aprotimn, lpg/m l leupeptin and 
lOOjUg/ml PMSF) using 200pl o f suspension buffer for every 5 x 106 cells An equal 
volume o f 2 x SDS gel loading buffer [lOOmM Tns-HCl pH 7 6, 4% (w/v) SDS, 20% 
(v/v) glycerol, 10%(v/v) 2-mercaptoethanol, 0 2% (w/v) bromophenol blue] was 
immediately added to the cell suspension, after which the sample becomes extremely 
viscous The sample was then placed m a boiling water bath for 10 min and then 
subjected to somcation for 1 min on full power to shear the DNA The lysate was 
clarified by centrifugation at 12,000 x g for 10 mm at room temperature The supernatant 
was aliquoted and stored at -20°C  Samples were analysed by SDS-PAGE, loading 
equivalent amounts o f protein from approximately 5 x 105 cells per lane
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2.6.1.2 Preparation of cellular proteins- Method B
This method extracts cytoplasmic and some membrane proteins but not nuclear proteins 
and was used for the extraction o f HA-tagged Bfl-1 protein (D ’sa Eipper et a l , 1996) 
Cells were harvested as described in Section 2 6 11 Cell lysis was performed by 
resuspending the cell pellet m ice-cold lysis buffer [ l% (v/v) NP-40, 0 5% (w/v) sodium 
deoxycholate, 1% (v/v) Triton X-100, 150 mM NaCl, 50 mM Tns-HCl (pH 8 0), Im M  
sodium orthovanadate, 100 pg/ml PMSF and 2 (ig/ml leupeptin] using 100 pi o f lysis 
buffer for every 5 x 106 cells Cell lysis was carried out for 30 mm on ice with occasional 
mixing Lysates were clarified by centrifugation at 13,000 x g for 15 mm at 4°C The 
supernatant was saved, dispensed into aliquots and stored at -20°C  Protein 
concentration o f the lysates was determined by using the BCA protein assay as described 
in section 2 6 2 and equal amounts o f protein (30-50 pg) used in SDS-PAGE
2.6.1.3 Preparation o f cellular proteins -  Method C
This method was used to extract the membrane protein CD40 (Baker et a l , 1998) Cells 
were harvested as described m Section 2 6 11 Cell lysis was performed by resuspending 
the cell pellet in ice-cold lysis buffer [1% (v/v) Triton X-100, 150 mM NaCl, 25 mM 
Tns-HCl (pH 7 6), 1 mM disodium EDTA, Im M  sodium orthovanadate, 50 mM  NaF, 
100 pg/ml PMSF and 2 pg/ml leupeptin] using 100 pi o f lysis buffer for every 5 x 106 
cells Cell lysis was carried out for 30 min on ice with occasional mixing Lysates were 
clarified by centrifugation at 13,000 x g for 15 mm at 4°C The supernatant was saved, 
dispensed into aliquots and stored at -20°C  Protein concentration o f the lysates was 
determined by using the BCA protein assay as described in section 2 6 2 and equal 
amounts o f protein (30-50 pg) was used in SDS-PAGE
2.6.1.4 Preparation o f cellular proteins -  Method D
This method was used to extract the phosphorylated and non-phosphorylated forms o f 
the Bcl-2 protein from cells and has been described previously (Haidar et a l , 1995) Cells
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were harvested as described in Section 2 6 11 Cell lysis was performed by resuspending 
the cell pellet in ice-cold lysis buffer [3% (v/v) Triton X-100, 150 mM  NaCl, 10 mM 
sodium phosphate (pH 7 4), 5 mM disodium EDTA, Im M  sodium ortho vanadate, 50 mM 
NaF, lOmM sodium pyrophosphate, 100 jag/ml PMSF and 2 pg/ml leupeptm] using 100 
p.1 o f lysis buffer for every 5 x 106 cells The extracts were subjected to three freeze-thaw 
cycles and lysis then continued on ice for 30 mm with occasional mixing Lysates were 
clarified by centrifugation at 13,000 x g for 15 mm at 4°C The supernatant was saved, 
dispensed into aliquots and stored at -20°C Protein concentration o f the lysates was 
determined by using the BCA protein assay as described m section 2 6 2 and equal 
amounts o f protein (30-50 pg) used in SDS-PAGE
2.6.2 Estimation of protein concentration
In order to standardise the amount o f protein used in SDS-PAGE or EMSA, the 
concentration o f protein in the cell extracts was determined using the BCA (bicinchonimc 
acid) protein assay kit essentially according to manufacturer’s instructions The 
‘microwell plate protocol’ was used A standard curve was constructed using BSA, with 
concentrations ranging from 0 to 2000 pg/ml using PBS as the diluent The sample 
concentration was determined within this range with test solutions diluted 1 5 and 1 10 in 
PBS (diluent) As a control for interference m the readings by substances in the 
extraction buffers, similar dilutions o f  extraction buffer as with the test solutions were 
included Also, all samples were prepared and assayed in duplicate The BCA assay 
reagent was prepared on the day o f use and incubated with the samples in a microwell 
plate at 37°C for 30 mm in the dark Absorbance was measured at 560nm on a plate 
reader and the readings subtracted from the appropriate controls and averaged 
accordingly A standard curve was plotted for the BSA standards (concentration versus 
absorbance) from which the protein concentration for each unknown sample could be 
determined
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2.6.3 Protein electrophoresis, preparation of SDS-PAGE gels
A two phase SDS-PAGE system was used to analyse proteins with a 5% stacking gel and 
either a 10% (LMP-1, phosphotyrosme containing proteins, CD40), or a 15 0% (Bcl-2, 
HA-Bfl-1) resolving gel prepared as outlined below
Resolving Gel
10 ml 10% (ml) 15% (ml)
acrylagel 3 33 5 0
bis-acrylagel 1 35 2 025
1 5 M T ns (pH8 8) 2 5 2 5
dH20  2 61 0 265
10% (v/v) SDS 0 10 0 10
10% (v/v) APS 0 10 0 10
TEMED 0 01 0 01
Stacking Gel
2 5 ml 5% (ml)
acrylagel 0 42
bis-acrylagel 0 168
1 M T ns (pH6 8) 0 312
dH20  1 5475
10% (v/v) SDS 0 025
10% (v/v) APS 0 025
TEMED 0 0025
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2.6.4 Polyacrylamide gel electrophoresis (PAGE)
An ATTO protein gel electrophoresis system was used in this study. Glass plates were 
washed with detergent, rinsed first with tap water and then with dH 2 0  and finally wiped 
in one direction with tissue soaked with 100 (v/v) ethanol. The gasket was placed about 
the ridged plate, the plates were put together and secured with clamps. The depth o f the 
resolving gel was marked on the outer plate. The resolving gel was then poured to within 
2 cm o f the top o f the larger plate and overlaid with 100% (v/v) ethanol. When set, the 
ethanol was removed and the stacking gel was poured. A clean comb was inserted and 
the gel was allowed to polymerise for 45 min-1 hr. The electrophoresis tank was filled 
with IX  Tris-glycine running buffer to the level o f the horizontal rubber gasket. After 
polymerisation the gaskets clamp stands and comb were removed. Unpolymerised gel 
was removed by gently rinsing the wells with running buffer and the wells were then 
straightened using a needle. The prepoured gels were lowered into the buffer at an angle 
to exclude air bubbles from the gel-buffer interface. The chamber formed by the inner 
plates was filled with IX  running Buffer, the samples were loaded (after addition o f SDS 
loading buffer containing 2-mercaptoethanol to a final concentration o f 1 x and heating to 
95°C for 5 min) and the electrodes were attached. The gels were electrophoresed at a 
constant current o f 30 mA per gel for approximately 1 hr in the case o f the 10% resolving 
gel or lh  30 min in the case o f the 15% resolving gel. After electrophoresis, the plates 
were disassembled and the gel was either placed in transfer buffer prior to western 
blotting or stained in Coomassie blue (Appendix). Staining took place for 30 min, 
agitating constantly. The gel was then washed several times in destain solution (see 
Appendix) with constant agitation, until all background staining was removed.
2.6.5 Western blot analysis
An SDS-PAGE gel was used for electrophoresis o f protein samples together with pre­
stained molecular weight markers (New England Biolabs) as described in section 2.6.4. 
Two pieces o f 3MM filter paper were cut to size o f the gel as was the nitrocellulose 
membrane. The sponges from the transfer apparatus along with 2 pieces o f 3 MM filter
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paper cut to size and the SDS gel were soaked in transfer buffer. One pre-soaked sponge 
was placed on one side o f the transfer apparatus, followed by one piece o f filter paper. 
The gel was then placed on top o f the filter paper. The nitrocellulose membrane which 
had been pre-wet in distilled water and then soaked in transfer buffer for 5 min was 
placed on top o f the gel, ensuring that no bubbles were trapped between any o f the layers. 
The second stack o f filter paper and sponges were placed on top o f the membrane, the 
transfer apparatus was assembled and placed in the blotting apparatus with the gel on the 
side o f the negative (black) electrode and the nitocellulose on the side o f the positive 
(red) electrode. Protein transfer was allowed to take place at a constant voltage o f 75 V 
for 2 h with the buffer kept chilled by an ice pack (placed in the transfer apparatus) and 
recirculated. After transfer, the apparatus was disassembled and the membrane was 
washed briefly in TBS to remove any traces o f gel. The membrane was then incubated in 
Blocking buffer for 1 - 2 h at room temperature followed by incubation with the 
appropriate antibody (diluted in Blocking buffer-Table 2.4) at 4°C overnight. Sodium 
azide was added to each antibody solution to a final concentration o f 0.02% (w/v) as a 
preservative thus permitting reuse o f the antibody.
T ab le  2.4: Incubation  conditions for an tibodies used in w estern  b lo tting
Antibody Name Dilution/conce 
ntration
Blocking buffer
Anti -LMP1 
Anti - HA 
Anti-Bcl2
Anti-phosphotyrosine
Anti-CD40
CS1-4* 1/100 
HA 1/1000 
B cl2100/124* 1/10 
PT-66 0.5(xg/ml
G28.5 lpg/m l
Blotto
Blotto
Blotto
5% (w/v)BSA, 0.05% (v/v) 
Tween20 in TBS 
Blotto
* Tissue culture supernatant
After overnight incubation, the membrane was washed three times in TBST (0.1%(v/v) 
Tween-20 in TBS) for 10 min and then incubated for 10 mm in blocking buffer. The
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filter was then incubated with the appropriate secondary antibody (an alkaline 
phosphatase-conjugate anti-mouse antibody (Promega) diluted 1/5000 in Blocking buffer 
or an alkaline phosphatase-conjugate anti-rabbit antibody (Boehringer Mannheim) diluted 
1/1250 in Blocking buffer, for 1 hr at room temperature, followed by washing three times 
with TBST for 10 mm each All o f the above incubations were carried out w ith agitation 
Membranes were then placed in a clean container and covered with BCIP/NBT substrate 
The container was placed in the dark at room temperature without shaking for 30 mm or 
longer if  required The filter was then rinsed in distilled water to stop the reaction, 
photographed and then wrapped in cling film and stored in the dark
2.7 ELECTROPHORETIC MOBILITY SHIFT ASSAY (EMSA)
2.7.1 Preparation of nuclear extracts
Nuclear extracts were prepared essentially according to the method o f Dignam et al 
with modifications (1983) The composition o f all buffers used is described in the 
Appendix Briefly, 5 x 106 cells were pelleted at 1,000 x g for 5 mm and washed with 5 
ml o f ice-cold PBS The pellet o f cells was then resuspended in 1 ml o f ice-cold PBS 
and transferred to a microfuge tube After centrifugation at 5000 x g for 4 mm at 4° C, 
the cells were resuspended in 1 ml o f Buffer A The cells were pelleted at 5000 x g for 
10 mm at 4° C, the supernatant removed and the cells were then lysed in 20pl o f Buffer 
A containing 0 1% NP 40 for 15 mm on ice The nuclei were pelleted by centrifugation 
at 13000 x g for 10 mm at 4° C, the supernatant removed and the nuclei lysed in 15 pi o f 
a hypertonic buffer (Buffer C) for 15 mm on ice The extracts were clarified by 
centrifugation at 13000 x g for 10 mm at 4° C after which the supernatant was mixed 
with 50pl o f Buffer D in a fresh microfuge tube The concentration o f protein in the 
extracts was determined by using the BCA assay (section 2 6 2) and the extracts were 
ahquoted and stored at -80° C until use
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2.7.2 Nature of the oligonucleotide probes and their labeling for use in EMSA
Unlabeled double stranded oligonucleotide probes for use in EM SA were either 
purchased (a 22 bp oligonucleotide containing the ‘consensus’ NF-kappa B binding site 
5 ’-GGGGACTTTCC-3’ from the Immunoglobulin kappa light chain enhancer region and 
called NF-KB-con), synthesised as single stranded oligonucleotides and then annealed in 
solution (a 14bp oligonucleotide corresponding to -5 4  to -41 o f the bfl-1 promoter 
region containing the NF-kappaB-like site 5’AGAAATTCCA-3’ and called -54/-41B fl-l 
NF-kB) or prepared by restriction digestion o f the bfl-1 promoter region -129  to +81 
contained in the reporter plasmid -129/+81 Bfl-1 CAT In all three cases labeling was 
based on the usage o f bacteriophage T4 polynucleotide kinase which catalyses the 
transfer o f the radiolabeled y-phosphate o f y-32P ATP to the 5 ’ terminus o f  the 
dephosphorylated double-stranded substrate DNA NF-KB-con is double stranded and 
contains 5’-hydroxyl blunt ends For preparation o f the double stranded —54/-41Bfl-l 
NF-kB oligonucleotide, equimolar amounts o f the complimentary -54/-41 NF-kB 
oligonucleotides (containing 5 ’-hydroxyl terminn) in IX  T4 polynucleotide kinase buffer 
were mixed in a microfuge tube and the tube placed in a heating block at 95°C for 2 
minutes to denature the oligonucleotides The heating block was then removed from the 
apparatus and allowed to cool to room temperature (60 -  75 m m ) for annealing o f the 
oligonucleotides to ensue The annealed oligonucleotides were either used immediately 
in the labeling reaction or stored at -20°C  The preparation o f restriction fragments from 
the -129  to +81 region o f bfl-1 for use as probes in EMSA is described in a following 
section (Section 2 7 2 1)
The labeling reaction was performed by adding
10 pmol o f substrate DNA containing 5 ’ -hydroxyl termini 
10X kinase buffer to give a final concentration o f IX  
50 pmol o f y-32P ATP (3000Ci/mmol, lOmCi/ml)
20 U T4 polynucleotide kinase 
d t^ O  to a final reaction volume o f 50jal
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The reaction was incubated at 37°C for 20 nun after which end-labeled oligonucleotides 
were purified away from unincorporated labeled nucleotides by spin-column 
chromatography through MicroSpin™  G-25 columns essentially according to 
manufacturer’s specifications (Amersham Pharmacia Biotech)
2.7.2.1 Preparation of restriction DNA fragments and their labeling for use as 
probes m EMSA
The -129/+81 region o f the bfl-1 gene was cloned as a Sail -  Xbal fragment in the pG 
CAT basic vector (Zong et a l , 1999) Probes spanning the entire -129/+81 region (SalI- 
Xbal) as well as overlapping parts withm this region (Saft-Apol, Sall-Alul and Apol- 
Xbal) were generated for use in EMSA (Figure 3 49)
Fifteen pg (equivalent to approximately lOpmol) o f the -129/+81 Bfl-1 CAT plasmid was 
linearised with either Sail or Xbal enzyme (both o f which generate 5 ’ protruding ends 
suitable for the subsequent labeling reaction with T4 polynucleotide kmase) The 
linearised fragments were then dephosphorylated as described in Section 2 3 5 
Following purification by phenol-chloroform extraction and ethanol precipitation, the 
fragments were end-labeled using T4 polynucleotide kmase and y-32P ATP as described 
in Sections 2 3 3 and 2 7 2 End-labeled fragments were separated from unincorporated 
labeled nucleotides by phenol-chloroform extraction and ethanol precipitation in the 
presence o f 0 5M ammonium acetate Following salt removal with 70% ethanol, the 
pellets were air-dried and dissolved in dFhO The 5’end-labeled Sail fragments were 
cleaved with either Apol, A lul or Xbal while the 5’end-labeled Xbal fragments were 
cleaved with Apol The now dual restriction enzyme digested fragments were size- 
fractionated by non-denaturing PAGE (section 2 7 4) followed by autoradiography to 
locate and excise the fragments o f interest from the gel
2.7.3 Binding reaction
The composition o f all buffers used in the binding reaction are given in the Appendix
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The binding o f nuclear proteins to labeled DNA probe was performed in a reaction 
comprising
10 X Binding reaction buffer 2jal
non-specific competitor DNA poly dl-dC (2pg/|_il) l\i\
32P-labeled DNA probe (15,000-20,000 cpm/pl) lp l
upto 15(o,g o f nuclear extract (in a volume made up to 16pi with Buffer D)
A ‘control reaction’ lacking nuclear extract but containing all other components o f the 
binding reaction was also set up The reaction components were mixed gently and 
incubated at room temperature for 30 minutes The reactions were terminated by the 
addition o f sample buffer (DNA loading buffer lacking bromophenol blue)
2.7.3.1 Competition studies
The specificity o f binding o f a nuclear protein (s) to the labelled DNA fragment can be 
assessed by attempting to compete out binding o f the protein(s) to the labelled probe by 
an excess o f unlabelled (‘cold’) probe If the bandshift observed with labelled probe is 
specific it should disappear in a competition study with cold probe Competition studies 
were carried out by pre-mcubatmg the nuclear extract (m a total volume of 16pl made up 
with Buffer D) with an excess o f  cold probe (upto 100 X excess in a volume o f 1 Opl) 
under similar binding reaction conditions as described in section 2 7 3 except with the 
addition o f ‘cold’ instead o f labeled probe, followed by the addition o f labeled probe (m a 
volume o f 1 Opl) and incubating the reaction for a further 30 mm at room temperature
The reactions were terminated by the addition o f sample buffer (DNA loading buffer
lacking bromophenol blue)
2.7.3.2 Supershift studies
The identity o f a transcription factor in a bandshift complex can be verified by incubating 
the nuclear extract with an antibody that recognises the factor prior to performing the 
binding reaction with the labeled probe Depending on whether the antibody recognises
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an epitope within the DNA-binding domain or elsewhere, the complex formation will 
either be prevented (observed as only a decrease in intensity o f the shifted complex) or 
further retarded in mobility in the gel (termed a ‘supershift’). ‘Supershift’ studies were 
conducted by incubating the nuclear extract (in a total volume o f 15 pi made up with 
Buffer D) with 1 .Ofil o f an antibody that recognises the transcription factor o f interest 
(p65, c-rel or p50) or an ‘irrelevant’ protein (Mcl-1) as a control on ice for 20 min. This 
was followed by the addition o f 2pl o f 10 x Binding reaction buffer, lp l o f poly dl.dC 
(2fig/ul) and lp l o f 32P-labeled DNA probe and the reaction incubated for 30 min at room 
temperature. The reactions were terminated by the addition o f sample buffer (DNA 
loading buffer lacking bromophenol blue).
2.7.4 Nondenaturing polyacrylamide gel electrophoresis
Size-fractionation o f the 5’ end-labeled DNA fragments that map to or within the -1 2 9  to 
+81 region o f the bfl-1 gene (section 2.7.2) and the resolution o f the bandshift complexes 
were conducted by nondenaturing polyacrylamide gel electrophoresis using the Protean II 
cell system (Biorad).
2.7.4.1 Preparation of the Protean II cell electrophoresis system
The glass plates, spacers and combs were cleaned with detergent, rinsed thoroughly with 
tap water followed by upH20 , and wiped dry with clean dry tissue paper. 100% (v/v) 
ethanol was poured onto the glass plates and the plates wiped dry with tissue paper. The 
spacers and combs were wiped with tissue paper soaked in 100% (v/v) ethanol. The 
apparatus was then assembled and clamped together according to manufacturer’s 
instructions (Biorad).
2.7.4.2 Casting the gel
An 8% gel was used for size-fractionation o f the 5’ end-labeled DNA fragments that map 
to or within the -129  to +81 region o f the bfl-1 gene while a 4% or 5% gel was used for
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the resolution o f the bandshift complexes. The composition o f the gels is outlined in the 
Appendix. After addition o f TEMED to the gel mix, the gel solution was poured 
immediately into the gel mould and the comb inserted. The gel was allowed to set for at 
least an hour, after which the gel mould was removed and placed in the electrophoresis 
tank. The lower chamber o f the tank was filled with 1.2 litres o f electrophoresis buffer 
(0.5 X TBE) whilst the upper chamber was filled with approximately 350 ml o f 0.5 X 
TBE. The comb was carefully removed and the wells were washed thoroughly with 
electrophoresis buffer to remove any unpolymerised acrylamide that would otherwise 
impair the migration o f the sample. The gel was pre-run for 30^10 min at a constant 
voltage o f MOV before the samples were loaded and electrophoresis was carried out at 
the same voltage for approximately 2h at room temperature for EMSA analysis with the 
consensus NF-kB oligonucleotide and the oligonucleotide containing the NF-KB-like site 
at position -5 2  o f bfl-1. For size-fractionation o f the 5’end-labeled fragments and EMSA 
with these fragments, electrophoresis was carried out at a constant voltage o f 200V for
2.5 h. It should be pointed out that bromophenol blue was excluded from the loading 
buffer added to the samples as it has been reported to disrupt protein-DNA interactions in 
certain cases (Promega Technical Bulletin No. 110). It was therefore necessary to run 
just loading buffer containing bromophenol blue into one well o f the gel to locate the 
leading edge o f the gel. After electrophoresis, the gel was either exposed to X-ray film 
and processed for excision o f end-labeled DNA fragments for use as probes in EMSA or 
vacuum dried and exposed to X-ray film to visualise bandshifts.
2.7.4.3 Purification of 5’end-labelled DNA fragments from polyacrylamide gels
After polyacrylamide gel electrophoresis o f the 5’end-labeled fragments, the plates were 
disassembled. ‘Orientation’ markers were prepared by carefully streaking y32P-ATP- 
containing loading dye (containing bromophenol blue) across a piece o f filter paper in a 
recognisable shape and wrapping the filter paper tightly with selotape. Two o f such 
‘orientation’ markers were placed directly on the gel at positions away from the lanes 
containing the samples o f interest. The gel was then wrapped in cling film and exposed to 
X-ray film for a length o f time (usually 1-2 min) that permitted visualisation o f the bands
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o f interest and the orientation markers Once the appropriate exposure o f the gel was 
achieved, the X-ray film was placed on the gel and aligned using the ‘orientation’ 
markers The DNA fragments o f interest could thus be located in the gel and were 
excised using a clean sharp razor blade After excision o f the gel slices, the fragments 
were eluted by the crushing the gel slices in TE buffer (pH 7 5) contained in a microfuge 
tube and allowing passive elution to occur overnight at room temperature The gel pieces 
were removed from the eluate by centrifugation at 13,000 x g for 20 mm at room 
temperature and the DNA fragments contained in the supernatant purified by phenol- 
chloroform extraction followed by ethanol precipitation Following salt removal with 
70% ethanol, the pellets were air-dried and dissolved m 20pi TE buffer (pH 7 5) A lp l 
sample o f each labeled probe was used to measure the level o f incorporation o f radiolabel 
in a scintillation counter
2.7.4.4 Gel drying and autoradiography
After electrophoresis, the buffer was poured out o f the electrophoresis tank and the plates 
disassembled A piece o f W hatmann 3MM filter paper (cut to size) was placed on top o f 
the gel, avoiding air bubbles and the paper lifted gently with the gel attached to it This 
was then covered with cling film and placed in a vacuum gel dryer, with the gel facing 
up The gel was dried at 80°C for 2h Once dry, the gel was placed in a cassette and 
exposed to X-ray film in the dark for at least 12 hours at -80 °C The film was developed 
manually by successively immersing the film in developer for 3 mm, water for 1 mm, 
fixer for 3 min and water for 1 min The film was then air-dried for approximately 1 hour 
In some cases, development o f x-ray film was also carried out using a manual developer
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CHAPTER 3
RESULTS
3.1 INTRODUCTION
Bcl-2 is the prototype o f a family o f related proteins classified as either apoptotic death 
agonists or antagonists All members possess at least one o f four conserved motifs 
known as Bcl-2 homology domains (BH1 to BH4) (reviewed by Adams and Cory, 1998) 
(Figure 3 1) Most pro-survival members, contain at least BH1 and BH2, and those most 
similar to Bcl-2, such as B c 1 -x l , have all four BH domains There are two pro-apoptotic 
subfamilies and these differ markedly in their relatedness to Bcl-2 Bax, Bak and Bok, 
which contain BH1, BH2 and BH3, resemble Bcl-2 In contrast, the second subfamily o f 
pro-apoptotic proteins, exemplified by Bik, Bad and Bid, possess only the central short (9 
to 16 residues) BH3 domain The BH3 domain o f the “BH3 domain” proteins is crucial 
to their pro-apoptotic activity Pro- and anti-apoptotic family members can 
heterodimerise and seemingly titrate one another’s function, suggesting that their relative 
concentration may act as a rheostat for the apoptotic death program (reviewed by Cory 
and Adams, 1998) Mutagenesis has established that the BH1, BH2, and BH3 domains 
strongly influence homo- and hetero- dim ensation and the three-dimensional structure o f 
B c 1 -x l  has provided clues as to how this might occur (reviewed by Cory and 
Adams, 1998) Coalescence o f the a  helices m its BH1, BH2 and BH3 regions creates an 
elongated hydrophobic cleft to which a BH3 amphipathic a-helix  can bind BH3-cleft 
coupling may account for all dim ensation within this family Hence, it is thought that 
Bax and its analogs may have alternate conformations, one like Bcl-xL and another with 
BH3 rotated outside to allow its insertion into the groove o f pro-survival proteins The 
BH4 region o f Bcl-xL is required for pro-survival activity Heterodimensation does not 
appear to be required for pro-survival function but is essential for pro-apoptotic activity 
particularly for members o f the BH3 domain group Some death agonists may 
preferentially target subsets o f the death repressors Bok, for example, interacts with 
Mcl-1 and the Epstein-Barr viral protein BHRF1 but not with Bcl-2, Bcl-xL or Bcl-w 
W ithin the BH3 group, Bid is promiscuous, binding to Bax and Bak as well as to the anti- 
apoptotic proteins, but the other members bind only to certain o f  the death inhibitors 
(Bruckheimer, 1998)
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Bcl-2 resides on the cytoplasmic face o f the mitochondrial outer membrane, endoplasmic 
reticulum and nuclear envelope and may register damage to these cellular compartments 
Bcl-2 may thus affect the behaviour o f these organelles by modifying the flux o f small 
molecules or proteins (reviewed by Cory and Adams, 1998) The carboxy-terminal 
hydrophobic domain o f Bcl-2 appears to be required for membrane docking The pro- 
survival proteins seem to maintain organelle integrity Bcl-2, for instance, prevents the 
release from mitochondria o f cytochrome c The structure o f B c 1 -x l  (particularly its a 5  
and a 6  helices) resembles the membrane insertion domains o f bacterial toxins This 
observation has prompted the hypothesis that members having the BH1 and BH2
domains function by forming pores in organelles such as mitochondria "BcI-xl, Bcl-2 and
\
Bax do form channels in lipid bilayers in vitro, and those created by Bax and Bcl-2 have 
distinct features including some ion selectivity (reviewed by Cory and Adams, 1998)
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subfamily but lacks a functional BH4 domain Except for the BH3 domain, the BH3 subfamily is unrelated 
to Bcl-2 a l  to a l  indicates helices identified in Bcl-xL, in which a core o f  two hydrophobic helices (a5  
and a 6 )  is flanked by five amphipathic helices, and a flexible (nonconserved) loop connects a l  with a 2  
Small arrows indicate serine and threonine residues phosphorylated in Bcl-2 All proteins compared are 
mammalian (usually human), except for N R -13 (chicken), CED-9 and EGL-1 (C elegans), and the viral 
proteins BHRF1, LM W 5-HL, ORF-16, KS-Bcl-2, and E1B-19K A dapted  fro m  Cory and Adams, 1998
A central component o f the overall EBV strategy and its role in the development o f 
related malignant disease is the ability o f the viral latent proteins to suppress the cellular 
apoptotic program (Allday, 1996, Klein, 1994) Group I BL cell lines and many EBV- 
negative BL lines can readily be triggered into apoptosis, whereas group III BL cell lines 
are relatively resistant to a variety o f triggers o f apoptosis including growth factor
‘j iwithdrawl, Ca lonophore treatment and overexpression o f the p53 tumour suppressor 
gene (Henderson et a l , 1991 and Okan et a l , 1995) EBV-negative BL cells converted 
to the type 3 latency state by infection with the B95-8 strain o f EBV also display elevated 
thresholds o f resistance to apoptotic stimuli (Gregory et a l , 1991)
Transfection o f individual EBV latent genes into EBV-negative BL cell lines has shown 
that upregulation o f Bcl-2 expression correlates with the expression o f LMP-1 (Liu et a l , 
1991, Henderson et a l , 1991, Rowe et a l , 1994) and possibly EBNA2 (Finke et a l , 
1992) and EBNA3B (Silins and Sculley, 1995) Several lines o f evidence, however, 
point to additional Bcl-2-mdependent survival mechanisms being important in BL cells 
and during B-cell differentiation within germinal centers (i) hyperexpression o f Bcl-2 
protein in group I cells (well beyond the levels in group III cells) is necessary to attain the 
high levels o f protection observed m group III cells (Milner et a l , 1992), (n) prolonged 
culture o f group I lines in vitro has been shown to result in enhanced survival in the 
absence o f Bcl-2-upregulation (Milner et a l , 1992), (111) Bcl-2 is not detectable in 
germinal centre B cells in vivo, the normal equivalent o f BL cells, and only appears when 
the cells reach the follicular mantle (Pezzella et a l , 1990, Aiello et a l , 1992, Akagi et a l , 
1994) and ( i v )  The induction o f Bcl-2 by LMP-1 is a delayed response with maximal 
levels detectable after 2 days o f LMP-1 induction (Rowe et a l , 1994) LMP-1 has been 
shown to also upregulate the expression o f two other host stress-response proteins that
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prevent apoptosis, A20 and Mcl-1 (Laherty et a l ,  1992; Fries et al., 1996; Wang et al., 
1996), with the latter probably serving as a rapidly inducible, transient and short-term 
effector o f cell viability before Bcl-2 induction.
This study set out to investigate EBV-associated changes in the level o f expression o f a 
panel o f 6c/-2-related genes by comparing BL cell lines exhibiting a group I and group III 
phenotype as well as comparing an EBV-negative BL cell line with its EBV-infected 
counterpart (expressing all o f the latent genes) and LCLs. As LMP-1 is a key effector o f 
EBV-mediated transformation and o f promotion o f survival o f B cells, the contribution o f 
this viral protein to cell survival was investigated, based on findings o f the preliminary 
RPA experiments o f EBV-associated changes.
3.2 RESULTS
3.2.1 EBV-associated changes in the level of expression of b c l - 2 -related genes
As the apoptotic threshold o f a cell is determined by the level o f functional expression o f 
a combination o f pro- and anti- apoptotic proteins, changes in the relative level o f 
expression o f these proteins are important in determining the cellular response to 
apoptotic signals. Cytokine-mediated changes in the level o f expression o f several o f 
these proteins is controlled at the level o f transcription (Adams and Cory, 1998). This 
study set out to investigate EBV-associated changes in the expression o f a panel o f bcl-2- 
related genes in BL cells. In a preliminary experiment using two established isogenic 
EBV-positive BL cell lines, group I Mutu-BL (Mutu I) and group III Mutu-BL (Mutu 
III), the levels o f  mRNA transcribed from the bclxUs, bfl-1, bik, bak, bax, bcl-2 and mcl-1 
genes were compared using multiprobe ribonuclease protection assay (RPA; hAPO-2 kit, 
Pharmingen). This approach permitted the simultaneous detection and quantitation o f 
these mRNAs in a single sample and also enabled direct comparative analysis o f RNA 
from these two cell lines by the inclusion o f probes for transcripts from the two 
housekeeping genes GAPDH  and L32 (Figure 3.2). Group I BL cells (type I latency) 
express EBNA1 as the sole viral protein; when serially passaged in vitro, they ‘drift’ to
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express all o f the known latency-associated viral proteins (including LMP-1) and exhibit 
many o f the phenotypic features characteristic o f LCLs In this state, the cells are said to 
exhibit type III latent infection and have become group III BL cells (Gregory et a l , 
1990) It can be seen from this experiment that significantly elevated steady state levels 
o f bfl-1 and bcl-2 were present in Mutu III relative to Mutu I cells (Figure 3 2) The 
intensities o f the bands corresponding to bfl-1 were quantitated by densitometric scanning 
o f the autoradiogram GAPDH mRNA levels were similarly assessed and the values thus 
obtained were used to correct those for the bands o f interest to account for any 
differences in the amounts o f RNA analysed The results indicated that an approximately 
twenty-fold higher level o f bfl-1 mRNA is present in Mutu III cells relative to M utu I 
The observation o f a higher level o f bcl-2 mRNA in M utu III relative to M utu I cells is in 
keeping with the findings o f others (Henderson et a l , 1991)
In order to investigate if  upregulated bj7-1 expression is a general feature o f EBV- 
mfected B cells, bfl-1 mRNA levels in the EBV-negative BL cell line BL41 were 
compared to those in its EBV-supermfected derivative, BL41-B95 8, an EBV- 
transformed LCL (IARC171) derived by infection o f peripheral B lymphocytes from the 
same patient from whom BL41with the B95 8 strain and a reference LCL, X50-7 (Figure 
3 2) There were easily detectable levels o f bfl-1 mRNA in BL41, which were 
significantly elevated in BL41-B95 8 Higher levels o f bfl-1 mRNA were also detected 
in the two LCLs IARC171 and X50-7 relative to BL41 Comparison o f the level o f 
expression o f bcl-2 in BL41-B95 8 and the LCLs IARC171 and X50-7 relative to BL41 
also showed a similar trend to bfl-1 expression Thus, elevated expression o f bfl-1 and 
bcl-2 mRNA appear to be a general feature o f LCLs and BL cells expressing all o f the 
viral latency-associated proteins Transcript from the gene encoding the pro-apoptotic 
protein Bik is not detectable in the two LCLs examined in this experiment, an interesting 
observation in that it is also downregulated in Mutu-BL upon drift to the group III 
phenotype This does not however appear to be a general feature o f EBV-positive BL 
cells exhibiting a group III phenotype in that the level o f bik mRNA is significantly 
greater in BL41-B95 8 cells relative to BL41 Additionally, although elevated levels o f
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bak mRNA were observed in Mutu III relative to Mutu I, this effect is also inconsistent in 
that it is not observed in the BL41/B95 8 pair
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F ig u re  3 2 EB V -associated  m odulation  o f the  steady-sta te  levels o f m RNAs co rresp o n d in g  to  bcl-2 
re la ted  genes in B cells EBV-m fected LMP-1 expressing B cell lines exhibit increased steady-state 
levels o f expression o f bfl-1 and bcl-2 mRNAs RPA autoradiogram (18 h exposure) m which mRNA 
levels from the apoptosis-related genes bclxLS, bfl-1, bik, bak, bax, bcl-2 and mcl-1 were analysed in a 
range o f  BL cell lines and LCLs Unprotected [32-P]-labeled antisense nboprobes (5000 cpm, indicated on 
the figure as ‘Probes’) were loaded alongside RPA-processed samples and are shown linked to their 
smaller RNase-protected fragments which correspond to the steady-state levels o f  the corresponding 
mRNA in the sample The names o f  the cell lines used are given above each track The locations o f
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protected fragm ents derived from bcl-2 and bfl-1 mRNAs are highlighted with arrows The M utu I and 
M utut III tracks are from a separate RPA to the other four tracks
3.2.2 LMP-1 upregulates b f l - 1  expression in the EBV-negative Burkitt’s lymphoma 
cell line DG75
O f all o f  the EBV latent proteins, LMP-1 has been shown to make a major contribution to
promotion o f survival o f EBV-infected cells (Gregory, 1995) It was therefore o f interest
to investigate i f  expression o f this viral protein alone could contribute to the upregulation
o f bfl-1 by EBV To this end, an established tightly-regulatable expression system was
employed to induce LMP-1 expression in the EBV-negative BL cell line DG75-tTA-
LMP-1 (Floettmann et a l , 1996) In this system, the inducible promoter driving LMP-1
expression contains binding sites for a hybrid tetracycline-regulated transactivator (tTA)
that is constitutively expressed in the parental clone DG75-tTA Removal o f  tetracycline
from the growth medium leads to tTA binding to the promoter and the expression o f
LMP-1 The level o f induced LMP-1 was monitored by Western blot analysis using the
anti-LMP-1 mouse monoclonal antibody cocktail CS 1-4 (Rowe et a l , 1992) In this
experiment, LMP-1 was detectable m DG75-tTA-LM P-l cells at 12 hours post-induction
and its level rose to several times that observed in a reference LCL (X50-7) by 96 hours
(Figure 3 3 A) The lower molecular weight proteins detected below the major LMP1
band most likely correspond to breakdown products o f LMP1 and have been detected in
LMP1 expressing cells by anti-LM Pl antibodies in Western blots (Young et a l , 1988)
Total RNA prepared from cells harvested from the same pool and at the same time points
as used for monitoring the induction o f LMP-1 were used in RPA analysis with the same
set o f  probes as before The result o f  this experiment is shown m Figure 3 3 B The
steady-state level o f mRNA from the bfl-1 gene rose significantly in response to
induction o f LMP-1 m DG75-tTA-LM P-l cells Upregulation o f bfl-1 mRNA was
dramatic and was detectable at 12 hours post-induction (when the levels o f LMP-1 were
comparable to those observed in X50-7) Densitometric scanning indicated that the
degree o f induction o f bfl-1 was maximal by 48 hours at which time a 15-fold induction
was observed (after normalisation o f values to those for the GAPDH  internal control
mRNA) Although high levels o f induction o f bfl-1 mRNA were maintained thereafter, a
decrease in the extent o f induction to approximately 11 -fold was observed by 96 hours
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post-induction In the same experiment, the bcl-2 mRNA level also rose, although in this 
case much lower levels o f transcript were detected in the cell and maximal upregulation 
was only detected at 96 hours post induction o f LMP-1 upon prolonged exposure o f the 
autoradiogram to film (result not shown) This result o f the kinetics o f  induction o f bcl-2 
mRNA by LMP1 was supported by Northern analysis (Figure 3 60)
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F igu re  3.3 Induction  o f LM P-1 in D G 75-tTA  -L M P -1  cells co rre la tes  w ith an  increase in the  steady- 
s ta te  levels o f bfl-1  and  bcl-2  mRNAs. A) W estern blot o f DG75-tTA-LM P-l cells induced to express 
LMP-1 by reculturing cells in the absence o f tetracycline. Cells were harvested at various time points 
(indicated above each lane) after removal o f  tetracycline from the growth medium and analysed for LMP-1 
expression; also included was the reference LCL X50-7. B) RPA perform ed using RNA samples from the 
same experim ent as that in panel A. Exposure to film was for 18 hours. The numbers above the lanes 
correspond to the times (in hours) after LMP-1 induction at which RNA was harvested.
3.2.3 Northern blot analysis confirms that LMP-1 contributes to EBV-mediated  
upregulation of b f l - 1  mRNA expression
One drawback o f RPA is that it provides no indication o f the size o f a particular mRNA
species. Furthermore, owing to the nature o f the RPA assay, the identification o f
alternatively spliced transcripts may be obscured if  the probe spans a common region
within the different transcripts. Northern blot analysis can often compensate for these
deficiencies in RPA and thus allow for a more informative approach in RNA studies. For
Northern analysis, the same bfl-1 riboprobe used in RPA analysis was used to probe
nitrocellulose filters onto which the same RNA samples from DG75-tTA-LM P-l cells
induced to express LMP-1 were blotted. Also included in this Northern blotting
experiment were RNA samples from Mutu I and Mutu III cells and a non-LMP-1-
expressing variant o f Mutu III (Mutu III LMP'). The result o f  this experiment is shown
in Figure 3.4 and leads to the following conclusions: (a) only a single bfl-1 mRNA
transcript o f 0.8-0.85 kilobases is expressed in all cases, this being in agreement with the
previously reported size o f the transcript from this gene (Karsan et al., 1996a, Kenny et
al., 1997) (b) significantly higher levels o f bfl-l mRNA are observed in Mutu III cells
relative to Mutu I BL and upon induction o f LMP-1 expression in DG75-tTA-LM P-l
cells, confirming the result obtained by RPA; (c) the level o f bfl-1 mRNA in the non-
LMP-1 expressing variant o f Mutu III is significantly lower than in the wild-type Mutu
III cells (compare lanes 6 and 7, upper panel), implicating a role for other EBV latent
proteins in upregulating bfl-l mRNA levels, (d) The effect on bfl-1 mRNA expression in
the DG75-tTA-LM P-l cell system is specific to LMP-1, since the level o f expression o f
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this gene remained unchanged in the parental DG75-tTA cells on removal o f tetracycline 
from the growth medium (compare lanes 8 and 9)
1 2 3 4 5 6 7  8 9
b f l - 1
Fig 3 4 Northern blot analysis o f bfl-1 mRNA levels upon induction o f LMP-1 in DG 75-tTA-LM P- 
1 cells Total RNA samples (30|ig) from DG75-tTA-LM P-l cells grown in the presence o f  tetracycline 
(lane 1) or recultured in the absence o f  tetracycline for 12 (lane 2), 48 (lane 3) or 96 (lane 4) hours as well 
as Mutu I (lane 5), M utu III (lane 6) and M utu III LM P (lane 7) were subjected to N orthern analysis with 
an antisense bfl-1 riboprobe (upper panel) As a control, RNA from DG75-tTA cells grown either in the 
presence o f  tetracycline (lane 8) or in the absence o f  tetracycline for 48 hours (lane 9) were similarly 
analysed The blots were exposed to film for 20 hours (lanes 1 -7) or 18 hours (lanes 8 and 9) The lower 
panel shows the same blots stripped and reprobed with a G APDH  antisense riboprobe (exposure to film 
was for 12 h)
To strengthen the observation that upregulated bfl-1 expression is a feature o f EBV- 
mfected LMP-1-expressing B cells, RNA samples from a series o f EBV-negative cell 
lines, LCLs as well as EBV -  positive BL cell lines exhibiting either a group I or group 
III phenotype were used in Northern blots with the 32P-labelled antisense bfl-1 riboprobe 
Indeed, Northern analysis (Figure 3 5 B) revealed that the levels o f bfl-l mRNA were 
much higher m LCLs (IARC 171, X50-7, OKU LCL, IARC 290B) and EBV - positive 
BL cell lines with a group III phenotype (BL41-B95 8, Ag 876) than in EBV - negative 
BL cell lines (BL41, DG75) and EBV-positive cell lines with a group I phenotype (Mutu 
I, Rael, OKU BL) Furthermore, Western blot analysis with anti-LMP-1 antibodies,
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revealed that the cell lines exhibiting upregulated bfl-1 expression also expressed the 
latent viral protein LMP-1 (Figure 3 5 A) Thus, RPA and Northern analysis suggest that 
LMP-1 can contribute to the EBV-mediated upregulation o f bfl-1 mRNA in B 
lymphocytes
Figure 3 5 Northern blot analysis o f bfl-1 expression in a series o f EBV-negative and -p ositive  BL  
cell lines and LCLs. Upregulated bfl-1 mRNA levels is a feature o f EBV-positive LMP-1 expressing B 
lymphocytes A) W estern blot analysis o f  LMP-1 expression m a series o f  EBV-negative BL cell lines [ 
DG75 (lane 1), BL41 (lane 7)], EBV- positive BL lines with either a group I phenotype [ Rael (lane 2), 
M utu I (lane 3), OKU BL (lane 5)] or a group III phenotype [ M utu III (lane 4), BL41-B95 8 (lane 8), 
Ag876 (lane 12)] and LCLs [ OKU LCL (lane 6), IARC 171 (lane 9), X50-7 (lane 10), IARC 290B (lane 
11)] The position o f the 62 kDa Protein m olecular weight m arker is indicated on the left hand side o f the 
photograph B) Northern blot analyses o f  bfl-1 expression (upper panel) in EBV-negative BL cell lines [ 
BL41 (lane 1), DG75 (lane 5)], EBV- positive BL lines with either a group I phenotype [ Rael (lane 6), 
Mutu I (lane 7), OKU BL (lane 8)] or a group III phenotype [ BL41-B95 8 (lane 2), Ag876 (lane 11)] and 
LCLs [ IARC 171 (lane 3), X50-7 (lane 4), OKU LCL (lane 9), IARC 290B (lane 10)] The blots were
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exposed to film for 70 h (lanes 1-4) or 48 h (lanes 5 - 1 1 )  The lower panel shows the same blots stripped 
and reprobed with G APDH  riboprobe (exposure o f the blots was for 18 h)
3.2.4 Cell type-specific effect o f LMP-1 on b f l - 1  expression
Although many EBV-associated lymphomas (o f B- and T-cell origin) and NPCs exhibit 
expression o f LMP-1, there are tissue-specific differences to be seen in the effects of 
LMP-1 on gene expression For example, the upregulation o f Bcl-2 by LMP-1 is a B- 
lymphocyte-specific effect whereas LMP-1-mediated induction o f A20 is observed in 
both lymphocytic and epithelial cell contexts (Henderson et a l , 1991, Rowe et a l , 1994, 
Laherty et a l , 1992, Miller et a l , 1995, 1997, Fries et a l , 1996) It was therefore o f 
interest to investigate whether LMP-1-induced upregulation o f bfl-1 occurred m a T  cell 
or an epithelial cell background, the two other principal cell types that are relevant to 
EBV The following cell lines were used to address this question (a) a tetracycline- 
regulated LMP-1-expressing clone derived from the Jurkat T cell line, Jurkat tTA-LMP-1 
and (b) a stably transfected LMP-1-expressing clone o f the epithelial cell line C33A bfl- 
1 transcript was not detected in either o f these cell lines irrespective o f their LMP-1 status 
(Figure 3 6 A and B) indicating that bfl-1 is not expressed in either cell type nor is it 
upregulated by LMP-1 m either cell context Additionally, no change was observed in 
bcl-2 mRNA levels in either cell context on induction o f LMP-1 expression The absence 
o f bfl-1 upregulation was not due to an insufficient level o f expression o f LMP-1 since, at 
least in the case o f the Jurkat tTA-LMP-1 cells, levels similar to that expressed in the 
LCL X50-7 were observed It thus appears that LMP-1 does not upregulate bfl-1 
expression in T cells or epithelial cells However, this conclusion is subject to 
demonstrating known LMP-1 induced effects on parameters relevant to these cellular 
contexts such as NF-kB activation and expression o f the anti-apoptotic protein A20
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F igu re  3.6 LM P-1 does no t induce bfl-1  expression in a T-cell o r  an  ep ithelial cell context. A)
W estern blot analysis o f  expression o f LMP-1 in Jurkat tTA-LMP-1 cells and the stable transfectant 
C33ALM P-1. Jurkat tTA-LMP-1 cells were induced to express LMP-1 by reculturing cells in the absence 
o f  tetracycline (time after tetracycline-removal is indicated above each lane). Also included was the 
reference LCL X50-7 (X) and the parental C33A (P), the neomycin-resistant control transfectant C33Aneo 
(neo) and the LMP-1 transfectant C33ALMP1 (LM P1). B) RPA perform ed using RNA samples from the 
same experim ent as that in panel A using the hAPO-2 set o f  riboprobes. The location o f protected 
fragments derived from the bfl-1 (expected location) and bcl-2 probes are indicated by arrows. Exposure to 
film was for 18 hours.
3.2.5 Functional analysis of Bfl-1 expression in a type I Burkitt’s Lymphoma cell 
line
bfl-1 is one o f the relatively newer members o f the bcl-2 family o f genes. This gene 
bears closest homology to the mouse A1 gene since the proteins coded by these genes 
share about 72% amino acid identity. A1 has been shown to extend the survival o f 
myeloid precursor cells after growth factor withdrawl (Lin et a l ,  1996) and can also 
protect B lymphocytes from antigen-receptor ligation-induced apoptosis (Grumont et al., 
1999). Like A l, Bfl-1 can also protect cells from a number o f apoptotic stimuli. For 
example, Bfl-1 preferentially suppresses chemotherapy-induced apoptosis in a 
fibrosarcoma cell line (Wang et al., 1999) and protects endothelial cells from TNF-a- 
induced cell death (Karsan et al., 1996). Additionally, Bfl-1 suppresses p53-induced 
apoptosis, exhibits cell proliferative properties and cooperates efficiently with the E la  
oncogene in the transformation o f rodent epithelial cells (D ’Sa-Eipper et a l ,  1996). It 
was therefore o f interest to examine the functional consequence o f the upregulation o f 
bfl-1 expression by LMP-1 in BL cells. To this end, it was necessary to take two factors 
into consideration. The first factor relates to the detection o f human Bfl-1 protein. Owing 
to the lack o f appropriate antibodies to detect human B fl-1 protein, attempts to study the 
functional role o f Bfl-1 protein in different cell types have been based on expressing it as 
a fusion protein with an ‘irrelevant’ peptide (such as included the influenza virus 
hemagglutinin (HA) epitope and FLAG-octapeptide) that contains an epitope to which 
reactive antibodies are available. The second factor relates to the choice o f  the 
appropriate target cell line to achieve this purpose. Although the effects o f  LMP-1 on bfl-
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1 expression as reported in this thesis were conducted in the context o f the DG75 cell 
line, these cells are not as sensitive to apoptotic death induced by various stimuli 
including growth factor-deprivation compared to many other EBV-negative and group I 
EBV-positive BL cell lines (result not shown) On the other hand, M utu I cells, which 
exhibit a type I latent infection, are extremely sensitive to apoptotic death (Gregory et a l , 
1991, Henderson et a l , 1991, Milner et a l , 1992) and express extremely low levels o f 
6/7-1 and bcl-2 mRNA (Figure 3 1) Furthermore, these cells have also been shown to be 
easy to transfect by electoporation (Milner et a l , 1992) Hence, M utu I cells were 
chosen as the target cell line to study the functional effects o f ectopic expression o f Bfl-1
An expression vector, pcDNA3-HA-Bfl-l, which has been shown to ensure high levels o f 
expression o f HA-tagged Bfl-1 protein in mammalian systems was employed for the 
purpose (D ’Sa-Eipper et a l , 1996) Figure 3 7 A shows the map o f the vector pcDNA3 
and the restriction sites in the polylmker region into which HA-bfl-1 was cloned and 
figure 3 7B shows the results o f the restriction enzyme analysis used to confirm the 
organisation o f the DNA fragment encoding HA-Bfl-1 in the vector pcDNA3-HA-Bfl-l
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F ig u re  3 7 A M ap  o f the  expression vecto r pcDNA3 The polylinker containing multiple cloning 
restriction sites is flanked by the T7 and Sp6 promoters The HA epitope was cloned between the H ind  III 
and Bam  HI sites and the bfl-1 ORF was cloned between the Bam  HI and X ho  I sites m the polyhnker 
region pCM V = CM V prom oter directing strong expression o f  HA-Bfl-1 BGHpA = polyadenylation 
signal from  the bovm e growth hormone B  R estric tion  enzym e analysis o f the  expression vecto r 
pcD N A 3-H A -B fl-l Digestion with either H ind  III (lane 4 ) ,  Bam  HI (lane 5) ox X ho  1 (lane 6) linearises 
the plasmid (approxim ately 6 00 kb ) Digestion o f the plasmid with Bam  H I and X ho  1 excises the 570 bp 
BFL-1 ORF encodmg DNA fragment (lane 8) Lane 2 = undigested plasmid M = DNA m olecular weight 
markers (sizes in kb indicated on the left hand side o f  the photograph) Lanes 1, 3 and 7 were unused A 
0 8% agarose gel in 1 x T A E  was used and electrophoresis was carried out for at 100 V for 1 h 20 mm m 1 
x T A E
As a control for the generation o f cells transfected with pcDN A3-HA-Bfl-1 it was 
necessary to derive the corresponding vector expressing only the HA epitope The 
strategy used to construct pcDNA3HA involved excision o f the bfl-1 cDNA from 
pcDNA3-HA-Bfl-1 with Bam  HI and Xho  I (Figure 3 7A), conversion o f the restricted 
sites to blunt ends and subsequent rehgation o f the vector (not shown)
The pcDNA3 vector carries the neomycin-resistance gene (Figure 3 7A), and hence 
selection o f transfectants transduced with pcDN A3-HA-Bfl-1 or pcDNA3-HA was based 
on resistance to G418 when included in the growth medium Prior to transfection, the 
sensitivity o f  the target cell line, Mutu I, to G418 was determined as described in section 
2 4  9 1 It was found that G418 when added to the growth medium at an ‘active’ 
concentration o f 1400 jag/ml was sufficient to kill >95% o f M utu I cells by 12 days 
Mutu I cells were transfected with either pcDNA3-HA-Bfl-1 or pcDNA3-HA by 
electroporation using conditions described in section 2 4  8 1. G418-selection was 
initiated 48 hours post-electroporation and continued for the next 21 days before 
analysing the respective transfected pools o f cells for expression o f HA-Bfl-1 or HA and 
sensitivity to apoptosis Northern Blot analysis with a bfl-1 antisense nboprobe showed 
that bfl-1 mRNA was expressed in only the pcDNA3-HA-Bfl-1-transfected pool and not 
the pcDNA3-HA transfected pool (Figure3 8A) The level o f bfl-1 mRNA expression in
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the pcDNA3-HA-Bfl-l-transfected pool was lower than that expressed in either Mutu III 
or the LCL IARC171 W estern blot analysis with anti-HA polyclonal antibodies revealed 
the presence o f a novel band at 20 kDa, corresponding to the molecular weight expected 
for HA-Bfl-1, with lysate from only the pool transfected with pcDNA3-HA-Bfl-l (Figure 
3 8B)
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Figure 3 8 Generation o f a pool o f transfectants o f M utu I cells expressing H A-tagged Bfl-1 M utu I 
cells were transfected with either pcDNA3-HA-Bfl-l expressing HA-tagged Bfl-1 or control vector 
(pcDNA3-HA) and subjected to selection for 21 days with G418 Total RNA and protein were then 
prepared for analysis A) The upper panel shows a Northern blot analysis o f  bfl-1 mRNA in M utu III (lane 
1), cell pools transfected with either pcDNA3-HA (lane 2) or pcDNA3-HA-Bfl-l (lane 3) and the LCL 
IARC171 (lane 4) The lower panel is a photograph o f  the 18S rRNA band from the same ethidium 
brom ide-stained gel used for blotting B) W estern blot analysis using polyclonal anti-HA antibodies to 
detect HA-Bfl-1 expression in cell extracts from the same transfected Mutu I cell pools (lane 1, pcDNA3- 
HA, lane 2, pcDNA3-HA-Bfl-1) as shown in panel A The position o f H A -Bfl-l is indicated
The growth kinetics o f the Bfl-1 transfected and control-transfected pools were then 
compared under optimal (10% FBS) and sub-optimal culture conditions (0 1% FBS) 
The results o f this experiment are represented in Figure 3 9 A In 10% FBS, after an 
initial lag phase, both pools o f transfected cells exhibited rapid growth to high saturation 
density followed by a slight fall m viability However, m 0 1% FBS, the behaviour o f the 
two pools differed significantly in that while the control cells showed a rapid decline in 
viability with time, the Bfl-1 expressing cells exhibited a slight increase in proliferation
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over the first 72h in culture followed by a gradual decline m viability To assess if  the 
decline in viability o f the control cells cultured in the presence o f 0 1% FBS was due to 
apoptotic death two assays were employed The first, the ‘DNA ladder assay’, is based on 
the usage o f agarose gel electrophoresis to detect intemucleosomal DNA fragmentation 
(observed as a ladder o f DNA fragments after ethidium bromide-staining o f the gel) The 
second, is based on the detection o f chromatin condensation by acridine orange staining 
o f cells followed by fluorescence microscopy A marked increase in DNA fragmentation 
was detected when the control cells were grown under low-serum conditions (Figure 
3 9B, compare lanes 1 and 2) In contrast, the HA-Bfl-1 transfected cells exhibited much 
less DNA fragmentation when grown under similar sub-optimal conditions (Figure 3 9B, 
compare lanes 2 and 4) The abiltiy o f Bfl-1 to promote cell survival during growth 
factor deprivation was further supported by the observation that while an average o f 82% 
o f the control cells exhibited chromatin condensation on staining with acridine orange 
after 72h o f culture in 0 1% FBS, 35% o f HA-Bfl-1-transfected cells contained 
condensed chromatin under similar culture conditions In 10% FBS-containmg medium, 
approximately 7% o f the cells m both pools o f transfectants exhibited chromatin 
condensation Based on these observations, it is clear that Bfl-1 can protect BL cells 
from apoptotic death induced by serum-deprivation The fact that a minority o f cells in 
the HA-Bfl-1 - expressing pool continue to undergo apoptotic death in response to serum 
depnvation is likely to reflect heterogeneity in HABfl-1 levels between individual 
transfected cells, some o f which may express this protein at very low levels Indeed, the 
overall bfl-1 mRNA level in the transfected pool was lower than that m Mutu III or 
IARC-171 cells (Figure 3 8A)
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Figure 3 9 Functional analysis o f Bfl-1 expression in Mutu I BL cells A) Growth curves o f  M utu I 
cells transfected with either control [pcDNA3-HA (solid symbols)] or HA-Bfl-1 expression vector 
[pcDNA3-HA-Bfl-l (open symbols)] Cells from exponentially growing cultures o f  the pools o f 
transfected cells were seeded at 2 x 105 cells per ml o f growth medium containing either 10% FBS (circles) 
or 0 1% FBS (triangles) and assessed at daily intervals for viable-cell numbers by trypan blue exclusion 
B) DNA fragmentation assay was carried out on the transfected Mutu I cells described in panel A cultured 
in medium containing either 10% FBS (lanes 1 and 3) or 0 1% FBS (lanes 2 and 4) for 72h as described in 
M aterials and M ethods section 2 4 10 1 Lanes 1 and 2 contain DNA from cells transfected with control 
plasmid (pcDNA3-HA), and lanes 3 and 4 contain DNA from cells transfected with pcDNA3-HA-Bfl-l
3.2.6 LMP-1 increases the half-life o f b f l - 1  mRNA
The increase in the steady-state levels o f bfl-l mRNA could be due to an increase in 
either the rate o f transcription o f the bfl-l gene or stability o f previously transcribed 
mRNA or a combination o f both mechanisms b fl-l has already been classified as an 
immediate-early response gene (Karsan et a l , 1996; Lin et a l , 1996, Moreb and
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Schweder, 1997) Since many early response genes are regulated at the level o f mRNA 
stability it was o f interest to investigate if  this was a factor in regulating bfl-1 expression 
in BL cells with a latency group III phenotype and in response to LM P-1 expression The 
rate o f decay o f bfl-1 mRNA was monitored by Northern blotting after treatment o f cells 
with an inhibitor o f RNA polymerase II, actinomycin D (5|j,g/ml) (Figures 3 10 and 3 11, 
A and B upper panel) bfl-l mRNA levels in the untreated and treated cells were 
determined after Northern blotting by densitometric analysis o f autoradiograms and 
values were corrected for variations due to loading after estimating 18S rRNA levels m 
each lane (as determined by densitometric analysis o f ethidium bromide stained gels) 
Values thus obtained were expressed as a percentage o f the bfl-l mRNA level seen in 
untreated cells (taken as 100%) The half-life o f bfl-1 mRNA was then determined from 
the best-fit semi-logarithmic line o f the graph o f these values plotted against time (hours) 
o f exposure to actinomycin D (Figures 3 10 and 3 11, A and B, lower panel) generated 
from the relative amounts o f bfl-1 mRNA as determined by densitometric scanning o f the 
Northern blots The half-hfe o f bfl-1 mRNA m BL41 cells was found to be 
approximately 1 hour, which was increased to 7 4h in BL41-B95 8 cells and 5 2h m the 
corresponding LCL IARC-171 (Figure 3 10 B) Under similar experimental conditions, 
the half-life o f bfl-1 mRNA in unmduced DG75-tTA-LM P-l cells was 4 25h and this 
subsequently increased to 11 5h on induction o f LMP-1 (Figure 3 11 B) It is not clear 
why the stability o f bfl-l mRNA in unmduced DG75-tTA-LM P-l cells was higher than 
that m BL41 cells, although both are EBV-negative BL cell lines It is possible that the 
rate o f inhibition o f RNA synthesis by actinomycin D differs between the two cell lines 
Alternatively, the uninduced DG75tTA-LM P-l cells may exhibit ‘leaky’ expression o f 
LMP-1 below the level o f sensitivity o f detection o f LMP-1 expression by western 
blotting which may account for the higher stability o f the bfl-1 transcript Nevertheless, 
against a similar cellular background, EBV infection or LMP-1 expression resulted in 
significant increases m the stability o f bfl-1 mRNA
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A. BL41 BL41-B95.8 IARC-171
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Figure 3 10 EBV infection increases the stability o f b fl- l  mRNA in BL cells Exponentially growing 
cultures o f  the EBV-negative BL cell line BL41, its EBV (B95 8 strain) -in fected  derivative BL41-B95 8 
and the corresponding LCL IARC-171 were treated with 5(ig/ml actmomycin D to block RNA synthesis 
The cells were then further incubated for the 2, 4, 6, 8, 12 and 24 hours before total cellular RNA was 
extracted and the rate o f decay o f  b fl-l mRNA monitored by Northern analysis A) The upper panel shows 
the Northern blot analysis o f the decay o f  b fl-l mRNA over time (indicated m hours above each lane) after 
treatm ent with actmomycin D m BL41, BL41-B95 8 and IARC-171 cell lines The lower panel is a 
photograph o f  the 18S rRNA band from the same ethidium bromide-stained gel used for blotting B) The 
graphs show the best-fit semilogarithmic lines generated from the relative amounts o f  b fl- l mRNA as 
determ ined from densitom etric scanning o f  the autoradiogram s o f  the Northern blots in panel A above
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plotted against time o f  exposure to actinomycin D. All values were normalised for loading based on the 
intensity o f  the 18S rRNA bands on the corresponding ethidium bromide-stained gels. Relative levels o f 
bfl-1 mRNA as determined in BL41 ( O  ), BL41-B95.8 (□) and 1ARC-171 ( • ) .
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F igu re  3.11 Induction  o f LM P-1 in D G 75-tT A -L M P -l cells increases the  stab ility  o f bfl-1  mRNA.
DG 75-tTA -LM P-l cells were grown in the presence (+ tet) or absence (-tet) o f  tetracycline for 36 hours 
before addition o f  5ng/ml actinomycin D. The cells were then further incubated for the 2, 4, 6, 8, 12 and 
24 hours before total cellular RNA was extracted and the rate o f decay o f  bfl-1 mRNA m onitored by 
Northern analysis. A) The upper panel shows the Northern blot analysis o f  the decay o f  bfl-1 mRNA over 
time (indicated in hours above each lane) after treatment with actinomycin D in uninduced DG75-tTA- 
LMP-1 cells (+ tet) and 36 hours after LM P-1-induction (-tet). The lower panel is a photograph o f  the 18S 
rRNA band from the same ethidium bromide-stained gel used for blotting. B) The graphs show the best-fit
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semilogarithmic lines generated from the relative amounts o f  bfl-1 mRNA as determ ined from 
densitometric scanning o f the autoradiogram s o f  the Northern blots in panel A above plotted against time o f 
exposure to actinomycin D Relative levels o f  bfl-1 mRNA as determined in umnduced D G 75-tTA -LM P-l
cells (A ) and at 36h after LMP-1 induction ( A )
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3.2.7 Effect o f LMP-1 on b f l - l  promoter activity
To investigate if  the increase in the steady-state levels o f bfl-l mRNA induced by LMP-1 
expression could also be due to an increase in the rate o f transcription o f the b fl-l gene, 
the effect o f expression o f this EBV gene on the promoter activity o f bfl-1 as an indirect 
parameter was analysed
Promoter-reporter assays are one o f the most common and convenient ways o f assessing 
transcriptional activity The activity o f the promoter o f interest is assessed by 
transfection o f a construct containing the promoter sequence fused to a reporter gene into 
an appropriate cell line Promoter activity in response to a chemical stimulus or a protein 
expressed from another plasmid that is cotransfected with the promoter-reporter construct 
is then measured by assaying for reporter activity Two o f the commonly used reporter 
genes in promoter-reporter constructs encode the enzymes chloramphenicol acetyl 
transferase (CAT) and luciferase (luc) However, the greater sensitivity and rapidity o f 
luciferase assays has resulted in the popular usage o f luc-based rather than CA T-based 
promoter-reporter constructs for evaluating transcriptional activity in transfected cells It 
was therefore decided to investigate the regulation o f bfl-\ promoter activity by LMP-1 
using a luciferase-based system
The promoter region o f the human bfl-l gene has been cloned (Zong et a l , 1999, 
Edelstein and Gelinas, unpublished observations) and increased activity o f a 1 4 kb 
region upstream o f b fl-l has been demonstrated in response to TN F-a in promoter- 
reporter assays (Zong et a l , 1999) The 1 4 kb DNA sequence from the 5 ’ regulatory 
region (-1374 / +81) o f the bfl-l gene was obtained as a fragment cloned into the 
promoterless pCAT-basic plasmid (Zong et a l , 1999) In order to change the reporter- 
context o f the p-1374/+81Bfl-l-CA T construct to a luciferase-based system, a cloning 
strategy based on replacing the CAT gene with the luciferase gene from pGL2-basic 
vector (Promega) in the pCAT basic background was employed The circle maps o f 
pCAT-basic and pGL2-basic are shown in Figure 3 12 The sites m the polylinker region
126
o f pCAT-basic into which the -1374/+81 region o f the bfl-1 gene was cloned is also 
indicated in Figure 3 12
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F ig u re  3.12 A) Schem atic  c ircu la r m ap  o f pC A T  Basic vecto r Indicated on the map are the sites (Sal I, 
X ba  I) in the polyhnker into which the - 1 3 7 4 /+ 8 1  region o f  bfl-1 was cloned by Zong et al (1999 )  to create 
P-1374/+81 Bfl-1-CAT The Dam HI and X ba  I restriction enzymes (sites indicated by arrows) were used to
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excise a 4 175 kb fragment containing the bfl-1 prom oter B) Schematic circular map o f pGL2-Basic 
vector The B am H  I and H ind  III restriction enzymes (sites indicated by arrows) were used to excise a 
2 691 kb fragm ent containing the luciferase reporter gene The EcoR  I site in the luciferase gene (position 
663) is also indicated
The bfl-1 promoter region (-1374/+81) had previously been inserted by directional 
cloning into the Sal I and Xba  I sites o f pCAT-basic to create the p-1374/+81Bfl-l-CAT 
plasmid (Zong et a l , 1999) To construct the p-1374/+81Bfl-l-luc plasmid containing 
the -1374/+81 region o f bfl-1 cloned just upstream o f the luc gene, the 4 175 kb Bam H  I- 
Xba  I DNA fragment (containing the bfl-1 promoter region) from p-1374/+81Bfl-l-CAT 
was ligated to the 2 691 kb BamH  l-Hind  III fragment (containing the luc gene) o f the 
pGL-2 basic plasmid In summary, the ligation reaction involved blunt-end ligation 
between the ‘filled-in’ Xba  I and H ind  III ends and ‘sticky-end’ ligation between the 
Bam H  I ends Figure 3 13 shows the restriction enzyme analysis o f p-1374/+81 Bfl-1 - 
CAT and pGL-2 basic to excise the DNA fragments o f interest for use in ligation to 
create the p-1374/+81Bfl-l-luc plasmid
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F igu re  3.13 R estric tion  enzym e analysis o f p-1374/+81 Bfl-CAT and  pG L 2-basic . A) The 5.819 kb. 
p-1374/+81B fl-l-C A T plasmid was digested with Bam H  I and X ba  I to generate the bfl-1 promoter 
containing DNA fragment o f  4.175 kb. (marked by an asterik *). lane 1: undigested plasmid, lane 2: 
Bam H  I-digested plasmid, lane 3: X ba  I-digested plasmid, lane 4: plasmid digested with Bam H  I and X ba  I. 
M= DNA m olecular weight markers B) The 5.597 kb. pGL2-basic plasmid was digested with H ind  III, 
Bam H  I and Sea  I to yield a 2.691 kb H ind  III-BamH  I fragment (m arked by an asterisk *) containing the 
luc gene. Lane 1: undigested plasmid, lane 2: H ind  Ill-digested plasmid, lane 3: Bam H  I- digested plasmid, 
lane 4: Sea  /-digested plasmid, lane 5: plasmid digested with H ind  III, Bam H  I and Sea  I. A 1% agarose-1 x 
TAE gel was used and electrophoresis was carried out at 100 V for 1 h.
The p-1374/+81 Bfl-1-luc plasmid created by ligating the 4.175 kb. BamH  I -Xba I 
fragment from p-1374/+81Bfl-l-CAT to the 2.691 kb. Hind  III-BamH  I fragment from 
pGL2-basic was confirmed by restriction enzyme analysis (Figure 3.14). The EcoR  I 
enzyme has two recognition sites in the p-1374/+81 B fl-l-luc plasmid, one within the 
luciferase gene (figure 3.12B) and the other within the vector backbone derived from the 
p-1374/+81Bfl-l-CAT plasmid (figure 3.12A) and was thus useful in confirming that the 
ligation worked.
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F igu re  3.14 R estric tion  enzym e analysis o f p-1374/+81 B fl-l-luc. The EcoR  I restriction digestion
pattern o f  p-1374/+81 B fl-l-luc plasmid confirms the expected organisation o f  the plasmid. Lanes 1-3 : p-
1374/+81 B fl-l-luc preparation 1 and lanes 4-6: p-1374/+81 B fl-l-luc preparation 2. Lanes 7-9: p-
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1374/+81 B fl-l-C A T  Lanes 1, 4 and 7 Undigested plasmid, lanes 2, 5 and 8 EcoR  I digestion pattern, 
Lanes 3, 6 and 9 Bam H  1 digestion pattern Restriction digestion with B am H  I linearises p-1374/+81 Bfl-
1 -lue (6 866 kb) and p-1374/+81 B fl-l-C A T  (5 819 kb) Restriction digestion o f  p-1374/+81 B fl-l-luc 
with EcoR  1 yields two fragments o f  4 781kb and 2 085 kb as expected o f the ligation o f  the the 4 175 kb 
Bam H  l-Xba  I fragment from p-1374/+81B fl-l-C A T to the 2 691 kb H ind  U l-Bam H  I fragment from 
pGL2-basic
The promoterless reporter vector (basal/basic vector) was constructed by ligating the
2 720 kb B am H l-Sa l I fragment from p-1374/+81-Bfl-l-CAT to the 2 691 kb B a m H I- 
Hind  III fragment from pGL2-basic (Figure 3 12B) and involved prior conversion o f the 
Sal I and Hind  III ends to blunt ends Restriction enzyme analysis confirmed the 
organisation o f the derived basal/basic luciferase reporter plasmid (Figure 3 15)
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Figure 3 15 Restriction enzyme analysis o f the promoterless (basic/basal) luciferase vector The EcoR  
I restriction digestion pattern o f the promoterless luciferase plasmid confirms the expected organisation o f 
the plasm id Lanes 1-3 p-1374/+81 Bfl-1 lue and lanes 4-6 promoterless luciferase plasm id Lanes 1, 4 
Undigested plasm ids Lanes 2, 5 B am H  I digestion pattern Lanes 3, 6 EcoR  I digestion pattern 
Restriction digestion with Bam H  I linearises p-1374/+81 Bfl-1-lue (6 866 k b )  and the promoterless 
luciferase plasm id (5411  kb) Restriction digestion o f  the promoterless luciferase plasm id with EcoR  I 
yields two fragments o f  3 326 kb and 2 085 kb as expected A 1% agarose-1 x TAE gel was used and 
electrophoresis was carried out at 100 V for lh  in 1 x TAE
130
The LMP-1 expression plasmid, pEFCXLMP-1, has been described previously 
(Liljeholm et al., 1998) and was constructed by cloning the LMP-1 cDNA into the 
‘empty’ vector, pEFCX. The expression o f LMP-1 from pEFCXLMP-1 is driven by the 
strong polypeptide chain elongation factor 1 a  promoter. A key feature o f this promoter is 
that its activity is not NF-KB-dependent and thus allows the usage o f NF-kB inhibitors to 
study any NF-KB-dependent effects o f LMP-1 without affecting LMP-1 expression.
The upregulation o f bfl-1 mRNA by LMP-1 was observed in the context o f the EBV- 
negative BL cell line, DG75. This cell line also exhibits a high efficiency o f transfection 
by the DEAE-dextran method and by electroporation (Ricksten et al., 1988; Liljeholm et 
al., 1998) and was thus a convenient and relevant target cell line for investigating the 
effect o f transient expression o f LMP-1 on bfl-1 promoter activity. Although the 
majority o f the promoter studies were conducted using this cell line, some o f the 
promoter studies were also repeated in another EBV-negative BL cell line, BL41, and in 
the T-cell line, Jurkat. Although the induction o f LMP-1 in Jurkat-tTA-LMP-1 cells 
failed to induce bfl-1 mRNA, the lack o f an effect may be explained by the functional 
deficiency o f the necessary components in the transduction pathway in this clone. 
Indeed, clonal variants with widely different characteristics have been isolated in case o f 
Jurkat-T cells (Martinez-Lorenzo et al., 2000) and the Jurkat-tTA-LMP-1 cells may 
represent a clonal variant o f the original population o f cells. Hence, promoter studies o f 
bfl-l gene were extended to the parental Jurkat T cell population. This cell line has been 
shown to exhibit many o f the LMP-1-induced changes in gene expression observed with 
B cell lines in transient transfection studies (Huen et al., 1995).
3.2.7.1 LMP-1 increases b f l - 1  promoter activity in the BL cell Line DG75
Transfection o f increasing amounts (0.5, 1.0, 2.5 or 5.0 (ig) o f the LMP-1-expression 
plasmid, pEFCXLMP-1, into DG75 cells led to a dose-dependent increase in the levels o f 
expression o f LMP-1 protein as assessed by Western blot analysis (Figure 3.16 A). As 
expected, transfection with the empty vector, pEFCX, did not result in the expression o f a
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protein that reacted specifically with the anti-LMP-1 antibodies Since LMP-1 has been 
demonstrated to activate the transcription factor NF-kB, the functionality o f LMP-1 
expressed from pEFCXLMP-1 in DG75 cells was assessed by cotransfection o f an NF- 
KB-dependent luciferase reporter plasmid, 3 x enh NF-kB-1uc (containing three tandem 
repeats o f the IgK-light chain NF-kB element fused to the minimal conalbumin promoter) 
and measuring luciferase activity at 24h post-transfection As shown in Figure 3 16 (A 
and B) increased levels o f LMP-1 expression correlated with increased activation o f NF- 
kB with peak activation o f approximately 4 5-fold measured with transfection o f 2 5 |ag 
o f pEFCXLMP-1 Transfection o f the higher amount o f 5 0 (_ig o f the expression vector 
for LMP-1 did not result in a further increase in luciferase activity A similar dose- 
dependent effect was observed when the effect o f expression o f increasing amounts o f 
LMP-1 on bfl-1 promoter activity was assessed on cotransfection o f the ¿/7-7-promoter- 
luciferase construct, p-1374/+81-Bfl-l-luc Indeed, maximal activation o f 7 8-fold was 
detected with transfection o f 2 5 (ig o f pEFCXLMP-1 and transfection o f a higher 
amount o f the LMP-1 expression plasmid did not result in a further increase in this level 
o f activation (Figure 3 16 C)
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F igu re  3.16 D ose-dependent effect o f LM P-1 expression on bfl-1  p ro m o te r activ ity . DG75 cells were 
cotransfected with increasing amounts (0.5, 1.0, 2.5. 5.0 ng) o f either pEFCX or pEFCX-LMP-1 and either 
2.5 ng o f 3 x enh k B  luc (panel B) or p-1374/+81 Bfl-1 -luc (panel B) or 3xenh kB luc (panel C). Cells were 
harvested 24 h post-transfection and analysed for LMP-1 expression by W estern blot analysis (A) and 
luciferase activity produced from either the NF- k B  -lu c  construct (B) or the bfl-1 prom oter -  luc construct 
(C ) was measured. Fold-activation represent the normalised (for transfection efficiency based on (3- 
galactosidase activity measured from cotransfected pCM VlacZ reporter included in all transfections) 
luciferase activity due to transfection o f  the LMP-1 expression plasmid, pEFCXLM P-1, relative to that due 
to transfection o f  the empty vector pEFCX (luciferase activity o f  reporter obtained on transfection with
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empty vector was arbitrarily assigned a value o f  1 0) and depict the mean +_ s d o f  two independent 
experiments
The effect o f LMP-1 was specific to the DNA sequence o f p -13 74/+81 B fl-1 luc spanning 
the promoter region o f bfl-1 since LMP-1 expression did not affect luciferase activity 
from the cotransfected basic vector (Figure 3 17) In the same transfection set and under 
similar experimental conditions, LMP-1 expression stimulated luciferase synthesis from 
the p-1374/+81Bfl-l-luc reporter approximately 8 5-fold relative to empty vector These 
results indicate that LMP-1 upregulates bfl-1 promoter activity in the Burkitt’s lymphoma 
cell line DG75
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Figure 3 17 Expression o f LMP-1 does not affect the activity o f the basic/ promoterless luciferase 
reporter DG75 cells were cotransfected with 2 5jj.g o f  LMP-1 expression vector pEFCXLMP-1 or control 
plasm id pEFCX and an equal amount o f  the basic/prom oterless reporter or the bfl-1-promoter- luciferase 
construct, p-1374/+81 B fl-l-luc and luciferase activity was analysed 24 h post-transfection N orm alised 
luciferase readings from one representative experiment are plotted and the values are indicated above each 
column in the graph
2 ) 2 . 1 . 2  Identification o f LMP-1 signaling domains required for induction o f b f l - 1  
promoter activity
The LMP-1 molecule comprises a short N-terminal cytoplasmic domain, six membrane 
spanning helices that facilitate aggregation and a long cytoplasmic carboxy-terminus
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(Figure 1 7) As described in Section 1 6 5, the majority o f the signaling functions o f 
LMP-1 have been assigned to two domains, CTAR1/TES1 and CTAR2/TES2, within the 
carboxy-terminus o f the cytoplasmic portion o f the protein (Huen et a l , 1995, Mitchell 
and Sugden, 1995) (Figure 3 18) Although both o f these domains contribute 
independently to activation o f NF-kB by LMP-1 in a TRAF-dependent mechanism, 
CTAR2 exerts a predominant effect in most cell types, accounting for 70 -  80 % o f the 
activation o f this transcription factor by LMP1 CTAR2 alone is responsible for the 
activation o f AP-1 by wild-type LMP-1 LMP-1 can also activate the p38 MAPK 
(mitogen-activated protein kinase) pathway and both CTAR-1 and CTAR-2 are 
responsible for mediating this effect in a TRAF2-dependent manner (Ehopoulos et a l , 
1999) A third functional domain o f LMP-1, CTAR3, has recently been identified which 
localises to a region o f the carboxy terminus o f LMP-1 located between CTAR-1 and 
CTAR-2 (Figure 3 18) This domain is responsible for the interaction o f LMP-1 with 
Janus kinase (JAK)-3 which in turn activates STAT (signal transducers and activators o f 
transcription) proteins (Gires et a l , 1999)
To identify the domain(s) o f LMP-1 that are responsible for the effect on bfl-1 promoter 
activity, plasmids expressing LMP-1 mutants containing point mutations o f critical 
residues in CTAR-1 and CTAR-2 were used in comparative analysis with wild-type 
LMP-1 in promoter-luciferase assays Three different LMP-1 mutants were used (Figure 
3 18) The first, LMP-AAA, contains a triple mutation in the central core o f the TRAF 
interaction domain o f CTAR-1 (P204xQ206xT208 -»  AxAxA) This triple mutation has 
been previously shown to block CTAR-1-mediated NF-kB activation by abrogating 
TRAF binding to this domain (Devergne et a l , 1996, Ehopoulos et a l , 1997, 1999) The 
second, LMP G, contains a single point mutation in CTAR-2 such that the tyrosine 
residue at position 384 is mutated to glycine This mutation has been shown to potently 
inhibit activation o f NF-kB and AP-1 by LMP-1 by inhibiting TRADD binding 
(Ehopoulos et a l , 1999, Floettmann et a l , 1997) The third, LMP AAAG, encompasses 
the mutations present in LMP AAA and LMP G and is unable to activate NF-kB or AP-1 
(Brennan et al., 2001).
135
CTAR1/TES1 CTAR3 CTAR2/TES2
187 231 275 307 352 386
204 208
P * Q Q *  A T *
384
Y *
Figure 3 18 Schem atic representation o f the carboxy-term inal cytoplasm ic region o f LMP1 The three 
signaling domains, CTAR1/TES1 (aa 187 to 231) and CTAR2/TES2 (aa 352 to 386) and CTAR3 (aa 275 
to 307) are represented by empty boxes The amino acid residues within CTAR1 and CTAR2 that are 
directly implicated in TRAF and TRADD binding respectively are indicated The CTAR3 domain is 
implicated in JAK3 activation Residues withm the TRAF binding core o f CTAR1 that are marked with an 
asterik were mutated to alanine m the LMP1 mutant LMPAAA The Y384 residue in CTAR2 that is 
important for TRADD binding was mutated to glutamate in the LMP1 mutant LMP G LMP AAAG is a 
double mutant containing the mutations present in both LMP AAA and LMP G
The constructs from which wild-type and mutant LMP-1 molecules were expressed were 
all based on the pSG5 vector (Stratagene) from which expression is driven by the SV40 
early gene promoter A comparison o f the plasmids by agarose gel electrophoresis 
suggested that the preparations were o f similar quality suitable for use in transfections 
(Figure 3 19)
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Figure 3 19 Analysis o f the quality o f the expression constructs for wild-type (W T) and mutant LM P- 
1 proteins Lane 1 pSG5 (empty vector), lane 2 pSG5-LMP WT, lane 3 pSG5-LMP AAA, lane 4 pSG5- 
LMP G, lane 5 pSG5-LMP AAAG A 1% agarose-1 x TAE gel was used and electrophoresis was carried 
out for lh at 100 V in 1 x TAE
The effect o f expression o f wild-type and mutant LMP-1 proteins on the activity o f the 
bfl-1 promoter was compared by cotransfection o f expression vectors for the effector 
proteins together with the bfl-1 promoter-luciferase construct p-1374/+81 Bfl-1-luc into 
DG75 and Jurkat cells and assaying for luciferase activity 24 h post-transfection The 
effect o f expression o f the wild-type and mutant LMP-1 proteins on NF-kB activity was 
investigated in a similar experimental strategy but involving cotransfection o f the 3 x enh 
kB-1uc construct Expression o f wild-type LMP-1 activated b fl-l promoter activity 6 4- 
fold (Figure 3 20 A middle panel) and induced luciferase synthesis from the 3 x enh kB- 
luc construct approximately 3 6-fold in DG75 cells (Figure 3 20 A lower panel) 
Although not formally investigated, the slightly lower extent o f activation o f bfl-1 
promoter activity and NF-kB activation by LMP-1 expressed from pSG5LM P-l relative 
to that observed with pEFCXLM Pl in DG75 cells is likely to be due to differences in the 
level o f expression o f LMP-1 from the two expression vectors Expression o f LMP AAA
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induced bfl-1 promoter activity that was approximately 76% o f wild-type LMP-1 activity 
and induced approximately 73% o f the NF-kB activity induced by wild-type LMP-1 In 
comparison, expression o f LMP G induced bfl-1 promoter activity to approximately 20% 
o f wild-type LMP-1 activity and NF-kB activity to approximately 25% o f wild-type 
LMP-1 activity LMP AAAG was unable to activate NF-kB or induce b fl-l promoter 
activity when ectopically expressed in DG75 cells (Figure 3 20 A middle and lower 
panels) The effects o f the LMP mutants on bfl-l promoter activity and NF-kB 
activation did not seem to be due to differential levels o f expression o f these proteins 
since W estern blot analysis revealed similar levels o f expression o f wild-type and mutant 
LMP1 proteins when the corresponding expression vectors were transfected (Figure 3 20 
A, upper panel) These results indicate that in DG75 cells, the CTAR-1 and CTAR-2 
domains o f LMP-1 can independently contribute to activation o f bfl-l promoter activity, 
with CTAR-2 being the predominant contributor in this effect Furthermore, the 
functional activity o f  both domains is required for maximal activation o f  the bfl-1 
promoter and NF-kB activity Also, the relative contribution o f the individual domains 
o f LMP-1 to inducing bfl-1 promoter activity correlates with the effect on NF-kB 
activation, an observation that suggests that NF-kB activation may be important in 
mediating the effect o f LMP-1 on activation o f bfl-l The observation that the double 
mutation in CTAR-1 and CTAR-2 completely abrogates LMP-1-mediated activation o f 
the bfl-l promoter does not necessarily exclude the functional involvement o f signaling 
domains mapping to other regions o f LMP-1 such as CTAR3 since the function o f 
CTAR3 may be may be dependent on CTAR1 and/or CTAR2 (Brennan et a l , 2001)
In Jurkat cells, expression o f wild-type LMP-1 induced a 3 4-fold activation o f the bfl-1 
promoter and activated NF-kB 104-fold Expression o f LMP AAA (which contains an 
intact CTAR2 domain) resulted in retention o f 40% and 32% o f wild-type LMP-1 
transactivation o f the bfl-l promoter and NF-kB respectively (Figure 3 20 B, middle and 
lower panels) suggesting that in Jurkat cells CTAR-2 makes a lower contribution to 
induction o f bfl-l promoter activity and NF-kB activation compared to the BL cell line 
DG75 Expression o f LMP G (which contains an intact CTAR1 domain) resulted in
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retention o f even lower levels o f bfl-1 promoter activation and NF-kB activity, retaining 
approximately 5% o f wild-type LMP-1 activity in both cases This result suggests that in 
Jurkat cells, the function o f CTAR1 is more severely impaired than CTAR2 LMP 
AAAG did not activate the bfl-1 promoter and barely activated NF-kB m Jurkat cells 
Thus, the pattern o f contribution o f the CTAR-1 and CTAR-2 o f LMP-1 to bfl-1 
promoter activity and NF-kB activation in Jurkat cells would appear to differ to that in B 
cells, in that the independent functions o f these domains is less efficient in Jurkat cells 
than in DG75 with CTAR-1 function being the more severely impaired The finding that 
the extent o f CTAR-1- and CTAR-2- mediated signaling in LMP-1 mutants can vary with 
the cellular background is consistent with previous reports (Huen et a l , 1995, Floettmann 
et a l , 1998)
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Figure 3 20 Analysis o f the function o f CTAR-1 and CTAR-2 domains o f LMP-1 in upregulating  
bfl-1 prom oter activity (middle panel) and NF-kB activity (lower panel) in DG75 (A) and Jurkat T
(B) cells Cells were cotransfected with 2 5 jag o f either pSG5 (vector control), pSG5 LMP wt (expressing 
wild-type LMP-1), pSG5LM P AAA (expressing LMP-1 containing a non-functional CTAR-1 domain),
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pSG5LM P G (expressing LMP-1 containing a non-functional CTAR-2 domain) or pSG5 LMP AAAG 
(expressing LMP-1 mutant that is non-functional in both CTAR-1 and CTAR-2) and 2 5 jig o f  either p- 
1374/+81-B fl-l-luc (middle panel) or 3 x enh kB-1uc (lower panel) Cells were harvested 24 h post- 
transfection and analysed for LMP-1 expression by W estern blot analysis (upper panel) and luciferase 
activity produced from either the b fl-l  prom oter -  luc construct (middle panel) or the N F- kB-1uc construct 
(lower panel) was measured Norm alised luciferase activities were expressed as fold activation over 
control (em pty-vector) as before
3.2.7.3 D om inant negative action of the double m u tan t of LM P1, LM P AAAG
Although LMP-1 lacks an extracellular ligand-binding domain it mimics a constitutively 
activated receptor and oligomerisation is required for its functional activation (Gires et 
a l , 1997) Furthermore, cooperation between CTAR1 and CTAR2 has to occur within a 
hetero-oligomeric complex for a fully functional signal to be generated (Floettmann et 
a l , 1998) The requirement o f physical cooperation between CTAR1 and CTAR2 
domains present on different LMP-1 molecules within the same complex for functional 
activity, forms the basis o f the dominant-negative action o f LMP AAAG Thus, 
coexpression o f an equimolar amount o f LMP AAAG was shown to result in up to 90% 
inhibition o f the NF-kB activity o f wild-type LMP-1 in Jurkat cells (Brennan et a l , 
2001) In a preliminary experiment, the dominant negative action o f LMP AAAG was 
tested m DG75 cells coexpressing wild-type LMP-1 in transient transfection assays with 
a NF-KB-dependent luciferase reporter or the-1374/+81 ¿^/-/-luciferase reporter It can be 
seen from Figure 3 21 that coexpression o f LMP AAAG potently inhibited wild-type 
LMP-1-induced NF-kB activation and b fl-l promoter activity in a dose-dependent 
fashion Thus, cotransfection o f 1 25 jig and 2 5 p,g o f pSG5-LMP AAAG resulted m a 
72% and 91% inhibition o f NF-kB activation induced by expression o f wild-type LMP-1 
from 2 5 |ag o f the corresponding plasmid (Figure 3 21 A) Transfection o f higher 
amounts o f pSG5-LMP AAAG completely blocked the LMP-1-mediated effect The 
effect o f expression o f LMP AAAG on induction o f b fl-l promoter activity by LMP-1 
paralleled its effect on activation o f NF-kB with transfection o f 1 25 jig and 2 5 |j.g o f 
pSG5-LMPAAAG resulting in approximately 60% and 90% inhibition o f wild-type 
LMP-1 activity o f the promoter (Figure 3 21 B)
142
cA. 3 x enh kB luc
>u03
2"ob-
□ pSG 5  
■ pSG5-LMP1
|ig  LM P AAAG 1 25 2 5 5 0 10 0
B .
- 1 3 7 4 / + 8 1  B f l - 1  l u c
63
u
CQ
o
□ pSG5  
■ pSG5-LMP1
\ig LM P AAAG 1 25 2 5 5 0 10 0
Figure 3 21 Dom inant negative effect o f the LMP-1 mutant LM P AAAG DG75 cells were 
cotransfected with 2 5 ng o f pSG 5-LM P-l or empty vector pSG5 and 2 5 |ig  o f either 3 x enh k B-1uc 
(panel A) or p-1374/+81-B fl-l-luc (panel B) together with various amounts o f  (0, l 25, 2 5, 5 0 or 10 0 n g ) 
o f  a plasm id expressing dominant negative LMP-1 mutant, pSG5-LM P-AAAG Cells were harvested 24h 
post-transfection and analysed for luciferase activity as before Normalised luciferase activities were 
expressed as fold activation over control (empty vector in the absence o f  expression o f  LM P-AAAG = 1) as 
before
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3 . 2 . 7 . 4  LMP-1 induces b f l - 1  promoter activation via a mechanism involving TRAF2
TRAF2 has been shown to bind to the cytoplasmic tail o f LMP-1 and is an important 
mediator o f NF-kB activation by LMP-1 (Kaye et al., 1996). TRAF2 binds directly to the 
CTAR1 domain o f LMP-1 and via the adaptor protein TRADD to CTAR2. The carboxy- 
terminal domain o f TRAF-2 mediates TRAF-2-binding to CTAR1 and TRADD whereas 
the amino-terminal RING-finger containing domain is involved in homo- and 
heterodimerisation o f TRAF family members, binding to c-IAPs and is essential for 
TRAF-2-mediated activation o f NF-kB and JNK (Kaye et al., 1996; Rothe et al., 1995; 
Hsu et al., 1996). A dominant negative mutant o f TRAF-2, TRAF2A(6-86), that is 
deleted for aminoacids 6-86 in the N-terminal region, has been demonstrated to inhibit 
activation o f NF-kB and JNK by LMP-1 (Eliopoulos et al., 1997; 1999).
In order to examine a direct role for TRAF-2 in mediating LMP-1-induced activation o f 
bfl-1 promoter activity, DG75 cells were transiently co-transfected with 2.5 (ig o f 
pEFCXLMP-1 or control vector (pEFCX) and 2.5 jag o f the bfl-l-bxc  construct (p- 
1374/+81 B fl-l-luc) in the presence or absence o f increasing amounts o f  a plasmid 
expressing TRAF2A(6-86). Expression o f TRAF2A(6-86) was found to significantly 
reduce bfl-1 promoter activation by LMP-1 in a dose-dependent manner, such that 
transfection o f 5.0 |ag o f pSG5-TRAF2A(6-86) caused a 25% decrease in LMP-1 -  
mediated transactivation o f bfl-l and transfection o f 10.0 ^g o f the TRAF2A(6-86) 
resulted in a further decrease (by 48%) in LMP-1-mediated activation o f the bfl-l 
promoter (Figure 3.22 panel B). As a functional control for TRAF2A(6-86), the effect o f 
TRAF2A(6-86) expression on LMP-1-mediated activation o f NF-kB was investigated in 
a similar experimental strategy but with transfection o f the 3 x enh kB-1uc construct 
instead o f  the b fl-l luciferase construct. In this experiment, transfection o f 5.0 (ig o f 
pSG5TRAF2A(6-86) resulted in a 40% decrease while transfection o f 10.0 ^g o f 
pSG5TRAF2A(6-86) caused a 65% decrease in LMP-1 mediated activation o f NF-kB 
(Figure 3.22 panel C). Western blot analysis revealed that the inhibitory effect o f
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TRAF2A(6-86) on LMP-1-mediated activation o f the bfl-1 promoter is not due to 
inhibition o f LMP-1 expression (Figure 3 22 panel A) These results therefore implicate 
the involvement o f TRAF2 in LM P-1-mediated upregulation o f bfl-1 promoter activity
The observations with TRAF2A(6-86) were supported by experiments in which A20 was 
overexpressed in DG75 cells in the presence o f LMP-1 A20 is an anti-apoptotic RING 
finger protein that interacts with TRAFs and efficiently inhibits NF-kB and JNK 
activation by LMP-1 by associating with LMP1-TRAF and LMP1-TRADD complexes 
and displacing the TRAF and TRADD molecules (Eliopoulos et a l , 1997, 1999, Fries et 
a l , 1999) To examine whether A20 expression could inhibit LMP-1-mediated activation 
o f NF-kB activation in DG75 cells, 2 5 ^g o f pEFCXLMP-1 or pEFCX was 
cotransfected with various amounts o f a vector that expresses A20 (0, 2 5, 5 0 or 10 0 jxg 
o f pSG5-A20) in the presence o f the NF-KB-dnven luciferase reporter As shown in 
Figure 3 23 (panel B), A20 expression potently inhibited NF-kB activation by LMP-1 in 
DG75 cells, with transfection o f 5 0 |ug and 10 0 |^g o f pSG5-A20 resulting in 
approximately 80% and 94% inhibition o f bfl-l promoter activation by LMP-1 A similar 
degree o f inhibition o f LMP-1-mediated activation o f NF-kB was observed when the 
effect o f A20 expression on LMP-1-induced luciferase synthesis from the 3 x enhKB- 
luciferase reporter was investigated (Figure 3 23 panel C) A20 expression did not alter 
basal bfl-1 promoter activity or NF-kB activation suggesting that A20 only affects LMP- 
1-induced signaling A20 expression did not interfere with LMP-1 expression from 
pEFCXLMP-1 as assessed by Western blot analysis o f lysates prepared from the 
transfected cell populations (Figure 3 23 panel A) Taken together, the results obtained in 
the experiments based on the usage o f the dominant negative TRAF2 mutant, 
TRAF2A(6-86), and the TRAF2 interacting protein, A20, suggest a likely role for TRAF2 
in the positive effect o f LMP-1 on bfl-l promoter activity
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Figure 3 22 Involvement o f TRAF2 in LM P-l-m ediated activation o f the bfl-1  prom oter in DG75 
cells DG75 cells were cotransfected with 2 5 (ig o f either pEFC X-LM Pl or empty vector pEFCX and 2 5 
(xg o f either p -1374/+81 -Bfl-1—luc (panel B )  or 3 x enh k B-1uc (panel C) together with various amounts (0, 
5 0 or 10 0 jag) o f  a plasmid expressing dominant-negative TRAF2 mutant [pSG5-TRAF2A(6-86)] Cells 
were harvested 24 h post-transfection and analysed for LMP-1 expression by W estern blot analysis (A) and 
luciferase activity produced from either the bfl-1 prom oter -  luc construct (B) or the NF- k B  - lu c  construct 
(C) N orm alised luciferase activities were expressed as fold activation over control [em pty-vector m the 
absence o f  expression o f TRAF2A(6-86)] as before
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Figure 3 23 Overexpression o f A20 blocks L M P-l-m ediated activation o f the bfl-1  prom oter in DG75 
cells DG75 cells were cotransfected with 2 5 o f pEFCX-LM Pl or empty vector pEFCX and 2 5 ng o f 
either p -1374/+ 81 -B fl-1—luc (panel B) or 3 x enh kB-1uc (panel C) together with various amounts (0, 2 5, 
5 0 or 10 0 fig) o f a plasm id expressing A20 (pSG5-A20) Cells were harvested 24 h post-transfection and 
analysed for LMP-1 expression by W estern blot analysis (A) and luciferase activity produced from either 
the bfl-1 prom oter -  luc construct (B) or the NF- kB -lu c  construct (C) Normalised luciferase activities 
were expressed as fold activation over control (empty vector m the absence o f A20 expression= l)
In Jurkat cells, expression o f dominant-negative TRAF2 mutant, TRAF2A(6-86) (Figure 
3 24), or A20 (Figure 3 25) also inhibited LMP-1-mediated activation o f NF-kB and the 
bfl-1 promoter As observed in DG75 cells, expression o f TRAF2A(6-86) caused a partial 
inhibition [approximately 50% with transfection o f 10 0 jag o f pSG5 TRAF2A(6-86)] o f 
LMP-1-mediated activation o f NF-kB and the bfl-l promoter and expression o f A20 
almost completely inhibited these LMP-1-mediated effects m Jurkat cells Western blot 
analysis revealed that expression o f TRAF2A(6-86) or A20 did not alter LMP-1 
expression relative to controls
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F igu re  3 24 Involvem ent o f TR A F2 in L M P -l-m ed ia ted  activation  o f the  bfl-1  p ro m o te r in J u r k a t  T 
cells Jurkat cells were cotransfected with 2 5 ng o f  pEFCX-LM Pl or empty vector pEFCX and 2 5 ng o f 
either p -1374 /+ 81 -Bfl-1 —luc (panel B )  or 3 x enh kB-1uc (panel C) together with various amounts (0, 5 0 or 
10 0 jig) o f  a plasm id expressing dominant-negative TRAF2 mutant [pSG5-TRAF2A(6-86)] Cells were 
harvested 24 h post-transfection and analysed for LMP-1 expression by W estern blot analysis (A) and 
luciferase activity produced from either the bf l -1  prom oter -  luc construct (B) or the NF- k B  - lu c  construct
(C ) The experim ent in panel C was only perform ed once Norm alised luciferase activities were expressed 
as fold activation over control [empty-vector in the absence o f  expression o f  TRAF2A(6-86) = 1]
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Figure 3 25 Overexpression o f  A20 blocks LM P-l-m ediated activation o f  the bfl-1 prom oter in 
Jurkat T cells Jurkat cells were cotransfected with 2 5 Mg o f  pEFCX-LM Pl or empty vector pEFCX and 
2 5 |ig  o f  either p-1374/+81-B fl-l-luc (panel B) or 3 x enh kB-1uc (panel C) together with various amounts 
(0, 2 5, 5 0 or 10 0 Mg) o f  a plasmid expressing A20 (pSG5-A20) Cells were harvested 24 h post- 
transfection and analysed for LMP-1 expression by W estern blot analysis (A) and luciferase activity 
produced from either the bfl-1 promoter -  Iuc construct (B) or the NF- kB - lu c  construct (C ) Normalised 
luciferase activities were expressed as fold activation over control (em pty-vector in the absence o f  A20 
expression =1)
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3.2.7.5 Activation of 6/7-1 promoter activity by LMP-1 is mediated by the
transcription factor NF-kB
It is now well established that LMP-1 can activate the transcription factor NF-kB in 
several cellular contexts (including B and T lymphocytes and epithelial cells) and that 
many o f the LMP-1-induced changes in gene expression such as A20  and ICAM-1 appear 
to be regulated by this transcription factor (Hammarskjöld and Simurda, 1992; Laherty et 
ah, 1992; Huen et ah, 1995; Liljeholm et ah, 1998; Eliopoulos et ah, 1999; Mehl et ah, 
2001). Members o f the NF-kB family, which include p50 (N FkBI), p52 (NFkB2), p65 
(RelA), c-rel and RelB, can form both homodimers and heterodimers (Baeuerle and 
Baltimore, 1996; Baldwin, 1996). The prototype NF-kB is the NF-KB/Rel heterodimer 
p50/p65. These dimers are normally held in the cytoplasm as inactive complexes with an 
inhibitory component, Ik B . Activation appears to involve phosphorylation and
subsequent release and degradation o f the Ik B  component, thus permitting translocation 
o f the active heterodimers to the nucleus, where they bind to specific DNA sequences in 
the promoters o f the genes they activate. There are a number o f different types o f Ik B , 
and evidence suggests that LMP-1 activates NF-kB through phosphorylation o f Ik B gc on 
serine residues at positions 32 and 36 (Herrero et ah, 1995).
As observed in section 3.2.7.1, the extent o f activation o f NF-kB by LMP-1 parallels its 
effect on bfl-1 promoter activity in DG75 cells. In addition, TRAF-2 which has been 
shown to be required for activation o f NF-kB by LMP-1, is also required for LMP-1 
mediated induction o f bfl-1 promoter activity (section 3.2.7.4). These observations 
together with the now well-established fact that several o f the LMP-1-induced changes in 
gene expression are NF-KB-mediated suggested that the regulation o f bfl-l promoter 
activity by LMP-1 could also be mediated by this transcription factor. To directly test 
this hypothesis, DG75 cells were cotransfected with either an NF-KB-dependent
luciferase reporter construct (3 x enh k B -Iuc) , or the p-1374/+81 B fl-1  luc reporter and
the pEFCX-LMP-1 plasmid together with a plasmid encoding a dominant negative
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mutant form o f IkBoc (pEFCX-lKBaDN) IkBocDN i s  a double mutant with the 
phosphorylatable sermes at positions 32 and 36 mutated to alanines such that it can no 
longer be phosphorylated and is consequently not proteolysed upon NF-kB stimulation 
(Brown et a l , 1995) This mutant efficiently retains NF-kB in the cytoplasm, unable to 
translocate to the nucleus and induce transcription (Liljeholm et a l , 1998) Expression o f 
IkBocDN efficiently inhibited LMP-1-induced NF-kB activity in DG75 cells as assessed 
by measuring luciferase activity after cotransfection o f 3 x enh kB-1uc (2 5 jig) and 
pEFCX-LMP-1 (2 5 fig) plasmids together with pEFCX-hcBaDN (2 5 to 10 0 |ig) 
(Figure 3 26B) The effect o f IkBocDN on NF-kB activity was dose-dependent, with 10 0 
jig o f pEFCX-lKBaDN resulting m complete inhibition o f LMP-1-induced NF-kB 
activation Transfection o f pEFCX-lKBaDN also inhibited the basal NF-kB activity in 
DG75 cells with cotransfection o f 10 0 jig o f pEFCX-lKBaDN resulting in an 
approximately 60% decrease in basal NF-kB activity In a similar experimental strategy 
but with cotransfection o f the p-1374/+81 Bfl-1 luc reporter instead o f 3 x enh kB-1uc, 
expression o f IkBocDN also inhibited LMP-1-induced upregulation o f bfl-1 promoter 
activity in a dose-dependent manner (Figure 3 26C) In this experiment, 10 0 jig of 
pEFCX-lKBaDN, inhibited LMP-1-mediated activation o f the bfl-l promoter to near 
basal (vector control) levels This amount (lOjig) o f pEFCX-lKBaDN, i s  the same as that 
which completely inhibited LMP-1-induced NF-kB activity The inhibitory action o f 
IkBocDN on these LMP-1-induced effects on promoter activity is not the result o f 
inhibition o f LMP-1 expression from pEFCX-LMP-1 as revealed by W estern blot 
analysis for LMP-1 expression (Figure 3 26A) These results strongly suggest that the 
activation o f the b fl-l promoter induced by LMP-1 is NF-KB-dependent Expression o f 
IkBocDN also inhibited basal bfl-1 promoter activity (transfection o f 10 0 jig o f pEFCX- 
IkBocDN caused an approximately 30% decrease in basal bfl-1 promoter activity), 
thereby suggesting that the basal activity o f the bfl-l promoter in DG75 cells may be, at 
least in part, NF-KB-dependent
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Figure 3 26 Inhibition o f LM P-l-m ediated activation o f bfl-1 prom oter activity by overexpression of 
a dom inant negative mutant o f iK B a (IkBocDN) in DG75 cells DG75 cells were cotransfected with 2 5 
jag o f pEFC X -LM Pl or empty vector pEFCX and 2 5 |ig  o f  either 3 x enh k B-1uc (panel B )  or p-1374/+81- 
Bfl-1 - lu c  (panel C) together with various amounts (0, 2 5, 5 0 or 10 0 fig) o f  a plasmid expressing 
IkBcxDN Cells were harvested 24 h post-transfection and analysed for LMP-1 expression by W estern blot 
analysis (A) and luciferase activity produced from either the NF- k B  - lu c  construct (B) or the bfl-1 
prom oter -  luc construct (C) was measured Normalised luciferase activities were expressed as fold- 
activation over control (em pty-vector in the absence o f expression o f  IxB aD N  =1)
The effect o f LMP-1 expression on bfl-1 promoter activity was also investigated in the 
context o f another EBV-negative BL cell line, BL41, in order to rule out the possibility 
that the effect is specific to DG75 cells Indeed, transient expression o f LMP-1 in BL41 
cells enhanced luciferase synthesis from the NF-kB-1uc construct, 3 x enh-KB-luc, 
approximately 4-fold (Figure 3 27B) and stimulated b fl-l promoter activity from the p- 
13 74/+81 B fl-1 -luc construct approximately 5 4-fold (Figure 3 27C) As observed with 
DG75 cells, expression o f the dominant negative IkBoc mutant, IkBocDN, also inhibited 
the effect o f LMP-1 on NF-kB activation and bfl-l promoter activity in BL41 cells in a 
dose-dependent manner, however much lower amounts (5 fag) o f pEFCX- IkBocDN were 
required to achieve complete inhibition o f these effects on reporter activity in BL41 cells 
(Figure 3 27)
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F ig u re  3 27 Inh ib ition  o f L M P -l-m ed ia ted  activation  o f bfl-1  p ro m o te r ac tiv ity  by overexpression  o f 
a d o m in an t negative m u tan t o f IicBa (IicBaD N ) in BL41 cells BL41 cells were cotransfected with 2 5 
Mg o f  pEFC X -LM Pl or empty vector pEFCX and 2 5 Mg o f  either 3 x enh kB-1uc (panel B) or p-1374/+81 - 
Bfl-1 - lu c  (panel C) or together with various amounts (0, 2 5, 5 0 or 10 0 Mg) o f a plasm id expressing 
IkBocDN Cells were harvested 24 h post-transfection and analysed for LMP-1 expression by W estern blot
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analysis (A) and luciferase activity produced from either the NF- kB - lu c  construct (B) or the bfl-1 
prom oter -  luc construct (C) was measured Norm alised luciferase activities were expressed as fold- 
activation over control (em pty-vector in the absence o f expression o f IkB(xDN=1)
A role for NF-kB in mediating LMP-1-induced activation o f bfl-1 promoter activity was 
also observed m Jurkat T cells Transient expression o f LMP-1 m Jurkat cells activated 
the NF-kB-1uc construct, 3 x enh-icB-luc, approximately 145-fold (Figure 3 28B) and 
stimulated bfl-1 promoter activity from the p -13 74/+81 B fl-1 -luc construct approximately 
4 2-fold (Figure 3 28C) Expression o f the dominant negative IkBcx mutant, IkBocDN, 
inhibited the effect o f LMP-1 on NF-kB activation and bfl-l promoter activity in Jurkat 
cells in a dose-dependent manner, however, unlike DG75 cells much lower amounts (5 0 
(j.g) o f pEFCX- IkBocDN were required to achieve complete inhibition o f the effects on 
these reporter constructs in Jurkat cells (Figure 3 28 B and C) The basal activity o f the 
bfl-1 promoter was only marginally inhibited in Jurkat cells in that only a 20% inhibition 
o f basal bfl-1 promoter activity was detected on transfection o f 5 0 (ig o f pEFCX- 
IkBccDN and the extent o f inhibition was not increased on transfection o f a higher 
amount (10 0 (ig) o f pEFCX-IicBaDN even though a dose-dependent decrease in NF-kB 
activity was detected in a similar experiment but with transfection o f the NF-kB-1uc 
reporter These results suggest that the basal activity o f the bfl-l promoter in Jurkat cells 
may not be dependent on NF-kB activity to the same extent as in B cell lines
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F igu re  3 28 Inh ib ition  o f L M P -l-m ed ia ted  activation  o f bfl-1  p ro m o te r activ ity  by overexpression  of 
a d o m in an t negative m u tan t o f IicB a (IkBoiDN) in J u rk a t  cells Jurkat cells were cotransfected with 
2 5 |ig  o f  pEFC X -LM Pl or empty vector pEFCX and 2 5 |_ig o f  either 3 x enh kB-1uc (panel B) or p- 
1374/+81 -Bfl-1—luc (panel C) together with various amounts (0, 2 5, 5 0 or 10 0 |ig) o f  a plasmid 
expressing IkBocDN Cells were harvested 24 h post-transfection and analysed for LMP-1 expression by 
W estern blot analysis (A) and luciferase activity produced from either the N F- kB - lu c  construct (B) or the 
bfl-1 prom oter -  luc construct (C ) was measured Norm alised luciferase activities were expressed as fold 
activation over control (em pty-vector in the absence o f expression o f  IkBccDN=1)
3.2.7.6 LM Pl-induced activation of the bfl-1 promoter does not involve an NF-kB 
site at position -833  (-833 to -823)
LMP-1 upregulates bfl-1 expression, in part, by increasing the activity o f the -1374/+81 
region o f the gene and this effect is mediated by at least one transcription factor, NF-kB 
An NF-kB binding site (GGGGATTTACC) identified at position -833  (-833 to -823) 
relative to the transcription start site o f bfl-l has previously been shown to be essential 
for c-rel-mediated activation o f the bfl-l promoter in the HeLa cell line by mutation 
analysis (Zong et a l , 1999) To investigate if  this NF-kB site may also be important for 
the LMP-1-mediated activation o f bfl-1, a bfl-l promoter-luciferase construct, p- 
1374/+81 mKB Bfl-l-luc, containing a GGG—»TTT mutation in the NF-kB m otif at -833 
in the context o f the -1374/+81 promoter region (Zong et a l , 1999) was used m 
cotransfection studies with the LMP-1-expression plasmid pEFCX-LMP-1 The p- 
1374/+81mKB-Bfl-l-luc construct was derived from the corresponding CAT-based 
vector (Zong et a l , 1999) using the same strategy used for the derivation o f the wild type 
-1374/+81 bfl-l promoter containing luciferase reporter construct DNA sequencing was 
used to confirm the presence o f the mutation in the construct A schematic representation 
o f the -1374/+81 region o f the bfl-1 promoter showing the position o f the NF-kB site at -  
833 is shown in Figure 3 29
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F igu re  3 29 Schem atic rep resen ta tio n  o f L u c  re p o r te r  gene construc ts  d riven  by the  -1374/+81 region 
o f the  bfl-1  gene o r  a derivative  o f this region w ith a m u tation  in the  N F-kB  site (G G G G A T T T A C C  
->  G T T T A T T T A C C ) a t nucleotide position -8 3 3  (re la tive  to tran sc rip tio n  s ta r t  site) The sequence o f 
the NF-kB site at position -8 3 3  in -1374/+81 W T B fl-l-luc is indicated and the nucleotides in this site that 
were mutated in -1374/+81 mKB B fl-l-luc are underlined
Expression o f LMP-1 activated the p-1374/+81W T B fl-l-luc construct to a similar extent 
as its NF-kB (-833)-mutated derivative p-1374/+81mKB B fl-l-luc in transient 
transfection assays o f DG75 and Jurkat cells (Figure 3 30A and B) These results suggest 
that unlike c-rel, the NF-kB site at position -833  is not essential for the activation o f the 
bfl-1 promoter by LMP-1 in these B and T lymphocyte cell lines Also, the mutation at 
position -833  did not significantly affect basal bfl-1 promoter activity in either cell line
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F igure  3.30 LM P-1 m ediated  activation  o f the bfl-1 p ro m o te r in B and  T  lym phocyte cell lines does 
no t req u ire  the  N F-kB  site a t position -8 3 3 . DG75 (panel A), and Jurkat (panel B) cells were 
cotransfected with 2.5 |ig  o f pEFCX-LM Pl or empty vector pEFCX and 2.5 (ig o f  either p-
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1374/+81 W T B fl-l-luc  or its NF-kB (-833)-mutated derivative p-1374/+81triKB B fl-l-luc  Cells were 
harvested 24 h post-transfection and assayed for luciferase activity N orm alised luciferase activities were 
expressed as fold activation over control (transfection o f empty-vector and the wild-type bfl-1 promoter-luc 
construct =1)
3 2 . 1 . 1  Activation of the b f l - 1  promoter by PMA is NF-KB-dependent
Treatment o f a variety o f cell lines including those o f B cell origin with the chemical 
agent phorbol-12-myristate 13-acetate (PMA) has been shown to upregulate bfl-1 mRNA 
levels (Moreb and Schweder, 1997) PMA is also a well known activator o f the 
transcription factor NF-kB In order to examine if  PMA also activated NF-kB in DG75 
cells, luciferase activity from cells transfected with the NF-KB-dependent luciferase 
reporter, 3 x enh kB luc, was measured in the presence or absence o f PMA treatment In 
this experiment, treatment with PMA at the same concentration o f 10'7M as used by 
Moreb and Schweder (1997) activated NF-kB approximately 3 5-fold (Figure 3 31 A) 
The effect o f PMA treatment on bfl-1 promoter activity in DG75 cells was also examined 
using a similar experimental strategy but with transfection o f the p-1374/+81 B fl-l-luc 
construct In this experiment, PMA treatment resulted in a 6 8-fold increase in bfl-1 
promoter activity (Figure 3 3 IB) Furthermore, the effect o f PMA on the activity o f the 
bfl-1 promoter was demonstrated to be NF-KB-dependent since transfection o f an 
expression vector for the dominant negative mutant o f IkBoc (pEFCX-IkBocDN) 
significantly inhibited the induction o f luciferase activity from the cotransfected bfl-1- 
luciferase reporter construct by PMA in these cells (Figure 3 3 IB)
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F igu re  3.31 PM A  activates bfl-1  p ro m o te r activ ity  in an N F-K B -dependent m a n n e r in DG75 cells. A)
DG75 cells transfected with 2.5 |ig o f  the NF-KB-dependent luciferase vector, 3 x enh k B-1uc in the 
presence or absence o f 10.0 p.g pEFCX-lKBaDN were treated with either 10'7 M PMA or vehicle control 
(0.062%  ethanol ) 18h postransfection. After treatment for 24 h, cells were harvested and analysed for 
luciferase activity. Norm alised luciferase values are expressed as fold-increase over control (= the value 
obtained with p-1374/+81 Bfl-1-luc-transfected cells treated with vehicle control was arbitrarily assigned a 
value o f  1). B) DG75 cells transfected with 2.5 |ig  o f the -1374/+81 Bfl-1 luc vector in the presence or 
absence o f  10.0 |ug o f  p E F C X -kB aD N  were treated with either 10'7 M PMA or vehicle control (0.062%  
e th a n o l) 18h postransfection. Cells were harvested 24 h post-treatment and analysed for luciferase activity 
as in panel A.
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PMA treatment activated the wild-type and NF-icB-mutated Bfl-1 promoter-luciferase 
construct to approximately the same extent indicating that the NF-kB site at -833 is also 
not essential for the activation o f the bfl-1 promoter by PMA (Figure 3 32)
□ ushicle 
■ PMA
Figure 3 32 PM A- mediated activation o f the bfl-1 prom oter in DG75 cells does not require the NF- 
kB  site at position -8 3 3  o f the promoter DG75 cells transfected with 2 5 jag o f  either p-1374/+81 W TBfl- 
1—lue or its N F-kB (-833)-mutated derivative p-1374/+81mi<B B fl-l-luc were treated with either 10 7 M 
PMA or vehicle control (0 062%  ethanol ) 18h postransfection After treatment for 24 h, cells were 
harvested and analysed for luciferase activity as before Norm alised luciferase activities were expressed as 
fold activation over control (transfection o f  em pty-vector and p-1374/+81 W T B fl-lluc =1) This 
experim ent was perform ed once
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3.2.7.8 The b f l - l  promoter is responsive to the NF-kB subunit protein p65
To directly demonstrate the responsiveness o f the bfl-l promoter to NF-kB, the effect of 
overexpression o f the NF-kB subunit p65 (Rel A) on bfl-l promoter activity was assessed 
by cotransfection o f an expression vector for p65 together with the bj7-1 promoter- 
luciferase construct, p-1374/+81 W TBfl-l-luc, in DG75 cells It can be seen from Figure 
3 33A that expression o f p65 results in a 3 5-fold activation o f bfl-l promoter activity 
from the cotransfected p-1374/+81 B fl-l-luc construct p65 expression did not affect 
luciferase activity from the basal/ promoterless reporter vector (result not shown) 
Inactivation o f the NF-kB site at position -833 o f the bfl-l promoter did not alter the 
ability o f p65 to activate transcription from the -1374/+81 region o f the b fl-l promoter, 
indicating that as with LMP-1-expression and PMA treatment, the NF-kB site at position 
-833 is also not essential for the p65-mediated activation o f the bfl-l promoter (Figure 
3 33 A) As a control for the functional activity o f p65, the effect o f p65 expression on the 
activity o f a cotransfected NF-KB-dependent luciferase reporter construct was 
determined p65 expression resulted in an approximately 2 4-fold increase in luciferase 
activity from the 3 x enh kB-1uc reporter construct (Figure 3 33B)
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Figure 3 33 O verexpression o f the NF-kB  subunit p65 (Rel A) activates bfl-1 prom oter activity in 
DG75 cells but this effect is not mediated by the NF-kB site at position -8 3 3  o f the prom oter A)
DG75 cells were cotransfected with 5 0 |ig  o f the expression vector for p65 (pSG5-p65) or empty vector 
(pSG5) together with 2 5 jag o f  either the bfl-1 promoter-luciferase reporter construct p-1374/+81 W TBfl-1- 
luc or the NF-KB-mutated version p-1374/+81 micB B fl-l-luc Cells were harvested 24 h post-transfection 
and assayed for luciferase activity as before Norm alised luciferase values are expressed as fold-increase 
over control (transfection o f  empty vector with wild-type bfl-1 promoter-luc construct =1) B) DG75 cells 
were cotransfected with 5 0 jag o f  the expression vector for p65 (pSG5-p65) or empty vector (pSG5) 
together with 2 5 ng o f the NF-icB-dependent luciferase reporter, 3 x enh-KB-luc, and luciferase activity 
assayed m cells harvested 24 h post-transfection
3 2.7.9 Deletion analysis o f the b f l - 1  promoter
To identify the regions o f the bfl-1 promoter that mediate induction by LMP-1, a series o f 
bfl-1 promoter-luciferase constructs containing progressive deletions from the 5 ’ end was 
used in transient transfection assays Promoter-luciferase constructs containing DNA 
sequence from the -1240/+81, -367/+81 or -129/+81 regions o f the bfl-1 gene fused to 
the luciferase gene were derived from corresponding CAT-based constructs using the 
same strategy as for the derivation o f the p—1374/+81 B fl-l-luc construct (Figure 3 34, 
the —1240/+81 B fl-lluc, -367/+81 B fl-lluc and -129/+81 B fl-lluc reporter constructs
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were made by P Pegman in the laboratory) A schematic representation o f the luciferase 
reporter gene constructs driven by various regions o f the bfl-1 promoter is shown in 
Figure 3 34 Agarose gel electrophoresis confirmed the quality o f the bfl-1- promoter- 
luciferase constructs (Figure 3 35)
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F igu re  3 34 Schem atic rep resen ta tio n  o f b fl-l-p ro m o te r-lu c ife ra se  re p o r te r  co n stru c ts  con ta in ing  
N F-kB  (position  -8 3 3 , -1374/+81 rmcB) an d  5’ deletion m u tan ts  (-1240/+81, -367/+81, -129/+81) o f the 
-1374/+81 region o f bfl-1  The sequences o f  the NF-kB site at position -8 3 3  and an ‘NF-KB-like’ site at 
position -5 2  are indicated The arrows near the sequence o f  these sites correspond to the orientation o f  the 
binding sites The TATA box is located at position -6 9  (not indicated m the figure)
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F ig u re  3 35 A garose gel electrophoresis o f bfl-1 p rom oter-Iuciferase  construc ts  One (lanes 1,3, 5, 7, 9) 
or 2 5 (lanes 2, 4, 6, 8, 10) Mg o f  the prom oterless/basic (lanes 1, 2) or bfl-1-promoter-Iuciferase constructs 
encompassing -1374/+81 (lanes 3, 4 ), -1240/+81 (lanes 5, 6) , -367/+81 (lanes 7, 8) o r-129 /+ 81(lanes  9, 
10) regions o f  bfl-1 were electrophoresed in a 1 % agarose- 1 x TAE gel for 1 h at 100 V
The effect o f expression o f LMP-1 on the activity o f various regions o f the bfl-1 promoter 
was investigated by cotransfection o f the LMP-1 expression plasmid, pEFCX-LMP-1, or 
the empty vector, pEFCX, together with the individual bfl-1 promoter-Iuciferase reporter 
constructs containing the -1374/+81 region o f bfl-1 or 5’ progressive deletions thereof 
into DG75, BL41 and Jurkat cells and assaying for luciferase activity 24 h post- 
transfection As shown in Figure 3 36A, LMP-1 expression m DG75 cells activated 
transcription from the -1374/+81 region o f bfl-l approximately 8 2 -fo ld  over control 
Surprisingly, LMP-1 expression was still able to induce considerable activation o f the 
promoter fragments bearing progressive 5 ’deletions, with a 6 5-, 6 2- and 5 6-fold 
activation measured with the -1240/+81, -367/+81 and -129/+81 -bfl-1  promoter- 
Iuciferase constructs, respectively, in DG75 cells Thus, in DG75 cells, the -129/+81 
region o f b fl-l makes a considerable contribution to the LMP-1-induced activation o f bfl- 
1 promoter activity, retaining 64% o f the LMP-1 -induced activity o f the -1374/+81 
region o f this gene A similar trend in the extent o f activation o f the bfl-1 prom oter- 
deletion luciferase reporter constructs by LMP-1 was also found when the transfections
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were performed in BL41 cells, with the -129/+81 region retaining 69% o f the LMP-1 - 
induced activity o f the -1374/+81 region o f bfl-1 (Figure 3 36B) A different trend was 
observed when the same experiments were performed in Jurkat T cells In this cell line, 
LMP-1 expression enhanced luciferase activity from the -1374/+81 and -1240/+81 
promoter constructs by 4 5 and 5 1 -fo ld  respectively However, activity from the -  
367/+81 and -129/+81 promoter constructs was enhanced 2 2 and 1 8-fold respectively 
by LMP-1-expression in Jurkat cells (Figure 3 36C) The -367/+81 and -129/+81 
regions retained approximately 34% and 23% o f the LMP-1-induced activity o f the -  
1374/+81 region o f bfl-1 respectively, which is significantly lower than that observed in 
similar transfections o f DG75 and BL41 cell lines Thus, in the B cell lines DG75 and 
BL41, the -129/+81 region o f bfl-1 contains elements whose activation by LMP-1 
account for the majority o f LMP-1-induced activation o f the promoter However, m 
Jurkat cells, the region o f the bfl-1 promoter between -1240 and -3 67  accounts for the 
majority o f the LMP-1-induced transcriptional activation o f this gene It can be 
concluded from these results that LMP-1 may exert cell type-specific differences in the 
elements o f the bfl-1 promoter targeted for activation
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F igu re  3.36 Iden tifica tion  o f the  regions o f the  bfl-1  p ro m o te r ta rg e ted  by L M P 1 fo r ac tivation .
DG75 (panel A), BL41 (panel B) and Jurkat T cells (panel C) were transfected with 2.5pg o f  either the 
LMP-1 expression plasmid, pEFCX-LMP-1 or empty vector, pEFCX, together with 2 .5pg o f  the individual 
6/7-promoter-luciferase reporter constructs, -1374/+81 B fl-lluc, -1240/+81 B fl-lluc, -367/+81 B fl-lluc o r -  
129/+81Bfl-lluc. Cells were harvested 24 h post-transfection and assayed for luciferase activity as before. 
N orm alised luciferase activities were expressed as fold-activation over control (em pty vector =1). The 
experim ent in panel B was performed once.
3.2.7.10 LM P-l-m ediated activation of the -129/+81 region of b f l - 1  in DG75 cells is 
NF-KB-dependent
To investigate if  the activation o f the -129/+81 region o f the bfl-/gene by LMP-1 in 
DG75 cells is also NF-kB dependent, the LM P-1-expression plasmid pEFCX-LMP-1 was 
cotransfected with the ¿/7-7-promoter luciferase reporter p—129/+81 B fl-1 -luc in the 
presence o f increasing amounts (0, 2.5, 5.0 or 10.0 |ig) o f a plasmid expressing the 
dominant negative mutant IkBocDN. As observed with the -1374/+81 promoter region, 
expression o f IkBocDN inhibited LM P-l-m ediated activation o f the -129/+81 bfl-1 
promoter region from p-129/+81 Bfl-1 -luc in a dose-dependent fashion with transfection 
o f 10.0 \xg o f pEFCX-lKBaDN resulting in complete inhibition (Figure 3.37).
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F igu re  3.37 LM P-1 m ediated  activation  o f the  —129/+81 region o f the  A/7-1 p ro m o te r is inh ib ited  by 
expression o f a do m in an t negative m u tan t o f I k B cx (IkBocDN) in DG75 cells. DG75 cells were 
cotransfected with 2.5 pg o f the L M P -1-expression vector, pEFCX-LMP-1 or empty vector pEFCX and 2.5
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Mg o f  p-129/+81-B fl-l-luc together with various amounts (0, 2 5, 5 0 or 10 0 Mg) o f  a plasm id expressing 
IkBocDN  Cells were harvested 24h post-transfection and analysed for luciferase activity Norm alised 
luciferase activities were expressed as fold activation over control (empty vector m the absence o f 
expression o f IkB ocDN = 1)
The activity o f the -129/+81 region o f bfl-1 could also be stimulated by PMA and as 
observed with the -1374/+81 region, this effect was NF-KB-dependent (Figure 3 38) 
PMA stimulated activity from the -129/+81 region by 4 5-fold which represents 
approximately 60% o f the PMA-mediated activation o f the -1374/+81 region o f bfl-1 (by 
comparison to Figure 3 32) Thus, the -129/+81 region is the minimal region o f bfl-1 that 
is also responsible for PMA activation o f the bfl-l promoter in DG75 cells
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Figure 3 38 PM A activates the -129/+81 region o f the bfl-1 prom oter in an NF-KB-dependent manner 
in DG75 cells. DG75 cells transfected with 2 5Mg o f  the -129/+81 Bfl-1 luc vector in the presence or 
absence o f  10 0 Mg o f  pEFCX-IicBccDN were treated with either 10-7 M PMA or vehicle control (0 062%  
ethanol) 18 h post-transfection After treatment for 24 h, cells were harvested and analysed for luciferase 
activity as before Norm alised luciferase values are expressed as fold-increase over control (-129/+81 Bfl-1 
luc in the absence o f  expression o f  IkBcxDN treated with vehicle = 1)
Overexpression o f the NF-kB subunit p65 enhanced expression from the -129/+81 
promoter luciferase construct approximately 2 7-fold which is lower than that obtained 
when the -1374/+81 promoter luciferase construct was used (3 5-fold) (Figure 3 39) 
The results suggest that the -129/+81 region o f the bfl-1 promoter is still significantly 
responsive to NF-kB
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F ig u re  3 39 O verexpression  o f p65 activates expression from  the  -129/+81 region o f the  bfl-1  
p ro m o te r in DG75 cells DG75 cells were transfected with 5 0 ng o f  an expression vector for p65 (pSG5- 
p65) or the empty vector (pSG5) together with 2 5 p.g the bfl-1 prom oter construct p-1374/+81 B fl-l-luc or 
p-129/+81 B fl-l-luc Cells were harvested 24 h post-transfection and assayed for luciferase activity as 
before N orm alised luciferase values are expressed as fold activation over control (em pty vector) Control 
values were arbitrarily assigned a value o f  1
To identify the signaling domains o f LMP-1 responsible for activating the -129/+81 
region o f bfl-1, DG75 cells were cotransfected with the -129/+81 bfl-1 promoter- 
luciferase construct together with expression vectors for either wild-type (LMP WT) or 
LMP-1 molecules mutated in either CTAR1 or CTAR2 or both domains It can be seen 
from Figure 3 40A, that as observed with the -1374/+81 B fl-l-luc reporter construct, 
both the CTAR1 and CTAR2 domains contribute to activation o f the -129/+81 region o f 
bfl-1 with the CTAR2 domain exerting a predominant effect A role for TRAF2 in 
mediating the effect o f LMP-1 on the -129/+81 region o f the bfl-1 promoter is again 
suggested by the observation that overexpression o f a dominant negative TRAF2 mutant, 
TRAF2A(6-86), or the TRAF2-interacting protein, A20, significantly inhibited the 
stimulatory effect o f LMP-1 on the activity o f the -129/+81 region o f the b fl-l (Figure 
3 40 B and C)
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Figure 3 40 LM P-1 mediated activation o f the -129/+81 region o f bfl-1 requires both the CTAR1 and 
CTAR2 domains o f LMP-1 and involves a TRAF-2 dependent mechanism in DG75 cells A)
Identification of the signaling domains of LMP-1 that mediate stimulation of activity of the -129/+81 
region of bfl-1  DG75 cells were cotransfected with 2 5 |ig of either pSG5 (‘empty vector’), pSG5-
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LM P1W T (expressing wild-type LMP1), pSG5-LM P AAA (expressing LMP1 with a non-functional 
CTAR1 domain), pSG 5-LM Pl G (expressing LMP1 with a non-functional CTAR2 domain) or pSG5- 
LMP1 AAAG (expressing LMP1 that is non-functional in both the CTAR1 and CTAR2 domains) together 
with 2 5 |ig  o f  p -129/+81 B fl-l-luc B) Inhibition o f  LM P1-mediated activation o f  the -129/+81 region 
o f  bfl-1 by the dominant negative mutant o f  TRAF2, TRAF2A(6-86) DG75 cells were cotransfected with 
2 5 |ag o f  pEFC X-LM Pl or pEFCX and 2 5 (ig o f —129/+81 B fl-l-luc in the absence or presence o f  a 
plasmid expressing TRAF2A(6-86) (5 0 or 10 0 ng) C) Inhibition o f LMP-1 -mediated activation o f the -  
129/+81 region o f  bfl-1 by expression o f the TRAF2-interacting protein, A20, in DG75 cells DG75 cells 
were cotransfected with 2 5 Mg o f  pEFC X -LM Pl or pEFCX and 2 5 Mg o f p-129/+81 B fl-l-luc in the 
absence or presence o f  a plasmid expressing A20 (2 5, 5 0 or 10 0 Mg) Cells were harvested 24 h post- 
transfection and luciferase activity measured as before
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3.2.7.11 Treatment of Jurkat T cells with PMA plus ionomycin transactivates the 
b f l - 1  promoter
Treatment o f Jurkat T cells with PMA plus ionomycin has been previously shown to 
upregulate steady-state bfl-1 mRNA levels in an NF-KB-dependent manner (Zong et a l ,
1999) However, analysis o f bfl-1 promoter activity was not included in this study To 
investigate if  the effect o f PMA plus ionomycin treatment on bfl-l mRNA is due to, at 
least in part, an effect on bfl-1 promoter activity, Jurkat cells were transfected with the -  
1374/+81 6/7-7-promoter-luciferase or -129/+81 bfl-1 promoter-luciferase reporter 
construct and treated with PMA plus ionomycin 18 h post transfection for 24 h after 
which luciferase activity was measured It can be seen from Figure 3 41 that 
PMA/ionomycin treatment transactivated the -1374/+81 promoter region approximately 
200-fold and the -129/+81 region to a lesser extent o f approximately 74-fold (equal to 
approximately 37% o f activation o f the -1374/+81 region) PMA-treatment alone led to 
a 50-fold transactivation o f the -1374/+81 region and a 12 8 -fold transactivation o f the -  
129/+81 region By comparison, ionomycin treatment on its own resulted in only a less 
than 3-fold transactivation o f either promoter region These results suggest that PMA and 
ionomycin synergise in activating the bfl-1 promoter in Jurkat T cells Furthermore, the 
effect o f the treatment o f Jurkat cells with PMA and ionomycin on bfl-1 promoter activity 
is NF-icB-dependent since expression o f a dominant negative mutant o f iKBa abrogated 
this effect The observation that the -129/+81 region o f the bfl-l promoter accounts for 
only 35% o f the extent o f transactivation o f the -1374/+81 region by PMA + ionomycin 
is similar to that obtained when LMP-1 was used as the effector in transfections o f Jurkat 
cells Thus, the differential effect o f LMP-1 expression or PM A/ionomycm treatment on 
the activity o f different regions o f the bfl-1 promoter may be cell-type dependent
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Figure 3 41 Treatm ent o f Jurkat T cells with PM A and lonomycm activates the bfl-1  prom oter Jurkat 
T  cells were transfected with either the -1374/+81 Bfl-1 luc (A) or -129/+81 b fl-l luc (B) reporter 
constructs or the 3 x enh kB luc (C) reporter in the presence or absence o f  10 0 |ig  o f  pEFC X IxB aD N  and 
treated at 18 h post-transfection with either vehicle control (0 062%  ethanol, 0 05%  DM SO) or l^iM 
lonomycm or 1 0 7 M PM A or a combination o f  1 |iM lonomycm and 1 0 7 M PMA After 24 h treatment 
with the various agents, cells were harvested and analysed for luciferase activity as before N orm alised 
luciferase values were expressed as fold activation relative to control (vehicle treatm ent in the absence o f 
expression o f  lK B aD N =l) This experiment was performed once
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3.2.8 LMP-1 regulates b f l - 1  promoter activity in lymphoblastoid cell lines
LMP-1 can induce several o f the changes in gene expression that are observed during 
EBV infection o f primary B-lymphocytes Studies addressing the role o f LMP-1 during 
EBV transformation o f B-lymphocytes have been based on the usage o f EBV 
recombinants that are mutated m different functional domains o f LMP-1 These studies 
have revealed that EBV recombinants that express LMP-1 molecules containing only 
aminoacids 1-231 ( le  lacking CTAR2) can drive initial proliferation o f infected B 
lymphocytes but are functionally impaired in causing LCL outgrowth (Izumi et a l , 
1997) Further studies using EBV recombinants expressing LMP-1 molecules with point 
mutations m CTAR2 confirmed that this domain o f LMP-1 is critical in enabling 
efficient, long-term LCL outgrowth (Izumi and Kieff, 1997) In LCLs, LMP-1 is 
constitutively associated with TRAF molecules and TRADD (Devergne et a l , 1996, 
Izumi et a l , 1999)
LCLs express substantial levels o f bfl-1 mRNA (Figures 3 2 and 3 5) To examine the 
extent o f  activation o f the bfl-1 promoter in LCLs, the bfl-1 -promoter-luciferase reporter 
constructs were transfected into IARC 290B and IB4 and luciferase activity measured 
24h post-electroporation The IARC 290B and IB4 LCLs were found to be more efficient 
to transfect amongst a range o f LCLs (including IARC171 and OKULCL) examined and 
were hence chosen as target cell lines for the promoter studies Relative to the activity 
obtained with the basic (promoterless) luciferase reporter construct, an approximately 64- 
fold activation o f the -1374/+81 region o f the bfl-1 promoter was obtained in IARC 290B 
cells (Figure 3 42A) Progressive 5’ deletions o f the -1374/+81 region o f the bfl-l 
promoter to position -129  (Figure 3 34) did not significantly alter the extent o f activation 
Thus, relative to the promoterless luciferase construct, expression from the -1240/+81, - 
367/+81 and -129/+81 promoter luciferase constructs was enhanced approximately 78- 
fold, 64-fold and 59-fold respectively (Figure 3 42A) Although a lower extent o f 
activation was observed in IB4 cells than in IARC 290B cells a similar trend in activation 
o f different regions o f the bfl-l promoter was observed in IB4 cells (Figure 3 42B) 
Transfections in IB4 cells revealed that relative to the activity obtained with the basic
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reporter construct, a 31-, 36-, 35- and 28- fold increase in luciferase expression was 
obtained from the -1374/+81, -1240/+81, -367/+81 and -129/+81 promoter luciferase 
constructs respectively These results suggest that in both IARC 290B and IB4, the -  
129/+81 region is sufficient to drive optimal transactivation o f the bfl-1 gene Further 
mapping studies were not carried out on the promoter in this study
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Figure 3 42 A ctivity o f bfl-1 prom oter-luciferase constructs in the LCLs IARC290B (A) and IB4 (B)
Ten million cells were electroporated (300 V, 960 |iF) with 2 5 |ig o f the prom oterless-luciferase reporter 
or the bfl-1 promoter-luciferase reporter constructs containing bfl-1 promoter regions -1374/+81 , - 
1240/+81, -367/+81, -129/+81 and then incubated under normal growth conditions for 24h before 
harvesting for analysis o f  luciferase activity Norm alised luciferase values were expressed as fold- 
activation relative to control (basal/prom oterless luciferase vector)
Several lines o f evidence indicate that the high level o f activation o f NF-kB and AP-1 
observed in LCLs is maintained by LMP-1 (Kilger et a l , 1998, Spender el a l , 1999) 
Also, association o f LMP-1 with the TRAF molecules TRAF-1, 2, 3 and 5 and also with 
TRADD and RIP has been demonstrated in LCLs (Devergne et a l , 1998, Izumi et a l ,
1999) Recently, the growth and survival o f LCLs has been shown to be NF-kB- 
dependent and inhibition o f NF-kB activity in the LCL IB4 was shown to result in 
downregulation o f bfl-1 expression but not o f bcl-2 or bcl-x/L (Cahir-McFarland et a l ,
2000) Based on these observations it was reasonable to hypothesise that the high levels 
o f b fl-l mRNA in LCLs may be maintained by LMP-1
In a preliminary experiment it was found that expression o f LMP-AAAG (Figure 3 21) or 
a dominant negative IkBcc (Figure 3 26) mutant could efficiently inhibit wild-type LMP- 
1-mediated activation o f NF-kB and the bfl-1 promoter in transient transfection assays in 
DG75 cells It was therefore o f interest to examine the efficiency o f  these dominant 
negative mutants in inhibiting bfl-l promoter activity and NF-kB activation when present 
as constitutive signals such as exists in LCLs To this end, the LCLs IARC290B and IB4 
were chosen as target cell lines It was found that expression o f the dominant negative 
LMP1 mutant, LMP-AAAG, reduced NF-kB activity by approximately 55% in IARC 
290B (Figure 3 43A) and by 60% in IB4 (Figure 3 43B) suggesting that LMP-1 
contributes significantly to the level o f NF-kB activation in these cells Importantly, 
expression o f the mutant LMP AAAG also resulted in a parallel reduction o f bfl-1 
promoter activity from the -129/+81 bfl-l promoter-luciferase construct in these cell 
lines, resulting in an approximately 52% and 64% inhibition in IARC290B (Figure 
3 43A) and IB4 (Figure 3 43B) respectively These results suggest an important role for
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LMP-1 m maintaining bfl-1 transcriptional activity in LCLs In order to investigate if 
NF-kB activation is responsible for the high level o f activation o f bfl-1 promoter activity 
in IARC290B and IB4, the effect o f expression o f the dominant negative IkBoc mutant, 
IkBccDN, on bfl-l promoter activity was investigated Surprisingly, although expression 
o f IkBccDN reduced bfl-l promoter activity by approximately 66% in IB4 cells, IkBccDN 
expression resulted in only an 8% reduction o f activity from the -1374/+81 region and a 
14% reduction from the -129/+81 region o f bfl-l in IARC 290B cells (Figure 3 43) The 
inhibitory effects o f LMP AAAG and dominant negative IkBcc on NF-kB activation and 
b fl-l promoter activity did not seem to be due to a decrease m viability o f  the transfected 
cells since their transfection did not significantly affect the activity o f (3-galactosidase 
expressed from a cotransfected plasmid The minor effect on bfl-1 promoter activity in 
IARC 290B cells was not likely to be due to a lack o f functional expression o f IkBccDN 
since a 68% reduction in activity o f an NF-KB-dependent reporter was observed on 
expression o f IkBocDN in these cells The extent o f reduction in NF-kB activity on 
expression o f IkBocDN in IB4 cells is similar to that observed in IARC290B and excludes 
the possibility that the lack o f a major effect on the bfl-l promoter was due to an 
insufficient reduction in NF-kB activity by IkBocDN Interestingly, expression o f the 
dominant negative TRAF2 mutant, TRAF2A(6-86), in IARC-290B cells did not 
significantly affect bfl-1 promoter activity or NF-kB activity Based on these results it 
can be concluded that LMP1 makes a major contribution to NF-kB activity and bfl-1 
promoter activity in the LCLs IARC 290B and IB4 and that CTAR1 and/or CTAR2 are 
required for this effect Furthermore, at least m IARC290B, the mechanism by which 
LMP-1 upregulates bfl-l is most likely TRAF-2-independent However, NF-kB 
activation may not be the only mechanism responsible for activating the bfl-1 promoter in 
different LCLs and other mechanisms such as activation o f AP-1 may also play an 
important role These observations have implications for the mechanisms used by LMP1 
in regulating gene expression in different LCLs and warrants further investigation
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F ig u re  3 43 LM P1 co n trib u tes  to bfl-1  p ro m o te r activation  in the  L C L s by bo th  N F-K B -dependent 
an d  -in d e p e n d e n t m echanism s IARC 290B (A) and IB4 (B) were transfected with 10 0 jug o f  either 
empty vector (pSG5) or pSG5-based vectors expressing either the dominant negative LMP1 mutant LMP- 
AAAG, dom inant negative IicBa, I k B oiD N  or dominant negative TRAF2, TRAF2A(6-86) (the latter was 
only transfected into IARC-290B) and 2 5 |ig o f  either the —1374/+81- (only transfected into IARC 290B) 
or -129 /+ 81- bfl-1 prom oter luciferase constructs or the NF-KB-dependent luciferase reporter constructs 
Cells were harvested and analysed for luciferase activity as before N orm alised luciferase activities were 
expressed relative to values obtained for empty vector that was assigned a value o f 100%
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3.2 9 Bandshift analysis
3.2.9.1 Introduction
The results presented so far indicate that increased transcriptional activity o f the bfl-1 
gene partly accounts for the LMP-1 -mediated upregulation o f the steady-state levels of 
bfl-1 mRNA in B cells Furthermore, deletion analysis o f  the 5’ region o f the gene, 
suggests that the major elements mediating transcriptional activation o f the bfl-1 gene by 
LMP-1 in this cellular context are located between positions -129  and +81 [positions are 
relative to the transcriptional start site proposed by Zong et a l , (1999)] (Figure 3 36) To 
identify potential regulatory elements within this region that may mediate the effect o f 
LMP1 on the bfl-1 promoter activty, electrophoretic mobility shift assays (EMSA) were 
performed
EMSA is widely used in studying the sequence-specific binding o f nuclear proteins such 
as transcription factors and is based on the observation that complexes o f  protein and 
DNA migrate through a non-denaturing polyacrylamide gel more slowly than free double 
stranded DNA fragments or oligonucleotides The gel shift assay is performed by 
incubating a purified protein or a complex mixture o f proteins (such as nuclear extracts)
O'}with a P end-labeled DNA fragment containing the putative protein-binding site, 
followed by analysis on a non denaturing polyacrylamide gel The specificity o f the 
DNA-bindmg protein for the putative binding site is established by competition 
experiments using unlabeled DNA fragments or oligonucleotides containing a binding 
site for the protein o f interest or other unrelated DNA sequences
The finding that the transactivation o f the -129/+81 region o f bfl-1 by LMP-1 is NF-kB- 
dependent suggests that there may be NF-icB-binding site(s) located within this region 
that mediate this effect A transcription factor search o f the -129/+81 region o f the bfl-1 
gene using the TESS program (Transcription Element Search Software, website 
www cbil upenn edu/tess) revealed the presence o f a number o f  potential transcription 
factor binding sites including a NF-kB binding site at position -5 2  (bp -5 2  to -43 ,
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positions relative to transcription start site) as well as two potential AP-1 binding sites, 
one at position -9 0  (bp -9 0  to -81 ) and the other at -1 6  (-16 to -7 ). The nucleotide 
sequence o f the -129/+81 region o f bfl-1 and the position o f these transcription factor- 
binding sites is shown in Figure 3.44.
-129 -90  ►CTCTTTCATACATGACATGAAACACAGCCTACGCACGAAAGTGACTAGGAGGAAGGATA
AP-1
-69 -52___________ -16 ___
TTATAAAGTGATGCAAACAGAAATTCCACCAGCCTCCATGTATCATCATGTGTCATAACT 
TA T A box N F-K B-like AP-1
*  £ — ►
CAGTCAAGCTCAGTGAGCATTCTCAGCACATTGCCTCAACAGCTTCAAGGTGAGCCAGCC
+81
AGCTCAAGACTTTGCTCTCCACCAGGCAGCTCTAG
F igu re  3.44 N ucleotide sequence o f the  -129/+81 region o f the  bfl-1  gene. The positions and 
orientation o f  putative transcription factor binding sites in the -129/+81 region o f  bfl-1 as identified by 
using the TESS program are indicated. The NF-kB site at position -5 2  represents a KB-like site in reverse 
orientation. The TATA box and the transcription start site (+1) are also indicated. The nucleotide sequence 
was provided by Professor C. Gelinas in whose laboratory the 5 ’ region o f  bfl-1 was cloned.
Classic N F-kB (p65/p50) binds the consensus sequence 5’-GGGRNNYYCC-3’ whereas
the RelA/c-Rel dimer binds to a sequence 5’-HGGARNYYCC-3’ [H indicates A, C or T;
R is purine (A or G); Y is pyrimidine (T or C)] (Baldwin, 1996). The NF-KB-like site at -
52 to -4 3  bears complete homology to a CD28-responsive NF-KB-binding element in the
IL-2 enhancer region (Civil et al., 1996; 1999; Butscher et al., 1998). The putative NF-
kB site at position -52 represents a KB-like site in reverse orientation (5’-
TGGAATTTCT-3’) and differs from the sequence o f the classic NF-kB consensus
binding site at 2 positions (TGGAATTTCT) while differing from the p65/c-rel consensus
binding site at one position (TGGAATTTCT). Functional ‘NF-KB-like’ sites in both
forward and reverse orientations have been identified in the promoters o f  several genes
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including anti-apoptotic genes such as bcl-x and c-IAP-2 and cytokines such as IL-8  
(Chen et a l , 1999, Hong et a l , 2000, Okamoto et a l , 1994) The potential involvement 
o f the NF-KB-like site at position -5 2  o f bfl-1 m the LMP-1 -induced enhancement o f bfl- 
1 promoter activity was investigated by electrophoretic mobility shift assays (EMSA) 
using nuclear extracts prepared from DG75-tTA-LM Pl cells before and after induction o f 
LMP1 expression Since the studies o f the kinetics o f induction o f bfl-1 mRNA by LMP- 
1 in these cells indicated that the magnitude o f induction was maximal by 48h post- 
mduction (Figure 3 3), nuclear extracts were prepared from the DG75-tTA-LM Pl cells at 
the earlier time-point o f LMP-1 induction o f 36h when bfl-1 mRNA levels are still 
increasing
3.2.9.2 LMP-1 induces activation o f p65-containing NF-kB complexes in DG75-tTA- 
LMP1 cells
As a preliminary experiment, the effect o f LMP-1 induction on NF-kB binding activity in 
DG75-tTA-LM Pl cells was assessed To this end, EMSA was performed with nuclear 
extracts prepared from DG75-tTA-LM Pl cells before and 36 h after induction o f LMP1 
using a 22 bp oligonucleotide containing the NF-kB site (5’-GGGGACTTTCC-3’) from 
the IgK light chain promoter This oligonucleotide will henceforth be referred to as the 
‘consensus’ NF-kB oligonucleotide for the purposes o f this thesis The sequence o f this 
N F-kB site is the same as that present in the NF-KB-dependent luciferase reporter 
construct (3 x enh kB luc) used for assessing NF-kB activation by LMP-1 in transient 
transection assays A titration experiment o f the amount o f nuclear protein used in the 
binding reaction with the consensus NF-kB oligonucleotide was first conducted to 
establish optimal binding conditions It can be seen from figure 3 45 that four protem- 
DNA complexes (C l, C2, C3 and C4) were detected with extracts from the unmduced 
DG75-tTA-LM P-l cells Induction o f LMP-1 did not result m the formation o f any new 
complexes and although complexes o f similar mobility were detected the intensity o f 
complexes C l, C2 was consistently higher with extracts from the LMP-1 expressing cells 
compared to the non-LMP 1 -expressing counterpart irrespective o f the amount o f protein
used To confirm that these shifted complexes are NF-kB specific, the binding
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experiment was repeated but with pre-incubation o f the extract w ith a 100-fold molar 
excess o f either ‘cold’ (unlabeled) NF-kB consensus oligonucleotide or a ‘cold’ 
mutagenic version o f this oligonucleotide as competitor before addition o f the labeled 
target oligonucleotide It can be seen from figure 3 45 that when cold NF-kB 
oligonucleotide is used as competitor, formation o f all four complexes is no longer 
detectable (1  e the four complexes are outcompeted) This result on its own would 
indicate that the four complexes are NF-kB specific However, when the competition 
experiment was repeated but with the mutagenic NF-kB oligonucleotide, it was only the 
formation o f complexes 3 and 4 that was inhibited, the intensity o f  complexes 1 and 2 
remained unchanged Taken together, the results o f the two competition experiments 
indicate that it is only complexes C l and C2 that are NF-KB-specific, formation o f 
complexes 3 and 4 is more likely to be the result o f non-specific binding o f nuclear 
proteins to the labeled oligonucleotide The ability to detect activated NF-kB complexes 
in the DG75-tTA-LM Pl cells in the absence o f LMP-1-induction is consistent with the 
high basal level o f NF-kB activation reported to be present in this BL cell line (Huen et 
a l , 1995, Rowe et a l , 1994) The increase in the extent o f formation o f NF-kB-DNA 
complexes on induction o f LMP-1 validates the experimental system and suggests that 
NF-kB-binding activity is preserved in the nuclear extracts under the conditions used
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Figure 3 45 EM SA o f the IgK light chain ( ‘consensus’) N F-kB oligonucleotide with nuclear extracts 
from D G 75-tT A -L M P-l cells before and 36 h after LMP-1 induction A double stranded, end-labeled 
oligonucleotide spanning the IgK light chain N F-kB site (consensus) was incubated with 5 (lanes 2, 5), 10 
(lanes 3, 6) or 15 (lanes 4, 7) fig o f  nuclear extracts from uninduced D G 75-tTA -LM Pl cells or cells 
induced to express LMP-1 36 h after removal o f  tetracycline Competition experiments were perform ed by 
pre-incubation o f  10 |!g o f extract from the LM P-1-induced cells with a 100-fold m olar excess o f  either 
unlabeled consensus N F-kB oligonucleotide (lane 8) or NF-KB-mutated oligonucleotide (lane 9) before 
addition o f  labeled oligonucleotide to the binding reaction A mock binding reaction containing all 
components except for nuclear extract was loaded in lane 1 After separating the protein-DNA complexes 
by nondenaturing polyacrylam ide gel (5%) electrophoresis (140 V, 2 h), the shifted bands were visualised 
using autoradiography Complexes C l and C2 are NF-kB specific complexes, complexes C3 and C4 are 
non-specific (n s ) The position o f  the free probe is indicated
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To characterise the nuclear protein complexes bound to the consensus NF-kB 
oligonucleotide, supershift assays were performed using antibodies against the NF-kB 
subunits p65, p50 and c-rel and an unrelated anti-Mcl-1 antibody In supershift assays, 
preincubation o f the nuclear extract with an antibody to a protein suspected to be 
involved in complex formation with the labeled oligonucleotide either diminishes 
complex formation or further retards the mobility o f the complex, depending on whether 
the antibody recognises an epitope m the DNA binding region o f the protein or not 
Supershift assays with the consensus NF-kB oligonucleotide were performed by 
preincubation o f extracts from the LMP-1 expressing DG75-tTA-LM P-l cells with 
antibodies to p65, p50, c-rel and Mcl-1 followed by addition o f the labeled consensus 
NF-kB oligonucleotide It can be seen from figure 3 46 that when the anti-p65 antibodies 
were used in the supershift assays both o f the specific complexes, namely C l and C2 
were further retarded in mobility However, antibodies to p50 and c-rel did not 
significantly diminish nor supershift either o f the specific complexes Antibodies to Mcl- 
1 used as a negative control did not supershift the specific complexes as expected 
indicating the specificity o f the reaction o f the p65 antibodies Thus, it can be concluded 
that each o f C l and C2 are NF-kB- specific complexes containing p65 as at least one NF- 
kB subunit and that the extent o f formation o f these complexes is increased upon 
induction o f LMP-1 expression
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Figure 3 46 Supershift analysis o f the NF-kB-DNA  complexes formed between nuclear proteins from  
the D G 75-tT A -L M Pl cells after LMP-1 induction and the oligonucleotide containing the IgK light 
chain ( ‘consensus’) NF-kB site 10 (ig o f  nuclear extract prepared from from the D G 75-tTA -LM P-l cells 
36 post- LMP-1 induction was left untreated (-) or preincubated with antibodies to either p65, p50, c-rel or 
Mcl-1 (control) for 30 min on ice before incubation with end-labeled consensus N F-kB oligonucleotide 
A mock binding reaction (M) was also set up as before Protein-DNA complexes were analysed by non­
denaturing PAGE and the shifted bands visualised by autoradiography The KB-specific com plexes C l and 
C2 and the non-specific complexes (n s ) C3 and C4 are indicated The supershifted complexes are 
indicated as s s
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3.2.9.3 Lack of demonstrable binding o f a specific LM P-l-activated NF-kB complex 
to the NF-KB-like site at -5 2  to -4 3  of the b f l - 1  promoter region inDG75-tTA-LM Pl 
cells
To determine whether nuclear proteins could bind to the NF-icB-like site withm the -  
129/+81 region o f the bfl-1 promoter, EMSA was performed using a 14 bp 
oligonucleotide derived from the bfl-1 promoter sequence that includes the icB-like site at 
position -5 2  and the same nuclear extracts used to demonstrate LMP-1-mediated 
enhancement o f NF-kB-DNA complex formation in DG75-tTA-LM P-l cells , The usage 
o f an oligonucleotide o f this length was justified since 14 bp oligonucleotides have been 
used successfully in EMSA to demonstrate involvement o f particular NF-icB-like sites in 
LMP1, TN F-a and CD40 -mediated activation o f the c-IAP-2 promoter (Hong et a l ,
2000) As can be seen in figure 3 47, EMSA revealed that expression o f LMP-1 in 
DG75-tTA-LM P-l cells resulted in the induction o f a single nuclear protein complex 
with the 14 bp oligonucleotide encompassing the NF-KB-like site in the -129/+81 region 
o f b fl-l Supershift assays indicated that while antibodies to p65 almost completely 
inhibited formation o f this complex, antibodies to p50 or c-rel did not (Figure 3 47)
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F ig u re  3 47 EM SA  and  su pe rsh ift analysis w ith  a 14bp oligonucleotide spann ing  the  NF-KB-like site 
p resen t a t  position  -5 2  o f the  b fl- l  p ro m o te r fo r n u c lear p ro te in  N F-kB  b ind ing  activ ity  10 0  |J.g o f
nuclear extracts prepared from unmduced DG 75-tTA -LM Pl cells or from cells 36 h post-induction o f 
LMP-1 were left untreated or prem cubated with antibodies to either p65, p50 or c-rel for 30 mm on ice 
before addition o f a double stranded end-labeled oligonucleotide spanning the NF-KB-like site present at 
position -5 2  o f  the b fl-l  promoter As a control, 10 ng o f nuclear extract from the LM P-1-expressing 
D G 75-tTA -LM Pl cells was subjected to supershift analysis with antibodies to p65 and the labeled 
consensus N F-kB oligonucleotide (IgK kB site) The protein-DNA complexes were analysed as before 
C5= nuclear protein complex formed with the oligonucleotide containing the N F-kB site at position -5 2  o f 
b fl-l  O ther annotations as in Figure 3 46
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The antibody to p65 is directed to an epitope located near the carboxy-terminal region o f 
the protein (Chemicon International In c ) This region is not involved in DNA binding 
but rather has transactivating functions It would therefore be expected that in supershift 
assays with this p65 antibody, p65-containing complexes will be further retarded in 
mobility rather than diminished It was therefore curious that the anti-p65 antibody 
inhibited complex formation in supershift assays with the oligonucleotide spanning the 
NF-kB site at position -5 2  Secondly, this complex (C5) was o f similar mobility to the 
non-specific complex C3 that was formed when the consensus NF-kB oligonucleotide 
was used in the binding reaction (Figure 3 47), suggesting that this complex may indeed 
be non-specific To investigate whether the shifted complex formed with the 
oligonucleotide spanning the -129/+81 NF-kB site is specific, the binding experiments 
were repeated using nuclear extracts from the LMP-1 expressing DG75-tTA-LM P-l cells 
and either cold oligonucleotide spanning this kB site or cold consensus NF-kB 
oligonucleotide or cold mutated consensus NF-kB oligonucleotide in competition with 
labeled oligonucleotide containing the kB site at -5 2  o f bfl-1 As shown in Figure 3 48, 
neither the oligonucleotide spanning the kB site at position -5 2  o f bfl-1 nor the consensus 
NF-icB-contaimng oligonucleotide or the corresponding mutagenic consensus 
oligonucleotide could compete for binding to labeled oligonucleotide containing the -  
129/+81 kB site even when 100-fold molar excess o f cold oligonucleotide was used 
Thus, the complex C5 formed with the oligonucleotide containing the kB site at position 
-5 2  o f the bfl-1 promoter is most likely non-specific It may be concluded from these 
experiments that it was not possible to demonstrate binding o f NF-kB proteins to the 14 
bp oligonucleotide spanning the NF-KB-hke site at postion -5 2  o f b fl-l on induction o f 
LMP-1 m th e  DG75tTALM P-l cell line
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Figure 3 48 Com petition studies o f binding o f nuclear proteins from LMP-1 expressing DG75-tTA- 
LM P-1 cells to the labeled oligonucleotide containing the NF-KB-like site at position -5 2  o f the bfl-1 
prom oter 10 0 p.g o f  nuclear extract from LM P-1-expressing D G 75-tTA -LM Pl cells was untreated (-) or 
preincubated with either 10-fold, 50-fold or 100-fold- molar excess o f unlabeled oligonucleotide containing 
either the N F-kB site at position -5 2  o f  bfl-1 or the consensus (IgK light chain) N F-kB oligonucleotide or 
the m utated consensus NF-kB oligonucleotide before addition o f  the labeled oligonucleotide containing the 
kB site em bedded within the -129/+81 region o f  bfl-1 The protein-DNA complexes were analysed as 
before
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3 2.9.4 Lack of demonstrable binding of NF-kB to the -129/+81 region of b f l - 1  in 
DG 75-tTA-LM Pl cells irrespective of expression of LMP1
A second approach towards identifying potential elements within the -129/+81 region o f 
bfl-1 that may be involved in the upregulation o f activity o f this promoter region by 
LMP-1, involved using different DNA fragments spanning this region as ‘probes’ in 
EMSA with the same nuclear extracts from DG75-tTA-LM Pl cells as used in the 
previous studies A partial restriction map o f the -129/+81 region o f bfl-1 and the 
relative positions o f the promoter-specific restriction fragments used as probes in EMSA 
is shown in figure 3 49A The end labeled DNA fragments encompassing various 
portions o f the -129/+81 region o f bfl-1 were size-fractionated in a non-denaturing 
polyacrylamide gel and then excised from the gel and purified as described in section 
2 7 4 3 The autoradiogram o f the gel after electrophoresis o f the fragments is also shown 
in figure 3 49B Four different restriction fragments were used in EMSA the S all-X bal 
(210bp, which contains the entire sequence o f the -129/+81 region), S a ll-A p o l (91bp), 
S a ll-A lu l (140bp) and A p o \-X b a \  (130 bp)
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Figure 3 49 Preparation o f end-labeled restriction fragments encom passing the -129/+81 region o f  
the bfl-1 gene or different portions thereof for use as probes in EM SA A) Partial restriction map o f  the
-129/+81 region o f  bfl-1 showing the restriction sites delineating the different fragments used as probes m 
EMSA The bfl-1-specific restriction fragments generated from S a ll/A lu l , S a ll/A p o l, S a ll/X b a l  and 
ApoM Xba\ double digests o f p-129/BfI-l CAT plasmid to be used as probes m EMSA are schematically 
shown as black boxes The relative positions o f the transcription factor sites AP-1 (-90 and -16), the NF- 
KB-like site (-52), the TATA box (-69), and the transcription start site (+1) are also indicated The 
restriction sites on the map are given in italics and the positions o f the transcription factor sites are marked 
on the map as black boxes B ) Autoradiogram o f  the gel after size-fractionation o f  the end-labeled 
fragments Size fractionation was carried out as described in section 2 7 4 3 The different restriction 
digests used to generate the probes are indicated above each lane and the position o f the labeled fragments 
o f  interest that were excised are indicated by an arrow Undesired but labeled fragments represent 
sequences from the plasmid backbone and do not include b fl-l specific sequences
The end-labeled S a ll-A lu l, S a ll-A p o l, Sal 1 -Xba 1 and A pol-X bal fragments were used 
in EMSA with nuclear extracts from DG75-tTA-LM P-l cells prepared before and after 
induction o f LM P-1 using similar conditions as for the NF-kB oligonucleotides except
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that the electrophoresis o f the complexes was carried out at 200 V for approximately 2 5 
h Under these electrophoresis conditions, specific binding o f nuclear proteins to the 
consensus NF-kB oligonucleotide was preserved (result not shown) As would be 
expected when DNA fragments o f this length are used m EMSA, several protem-DNA 
complexes were detected with each o f the four different probes (Figure 3 50 A and B) 
However, there did not appear to be any significant difference in the pattern o f complexes 
between the extracts prepared before and after LMP-1 induction m  DG75-tTA-LM Pl 
cells except perhaps for an increase in intensity o f two slow mobility complexes 
(complexes C6 and C7) with extracts from cells expressing LMP-1 when the Sal 1- 
A lu l fragment was used (Figure 3 50) and a decrease m intensity o f one (complex C8) and 
a complete absence o f another (complex C9) slower mobility complex when the A p o l-  
X ba\ fragment was used as the target in one experiment (Figure 3 50) The Sall-X bal 
fragment contains the DNA sequence present m the S al\-A lu \ and A po\-X ba\ fragments 
and similar changes in the extent o f complex formation was not observed with this 
fragment thereby questioning the validity o f the results with these fragments
198
A.
P rob e Sall/Alul SalMApoX Sall/Xbal Apol/Xbal
D G 7 5tT A L M P l (-------------- ! !-------------- , !-------------- . ,----------------
Tetracycline =t +t -t +t -t +t -t +t -t
199
B.
P ro b e  Sall/Alul Sall/Apol SalMXbaX Apol/Xbal
D G 7 5tT A L M P l | I I I I I I
T etracyc line  = t + t - t + t -t + t -t + t -t
F ig u re  3 50 EM SA  o f DNA fragm ents sp an n in g  d iffe ren t p a r ts  o f the  -129/+81 region o f bfl-1 w ith 
n u clear ex trac ts  from  D G 75tT A -L M P -l cells before and  36 h a f te r  LM P-1 induction  Double 
stranded end-labeled restriction fragments (S a ll/A lu l, S a ll/A p o l, S a ll/X b a l  and A p o l/X b a l)  spanning 
different lengths o f  the -129/+81 region o f bfl-1 were each incubated with 10 0 Mg o f  nuclear extract from 
umnduced (+ tetracycline) D G 75-tTA -LM Pl cells or cells induced to express LMP1 36 h after growth in 
the absence o f  tetracycline removal The protein-DNA complexes were analysed by electrophoresis in a 4%  
non-denaturing polyacrylam ide gel at 200 V for 2 5 h followed by autoradiography The restriction 
fragments used as probes are indicated above the respective lanes The position o f  complexes C6 and 
C7formed with the S a ll/A lu l  fragment and complexes C8 and C9 formed with the A p o l/X b a l  fragm ent are 
indicated by arrows Panel B is a shorter exposure o f panel A
The lack o f either an increase m the extent o f formation o f any o f the complexes or 
formation o f new complexes with the probe encompassing the -129/+81 region o f  bfl-1
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on induction o f LMP-1 does not necessarily exclude the involvement o f NF-kB. Recent 
reports suggest that in addition to the more commonly known mode o f activating 
transcription o f NF-KB-dependent genes by stimulus-induced occupation o f NF-kB sites 
in the promoter region o f the genes, some genes may already have occupied NF-kB sites 
and the stimulus-induced activation o f these genes involves an increase in the 
transactivation potential o f the already bound NF-kB. For instance, IL-1 which is also a 
member o f the TNFR superfamily, has been shown to increase the transactivation 
potential o f p65 by enhancing its level o f phosphorylation and thus increases the level o f 
transcription o f several o f its targets genes (Madrid et al., 2000; Sizemore et al., 1999). 
To investigate if  such a mechanism may be involved in the LMP-1-mediated 
transactivation o f the -129/+81 region o f bfl-1, it was necessary to investigate if  the 
nuclear protein complexes formed with the restriction fragment encompassing this 
region, namely, the SalX/XbaX fragment, contained any o f the NF-kB subunits. To this 
end, supershift analysis were conducted by preincubating nuclear extracts from LMP-1 - 
expressing DG75-tTA-LM P-l cells with antibodies to either p65, p50 or c-rel before 
incubation with the labeled SalX/XbaX fragment. Competition studies were also 
conducted simultaneously using a 100-fold molar excess o f either wild-type or mutated 
consensus NF-kB oligonucleotide. The molar amount o f the SalMXbaX fragment could 
not be accurately determined and was estimated without taking into account any losses 
that may have occurred during its preparation as a probe; hence, the amount o f 
competitor added in relation to the amount o f the SalX/XbaX fragment is likely to be in 
vast excess. Surprisingly, in this experiment (Figure 3.51) the pattern and relative 
intensity o f the complexes formed with the SalX/XbaX fragment was different to what was 
observed in the initial experiment (Figure 3.51 A). Several o f  the complexes o f slow 
mobility observed in the initial experiment were not detected and several complexes o f 
faster mobility were observed in this experiment. Nevertheless, with the pattern o f 
complexes detected in this experiment, there was neither any obvious supershift or 
specific competition observed. Similar inconsistencies were also observed when the Sal 1- 
Alu  1 fragment was used as the probe in a similar experimental strategy as with the 
SalX/XbaX fragment (Figure 3.51B). Owing to the inconsistencies observed in the pattern 
o f nuclear protein complexes, it was not possible to draw any firm conclusions from these
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experiments These inconsistencies are likely to be the result o f a procedural problem 
and possible contributing factors will be alluded to m the discussion section (section 4 6) 
o f this thesis
Although NF-kB plays an important role in mediating the activation o f the -129/+81 
region o f bfl-1 by LMP-1, it was not possible to demonstrate binding o f NF-kB to this 
region Although a procedural defect cannot be excluded, it is possible that NF-kB may 
be playing an indirect role in this effect as is thought to be the case with the NF-kB- 
mediated process o f upregulation o f CD40 and LFA-3 by LMP-1 (Devergne et a l , 1998)
A.
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Figure 3 51 Supershift and competition studies o f the binding o f nuclear extracts from DG75-tTA- 
LMP-1 cells to DNA fragments spanning the -129/+81 region o f bfl-1. 10 0 (xg o f  nuclear extracts from 
D G 75-tTA -LM P-l cells induced to express LMP-1 36 h after tetracycline removal were preincubated with 
either the antibodies to the NF-kB subunits p65, p50 or c-rel or control antibody (a-M cl-1) for supershift 
assays or an excess o f  unlabeled wild-type (wt) or mutated (mut) consensus (CON) N F- k B  oligonucleotide 
as com petitor before addition o f  labeled SalMXbaX (A) or S a l\/A p o \  (B) fragments as target DNA 
fragments m the binding reaction The protem-DNA complexes were size-fractionated as mentioned in 
Figure 3 50 and visualised by autoradiography
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3. 2.10 Activation o f CD40 upregulates b f l - 1  promoter activity
3.2.10.1 Introduction
CD40 is a 48 kDa membrane receptor o f the tumour necrosis factor receptor (TNFR) 
family It is activated by CD 154 (CD40L), its membrane-bound cognate ligand CD40 
was initially described as a B-lymphocyte activation antigen, but is now known to be 
expressed by a variety o f other cell types, especially endothelial and epithelial cells In 
resting B-cells, signaling through CD40 stimulates cell survival, growth and 
differentiation (Stamenkovic et a l , 1989, Banchereau et a l , 1994, Clark and Ledbetter, 
1994, Gordon, 1995) A key interaction o f CD40/CD40L in the humoral immune 
response involves CD40 expressed on B cells with its ligand expressed on helper T-cells 
resulting in costimulation o f the two lymphocytic cell types
CD40 ligation in B cells induces a number o f phenotypic changes similar to those 
observed upon LMP1 expression, including upregulation o f CD23 and CD54 expression, 
and induction o f IL-6 production and homotypic cell adhesion (Busch and Bishop, 1999, 
Devergne et a l , 1998, Eliopoulos et a l , 1997, Laman et a l , 1996) The similarities 
between the effects o f CD40 activation and LMP-1 signaling is most likely a reflection o f 
the fact that common biochemical pathways are activated by these molecules (Tewari and 
Dixit, 1996, Baker and Reddy, 1996, Busch and Bishop, 1999) Both CD40 and LMP-1 
stimulate activation o f the transcription factors NF-kB and AP-1 via recruitment of 
TRAF proteins Thus, TRAF2 and TRAF3 associate with the carboxy-terminal domains 
o f both LMP-1 and CD40 through the PXQXT/S domain, whilst TRAF1 interacts 
directly with LMP-1 but not with CD40 (Hu et a l , 1994, Cheng et a l , 1995, Mosialos et 
a l , 1995, Pullen et a l , 1999, Kehry, 1996) TRAF2 has been shown to be an important 
mediator o f NF-kB activation in the case o f both molecules (Rothe et a l , 1995, Kaye et 
a l ,  1996)
Both LMP-1 and CD40 signaling result in upregulation o f the expression o f certain anti- 
apoptotic proteins, such as A20, in B-cells, which may at least partly account for the
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survival advantage conferred by CD40 engagement or LMP-1 expression in B cells 
(Henderson et a l , 1991, Laherty et a l , 1992, Sarma et a l , 1995) Furthermore, CD40 
engagement on BL cells has recently been shown to also upregulate expression o f bfl-1 in 
addition to bcl-x (Lee et a l , 1999) However, this study did not include any investigation 
o f the bfl-1 promoter It was therefore o f interest to investigate if  CD40 -mediated 
upregulation o f bfl-1 mRNA involved promoter-activation and if  LMP1 and CD40 can 
cooperate in upregulating bfl-1 promoter activity
3.2.10.2 Expression o f LMP1 correlates with an upregulation o f CD40 levels
It is now well established that one o f the effects o f EBV infection o f primary B- 
lymphocytes or LMP-1 expression m BL cells is the upregulation o f CD40 expression 
(Gregory, 1995) Thus, examination o f the level o f CD40 expression in a series o f BL 
lines and LCLs by W estern blotting using an anti-CD40monoclonal antibody, G28 5, 
revealed that while EBV-negative (DG75, BL41) and EBV-positive cell lines with a 
latency type I phenotype (Mutu I, OKU BL) exhibit undetectable or low levels o f 
expression o f CD40, EBV-positive cell lines with a latency type III phenotype (Mutu III, 
BL41B5 8) and LCLs (IARC-171, OKU LCL, IARC 290B) exhibit relatively higher 
levels o f expression o f this molecule (Figure 3 52 ) The lack o f detection o f CD40 in 
some o f the EBV-negative BL cell lines and EBV-positive cell lines with a group I 
phenotype is likely to be due to the lower sensitivity o f this assay since expression o f 
CD40, albeit at low levels, has been detected in these cell lines by the more sensitive 
method o f FACS (Fluorescence activated cell sorter) analysis (Henriquez et a l , 1999) 
Also, as shown by others, induction o f LMP-1 expression in DG75tTA-LM P-l cells also 
results in upregulation o f expression o f CD40 (Floettmann et a l , 1996) CD40 
monomers migrate with a molecular weight o f 43-47 k D a , the lower molecular weight 
proteins detected in some of the cell lines, most likely represent deglycosylated forms o f 
the monomers (Braesch-Andersen et a l , 1989)
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Figure 3 52 Analysis o f expression o f CD40 in a series o f EBV-negative and -p ositive  BL cell lines, 
LCLs and D G 75tT A L M P-l cells induced to express LMP-1 W estern blot analysis o f  CD40 expression 
in a series o f EBV-negative BL cell lines [ DG75 (lane 1), BL41 (lane6)], EBV-positive BL lines with 
either a group I phenotype [ M utu I (lane 4), OKU BL (lane 9)] or a group III phenotype [ M utu III (lane 5), 
BL41B95 8 (lane 7)], LCLs [ IARC-171 (lane 8), OKU LCL (lane 10), IARC 290B (lane 11)], umnduced 
D G 75tTA LM P-l cells (lane 2) and DG75 tTALMP-1 cells induced to express LMP-1 48 h after teracycline 
removal (lane 3) The position o f  the protein m olecular weight markers is indicated on the left-hand side o f 
the photograph and the position o f  the CD40 protein (48 kDa)is indicated by an arrow
3.2.10.3 Ligation of CD40 upregulates expression of b f l - 1  mRNA
Ligation o f CD40 on B-lymphocytes has been shown to elicit a cell survival signal at 
least part o f which involves the upregulation o f expression o f the anti-apoptotic gene 
bclx/L (Lee et a l , 1999, Tuscano et a l , 1996) More recently, activation o f CD40 has 
been shown to also upregulate the expression o f bfl-1 in B cell lines (Lee et a l , 1999) 
Indeed, Northern blot analysis revealed that treatment o f the BL cell lines M utu I and 
BL41-B95 8 with the agonistic anti-CD40 antibodies, G28 5, resulted in an upregulation 
o f expression o f bfl-1 and bcl-x (Figure 3 53A) The upregulation o f bfl-1 and bcl-x on 
CD40 ligation was found to be transient with a significant upregulation detected by 8 h 
followed by a return to basal levels (i e levels m untreated cells) by 24 h post-CD40 
ligation The transient nature o f upregulation o f these mRNAs by CD40 activation has 
been found by others (Lee et a l , 1999) However, treatment o f the BL cell line Rael with 
the G28 5 antibodies did not have an effect on b fl-l and bcl-x mRNA levels (Figure 
3 53A) Although Rael expresses CD40 it has been shown by others to be unresponsive to
CD40
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several CD40-mediated effects on gene expression (Henriquez et a l , 1999) A more 
detailed analysis o f the kinetics o f upregulation o f bfl- 1 mRNA by CD40 ligation was 
attempted in DG75 cells (Figure 3 53B) In this experiment, upregulation of bfi-1 mRNA 
levels was detected as early as 4 h post-stimulation and these levels were maintained for 
at least 12 h and then decreased to near-basal levels by 24 h post-treatment with anti- 
CD40 antibodies G28 5
A.
Time (h) 0 8 24 0 8 24 0 8 24
G28 5
Rael M u tu I BL41B95 8
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F igu re  3 53 L igation  o f CD40 up regu la tes expression o f bfl-1  and  bcl-x  m RNAs in BL cell lines Rael, 
M utu I, BL41-B95 8 (A) and DG75 (B) cells were left untreated or treated with the CD40 agonistic 
antibodies G28 5 either as a 1 4000 dilution o f  ascites (Rael, Mutu I, BL41 B95 8) or at a concentration o f 
1 |ig/ml o f  purified antibody (DG75) Total RNA samples prepared from cells at 0, 8 and 24h (Rael, Mutu 
1, BL41-B95 8) or at 0, 4, 8, 12 and 24 h (DG75) post-treatm ent were subjected to Northern analysis with 
an antisense bfl-1 nboprobe (upper panel o f Figures A and B) The blots were then sequentially stripped 
and reprobed with antisense bcl-x (middle panel o f  Figure A) and G APDH  (lower panels o f  Figures A and 
B) probes
3.2.10.4 Investigation o f a cooperative effect between CD40 and LMP-1 in 
upregulating steady-state levels of b f l - 1  mRNA
Simultaneous provision o f signals from LMP-1 and CD40 has been shown to result in an 
additive or greater than an additive effect o f the individual signals on the expression o f 
cell surface proteins such as B7 1 and on IgM secretion (Busch and Bishop, 1999) The 
effect o f the dual signals on the expression o f other surface molecules such as ICAM-1, 
CD23 and LFA-1 was not found to be as dramatic and was not found to be greater than 
the effect o f either signal alone (Busch and Bishop, 1999) The effect o f  dual signaling 
from CD40 and LMP-1 on protein expression is dependent on the nature o f  the signaling 
pathway(s) involved i e whether there is a dependence on distinct intracellular pathways 
or a dependence on the availability o f intracellular components o f a single pathway
To analyse the effect o f dual signaling from LMP-1 and CD40 on bfl-1 mRNA 
expression, the effect o f CD40 ligation on unmduced DG75tTA-LM P-l cells and on the 
cells induced to express LMP-1 36 h after tetracycline removal was examined by 
Northern analysis (Figure 3 54) As expected, induction o f LMP-1 m DG75tTA-LM P-l 
cells 36 h after tetracycline removal, resulted in a marked upregulation o f b fl-l mRNA 
CD40 ligation on the LMP-1 expressing cells resulted in a further increase in bfl-l 
mRNA levels as detected 4 h after CD40 stimulation and these levels were maintained for 
at least 4h thereafter (Figure 3 54) The minor effect o f CD40 ligation on b fl-l mRNA 
levels in the unmduced DG75tTA-LM P-l cells may be a reflection o f the low levels o f 
CD40 expression in these cells (even lower than that in DG75 cells) which are 
significantly elevated on induction o f LMP-1 expression (Figure 3 52, Floettmann et a l ,
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1996) The increase in bfl-1 mRNA expression on ligation o f CD40 in the LMP-1 - 
expressing DG75-tTA-LM Pl cells may therefore be a result o f the increased levels o f 
expression o f CD40 observed on induction o f LMP-1 Thus, LMP-1 and CD40 exert a 
cooperative effect in upregulatmg è/7-imRNA levels in DG75tTA-LM P-l cells, though 
the contribution by CD40 may also be a result o f the upregulation o f CD40 expression by 
LMP-1
b f l - 1
G A P D H
D G 75tT A L M Pl +t -t +t +t -t -t +t +t -t -t 
(t = tetracycline)
G 28 5
Oh 4 h Nil
Figure 3 54 LMP1 and CD40 cooperate m upregulatm g bfl-1 mRNA in D G 75tT A -LM P-l cells.
Unmduced D G 75tTA -LM P-l cells (+tetracycline) or DG 75tTA -LM P-l cells induced to express LMP-1 36 
h after tetracycline removal (- tetracycline) were left untreated or stimulated with 1 |ig/ml o f  the anti-CD40 
antibody, G28 5 Total RNA extracted from cells at 0, 4 and 8 h after stimulation with G28 5 was used in 
Northern analysis with an antisense bfl-1 riboprobe (upper panel) The blots were sequentially stripped and 
reprobed with a GAPDH (lower panel) riboprobe Exposure to X-ray film was for 18 -  24 h
3.2.10.5 The regulation o f b f l - 1  expression by CD40 does not occur at the level 
of mRNA stability.
Control o f mRNA expression occurs at the level o f either mRNA stability or rate o f
transcription or a combination o f the two To investigate i f  the CD40-mediated
upregulation o f bfl-1 mRNA is due to an increase in mRNA stability, mRNA half-life
studies were conducted m the EBV-negative BL cell line BJABtTA The BJAB cell line
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expresses readily detectable levels o f bfl-1 mRNA which are upregulated on stimulation 
o f CD40 by G28 5 monoclonal antibodies (Lee et a l , 1999) CD40 stimulation o f 
BJABtTA cells was also found to result in upregulation o f bfl-1 mRNA levels (Figure 
3 55) The half-life o f bfl-1 mRNA was determined in BJABtTA cells m the presence or 
absence o f CD40 stimulation (5h treatment with G28 5 monoclonal antibodies) as 
described in section 2 5 5 The half-life o f b fl-l mRNA in unstimulated cells was found 
to be approximately 2 4 h Stimulation with the agonistic anti-CD40 antibodies resulted 
in only a marginal increase in the stability o f b fl-l mRNA to 3 Oh (Figure 3 55) Thus, 
unlike the effect o f EBV-infection or LMP-1 expression (Figures 3 10 and 3 11), 
increased mRNA stability does not appear to make a major contribution to the CD40- 
mduced upregulation o f bfl-l mRNA steady-state levels
A.
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Figure 3 55 Increased mRNA stability does not make a major contribution to CD40-m ediated  
upregulation o f bfl-1 mRNA levels in BJABtTA cells Unstimulated BJABtTA cells or cells stimulated 
for 5 h with 1 |ig/m I o f the anti-CD40 antibody, G28 5, were treated with 5|ig/'ml actinomycin D to block 
RNA synthesis Total RNA was then extracted from cells harvested at 0, 2, 4, 6, 8,9 and 22 h after 
treatm ent with actinomycin D and the rate o f  decay o f bfl-1 mRNA m onitored by Northern analysis A)
The upper panel shows the Northern blot analysis o f  the decay o f  bfl-1 mRNA over time (indicated m hours 
above each lane) after treatm ent with actinomycin D in unstimulated and CD40-stim ulated cells The 
lower panel is a photograph o f  the 18S rRNA band from the same ethidium brom ide-stained gel used for 
blotting B) The graphs show the best-fit semilogarithmic lines generated from the relative amounts o f  6/7- 
1 mRNA as determined from densitometric scanning o f the autoradiogram s o f  the Northern blots in panel 
A plotted against time o f  exposure to actinomycin D These values were normalised for loading based on 
the intensity o f the 18S rRNA bands Owing to the high level o f background hybridisation obtained with 
the bfl-1 riboprobe in this Northern Blotting experiment, it was only possible to obtain densitometric values 
for the ‘ bfl-1 bands’ corresponding to the 0, 2, 4 and 6h timepoints o f actinomycin D treatm ent and the 
graphs were plotted using the normalised values obtained for only these time points Relative levels o f  bfl- 
1 mRNA as determined in unstimulated BJABtTA cells (□) and cells stimulated with G28 5 for 5 h (■)
3.2.10.6 LMP-1 and CD40 cooperate in upregulating b f l - 1  promoter activity
Since mRNA stability was excluded as a mechanism involved in the CD40-mediated 
upregulation o f bfl-1 mRNA, it was o f interest to investigate the possible involvement o f 
the alternative mechanism o f increased promoter activity in this effect To this end,
DG75 cells transfected with the -1374/+81 bfl-1-luciferase reporter construct were left
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untreated or treated with 1 (ag/ml o f G28 5 at 36 h post-transfection After treatment with 
the anti-CD40 antibody for 12 h, cells were harvested and luciferase activity measured 
and compared to that o f untreated cells It can be seen from Figure 3 56 that stimulation 
o f CD40 resulted in a 2 2-fold increase in activity o f the bfl-1 promoter suggesting that 
CD40-induced upregulation o f bfl-1 mRNA levels is mediated by an increase in promoter 
activity Expression o f LMP-1 from the cotransfected pEFCX-LMP-1 plasmid resulted 
in a 3 4-fold-increase in bfl-1 promoter activity from the -1374/+81 bfl-1-luciferase 
reporter and this value was increased further to 4 8-fold on activation o f CD40 signaling 
by G28 5 The extent o f activation o f the bfl-1 promoter as a result o f the dual signaling 
from CD40 and LMP-1 is greater than that provided by each o f the individual signals but 
is less than that expected o f an additive effect o f both signals These findings suggest that 
CD40 and LMP-1 signaling pathways leading to upregulation o f bfl-1 promoter activity 
most likely converge However, it is possible that part o f the effect o f CD40 activation 
on bfl-1 promoter activity in the LMP-1 transfected cells is due to the increased surface 
expression o f CD40 by LMP-1 in these cells The lower extent o f activation o f the -  
1374/+81 -bfl-1 luc reporter by LMP-1 in these studies compared to the studies reported 
in section 3 2 7, is likely to be due to the differences in the time o f harvesting o f the 
transfected cells for the luciferase assays (Rowe et a l , 1994, Wang et a l , 1996)
As observed in section 3 2 7 5 LMP-1-mediated upregulation o f b fl-l expression is NF- 
KB-dependent To investigate if  CD40-mediated upregulation o f bfl-1 promoter activity is 
also NF-KB-dependent, DG75 cells were cotransfected with a plasmid expressing the 
dominant negative mutant IkBccDN (pEFCX-IkBcxDN) and the -1374/+81 6/7-luciferase 
reporter construct and then stimulated with the G28 5 antibody Expression o f iKBaDN 
inhibited the CD40-mediated activation o f bfl-l promoter activity suggesting that CD40- 
mediated activation o f the bfl-l promoter is NF-KB-dependent (Figure 3 56) The dual 
effect o f LMP-1 and CD40 activation on this parameter also appears to be NF-KB- 
dependent (Figure 3 56) However, in this case an indirect effect on the NF-KB-mediated 
process o f upregulation o f CD40 levels by LMP-1 cannot be excluded (Devergne et a l ,
1998)
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Figure 3 56 Expression o f a dominant negative mutant o f IkBo, inhibits the activation o f the bfl-1 
prom oter by CD40 signaling and by dual signaling from CD40 and LMP-1 DG75 cells were 
cotransfected with 2 5 |ag o f  the LMP-1 expression plasmid, pEFCX-LM P-1, or empty vector, pEFCX, and 
2 5 jj.g o f the bfl-1 promoter-luciferase construct, p-1374/+81 B fl-l-luc in the absence or presence o f  10 0 
jug o f  the IkB ocDN  expression plasmid, pEFCX IkB ccDN  At 36h post transfection, the cells were either 
left untreated or treated with 1 Mg/ml G28 5 for 12 h prior to harvesting for measurement o f  luciferase 
activity Norm alised luciferase activities are expressed as fold activation over control (empty vector in the 
absence o f  expression o f  IkB oc DN or treatm ent with G28 5 =1)
□ - G28 5 (CD40) 
■ +G28 5 (CD40)
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3.2.11 Mechanism of upregulation of Bcl-2 expression by LMP-1
3.2.11.1 BCL-2
bcl-2 was discovered by virtue o f its association with the t(14 ,18) reciprocal 
chromosomal translocation commonly found in follicular lymphoma (reviewed m 
Bruckheimer et a l , 1998) The bcl-2 open reading frame is not disrupted by the t(l 4,18) 
translocation and generates an otherwise normal bcl-2 gene product in inappropriate 
amounts Bcl-2 was shown to be a unique oncogene in that its deregulation did not result 
in an increase in cell proliferation, but rather enhancement o f cell survival
The assignment o f bcl-2 as a survival gene is based largely on in vitro observations 
Thus, introduction o f bcl-2 into IL-3 dependent cell lines results m their survival after IL- 
3 withdrawl (Vaux et a l , 1988, Nunez et a l , 1990) In the absence o f bcl-2 , withdrawl 
o f IL-3 from dependent cells results in their rapid demise by apoptosis Expression o f 
bcl-2 in vivo also suggests a survival function studies o f bcl-2 -transgenic mice indicate 
that the gene causes B-cell hyperplasia but not tumorigenesis (Bruckheimer et a l , 1998) 
Deregulated Bcl-2 expression is thought to be a primary genetic change that prolongs cell 
survival m order to permit the acquisition o f further pre-malignant changes Indeed, bcl- 
2 was shown to complement c-myc in the neoplastic process (Korsmeyer, 1995) 
Germinal center B cells (centrocytes) can be rescued from apoptosis by exposure in vitro 
to immobilised anti-Ig and CD40 monoclonal antibody (Liu et a l , 1991) However, Bcl-2 
expression is induced relatively late during CD40-mediated rescue o f germinal center B 
cells (Holder et a l , 1993)
Bcl-2 is a transmembrane protein and localises to the nucleus, rough ER and 
mitochondria (Hockenberry et a l , 1991, Korsmeyer, 1995) It is normally expressed in 
pro- and mature B cells but is downregulated in pre- and immature B-lymphocytes 
(Bruckheimer et a l , 1998) This differential expression points to the survival role o f Bcl- 
2 m B lymphocyte development High levels o f Bcl-2 are needed to ensure the survival 
o f pro-B cells and mature B cells in order to maintain a population o f functional
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lymphocytes But low levels o f Bcl-2 are necessary for cells that do not express 
functional surface immunoglobulin or are self-reactive to undergo apoptosis
EBV-positive BL cell lines can be readily triggered into apoptosis unless the full 
complement o f EBV-latent proteins is expressed by the cells (Gregory et a l , 1991) This 
protection against apoptosis is accompanied by upregulation o f Bcl-2 (Liu et a l , 1991, 
Henderson et a l , 1991) which is also induced following expression o f LMP-1 
(Henderson et a l , 1991) Furthermore, ectopic expression o f bcl-2 can provide BL cell 
lines with a survival advantage Although the induction o f bcl-2 expression by 
expression o f the entire complement o f EBV latent genes or LMP-1 only is well 
documented (Finke et a l , 1992, Henderson et al, 1991), the mechanism involved in its 
regulation has not been worked out This section attempts to address the gap in our 
knowledge o f the mechanism involved in the regulation o f Bcl-2 expression by LMP1
3.2.11.2 Correlation between expression of LMP-1 and Bcl-2 in BL cell lines
As an initial step towards studying the mechanism o f regulation o f Bcl-2 expression by 
LMP-1, the expression o f LMP-1 and Bcl-2 in a series o f BL cell lines was examined 
Indeed, as has been reported by others (Henderson et a l , 1991, Finke et a l , 1992), 
Western blot analysis revealed that cell lines that expressed LMP-1 (LCLs and BL lines 
with a group III phenotype) exhibited higher levels o f expression o f Bcl-2 protein than 
non-LMP-1 expressing BL lines (Figure 3 57)
1 2 3 4 5 6 7 8 9 10 11 12
LM P-1
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Figure 3 57 Expression o f LMP-1 correlates with upregulated expression o f Bcl-2 in BL cell lines
W estern blot analysis o f  LMP-1 expression (upper panel) and Bcl-2 expression (lower panel) in a series o f 
EBV-negative BL cell lines [DG75 (lanes 1, a), BL41 (lanes 7, e)], EBV- positive BL lines with either a 
group I phenotype [Rael (lanes 2, b), M utu I (lanes 3, c), OKU BL (lanes 5, h)] or a group III phenotype [ 
Mutu III (lanes 4, d), BL41-B95 8 (lanes 8, f), Ag876 (lanes 12, 1)] and LCLs [ OKU LCL (lanes 6, l), 
IARC171 (lanes 9, g), X50-7 (lanes 10, j )  IARC 290B (lanes 11, k)] The positions o f  the 62 kDa and 25 
kDa m olecular weight markers are indicated on the left hand side o f the photograph, whilst the positions o f 
the LMP-1 (64 kDa) and Bcl-2 (26 kDa) proteins are indicated by an arrow on the right hand side LMP-1 
expression was detected using the CS1-4 antibodies while Bcl-2 was detected using the Bcl-2 100/124 
antibodies
3.2.11.3Induction of LMP-1 expression results in upregulation o f Bcl-2 protein levels
The effect o f LMP-1 on Bcl-2 expression was addressed using the DG75tTA-LM Pl cell 
line in which the expression o f LMP1 is under the control o f a tetracycline-based system 
Indeed, induction o f LMP-1 on removal o f tetracycline from the growth medium resulted 
in induction o f Bcl-2 protein as assessed by Western blot analysis o f the same lysates 
used for analysis o f  LMP-1 induction m figure 3 3 (Figure 3 58) Upregulation o f Bcl-2 
expression was detected 24 h after tetracycline removal and the levels rose thereafter for 
the duration o f the experiment with maximal levels detected by 72-96 h post induction o f 
LMP-1
K D a  O 6 12 24 48 72 96
3 2 .5
2 5 - m ** —    <**■.. g  c l- 2
1 6 . 5 ^  "  ’
Figure 3 58 W estern blot analysis o f Bcl-2 levels in D G 75-tT A -LM P-l cells upon induction o f LMP-1
Cells were harvested at various times (indicated in hours above each lane) after removal o f  tetracycline 
from the medium, and total cellular protein extracted from 5 x 105 cells used in W estern blot analysis with 
anti-bcl-2 antibodies (bcl2100/124) The position o f  the protein m olecular weight markers are indicated on 
the left hand side o f the photograph
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3.2.11.4 Analysis of the phosphorylation status of Bcl-2
Serine-phosphorylation represents a post-translational modification that provides an 
additional mechanism o f control o f function o f the Bcl-2 protein. Phosphorylation o f 
Bcl-2 has been shown to inactivate its function in lymphoid cells, making them 
susceptible to apoptosis (Haidar et al., 1995; Srivastava et al., 1998). In these studies 
treatment o f cells with phosphatase inhibitors such as okadaic acid (OA) and calyculin A 
or chemotherapeutic agents such as taxol induced slower mobility forms o f Bcl-2 as 
revealed by Western blot analysis. However, in an EBV-immortalised lymphoblastoid 
cell line, GM1500, OA treatment did not result in Bcl-2 phosphorylation or apoptotic 
death suggesting that the kinase responsible for phosphorylating Bcl-2 is inactive in these 
cells (Haidar et a l ,  1995). Since LCLs express LMP-1, it was hypothesised that LMP-1 
may be responsible for inactivating this kinase and thus maintain Bcl-2 in an 
unphosphorylated state. To investigate this possibility, the effect o f OA treatment on the 
phosphorylation status o f Bcl-2 protein in DG75 tTALMP-1 cells before and after 
induction o f LMP1 was assessed. As a control for the effect o f OA, cells were treated in 
parallel with the tyrosine phosphatase inhibitor, sodium orthovanadate (VA) for 6h. 
Surprisingly, Western blot analysis revealed that treatment o f DG75 tTA-LMP-1 cells 
with 1 (iM OA before or 96 h after LMP-1 induction induced slower mobility forms o f 
Bcl-2 (Figure 3.59B). The presence o f the altered forms o f Bcl-2 is more obvious in the 
case o f the OA-treated LMP-1 expressing cells perhaps due to the relatively larger 
amount o f Bcl-2 protein induced by LMP-1 in these cells. These results would suggest 
that LMP-1 does not inactivate the kinase(s) involved in phosphorylating Bcl-2 in this 
cell line. Trypan blue staining o f cells at the time o f harvesting did not reveal an effect o f 
OA treatment on cell death. The untreated cells lacked any evidence o f slower mobility 
forms o f Bcl-2 either before or after LMP-1 induction. This suggests that Bcl-2 induced 
in the cells upon expression o f LMP-1 is mostly o f the non-phosphorylated form. 
However, it is possible that the lesser phosphorylated forms migrate at apparently the 
same molecular weight as the unphosphorylated form o f Bcl-2 because o f insufficient 
resolution on the gel. If  this is indeed the case then the pattern o f the phosphorylated 
forms and hence extent o f phosphorylation o f Bcl-2 in the LMP-1 expressing cells is not
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as great as that induced upon OA treatment Treatment o f the cells with the tyrosine 
phosphatase inhibitor, VA, did not induce any detectable alteration in the mobility o f Bcl- 
2, suggesting that the induction o f the slower mobility forms is specific to 
serine/threomne phosphatase inhibitors and that these forms are indeed phosphorylated 
on serine and/or threonine Furthermore, the lack o f an effect o f VA on Bel-2 
phosphorylation did not seem to be due to a lack o f an effect o f VA on protein tyrosine 
phosphorylation since W estern blot analysis with the anti-phosphotyrosme antibodies, 
PT66, revealed that VA treatment did increase tyrosine phosphorylation o f cellular 
proteins particularly in the 47 5 -  172 kDa molecular weight region (Figure 4 59C) 
Interestingly, LMP-1 -induction did not lead to any detectable increase in the tyrosine 
phosphorylation o f cellular proteins However, VA treatment, led to an enhancement in 
the amount o f Bcl-2 protein expressed in the DG75-tTA-LM Pl cells irrespective o f  their 
LMP-1 status, suggesting that tyrosine phosphorylation o f protem(s) may be involved in 
regulating Bcl-2 expression in these cells (Fig 4 59C lane 5 in particular) The effect o f 
VA on Bcl-2 expression did not seem to be due to an indirect effect o f this agent on the 
expression system in these cells leading to induction o f LMP-1 as revealed by Western 
blot analysis with anti-LMP-1 antibodies (Figure 4 3 A) The lack o f detectable 
phosphorylated forms o f Bcl-2 in the cells on induction o f LMP-1 is consistent with the 
anti-apoptotic function o f the induced Bcl-2 However, the potential for phosphorylation 
o f Bcl-2 does exist m a BL cell context despite LMP1 expression
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Figure 3 59 Analysis o f the phosphorylation status o f Bcl-2 m D G 75-tT A -L M Pl cells before and 
after induction o f LMP-1 DG75-tTA-LM P-l cells maintained in the presence or absence o f  tetracycline 
for 96 h were treated with 1 |iM OA or Im M  VA or 0 025%  DM SO (vehicle control) for 6 h and then lysed 
in a buffer containing phosphatase inhibitors The lysates were used in W estern blot analysis with 
antibodies to either LMP-1 (A), Bcl-2 (B) or phosphotyrosine (C) The position o f  molecular weight 
markers (M ) are indicated on the left-hand side o f  the photographs The position o f  the LMP1 and Bcl-2 
proteins are indicated by arrows In panel B, the position o f bands corresponding to phosphorylated forms 
o f Bcl-2 (P-Bcl2) are indicated by smaller arrows on the photograph
3.2.11.5 LMP1 upregulates steady-state levels of b c l - 2  mRNA in DG75-tTA-LM Pl 
cells
RPA analysis using the multiprobe set APO-2 revealed that induction o f LMP-1 
expression m DG75-tTA-LM P-l cells also resulted in an upregulation o f bcl-2 mRNA 
levels, however, a significant upregulation was not evident until 96 h post-induction o f 
LMP-1 upon prolonged exposure to film (Figure 3 3, result not shown) The same RNA 
samples used in this RPA study were subjected to Northern analysis with an antisense 
bcl-2 riboprobe As found m  the RPA analysis, the upregulation o f bcl-2 mRNA on 
induction o f LMP-1 expression followed different kinetics to bfl-1 upregulation in that 
whilst bfl-1 upregulation was detected as early as 12 h post-removal o f  tetracycline from 
the growth medium, upregulation o f bcl-2 mRNA expression was only detected at 48h 
Densitometnc scanning o f the bands corresponding to bcl-2 mRNA (followed by 
normalisation to GAPDH levels) revealed a 2-fold increase o f bcl-2 mRNA levels at 48 h 
which increased to approximately 3-fold by 96 h post-induction o f LMP-1 (Figure 3 60) 
Taken together with the data o f the kinetics o f induction o f Bcl-2 protein (Figure 3 58), it 
can be concluded that the upregulation o f Bcl-2 protein by LMP-1 occurs earlier than that 
o f bcl-2 mRNA In particular while significant upregulation o f Bcl-2 protein is detected 
24h post-induction o f LMP-1, there was no apparent effect on bcl-2 mRNA at this time 
point (compare Figures 3 58 and 3 60) These findings suggest that both transcriptional 
and translational mechanisms may be involved in the control o f Bcl-2 expression by 
LMP-1
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Figure 3.60 Northern blot analysis of bcl-2  mRNA in D G 75-tT A -LM P-l cells upon induction o f
LMP-1 Total RNA prepared at various times after LMP-1 induction (indicated in hours above each lane) 
in D G 75-tTA -LM Pl cells was used in Northern analysis with an antisense-6c/-2 riboprobe (upper panel). 
Exposure to film was for 24 h. The lower panel shows the same blot stripped and reprobed with an 
antisense G APDH  probe.
3.2.11.6 b c l - 2  promoter studies
Studies o f steady-state mRNA levels in cell lines representing different stages o f B-cell
development indicated that bcl-2 is developm ental^ regulated within the B-cell lineage.
Human pre-B cell lines express high levels o f bcl-2 mRNA, while cell lines representing
more mature B-cell stages generally express bcl-2 at low levels (Graninger et al., 1987).
Similar observations hold true for murine cell lines representing various stages o f B-cell
maturation. (Gurfmkel et al., 1987). A determination o f bcl-2 mRNA half-life revealed
that bcl-2 mRNA stability did not vary between different-stage B-cell lines (Seto et al.,
1988). Like B-cell lines, normal B cells purified from human tonsils or peripheral blood
demonstrate only low levels o f bcl-2 mRNA. However, various B-cell activating agents
such as PMA, can induce bcl-2 expression in purified human B cells (Graninger et al.,
1987; Reed et al., 1987). However, post-transcriptional/translational regulation may also
contributes to bcl-2 expression since although resting peripheral blood B lymphocytes
express Bcl-2 protein, mitogen stimulation causes a downregulation o f Bcl-2 protein
despite the high bcl-2 mRNA levels (Akagi et al., 1994).
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Characteristion o f the genomic organisation o f bcl-2 revealed that it consists o f three 
exons with the second and third exons separated by an extremely large, 225-kb mtron 
(Seto et a l , 1988) Two promoter regions are responsible for the initiation o f bcl-2 
transcription (Seto et a l , 1988) The predominant promoter region, P I , where 
approximately 95% o f transcripts initiate has been mapped to an area containing several 
GC boxes (Sp-1 binding sites) located between bp -1390 and -1440  upstream from the 
translation start site The PI promoter lacks a TATA box and consequently transcripts 
initiate from several sites in the general vicinity o f the GC boxes (Seto et a l , 1988) A 
second promoter, P2, is located approximately 80bp upstream o f the coding region and 
contains a TATA box, but fewer than 5% o f all transcripts initiate from this region A 
negative regulatory element (NRE) upstream o f the P2 promoter has been described 
previously (Young and Korsmeyer, 1993) and p53 has been shown to mediate 
downregulation o f bcl-2 either directly or indirectly through a 195 bp fragment (-279 to -  
85 relative to translation start site) o f this region (Miyashita et a l , 1994) Three rrl - 
binding sites located from 743 to 1510 bp upstream o f the NRE, function as negative 
regulators o f bcl-2 expression in pre-B cells but are non functional in mature B cells 
(Chen and Boxer, 1995) A positive regulatory region located just upstream o f PI 
between -1661 and -1526 contains a site for binding o f c-AMP response element binding 
protein (CREB) The CRE site has been shown to play a major role for maintenance o f 
constitutive expression o f bcl-2 in mature B cells as well as in the induction o f bcl-2 
expression during activation o f mature B cells and during rescue o f immature B cells 
from apoptosis by PMA trreatment (W ilson et a l , 1996)
A bcl-2 promoter-luciferase construct containing bp -3934 to -8 o f the 5 ’ untranslated 
region o f bcl-2 was transiently transfected into DG75tTA-LM P-l cells in which LMP-1 
expression was either blocked or induced 48 h after tetracycline removal Luciferase 
activity was measured 48h post-transfection (= 96h post-removal o f tetracycline) which is 
effectively the time at which a 3-fold increase in steady-state bcl-2 mRNA levels was 
detected on induction o f LMP-1 in these cells It was found that the activity o f the bcl-2 
promoter remained unchanged on induction o f LMP-1 in DG75-tTA-LM P-l cells (results
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not shown) Although this region o f the promoter contains the positively regulated CRE 
site, it also includes the negatively regulated NRE region located between the PI and P2 
promoters as well as the Ttl binding sites which may have masked any minor positive 
effect o f the full-length promoter (W ilson et a l , 1996) To exclude these possibility, a 
promoter-reporter construct containing only the PI promoter and upstream sequence (- 
3934 to -1287) or containing just the positively regulated region including the CRE site 
(-1640 to -1287) were used in similar transient transfection assays as the full-length bcl-2 
promoter-luciferase construct However, induction o f LMP-1 did not alter promoter 
activity from either o f these constructs as well (result not shown) Based on these results 
it may be concluded that LMP-1 does not alter the activity o f the -3934  to -8  region o f 
bcl-2 promoter However, complete validation o f this result would require parallel 
demonstration o f the functionality o f the ectopically expressed LMP1 which was not 
performed in this study
3.2.11.7 LM P-l-induced upregulation o f expression o f Bcl-2 protein does 
not involve factors secreted into the medium
In vitro , EBV-infected BL cells exhibiting a type III phenotype and LCLs induce the 
secretion o f a number o f factors into the growth medium including cytokines such as IL- 
1, IL-5, IL-6, IL-8, IL-10 and IL-12 which exert several phenotypic effects on the cell in 
an autocrine loop (reviewed in Kaye et a l , 1999) LMP-1 expression alone can account 
for the secretion o f several o f these cytokines and some o f them such as IL10 can induce 
Bcl-2 expression in other cell systems (W eber-Nordt et a l , 1996, Nakagomi et a l , 1994 
Eliopoulos et a l , 2000)
To investigate if factors secreted into medium upon induction o f LMP1 in DG75-tTA- 
LMP-1 cells may be responsible for the delayed response in Bcl-2 upregulation, 
conditioned medium was collected from DG75-tTA-LM P-l, 96 h after induction o f 
LMP-1 and used to culture DG75-tTA-LM P-l cells in the presence o f tetracycline Cells 
were harvested 24 and 48 h after growth in the conditioned medium and assessed for Bcl- 
2 expression by W estern blot analysis with anti-Bcl-2 antibodies. It can be seen from
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figure 3 61A that incubation with conditioned medium from the LMP-1 expressing cells 
did not result in an upregulation o f Bcl-2 levels in the unmduced DG75-tTA-LM P-l cells 
to the same extent as in the LMP-1 -  induced cells In a similar experimental strategy, 
neither did conditioned medium from Mutu III induce Bcl-2 upregulation in M utu I cells 
(Figure 3 6 IB) These experiments exclude the involvement o f secreted factors as
intermediaries in the LMP-1- or EBV-induced upregulation o f Bcl-2 in BL cells
A.
Time (h) of D + tet.
treatment with
cond. medium 0 24 4 8 1 D-tet.
B.
Time (h) o f Mutu I
treatment with
cond. medium ^ 0  24 48~* Mutu III
F ig u re  3 61 L M P -l-m ed ia ted  up reg u la tio n  o f Bcl-2 does not involve au toc rin e  fac to rs  secreted  in the 
m edium  A) D G 75-tTA -LM P-l grown in the absence o f tetracycline for 72 hours were transferred to fresh 
medium and growth continued for 24 h The conditioned medium was rendered cell-free, filtered (0 45(im 
filter) and then used to culture DG 75-tTA -LM Pl cells in the presence o f  tetracycline After growth in 
conditioned medium for 24 or 48h the cells were harvested, total cellular protein extracted and used in 
W estern blot analysis with either anti-LM Pl antibodies (upper panel) or anti-Bcl2 antibodies (lower panel) 
B) M utu III cells in exponential phase o f  growth were grown in fresh medium for 24 h Conditioned 
medium prepared as in (A) was used to culture M utu I cells After growth in conditioned medium for 24 or 
48 h, the cells were processed as m (A) for W estern blot analysis with anti-LM Pl antibodies (upper panel) 
or anti-Bcl2 antibodies (lower panel)
Thus, LMP-1 contributes to the upregulation o f Bcl-2 expression m BL cells by 
mechanisms that appear to involve both transcriptional and translational control, with the 
effect on translation predominating Furthermore, this effect does not appear involve an 
increase in promoter activity (at least m the region -3934 to -8  upstream o f the translation 
start site) and is also independent o f an indirect action by secreted factors
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CHAPTER 4
DISCUSSION
Discussion
One o f the main features o f the biology o f EBV is its ability to persist for life in healthy 
infected individuals and this is most likely as a latent infection in the B cell compartment 
(reviewed by Gregory, 1995) In vitro, expression o f the full complement o f latent viral 
genes in EBV-infected B cells has been found to protect the cells from apoptosis and this 
ability o f the virus provides a mechanism for its entry into the memory B cell 
compartment O f the latent genes, expression o f LMP1 in several cellular contexts 
including B cells has been shown to confer protection against apoptotic death by both 
Bcl-2-dependent and Bcl-2-mdependent mechanisms (Milner et a l , 1992, Fries et a l , 
1996, Laherty et a l , 1992, Wang et a l , 1996) The mam purpose o f this study was to 
identify other possible Bcl2-mdependent mechanisms triggered by EBV latent gene 
expression in the B cell context and to then investigate if  LMP1 can account for any o f 
these mechanisms The results presented m this study identify a relatively new member 
o f the bcl-2-family o f genes with anti-apoptotic properties, bfl-1, as being overexpressed 
in EBV-infected B cells expressing the entire complement o f latent genes and that LMP1 
is at least one o f the latent proteins that can mediate this effect The apoptotic threshold 
o f a cell is determined by the functional balance in the expression o f both pro- and anti- 
apoptotic proteins and hence the ability o f LM P1 to upregulate the expression o f several 
anti-apoptotic proteins would raise the apoptotic threshold o f the EBV-infected, LMP-1 
expressing cell
4.1 BFL-1
The human bfl-1 (Bcl-2-related gene expressed in fetal liver) gene was isolated from a 
human fetal liver cDNA library and identified by computer analysis o f expressed 
sequenced tag (EST) databases (Choi et a l , 1995) The open reading frame o f bfl-l 
encodes a protein o f 175 ammo acids and among the Bcl-2 related genes, it has the 
highest homology with murine A l (72% ammo acid identity) Bfl-1 shares highest 
homology with many Bcl-2-related proteins in two regions, BH (Bcl-homology)-l and 
BH2 that have been shown to be required for Bcl-2 function (Figure 3 1, Choi et a l ,
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1995) Currently available data suggest that bfl-1 and its mouse homolog A l  exhibit 
differences in expression in tissues m that while the expression o f the murine gene is 
restricted to hematopoietic tissue, expression o f the human homolog would appear to 
have a more widespread tissue distribution ( Karsan et a l , 1996a, Choi et a l , 1995, Lin 
et a l , 1996, Zong et a l , 1999) Expression o f the bfl-1 gene has been shown to protect 
against apoptosis in a variety o f cell types (D’Sa Eipper and Chinnadurai, 1996, Karsan 
et a l , 1996b, Zong el a l , 1999, Wang et a l , 1999) Furthermore, b fl-l expression is 
upregulated in cultured endothelial and leukemic cells by phorbol ester and inflammatory 
cytokines TN F-a and IL-1, suggesting a protective role for Bfl-1 during inflammation 
(Karsan et a l , 1996a, 1996b, Moreb and Schweder, 1997) bfl-1 expression is also 
upregulated during differentiation o f leukemic cells to granulocytes and macrophages 
(Moreb and Schweder, 1997) In addition to protecting against apoptosis, Bfl-1 has also 
been shown to exhibit proliferation and transforming properties in vitro (D ’Sa Eipper and 
Chinnadurai, 1998) Functional dissection o f the protein suggests that its anti-apoptotic 
and transforming properties may be linked and map to the BH1 and BH2 domains (D ’Sa 
Eipper and Chinnadurai, 1998) Northern analysis has revealed elevated levels o f 
expression o f bfl-1 in a significant proportion o f stomach and colon cancers (Park et a l , 
1997, Choi et a l , 1995), however, in situ hybridisation studies have indicated that in 
tumour tissue, expression is preferentially detected in infiltrating inflammatory cells 
rather than in cancer cells (Jung-Ha et a l , 1998) This discrepancy may explain the low 
rate o f expression o f bfl-1 observed in established stomach and colon cancer cell lines 
(Park et a l , 1997) However, it appears that cell lines derived from leukemias and 
lymphomas exhibit high levels o f expression o f b fl-l (Choi et a l , 1995, Kenny et a l ,
1997)
4.2 FUNCTIONAL SIGNIFICANCE OF UPREGULATION OF B F L - 1  
EXPRESSION BY LMP1
Initial experiments using a range o f EBV-infected cell lines revealed that elevated 
expression o f b fl-l and bcl-2 is a feature o f both BL and LCL cell lines expressing the 
full spectrum o f EBV latent genes. By comparison, EBV-negative BL lines and BL lines
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with a latency I phenotype express negligible or significantly lower levels o f these 
mRNA species, thereby suggesting that expression o f the entire complement o f  EBV 
latent genes upregulates bfl-1 and bcl-2 mRNA levels in BL lines. Upregulation o f bfl-1 
mRNA thereby represents a novel function o f EBV latent gene expression in BL lines 
and extends the list o f anti-apoptotic genes whose expression is regulated by EBV 
(Allday, 1996; Spender et al., 1999). In support o f the observations with the pattern o f 
bcl-2 mRNA expression, a strong correlation has been established between expression o f 
EBV latent proteins and elevated levels o f Bcl-2 protein in BL lines (Henderson et al., 
1991; Finke et al., 1992). The contribution that EBV latent gene expression makes 
towards the high levels o f bfl-1 mRNA expression observed in LCLs is unknown since 
information on the status o f expression o f this mRNA species in human peripheral B 
lymphocytes (PBLs) prior to EBV infection is lacking in the literature. Thus, in the case 
o f EBV-infected B lymphocytes, it is possible that if resting B cells express relatively 
low levels o f  bfl-1 mRNA, then EBV latent gene expression induces the high level o f 
expression o f this mRNA in LCLs. Alternatively, if  PBLs already exhibit high levels o f 
bfl-1 mRNA expression, then, EBV infection may serve to maintain the level o f bfl-1 
mRNA in LCLs as has been observed in the case o f Bcl-2 expression (Martin et al., 
1993).
Using a tetracycline-regulated system for induction o f LMP-1 expression in the EBV- 
negative BL cell line, DG75-tTA-LM Pl, it was possible to demonstrate that LMP-1 
upregulates expression o f bfl-1 and bcl-2 mRNAs. However, there was a clear difference 
in the kinetics o f induction o f expression o f these anti-apoptotic genes by LM P-1, in that 
while induction o f bfl-1 mRNA appears to be an immediate and direct effect o f LMP-1 
expression, induction o f bcl-2 mRNA appears to be a delayed response (Figures 3.3, 3.4, 
3.60). In this respect, the induction o f bfl-1 mRNA by LMP-1 is similar to the effect o f 
this EBV protein on induction o f A20  (Laherty et al., 1992).
In situ hybridisation studies have detected bfl-1 transcript in the germinal centers o f  the 
lymphoid follicles in tonsil and lymph nodes (Jung-Ha et al., 1998). The germinal centers 
are the sites for B-cell proliferation and differentiation (Liu et al., 1991; 1992; Gregory,
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1995). After interaction with antigens presented by follicular dendritic cells, B cells with 
high-affinity antigen receptors are selected for survival and differentiate into plasma cells 
or memory cells, whereas B cells with low-affmity antigen receptors die by apoptosis. 
The mechanisms for B-cell survival during the selection process have not been fully 
elucidated yet. Candidate mechanisms include interactions between cell surface 
molecules CD40 and CD40 ligand, CD21 and CD23 and LFA-1 and ICAM1 among 
others (Tuscano et al., 1996; Bonnefoy et al., 1993; Koopman et al., 1993). Although 
many o f the candidate rescue signals can induce Bcl-2 expression in germinal center B 
cells, immunohistochemical studies have localised Bcl-2 protein predominantly in the 
mantle zone and not in the germinal center region where rescue occurs (Hockenberry et 
al., 1991; Akagi et al., 1994). Recent evidence suggests that Bc1-xl is involved in 
centrocyte survival as centroblasts in the germinal center treated with CD40 rapidly 
increase Bc1-xl levels and expression o f Bc1-xl rescues B cells from programmed cell 
death (Tuscano et al., 1996; Lee et al., 1999). Moreover, higher levels o f Bc1-xl protein 
are detected in the germinal center than in the mantle zone (Krajweski et al., 1994). The 
similarity in the pattern o f expression o f bcl-x and bfl-1 in germinal centers suggests that 
like Bcl-x, Bfl-1 may also be involved in B-cell survival and differentiation. Studies in 
mice have shown that positive selection o f immature B cells from the bone marrow into 
the long-lived memory B cell pool involves resistance to apoptosis and an upregulation o f 
A l  mRNA expression (Tomayako and Cancro, 1998).
A specific association o f EBV with memory B cells has been detected in peripheral blood 
o f healthy carriers in which the virus maintains a latent infection (Miyashita et al., 1997; 
Babcock et al., 1999). However, the infection o f naive cells resulting in blast formation 
does not occur in the periphery but in secondary lymphoid tissue and is based on the 
finding o f EBV-infected lymphoblasts in tonsil (Babcock et al., 1999; Joseph et al., 
2000). It is thought that these lymphoblasts represent newly infected naive B cells and 
behave like normal B blasts and remain in secondary lymphoid tissue where they follow 
the normal pathways o f B cell activation and differentiation to gain access to the long- 
lived memory compartment. Since survival signals form an important component o f this 
selection process, the ability o f EBV latent gene expression to upregulate expression o f
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anti-apoptotic genes including bfl-1 levels allows the EBV-infected B cell to 
bypass/mimic the normal selection process and facilitate its entry into the memory B cell 
pool
The functional significance o f Bfl-1 expression in BL cells was investigated by ectopic 
expression o f the protein in an EBV-negative cell line exhibiting type I latency, M utu I 
These cells also exhibit several phenotypic features o f germinal center B cells including 
expression o f CD 10 and CD77 and a low threshold o f resistance to apoptosis (Gregory et 
a l , 1991, Gregory, 1995) It was found that Bfl-1 expression not only protected against 
apoptotic death but also exerted a proliferative effect when the cells were grown under 
conditions o f growth factor-depnvation Indeed, Bfl-1 has been shown to possess both 
anti-apoptotic and proliferative activities (D ’Sa-Eipper and Chinnadurai, 1998) Bfl-1 and 
its mouse homolog A l can confer resistance to a variety o f apoptosis-inducers in 
different cells For instance, Bfl-1 expression has been shown to protect endothelial cells 
against TNF-a-induced cytotoxicity (Karsan et a l , 1996b) and suppress chemotherapy- 
induced apoptosis in a fibrosarcoma cell line (Wang et a l , 1999) Bfl-1 can also protect 
against p53-mediated apoptosis and exhibits potent oncogene-cooperation activity (D ’Sa 
Eipper et a l , 1996, D ’Sa Eipper and Chinnadurai, 1998) Mouse A l can prolong survival 
o f a myeloid cell line grown under conditions o f growth factor deprivation (Lin et a l ,
1996) Also, neutrophils o f A 1-deficient mice exhibit increased spontaneous apoptosis 
relative to those from wild-type mice (Hamasaki et a l , 1998) Also, mouse A l can 
protect normal B cells from antigen-receptor ligation induced apoptosis (Grumont et a l , 
1999)
The ability o f LMP-1 to upregulate the expression o f several anti-apoptotic proteins is 
significant from the point o f view that there isn’t always a complete overlap in the range 
o f apoptotic stimuli to which different anti-apoptotic proteins can respond For instance, 
although Bcl-2 and A20 can independently protect cells against a number o f apoptotic 
stimuli, Bcl-2 but not A20 is effective against glucocorticoid-induced apoptosis 
(reviewed m Opipan et a l , 1992) Thus, by upregulating the levels o f  several anti- 
apoptotic proteins, LMP-1 expression can serve as one route by which the EBV-infected
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host cell can protect itself against several apoptotic stimuli The extent to which Bfl-1 and 
other anti-apoptotic proteins such as Bcl-2 overlap with regard to the range o f apoptotic 
stimuli against which they protect has not been fully established
Although the low level o f DNA fragmentation observed in the M utu I transfectant pool 
(Figure 3 9) could be due to the possible heterogeneity in expression o f Bfl-1 between 
cells in the pool, it may also be that the functions o f other anti-apoptotic proteins are 
required to confer greater protection against this apoptotic stimulus In support o f the 
latter interpretation, two other LM P-1-inducible anti-apoptotic proteins, A20 and Bcl-2, 
have been shown to independently protect against serum-deprivation-induced apoptotic 
death o f BL cells (Laherty et a l , 1992, Henderson et a l , 1991) In this respect, it will be 
interesting in future experiments to examine extent o f the protective effect o f expression 
o f A20 and Bcl-2 individually and m combination with Bfl-1 in Mutu I cells
4.3 UPREGULATION OF B F L - 1  mRNA BY LMP-1 APPEARS TO BE A B CELL  
EFFECT
The absence o f an effect o f LMP-1 induction on bfl-1 mRNA expression in the T cell 
line, Jurkat-tTA-LMP-1, and in the epithelial cell line C33A makes it tempting to 
speculate that LMP-1-mediated upregulation o f bfl-1 mRNA expression is a B-cell 
specific effect Indeed LMP1 has been shown to exhibit cell-type specific effects in 
gene/protein expression For instance, LMP-1-mediated upregulation o f Bcl-2 appears to 
be a B-cell specific effect (Rowe et a l , 1994) T lymphocytes and epithelial cells do 
exhibit considerable levels o f Bcl-2 expression constitutively and so it is thought that 
LMP-1-mediated upregulation o f Bcl-2 may be more relevant in a cellular context that is 
Bcl-2-negative or that has low levels o f Bcl-2 expression as exists in several EBV- 
negative BL lines However, the Jurkat tTALM Pl cell line and C33A epithelial cell line 
do not express detectable levels o f  bfl-1 mRNA constitutively and hence an LMP-1 - 
mediated upregulation o f Bfl-1 would have been expected Furthermore, expression o f 
LMP-1 in both o f these cellular contexts has been shown by others to bring about 
changes in gene/protein expression including activation o f NF-kB and upregulation o f
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expression o f A20 (Rowe et al., 1994; Huen et al., 1995; Floettmann et al., 1998; Miller 
et al., 1997; Devergne et al., 1998). It is possible that since these cell lines were 
themselves derived as a result o f clonal selection, they may have defects in signaling 
components required for upregulation o f bfl-1 mRNA. Nevertheless, it would be 
important in future experiments to test the functionality o f LMP-1 expressed in these cell 
lines using parameters such as NF-kB activation and upregulation o f markers that have 
been shown to be modulated by LMP-1 in these cellular contexts.
4.4 UPREGULATION OF B F L - 1  mRNA STABILITY BY LMP1
The steady state level o f a particular mRNA species in a cell is dependent on both the 
rates o f transcription and decay. Thus, a coordinated balance between transcriptional and 
post-transcriptional events is required. Investigations into the mechanism of 
upregulation o f bfl-1 mRNA levels by LMP-1 revealed the importance o f a role for both 
mRNA stabilisation and increased promoter activity. Several lines o f evidence indicate 
that bfl-l and its mouse homolog A l  are early-response genes i.e the expression o f these 
genes is induced rapidly. For example, granulocyte-macrophage colony stimulating 
factor (GM-CSF) and lipopolysaccharide induce A l mRNA in mouse macrophages 
within 1 h o f stimulation (Lin et al., 1993). Lipopolysaccharide can induce bfl-1 mRNA 
in a microvascular endothelial cell line within 3 h o f stimulation (Hu et al., 1998). In 
DG75tTALM P-l cells, the onset o f upregulation o f bfl-1 mRNA was observed in parallel 
with the detection o f LMP-1 expression (figure 3.3), suggesting that upregulation o f bfl-l 
by LMP-1 is a rapid response.
The induction o f expression o f many early-response genes such as c-myc and c-fos is 
controlled at the level o f mRNA stability (Chen and Shyu, 1995). Regulation o f mRNA 
stability is so far poorly understood. However, it is known that m -ac ting  elements 
within the mRNA molecule can be recognised by regulatory proteins, and c«-elem ents 
have been demonstrated to modulate mRNA stability both positively and negatively. 
Numerous mechanisms exist to degrade mRNA effectively (reviewed in Ross, 1995; 
Beelman and Parker, 1995). For example, deadenylation triggers decapping, thus
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exposing the mRNA to 5’ to 3 ’ degradation Deadenylation can also lead to 3’ to 5’ 
degradation o f mRNA independently o f decapping Alternatively, decay may be initiated 
independently o f deadenylation by sequence-specific cleavage o f the mRNA The 5’ and 
3 ’ untranslated regions (UTR) o f eukaryotic mRNAs have often been experimentally 
demonstrated to contain sequence elements crucial for regulating the stability o f the 
transcript (reviewed in Pesole et a l , 1999) In particular, adenylate/undylate-nch 
elements (AREs) found in the 3 ’ UTR o f many labile mRNAs (e g those encoding GM- 
CSF, c-fos and IL-3) represent a common determinant o f RNA stability in mammalian 
cells (Chen and Shyu, 1995) AREs range in size from 50 to 100 nucleotides and contain 
multiple copies o f the pentanucleotide AUUUA An examination o f the nucleotide 
sequence o f the 3 ’ UTR o f the human bfl-1 gene failed to reveal the presence o f an 
AUUUA m otif and therefore excludes this element as a target for control o f mRNA 
stability
4.5 UPREGULATION OF B F L - 1  PROM OTER ACTIVITY BY LMP-1
As described in the results section o f this thesis, in addition to increasing bfl-1 mRNA 
stability, LMP-1 can also upregulate bfl-1 promoter activity and that too in an NF-kB- 
dependent manner The NF-KB-dependence o f induction o f bfl-l expression is in 
keeping with the findings o f several published works For example, whereas cell lines 
exhibiting normal NF-kB nuclear function respond to treatment with lipopolysaccharide, 
TN F-a or etoposide with upregulation o f bfl-1 mRNA, their NF-KB-defective 
counterparts (i e expressing a modified form o f the NF-kB inhibitor, IkBcc, that cannot 
be phosphorylated) are non-responsive (Hu et a l , 1998, Zong et a l , 1999, Wang et a l ,
1999) Also, ectopic expression o f the NF-kB subunit proteins c-rel and p65 but not p50 
can independently upregulate bfl-1 mRNA expression in HeLa cells (Zong et a l , 1999) 
In the case o f TN F-a, induction o f bfl-1 mRNA expression was demonstrated to be due 
to an increase in promoter activity (Zong et a l , 1999) Furthermore, the same study 
demonstrated that ectopic expression o f the NF-kB subunit protein c-rel also led to 
induction o f bfl-l promoter activity and this effect was shown to be mediated by binding
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to an NF-kB site at position -833 o f the promoter. Interestingly, expression o f mouse A l 
is induced in response to mitogen stimulation o f primary B cells in a c-rel-dependent 
fashion (Grumont et al., 1999).
The LM P-1-mediated effect on the induction o f activity o f —1374/+81 region o f the bfl-1 
gene could be demonstrated in both EBV-negative BL cell lines (DG75 and BL41) and 
Jurkat T cells. The importance o f NF-kB in this process was conclusively demonstrated 
based on several lines o f evidence. Firstly, coexpression o f dominant negative Ik B oc, 
inhibited LMP-1-mediated induction o f bfl-1 promoter activity which paralleled its 
inhibitory effect on LMP-1-mediated activation o f NF-kB. Secondly, inhibition o f 
TRAF2-mediated activation o f NF-kB by LMP-1 by coexpression o f a dominant- 
negative TRAF2 molecule or A20 expression also led to a parallel inhibition o f the effect 
o f LMP-1 on the activity o f the bfl-1 promoter. Thirdly, expression o f the NF-kB subunit 
protein p65 could also moderately transactivate the bfl-1 promoter. Fourthly, treatment 
with PMA, a well-known activator o f NF-kB in many cell types, also stimulated bfl-1 
promoter activity.
In DG75 cells, titration o f the amount o f LMP-1 expression plasmid, pEFCXLMP-1, 
cotransfected with a fixed amount o f the bfl-1 promoter-luciferase construct, p-1374/+81 
B fl-lluc, revealed a dose-responsive effect on luciferase synthesis when up to 2.5 |^g o f 
the expression plasmid was used. Usage o f a higher amount (5.0 ^g) o f pEFCXLMP-1 in 
the cotransfection studies did not induce a further increase in luciferase activity even 
though a higher amount o f LMP-1 was expressed. A similar effect was also observed in 
titration experiments o f pEFCXLMP-1 and an NF-KB-luciferase reporter. Such a 
saturation effect in promoter activity when high amounts o f LMP-1-expression plasmid 
are used in transfection studies has been observed in the case o f activation o f the ICAM-1 
promoter by LMP-1 (Mehl et al., 2001) and may be a common phenomenon with many 
effector proteins and promoters. Nevertheless, the similar trend in responsiveness o f the 
NF-kB-1uc and —1374/+81 Bfl-1 -luc reporter constructs to expression o f increasing 
amounts o f  LMP-1 protein in DG75 cells lends some support to the importance o f NF-kB 
in activation o f the bfl-1 promoter.
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As mentioned in the introduction section o f this thesis, mutational analysis has identified 
two functional domains in the cytoplasmic carboxy terminus o f LMP-1 CTAR1/TES1 
(residues 187-231) and CTAR2/TES2 (residues 351-386) (Figure 3 18) A third 
activation domain, CTAR3, mapping to a region between CTAR1 and CTAR3 (residues 
275-307) has been shown to mediate activation o f Jak3 (Gires el a l , 1999) Several 
studies have indicated that CTAR1 and CTAR2 can independently mediate activation o f 
NF-kB by LMP-1, however, the extent o f contribution o f each o f these domains to the 
total activation o f NF-kB varies between cell lines (Floettmann and Rowe, 1997, Huen et 
a l , 1995, Mitchell and Sugden, 1995) However, in general, CTAR2 has been found to 
be a stronger activator o f NF-kB than CTAR1 The NF-KB-dependent upregulation o f 
A20 expression by LMP1 maps to both the CTAR1 and CTAR2 domains and the 
contribution o f each domain in this effect correlates with the relative extents o f activation 
o f NF-kB by the two domains (Miller et a l , 1995, 1997) Usage o f mutants (point 
mutants) o f LMP-1 shown to be defective in signaling from either CTAR1 (LMP-AAA) 
or CTAR2 (LMP-G) or both (LMP-AAAG) revealed that, in DG75 cells CTAR2 makes a 
greater contribution to activation o f the bfl-1 promoter than CTAR1 and that the mutant 
defective m signalling from both o f these domains is unable to transactivate the promoter 
Also, expression o f these mutants resulted in the expected responses in NF-kB activation 
in that CTAR2 is the predominant contributor in this effect Based on the findings o f 
Gires et al (1999), the result obtained with the double mutant would at first exclude the 
involvement o f CTAR3 in LMP-1 mediated activation o f bfl-1 However, the results o f 
Gires et a l , have recently been cast in a new light with the demonstration o f the 
dominant negative action o f LMP-AAAG In coexpression studies, LMP-AAAG which 
contains an intact CTAR3 domain, can not only inhibit activation o f NF-kB but also the 
activation o f JAK3 by wild-type LMP-1 (Brennan et a l , 2001) These observations have 
been interpreted to mean that there must be some cooperation between CTAR1 or 
CTAR2 and CTAR3, for stimulating the activity o f JAK3 Thus, even though LMP 
AAAG is unable to activate the bfl-1 promoter, this result does not necessarily exclude 
the potential involvement o f JAK3 function in activation o f bfl-1 by LMP-1
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In Jurkat cells, expression o f LMP-1 resulted in a high level o f NF-kB activation as 
revealed by luciferase assays and the extent o f this effect was much higher than that in 
DG75 cells (Figures 3 20, 3 26 and 3 28) The difference in the extents o f LMP-1 - 
mediated NF-kB activation can be explained by the differences in the basal level o f NF- 
kB activity between the cell lines, in that a lower basal level o f NF-kB activation would 
be expected to be elevated by a greater magnitude in response to a stimulus (Floettmann 
et a l , 1998) Thus, Jurkat cells which have a very low basal level o f NF-kB activation 
compared to many EBV-negative BL lines, may permit a greater extent o f activation o f 
this transcription factor in response to an appropriate stimulus (Floettmann et a l , 1998) 
DG75 (and BL41) exhibit higher constitutive levels o f NF-kB activation which can only 
be further increased to a limited extent (Huen et a l , 1995, Rowe et a l , 1994) Despite 
the requirement for NF-kB in LMP-1-mediated activation o f the -1374/+81 region o f bfl- 
1 in both Jurkat and DG75 cells, the greater extent o f activation o f NF-kB by LMP-1 m 
Jurkat cells relative to DG75 cells did not result in a greater extent o f activation o f this 
promoter region The basis o f this difference became evident when the effect o f LMP1 
expression on luciferase synthesis from luciferase reporter constructs containing 
progressive 5’ deletions o f the bfl-1 promoter in cotransfection studies was performed 
This analysis revealed that whereas elements within the -129/+81 region o f the bfl-1 gene 
were responsible for majority o f the LMP-1-induced transactivation o f the ‘full-length’ (- 
1374/+81) promoter region, elements located within the -1240/-367 region were more 
important in mediating this effect o f LMP-1 m Jurkat T cells (Figure 3 36) It therefore 
seems likely that the differential extents o f activation is related to the targeting o f 
different transcription factor binding sites by LMP1 in the two cell types Furthermore, 
the greater importance o f elements within the proximal region o f the promoter in 
mediating transactivation o f bfl-1 by LMP-1 was not specific to DG75 cells in that this 
phenomenon was also observed when the experiment was performed in the context o f 
another EBV negative BL line, BL41 It is thus tempting to generalise that at least in the 
context o f BL lines, LMP-1-mediated activation o f the bfl-1 promoter involves elements 
residing in the proximal region o f the promoter
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Consistent w ith previous reports that the extent o f CTAR1 and CTAR2-mediated 
signalling in LMP-1 mutants can vary with the cellular background (Huen et a l , 1995, 
Floettmann el a l , 1998), it was found that Jurkat is defective for CTAR1-mediated 
activation o f NF-kB and the bfl-1 promoter based on the studies with the LMP-1 mutant 
LMP G (Figure 3 20) Expression o f LMP G m Jurkat T cells resulted in retention o f 
approximately 5% o f bfl-1 promoter activity and NF-kB activation by wild-type LMP1 
and in DG75 cells this value was approximately 25% Although this result on its own 
would predict a sole role for CTAR2 in mediating the effects o f LMP-1 on activation o f 
NF-kB and the bfl-1 promoter in Jurkat cells, this did not appear to totally be the case 
since experiments with the LMP AAA mutant revealed that the function o f CTAR2 with 
respect to these parameters was still partially impaired (retention o f approximately 40% 
and 30% o f wild-type LMP1 transactivation o f the bfl-1 promoter and NF-kB activation), 
albeit to a lesser extent than CTAR1 in these cells These results can be explained by the 
recent findings that functional activation o f LMP-1 requires oligomerisation in the 
absence o f ligand binding and also requires cooperation between CTAR1 and CTAR2 
within a hetrooligom enc LMP-1 complex (Floettmann et a l , 1998, Floettmann and 
Rowe, 1997, Gires et a l , 1997) Furthermore, this cooperation between CTAR1 and 
CTAR2 results in a signalling event that can be qualitatively distinct from the signals 
generated by CTAR1 and CTAR2 independently (Floettmann et a l , 1998) The finding 
that the activation o f NF-kB and induction o f bfl-1 promoter activity by LMP-1 in Jurkat 
cells was not necessarily the additive effect o f independent signals from CTAR1 and 
CTAR2 is in keeping with the necessity for cooperation between these two domains for a 
fully functional signal to be generated by LMP-1
Expression o f the LMP-1 mutant, LMP AAAG, that is defective in signalling from both 
CTAR1 and 2 was nonfunctional with respect to activation o f not only NF-kB but also 
the bfl-1 promoter m both DG75 and Jurkat cells These findings suggest the crucial 
involvement o f signalling from both o f these domains in these LMP 1-mediated effects In 
fact, the LMP AAAG mutant has recently been demonstrated to function as a dominant 
negative mutant o f LMP1 and was shown to efficiently inhibit wild-type LMP-1 
activation o f NF-kB, JAK3 and Jun transcriptional activity (Brennan et a l , 2001) In
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keeping with these findings it was possible to demonstrate in cotransfection experiments 
that LMP AAAG can efficiently inhibit wild-type LMP-1-mediated activation o f not only 
NF-kB but also o f the bfl-1 promoter in DG75 cells (Figure 3 21) This mutant functions 
as a dominant negative by interacting with wild-type LMP-1 and interfering with its 
ability to bind TRAF2 (Brennan et a l , 2001) The requirement o f cooperation between 
CTAR1 and CTAR2 present on different LMP1 molecules withm the same hetero- 
oligomeric complex forms the basis o f the action o f LMP AAAG The high efficiency 
with which LMP AAAG was found to inhibit LMP 1-mediated signaling might be related 
to the possibility that only one LMP AAAG molecule withm the oligomeric complex (at 
least trimeric) may be required to alter signaling from the complex (Floettmann and 
Rowe, 1997, Floettmann et a l , 1998)
The existence o f a cooperative function between CTAR1 and CTAR2 o f LMP 1 cautions 
against over-interpretation o f data obtained with mutants non-functional for CTAR1 or 
CTAR2, but particularly with mutants containing large deletions that may adversely 
affect physical cooperation between CTAR1 and CTAR2 In agreement with this, there 
is evidence that differences m signalling from individual CTAR1/2 domains and full 
length LMP1 might result from changes in the components o f the TRAF complexes 
bound to LMP1 Thus, it has been found that aminoacid residues 187-386 o f LMP 1 bind 
less TRAF1 and 2 than deletion mutants encoding aminoacids 187-231 only (Devergne et 
a l , 1996, Sandberg et a l , 1997)
Much insight into the early events in signalling from LMP1 has been obtained over the 
last 6 years with the discovery that LMP-1 engages signalling proteins for TNFR family 
including TRAFs and TRADD (Mosialos et a l , 1995, Devergne et a l , 1996, Brodeur et 
a l , 1997, Sandberg et a l , 1997, Izumi et a l , 1997, Eliopoulos et a l , 1999) TRAF2 has 
been shown to play a key role in mediating activation o f NF-kB by LMP-1 Whereas 
TRAF2 has been shown to bind directly to CTAR1, it requires TRADD as a bridging 
protein to bind to CTAR2 and dominant negative TRAF2 mutants have been shown to 
inhibit NF-kB activation from both CTAR1 and CTAR2 (Devergne et a l , 1996, Kaye et 
a l , 1996, Izumi and Kieff, 1997; Sylla et a l , 1998) In this thesis, the LMP-1 mediated
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transactivation o f the bfl-1 promoter in both DG75 and Jurkat cells was shown to involve 
a TRAF2-dependent mechanism and was demonstrated by usage o f a TRAF2 dominant 
negative mutant, TRAF2A(6-86) (Figures 3 22 and 3 24), and the TRAF2-binding zinc- 
finger protein, A20 (Figures 3 23 and 3 25), in independent reporter assays However, o f 
the two, A20 appeared to be more efficient at inhibiting both the activation o f the bfl-1 
promoter and NF-kB by LMP-1 Similar findings with these TRAF2-inhibitors have been 
reported in literature by others working on LMP-1 and TN F-a (Kaye et a l , 1996, Hsu et 
a l , 1996, Reinhard et a l , 1997, Ehopoulos et a l , 1997, 1999) In the case o f LMP-1, this 
TRAF2 mutant has been shown by others to only partially block activation o f NF-kB by 
CTAR2 (40%) whilst almost completely blocking that mediated by CTAR1 (>75%) 
(Kaye et a l , 1996) The data on the effect o f expression o f the TRAF2A (6-86) mutant 
on LMP-1 mediated activation o f bfl-1, may be interpreted to mean that although TRAF2 
is a component o f the signaling pathway involved in the activation o f bfl-1 by LMP-1, 
additional contributions from other CTARl/2-associated proteins may also be involved 
such as other TRAFs (Devergne et a l , 1996) In this regard, it is also interesting to note 
that the receptor interacting protein (RIP) has also been shown to interact directly with 
CTAR2 but does not mediate activation o f NF-kB and is therefore not a likely candidate 
(Izumi et a l , 1999) Alternatively, it is possible that TRAF2 is bound in a stable complex 
with other proteins and that large amounts or prolonged incubations following 
transfection are required for TRAF2A(6-86) to displace endogenous wild-type TRAF2 
Indeed a number o f TRAF2-interacting proteins have been identified, such as TRAF1, 
TANK/I-TRAF and cellular inhibitors o f apoptosis (c-IAPs), which may influence 
TRAF2 heterocomplex stability and signaling (reviewed m Ehopoulos et a l , 1999) 
Consistent with this possibility is the observation that while CTAR1 can directly bind 
TRAF2, CTAR2 binds TRAF2 indirectly via TRADD, and hence the differences in the 
stoichiometry o f binding o f TRAF2 to these two domains o f LMP 1 may account for the 
inefficiency o f TRAF2A(6-86) to inhibit TRAF2-mediated signaling from the 
predominant signaling domain, CTAR2, relative to CTAR1 The A20 protein, a zinc 
finger protein, that is itself inducible by LMP-1 in an NF-KB-dependent manner, can 
inhibit both LMP 1-mduccd NF-kB and JNK activation thereby acting in a negative
feedback loop to control LMP-1 signalling Such control over the extent o f LMP-1
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signaling may be important m that overexpression o f LMP 1 can have toxic effects on the 
cell (Hammerschmidt et a l , 1989, Martin et a l , 1993, Fries et a l , 1999, Ehopoulos et 
a l , 1999) Although this activity o f A20 was initially presumed to depend on its
interaction with only TRAF2 (Ehopoulos et a l , 1999), more detailed studies suggest that 
A20 can function as a promiscuous inhibitor o f the activities o f  other TRAFs and 
TRADD (Fries et a l , 1999) In this context the data presented m this thesis 
demonstrating that A20 expression suppresses both LMP-1-induced NF-kB and bfl-1 
promoter activity while dominant-negative TRAF2 has only a partial effect may indicate 
an additional role for other LMP-1-interacting signaling molecules (such as other TRAFs 
or TRADD) in mediating activation o f the bfl-1 promoter
LMP-1 has also been demonstrated to activate the p38 mitogen-activated protein kinase 
(MAPK) pathway and both CTAR1 and CTAR2 have been demonstrated to mediate this 
effect in a TRAF-2-dependent mechanism with CTAR2 playing the predominant role 
(Ehopoulos et a l , 1999b) Activation o f p38MAPK has been shown to be involved in the 
coregulation o f IL6 and IL8 production by LMP1 (Ehopoulos et a l , 1999b) The 
downstream targets o f activated p38 MAPK include a number o f transcription factors 
including ATF2 (reviewed in Nebreda and Porras, 2000) ATF2 can homodimerise but 
can also form heterodimers with Jun and bind to API motifs in the promoters o f several 
genes Indeed transactivation o f the IL8 promoter by LMP1 was shown to require p38 
activation and LMP-1 induced binding o f ATF2-Jun dimers to an API m otif in the 
promoter was also demonstrated (Ehopoulos et a l , 2000) Given these findings and also 
the findings in this thesis that the pattern o f the extent o f contribution o f CTAR1 and 
CTAR2 to activation o f the bfl-1 promoter is similar to that reported for p38 activation, it 
seemed reasonable to hypothesise that the activation o f p38 may also contribute to the 
activation o f the bfl-1 promoter by LMP-1 This is further strengthened by the existence 
o f potential AP-1-binding sites in the bfl-1 promoter region However, in a preliminary 
experiment, a well-established and specific inhibitor o f p38 activation, SB203580, did not 
affect transactivation o f the bfl-1 promoter by LMP-1 in DG75 cells (result not shown) 
The ability o f LMP1 to activate p38 and the functionality o f the inhibitor were not 
established in this experiment, therefore questioning the validity o f this result The former
241
can be easily tested by performing in vitro kinase assays which would involve testing the 
ability o f LMP-1 to phosphorylate a downstream substrate '(such as ATF2) o f p38 
M APK Furthermore, it should be possible to also monitor the functionality o f  the 
inhibitor by measuring its effect on LMP-1-mediated upregulation o f IL6 and IL8 
production by ELISA Several o f the other members o f the TNFR family including 
CD40, TNFR and IL-1 can also activate p38 and activated p38 lsoforms have been shown 
to play essential roles in not only development, differentiation, proliferation but also cell 
survival (reviewed in Nebreda and Porras, 2000) An important role for p38 kinases in 
post-transcriptional regulation o f gene expression has been demonstrated (Lee and 
Young, 1999, Roulston et a l , 1998) Hence, a role for activation o f p38 m mediating 
induction o f bfl-1 expression by LMP1 at the post-transcriptional level cannot be 
excluded
The importance o f NF-kB activation in mediating the transactivation o f the bfl-1 
promoter by LMP-1 was conclusively demonstrated by using a dominant negative IkBcx 
mutant that contains mutations in two critical residues (serine 32 and serine 36) that are 
required for phosphorylation and subsequent proteolysis o f the molecule (Liljeholm et 
a l , 1998) Phosphorylation o f IkBcc on these residues is required for release o f NF-kB 
dimers from NF-kB-IkBcc complexes, thus allowing the dimers to translocate to the 
nucleus and activate transcription Binding o f NF-kB dimers to the non-phosphorylatable 
IkBcc mutant thus prevents their activation The IkBoc dominant negative mutant 
therefore targets a more downstream event in an NF-kB signalling pathway and is hence 
a useful tool in examining NF-KB-dependence o f gene expression Indeed this mutant 
inhibited both LMP-1-induced activation o f NFkB and the b fl-l promoter in DG75, BL41 
and Jurkat T cells (Figures 3 26, 3 27 and 3 28) However, expression o f higher amounts 
o f this IkBoc mutant were required to achieve equivalent extents o f inhibition o f these 
LMP-1 mediated effects m  DG75 cells compared to the other two cell lines This may be 
related to the higher basal levels o f NF-kB activation known to be present in the DG75 
cell line (Huen et a l , 1995, Rowe et a l , 1994)
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The NF-KB-responsiveness o f the bfl-1 promoter was also confirmed by demonstrating 
that PMA treatment or ectopic expression o f the NF-kB subunit protein p65 could 
transactivate the bfl-1 promoter PMA is a well known chemical activator o f NF-kB 
(reviewed in W ilkinson and H allam , 1994) and in both DG75 and Jurkat cells 
stimulation o f the bfl-1 promoter by PMA was inhibited by expression o f the dominant 
negative mutant IkBchAN, suggesting that in both o f these cell types PMA-mediated 
activation o f the bfl-l promoter is NF-KB-dependent (Figures 3 31 and 3 41) PMA has 
been shown to upregulate bfl-l mRNA expression in several leukemic cell lines (Moreb 
and Schweder, 1997) Activation o f Jurkat T cells by treatment with PMA and 
lonomycin has been shown by others to result in an upregulation o f steady-state bfl-l 
mRNA levels (Zong et a l , 1999) and results presented in this thesis demonstrate that 
transactivation o f the promoter via an NF-KB-dependent mechanism contributes to this 
effect (Figure 3 41) While lonomycin, a calcium lonophore that stimulates the calcium- 
dependent component o f lymphocyte activation, caused only minimal activation o f the 
bfl-1 promoter on its own, it exerted a synergistic effect with PMA on bfl-1 
transactivation Such a synergistic effect o f PMA and lonomycin on promoter activation 
has been demonstrated in the case o f the NF-KB-inducible A20 promoter (Laherty et a l ,
1993) However, NF-kB activation may not necessarily be the only transcription factor 
whose activation by PMA leads to transactivation o f b fl-l since this chemical agent can 
also activate several other transcription factors including AP-1 and AP-1 responsive 
elements have been identified in the bfl-1 promoter W ith respect to the possibility that 
NF-KB-independent mechanisms may also be involved in PMA (or PMA/ionomycin)- 
mediated activation o f the bfl-l promoter it is relevant to note that although LMP-1 
appears to be a stronger inducer o f NF-kB activity than PMA (or PMA/ionomycin) in 
Jurkat cells, PMA (and PMA/ionomycin) exerted a much greater effect on b fl-l promoter 
transactivation than LMP-1 However, this result may also be explained by the possible 
difference in the subunit composition o f NF-kB activated by the two different 
effectors/stimuli
One o f the biochemical consequences o f PMA treatment is activation o f the protein
kinase C (PKC) pathway PKC is a widespread family o f kmases responsible for many
243
diverse and critical cellular functions including aspects o f cellular growth and 
metabolism (reviewed m Wilkinson and Hallam, 1994) One o f the substrates o f 
activated PKC is IkBoc and phosphorylation o f IkBoc by PKC thus releases N FkB which 
can then translocate to the nucleus and activate transcription Many o f the PKC isoforms 
can be activated by a calcium-dependent mechanism (reviewed in W ilkinson and Hallam,
1994) and since ectopic expression o f LMP-1 in BL cells coincides with increased 
intracellular calcium levels (Wang et a l , 1988), it is tempting to speculate that PKC may 
be a downstream target o f LMP1 In this respect it is interesting to note that PMA has 
been shown to upregulate bcl-2 expression in EBV-negative BL lines (Genestier et a l ,
1995), so an mtact PKC-pathway is potentially available in BL cells However, to date 
there is no evidence that LMP-1 activates PKC
More direct confirmation o f the NF-KB-responsiveness o f the bfl-1 promoter was
obtained with the demonstration that ectopic expression o f p65 transactivated the bfl-l
promoter in DG75 cells (Figures 3 33, 3 39) However, the extent o f transactivation o f
the bfl-l promoter or even the control NF-KB-reporter construct (3 x enhKB luc) by p65
was much lower than that obtained when LMP-1 was used as the effector It is possible
that much higher levels o f p65 expression are required to obtain equivalent levels o f
transactivation as LM P-1 Studies have also indicated that coexpression o f two different
NF-kB subunit proteins (such as p65 and p50) can have a greater than additive effect on
transactivation o f NF-KB-responsive elements than expression o f the individual proteins
(Perkins et a l , 1992, Laherty et a l , 1993) so it is possible that cotransfection o f p65 and
a hetrodimeric partner such as p50 may activate the bfl-1 promoter and the control NF-
KB-reporter construct to a greater extent than that achieved with expression o f p65 alone
and this possibility needs to be tested The control NF-kB-1uc construct contains three
copies o f the KB-responsive element in the Ig k light chain' enhancer region This
element has been shown to have a greater affinity for p65/p50 heterodimers than p65
homodimers and since the specificity and extent o f NF-KB-mediated transcriptional
activation is determined by the combinatorial associations o f the subunits and the
sequence o f the kB site, it would be expected that p65/p50 dimers would result in a
higher level o f transactivation o f this NF-kB-responsive element than p65 homodimers
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(Perkins et a l , 1992) p65/p50 but not p65 homodimers appear to be one o f the dominant 
N F -kB  proteins activated by LMP-1 in EBV-negative BL lines (Herrero et a l , 1995) and 
this may also account for the observed differences in extents o f activation o f the control 
N F -kB-1uc reporter construct between LMP-1 and p65 (assuming that transfection o f p65 
results in a predominance o f p65 homodimers in the cell) It would be interesting in 
future experiments to analyse the effect o f expression o f other N F -kB subunit proteins 
and dual combinations thereof on activation o f the bfl-1 promoter
The demonstration o f the importance o f NF-kB in transactivation o f the bfl-1 promoter 
prompted a search for potential NF-kB binding sites m the promoter region o f bfl-1 
Using the TESS program, eight potential NF-KB-hke sites were identified One o f these 
sites, which has the sequence GGGGATTTACC is located at bp -833  to -823 o f the bfl-1 
promoter region (Figure 3 29) (Zong et a l , 1999) However, inactivation o f this site by 
mutation (Zong et a l , 1999) did not affect activation o f the promoter m either DG75 or 
Jurkat cells (Figure 3 30) This site has been shown to be mediate c-rel-mediated 
transactivation o f the b fl-l promoter in the HeLa epithelial cell context and although 
LMP-1 activates different subsets o f NF-kB proteins in a cell-type dependent manner 
(Paine et a l , 1995, Herrero et a l , 1995, Chien and Hammarskjöld, 2000), c-rel has been 
shown by others to be activated by LMP-1 in DG75 and Jurkat T cells (Liljeholm et a l , 
1998, Chien and Hammarskjöld, 2000) This would argue against the lack o f 
involvement o f the NF-kB site at -833 o f the bfl-1 promoter in LMP-1-mediated 
transactivation being a result o f the lack o f LMP-1-induced activation o f c-rel in the 
lymphocyte cellular context Furthermore, the NF-kB site at position -833  was also non- 
responsive in PMA-or p65-mediated activation o f the promoter in DG75 cells (Figures 
3 32 and 3 33), thereby indicating that the lack o f involvement o f this site in 
transactivation o f the bfl-l promoter is not restricted to LMP-1 These findings would 
suggest that the lack o f involvement o f the NF-kB site at -833 in transactivation o f bfl-1 
may be a lymphocyte-specific effect irrespective o f the stimulus used for transactivation 
It is possible that access to this site may be obstructed by lymphocyte-specific nuclear 
proteins binding in the vicinity o f this site In this respect it would be interesting to
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examine if LMP-1 can activate bfl-1 promoter activity in an epithelial cell context such as 
HeLa and test the responsiveness o f this N F -kB site.
Deletion analysis revealed that LMP-1 exerts differential effects on the regions o f the bfl- 
1 promoter targeted for mediating transactivation in BL lines and Jurkat cells. Thus, 
whereas the -129/+81 region o f the bfl-l gene accounted for the majority (64-69%) o f the 
transactivation o f the full-length promoter by LMP-1 in DG75 and BL41 cells, in Jurkat 
cells this region accounted for only 23% o f the LMP-1-induced transactivation o f the 
‘full-length’ promoter and elements within the -1240/-367 region appeared to targeted by 
LMP-1 to a greater extent in this cell line (Figure 3.36). However, even though the 
proximal region on its own mediates a minor fraction o f the transactivation o f the bfl-1 
promoter by LMP-1 in Jurkat cells, LMP-1-activated nuclear factors binding to elements 
within the -1240/-367 region would require interaction with proteins (at least with the 
basal transcription apparatus) binding to the proximal region to effectively and optimally 
transactivate the promoter. In DG75 cells, transactivation o f the -129/+81 region o f bfl-1 
was conclusively demonstrated to be NF-KB-dependent and involved a TRAF2- 
dependent mechanism. Although the mechanism underlying the low level o f  activation o f 
the -129/+81 region o f bfl-l by LMP-1 in Jurkat cells was not formally investigated, it 
was possible to speculate on a role for NF-kB based on the results obtained in 
experiments with PMA and PMA/ionomycin. PMA or PMA/ionomycin treatment o f 
Jurkat cells could activate the -129/+81 region o f bfl-l albeit to a lesser extent than the 
‘full-length’ promoter region but more effectively than when LMP-1 was used as the 
stimulus. Furthermore, PMA or PMA/ionomycin-mediated activation o f the -129/+81 
region o f b fl-l could be demonstrated to be NF-KB-dependent. Therefore, this region is 
potentially NF-KB-responsive in Jurkat cells. It is possible then that the differences in 
the extents o f activation o f the -129/+81 region o f bfl-l by PMA (or PMA/ionomycin) 
and LMP-1 may be due to differences in the subunit composition o f the NF-kB protein 
involved if LMP-1-mediated activation o f this region is NF-KB-dependent and the target 
o f NF-kB is the same as that o f PMA (or PMA/ionomycin) in Jurkat cells. As pointed out 
earlier, the subunit composition o f the NF-kB protein can greatly influence not only its 
ability to bind to a particular site but also the extent o f transactivation (Perkins et al.,
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1992) However, the possibility that PMA or PMA/ionomycin may be having an effect on 
a cryptic site m the reporter plasmid cannot be excluded owing to the exceptionally high 
level o f activation o f the bfl-1 promoter-luciferase construct in Jurkat T cells and this 
possibility needs to be investigated by analysing the effect o f PMA or PMA/ionomycin 
on the basic reporter construct containing a minimal promoter region (that binds the basic 
transcriptional apparatus)
4.6 ELECTROPHORETIC MOBILITY SHIFT ANALYSIS (EMSA)
The DG75tTALM P-l tet-off system was used to further investigate the role o f NF-kB in 
the transactivation o f the -129/+81 region o f bfl-1 by EMSA primarily because this 
system allows testing the effects o f LMP-1 on gene expression in a more controlled 
fashion (1  e excluding the possibility o f any effects resulting from clonal variation) and 
induction o f LMP-1 in this cell system could be shown to result in an upregulation o f bfl- 
1 mRNA levels (Figure 3 3) In agreement with the high constitutive levels o f NF-kB 
activation known to be present m the DG75 cellular context (Rowe et a l , 1994, Huen et 
a l , 1995), EMSA analysis with a 22 bp oligonucleotide containing the kB enhancer 
element from lmmunoglobulin-K-light chain gene, detected the formation o f two specific 
p65-containmg complexes with nuclear proteins from the cells in the absence o f LMP-1 
induction Induction o f LMP-1 led to an increase m the extent o f formation o f these two 
complexes and did not lead to the formation o f any new complex (Figure 3 45) 
Supershift studies also revealed that p65 was not dimerised to either p50 or c-rel m the 
two specific complexes (Figure 3 46) This results was surprising since LMP1 has been 
shown to induce the formation o f p65/p50 and p50/p50 as well as p65/p52 NF-kB 
complexes in an EBV-negative BL cell context (Herrero et a l , 1995) Also reporter 
assays have demonstrated that LMP-1 can transactivate both p65/p50-responsive and c- 
rel-responsive elements in DG75 cells (Liljeholm et a l , 1998) At least in the case o f 
p50, the possibility that the antibody to p50 is unable to bind its target and therefore 
function in supershifting was ruled out since this antibody could supershift a p50 
homodimer complex formed between the same oligonucleotide and nuclear proteins from 
an LCL (IARC290B) (result not shown). In the case o f c-rel, it is possible that the
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antibody does not function in supershifitmg or that c-rel is truly not activated in this clonal 
cell line o f DG75 even in the absence o f LMP-1 expression Also, it is not known at the 
time o f writing this thesis if  the p50 and c-rel antibodies used exhibit preferences for 
supershifting NF-kB complexes with specific subunit composition Candidate partners 
for p65 in the two NF-kB complexes formed with the consensus kB element in EMSA 
include p65 itself (homodimers) and p52 The possibility that p52 may be contained in 
one o f the complexes can be tested by performing supershift analysis with an appropriate 
antibody
A transcription factor binding site search o f the -129/+81 region o f bfl-1 revealed the 
presence o f a NF-KB-hke site at position -5 2  to -43  (5’-AGAAATTCCA-3’on the sense 
strand, or 5’-TGGAATTTCT-3’ on the antisense strand) (Figure 3 44) NF-KB-hke sites 
in both forward and reverse orientations that diverge from consensus NF-kB binding sites 
at one or more positions have been identified in promoters o f several genes including 
apoptosis-related genes such as bcl-x, c-IAP-1, C-IAP2 and mouse A1 as well as cytokine 
genes such as IL-8 and functionality o f these sites in promoter activation has been 
demonstrated in a few cases (Chen et a l , 1999, Hong et a l , 2000, Okamoto et a l , 1994) 
Classic NF-kB (p65/p50) binds the sequence 5’-GGGRNNYYCC-3’ whereas the 
RelA/c-Rel dimer binds to a sequence 5’-HGGARNYYCC-3’ [H indicates A, C or T, R 
is purine (A or G), Y is pyrimidine (T or C)] (Baldwin, 1996) The KB-site at position -  
52 o f bfl-1 m forward orientation diverges from the p65/p50 and p65/c-rel consensus 
binding sites at 3 and 2 nucleotide positions respectively, but in reverse orientation differs 
from the consensus p65/p50 binding site at 2 positions and from the p65/c-rel binding site 
at only one position (Table 4 1)
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Table 4 1 Degree of homology o f the NF-icB-like site at position -5 2  (-52/-43) of b fl-1  in 
forward and reverse orientations to the p65/p50 and p65/c-rel consensus binding sites
Consensus p65/p50 site 
GGGRNNYYCC
Consensus p65/c-rel site
HGGARNYYCC
-S2/-43 bfl-1 icB-like site
FORWARD
REVERSE
AGAAATTCCA (3) 
TGGAATTTCT (2)
AGAAATTCCA (2) 
T G G A A TTTC T(l)
k =  purine (A/G;, N= any nucleotide, Y = pyrimidine (1 iC), H= A, C or T 
The nucleotide positions that diverge from the consensus sequence are underlined 
The num ber o f  ‘divergent positions’ m the b fl-1  KB-like site are given m brackets 
Forward and reverse refer to the orientations o f the sequence as found on the sense and antisense 
strand respectively o f  the promoter region
Three potential KB-hke sites have been identified in A l, the mouse homolog o f bfl-1, and 
one o f these, AGAAATTCTA differs from the KB-like site at position -52  
(forward/sense orientation) o f bfl-1 at one nucleotide position (Chen e t  a l , 1999) Also, 
the promoter o f the human c-IAP-2 gene contains a homologous potential KB-like site 
and has the sequence AGAAATTTCA (Chen e t  a l , 1999) (Table 4 2) However it is not 
known if  both o f these NF-KB-like motifs are functional In the case o f  mouse A l, a 
functional c-rel-responsive element has been identified and has the sequence 
AGGGATCCC (Grumont e t  a l , 1999) The AGAAATTCCA KB-like site o f b fl-l bears 
100% homology to a CD28-responsive kB  site in the IL-2 promoter (Civil e t  a l , 1996, 
1999, Verweij e t  a l , 1991) CD28-mediated regulation o f the IL2 KB-like site was 
shown to involve c-Rel and p65 (Ghosh e t  a l , 1993)
Table 4 2 The KB-like site at position -5 2  (-52 to -4 3 )  o f bfl-1 differs from kB- 
like sites in the promoters o f mouse A l and human c-IAP-2 at one 
nucleotide position
Bfl-1 AGAAATTCCA
A l AGAAATTCTA
c-IAP-2 AGAAATTTCA
Divergent nucleotide positions are underlined
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Induction o f LMP-1 m the DG75tTALM P-l cells resulted in the formation o f a novel 
complex when nuclear extracts were incubated with a 14 bp oligonucleotide containing 
the NF-KB-like site o f the -129/+81 region o f bfl-1 and the intensity o f this complex was 
diminished when extracts were pretreated with a p65 antibody (Figure 3 47) However, 
the unlabelled 14 bp oligonucleotide itself or the consensus NF-kB oligonucleotide did 
not compete out the formation o f this complex with the labelled 14 bp oligonucleotide in 
EMSA (Figure 3 48), suggesting that this complex was non-specific These findings 
suggest the need to exert caution when interpreting results obtained with EMSA and the 
need to base the interpretation on a combination o f supershift and competition studies as 
far as possible The size o f the oligonucleotide used as a probe in EMSA, particularly in 
relation to the amount o f sequence flanking the icB-site that is included in the 
oligonucleotide, may have had some bearing on the failure to detect formation o f a 
specific NF-KB-containmg complex irrespective o f LMP-1-expression While it is useful 
to limit the size o f the oligonucleotide to about the size o f the binding site under study (to 
exclude non specific binding o f other proteins), it has now become clear, particularly in 
the case o f non-consensus/icB-like sites, that sequences in the 5’ and/or 3 ’ flanking 
regions may play a role in stabilising Rel protein binding and hence participate in 
directing transactivation as has been demonstrated in the case o f a variant KB-site in the 
ICAM-1 promoter (Paxton et a l , 1997) Hence, it is possible that if  NF-KB-binding at the 
KB-like site at position -5 2  o f bfl-1 does occur in vivo, this may not have been detected in 
vitro due to lack o f sufficient amount o f flanking sequence included in the 
oligonucleotide The amount o f flanking sequence should be taken into account in the 
design o f an oligonucleotide in future EMSA experiments to establish the role o f the NF- 
kB site at position -5 2  o f bfl-l It might also be more useful in future studies to 
investigate the role o f this site in the context o f the ‘full-length’ promoter by mutational 
analysis
EM SA studies using DNA probes encompassing the entire -129/+81 region or different 
portions thereof were inconclusive with respect to a role for NF-kB in mediating 
activation o f this region o f the bfl-l promoter by LMP1 Even though complex
250
formation was detected with these fragments, there did not appear to be any consistency 
in the pattern o f complex formation with nuclear extracts from DG75 tTA LM Pl cells 
irrespective o f LMP1 expression There was also no obvious difference in the pattern or 
intensity o f complexes between nuclear proteins extracted from DG75tTALM P-l cells 
before and after induction o f LMP1 in any experiment There are several factors that 
could account for the inconsistency observed in these EMSA studies Firstly, the quality 
o f the extracts may have diminished after recovery from storage, most likely during the 
binding reaction Degradation o f the proteins during the binding reaction could have 
occurred due to protease contaminants in any o f the components o f the binding reaction 
including the probe preparations Two protease inhibitors, PMSF and leupeptin, were 
included in the lysis and binding buffers However, the action o f these inhibitors is 
limited to a few proteases (Sambrook et a l ,  1989) and an improvement in the 
experimental protocol m this respect would be to include a cocktail o f protease inhibitors 
in the buffers used to extract the nuclear proteins and in the binding buffers Secondly, if 
the quality o f the extracts were optimum and binding did occur, the electrophoresis 
conditions may have been suboptimal to the extent o f altering the stability o f the 
complexes Two contributing factors in this case are buffer composition and the 
temperature at which electrophoresis is performed In addition to affecting the stability 
o f the complexes (particularly to those o f slower mobility) thèse factors may have also 
contributed to the smearing o f some o f the bands detected in these experiments (Figure 
3 51) Increase in temperature o f the gel or buffer during electrophoresis can be 
controlled by performing the electrophoresis at 4°C Smearing o f bands can also occur if 
detergent residues are left on the gel plates and m this regard it is known that NF-kB i s  
very sensitive to detergents (Promega Technical Bulletin No 110) Also, suboptimal salt 
or glycerol concentrations in the binding buffer can contribute to band smearing
Given that the reporter assays proved that LMP-1-mediated activation o f the -129/+81 
region o f bfl-1 is NF-KB-dependent and EMSA analyses suggest a lack o f an LMP-1 - 
mduced increase in the extent o f nuclear protein complex formation (or formation o f new 
complexes) with a probe encompassing this region, two speculative mechanisms can be 
arrived at regarding the role o f NF-kB m mediating activation o f the -129/+81 region of
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bfl-1 Firstly, the involvement o f NF-kB may be indirect m that being a transcription 
factor, it induces the expression o f another transcription factor which then directly 
contacts the promoter DNA and activates transcription Secondly, the transactivation 
potential o f a p65-contaimng complex bound to the NF-kB site at -5 2  can be stimulated 
by LM P1-mediated phosphorylation o f the activation domain o f p65 If the first scenario 
is true then it would mean that the binding conditions used in the EMSA analysis were 
not suitable for the binding o f this transcription factor to the -129/+81 region o f bfl-1
tSince this scenario would require intermediate protein synthesis, it would be possible to 
test this out by treating cells with a protein synthesis inhibitor such as cycloheximide 
prior to examining the mducibility o f  bfl-1 mRNA by LMP-1 In this respect it is 
interesting to note that CD40-mediated upregulation o f bfl-1 mRNA levels has been 
shown by others to be partially dependent on protein synthesis (Lee et a l , 1999) Cell 
systems in which LMP-1 signaling can be induced in a manner that is unaffected by a 
protein synthesis inhibitor are available and are based on the fact that the carboxy
i1cytoplasmic region o f LMP-1 encodes the signaling functions o f the molecule and that 
activation requires oligomerisation One example o f such a system involves the inducible 
activation o f LMP1 function from a fusion protein o f the extracellular domain o f Nerve 
Growth Factor and the carboxy cytoplasmic domain o f LMP-1 by addition o f NGF into 
the growth medium (Schwenger et a l , 1998, Gires et a l , 1998) The second scenario is 
dependent on successful demonstration that NF-kB binds to the kB site at position -5 2  
and that one o f the complexes formed with the -129/+81 fragment contains p65 in EMSA 
analysis using extracts from the DG75tTALM P-l cells This scenario is also compatible 
with a lack o f an LMP-1-induced increase in the extent o f complex formation with the -  
129/+81 promoter region in EMSA It has recently been demonstrated that Akt (or 
protein kinase B), a serine/threomne kinase, can suppress apoptosis by not only directly 
phosphorylatmg and inactivating proapoptotic proteins including Bad and procaspase 9 
but also stimulating the transactivation potential o f the NF-kB subunit p65 by targeting it 
for phosphorylation (Madrid et a l , 2000) Furthermore, IL-1 which is a member o f the 
TNFR superfamily can increase the transactivation potential o f p65 by inducing 
phosphorylation o f the transactivation domain in a PI3-kinase- Akt-dependent pathway 
(Sizemore et a l , 1999) LMP-1 has recently been shown to activate Akt in a
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phosphomositide-3-OH kinase (PI3K) -dependent pathway (Young et a l , 2000) and 
since LMP-1 activates bfl-1 expression in an NF-KB-dependent manner it is possible that 
LMP-1-mediated transactivation o f the -129/+81 region o f b fl-l in the DG75 cell context 
involves a mechanism in which LMP1-induced activation o f Akt leads to 
phosphorylation o f the p65 subunit o f an NF-KB-containmg complex bound to the kB site 
at position -5 2  in the bfl-1 promoter It may be relevant that the constitutive activity o f 
this region o f the promoter is also NF-KB-dependent and hence the kB site at position -  
52 may already be occupied by NF-kB proteins in the absence o f LMP-1 expression The 
fact that this NF-kB site is not a consensus site may make it a weak transactivation site 
(contributing to basal levels o f activation o f the promoter) in the absence o f 
phosphorylation o f a bound p65-containmg complex
4.7 A ROLE FOR LMP1 IN MAINTAINING ACTIVATION OF THE -129/+81  
REGION OF THE B F L - 1  PROM OTER IN LCLS
LCLs express high levels o f b fl-l mRNA and analysis o f the activity o f the promoter 
region o f the gene by promoter-luciferase assays conducted in two LCLs (IARC290B and 
IB4) suggests that transcriptional activation o f the promoter contributes to the steady- 
state mRNA levels o f bfl-l observed in these cells Deletion analysis o f the promoter 
region revealed that the -129/+81 region is optimal for transactivation o f the bfl-l 
promoter in both o f the LCLs LCLs, like BL lines expressing a type III latency 
phenotype, express all o f the latent proteins including LMP-1 Since LMP-1 expression 
can mimic several o f the changes in gene/protein expression and phenotype induced by 
EBV on infection o f primary B lymphocytes and LMP-1 can upregulate bfl-1 expression 
at the transcriptional level, it seemed reasonable to hypothesise that LMP-1 may 
contribute to the high constitutive activity o f the bfl-l promoter in LCLs Further support 
for this hypothesis comes from the observations that induction o f expression o f LMP1 
has been shown to result in activation o f NF-kB in resting B cells (Spender et a l , 1999, 
Kilger et a l , 1998) and inhibition o f NF-kB activation in an LCL has been shown to 
result in a downregulation o f bfl-1 mRNA levels (Cahir-McFarland et a l , 2000) Indeed 
it was found that transfection o f a dominant negative LMP1 molecule, LMP1-AAAG,
253
could downregulate bfl-1 promoter activity in IB4 and IARC290B by approximately 50- 
65% Nevertheless, the inhibition o f bfl-1 promoter activity, albeit partial, by LMP- 
AAAG in LCLs would suggest the requirement o f CTAR1 and/or CTAR2 domains o f 
LMP1 for maintaining the constitutive levels o f bfl-l promoter activity in LCLs 
Although this result might at first hand implicate the possible involvement o f other EBV 
latent proteins in also regulating bfl-l promoter activity in LCLs, the mechanism o f 
action/efficiency o f LMP-AAAG as a dominant negative has to be considered before 
interpreting the result LMP-AAAG may be acting by directly displacing wild-type LMP- 
1 in oligomeric complexes However, there isn’t any evidence o f any investigation in the 
literature addressing this possibility LMP-AAAG may also be acting by interacting with 
newly synthesised LMP1 molecules The active form o f LMP1 is the cytoskeletally- 
associated form and comprises at least half o f the bulk LMP1 protein in the cell 
Although, it is generally accepted that the nascent protein has a shorter turnover rate than 
the cytoskeletally-associated form, there is variability in the half-lives o f each o f the two 
forms (half-life o f nascent protein, less than 5 h, cytoskeletally-associated form, 3 — 15h) 
depending on the cell-type and detergent used for solubilisation (Kieff, 1996, Baichwal 
and Sugden, 1987, Martin and Sugden, 1987) In LCLs, the nascent protein has a half-life 
o f less than 30 mm but the bulk protein has a half-life o f less than 2 hours (Mann and 
Thorley Lawson, 1987) and therefore if  the dominant negative action o f LMP-AAAG 
requires it to oligomerise with newly-synthesised LMP-1 then a greater effect may have 
been realised if cells were harvested for analysis at a later timepoint Furthermore, LMP- 
AAAG can itself homo-ohgomense, thereby reducing its availability to interact with 
wild-type LMP1 However, given that as with other TNFR family members, 
oligomerisation o f LMP1 molecules occurs as at least tnm ers (Floettmann and Rowe,
1997), it is possible that only one LMP-AAAG molecule within the oligomeric complex 
may be required to disrupt signaling This seems likely based upon the results obtained 
with the study assessing the efficiency o f LMP-AAAG in inhibiting signaling from wild- 
type LMP1 in cotransfection assays In this study cotransfection o f expression plasmids 
for wild-type LMP-1 and LMP-AAAG in a 2 1 ratio resulted in an approximately 70% 
inhibition o f wild-type LMP-1 signaling, while transfection o f the plasmids in a 1 1 ratio 
led to a 90% inhibition It would be useful in future experiments to support these results
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by using another approach such as transfection o f an antisense LMP1 construct to 
downregulate expression o f LMP-1. LMP-AAAG expression also inhibited the 
constitutive levels o f NF-kB activation in both o f the LCLs tested in keeping with the 
observations that induction o f LMP1 expression in the context o f primary B lymphocytes 
stimulates activation o f NF-kB (Spender et al., 1999; Kilger et al., 1998). However, 
inhibition o f NF-kB activation by expression o f a dominant negative IkBoc molecule 
exerted different effects on constitutive bfl-1 promoter activation in the two LCLs. Thus, 
it was found that whereas expression o f dominant negative IkBoc decreased bfl-l 
promoter activity in the IB4 cell line, its expression did not significantly alter the activity 
o f the promoter in IARC290B. Also, neither did ectopic expression o f the dominant 
negative TRAF2 molecule, TRAF2A(6-86), alter bfl-l promoter activity in IARC290B. 
The latter finding may be related to the observation by others that most o f LMP1 in LCLs 
is associated with TRAF1 and TRAF3 and very little with TRAF2 (Devergne et al.,
1996). The finding that the activation o f the bfl-l promoter in IB4 cells is NF-kB- 
dependent is very significant since it supports the results o f Cahir-McFarland et al (2000) 
who found that inhibition o f NF-kB activation in this particular cell line resulted in a 
downregulation o f bfl-l mRNA levels. The results relating to the control o f bfl-l 
expression in LCLs presented in this thesis would suggest that different signalling 
mechanisms may be engaged by LMP1 in different LCLs to regulate expression o f a 
particular gene. In this regard, it is known that LMP-1 can also activate other signal 
transduction pathways including the JNK pathway (leading to API activation) (Kilger et 
al., 1998) and several potential AP-1 sites are present in the bfl-l promoter. The usage o f 
different signalling mechanisms to regulate gene expression in different LCLs may be 
related either to cell-type specific factors present in different LCLs either because o f their 
origin or EBV strain-dependent variation in LMP-1 sequence since while IB4 is derived 
from infection o f fetal cord blood B lymphocytes with the B95.8 strain (King et al., 1980) 
(LMP-AAAG was derived by mutating the LMP1 sequence from this strain), IARC290B 
is a spontaneous LCL derived from adult peripheral blood (Lenoir et al., 1985). It would 
be interesting in future experiments to examine the role o f NF-kB and LMP1 in 
activating the bfl-1 promoter in an extended panel o f LCLs by using the dominant 
negative LMP mutant, LMP-AAAG, and the dominant negative IkBoc mutant.
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4.8 CD40 UPREGULATES B F L - 1  PROM OTER ACTIVITY
Lee et al (1999) have recently reported that CD40 activation can transiently upregulate 
bfl-1 mRNA levels in BL lines The results presented in this thesis support the results o f 
Lee et al and also extend their study by 1) excluding mRNA stability as a possible level 
o f control by CD40 and 11) demonstrating that CD40 activates the b fl-l promoter in an 
NF-KB-dependent manner in this cellular context The lack o f an effect o f CD40 ligation 
on the stability o f bfl-l mRNA is surprising since regulation o f mRNA stability is a 
common method o f regulation o f expression o f genes displaying a quick response Since 
the mRNA stability studies were performed in only one cell line namely, BJABtTA, it is 
possible that a lack o f an effect o f CD40 activation on bfl-1 mRNA stability may be 
specific to this cell line An important aspect o f CD40 signalling m B cells is its ability 
to control apoptosis (reviewed in Gregory, 1995) Isolated germinal centre cells, which 
spontaneously undergo apoptosis in culture, are capable o f surviving for extended periods 
when treated with anti-CD40 antibodies or CD40 ligand In addition, CD40 is known to 
rescue immature B cells and mature B cells from surface IgM and Fas-mediated 
apoptosis (reviewed in Gregory, 1995) Many studies indicate that the anti-apoptotic 
function o f CD40 is mediated by upregulation o f Bcl-xL and A20 (Tuscano et a l , 1996, 
Lee et a l , 1999, Sarma et a l , 1995) The results presented in thesis and the study o f Lee 
et al (1999), extend this list to include bfl-1
Both CD40 and LMP-1 belong to the TNFR superfamily and in many respects, LMP1 is 
a constitutively active CD40 receptor (Baker amd Reddy, 1996) However, while CD40 
is dependent on ligand-binding for oligomerisation and signalling, LMP1 oligomerises 
independent o f ligand Similarities between CD40 and LMP1 functions include their 
ability to bind TRAFs through a PxQxT motif, and to activate the NF-kB, JNK and 
p38M APK pathways (Kehry, 1996, Aicher et a l , 1999, Kieser et a l , 1997, Ehopoulos et 
a l , 1999, Hatzivassihou et a l , 1998) Furthermore, LMP1 and CD40 show remarkable 
similarities in their downstream effects upon cellular phenotype, including upregulation 
o f a similar set o f cell surface (e g. CD54, CD23 and LFA-1) and anti-apoptotic proteins
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(e g A20) and in their effects upon cell differentiation, proliferation and apoptosis 
(Eliopoulos et a l , 1997, Kilger et a l , 1998, van Kooten and Banchereau, 1997, Zimber- 
Strobl et a l , 1996, Kehry, 1996) However, some differences in signaling by these two 
molecules do exist, since as demonstrated in this thesis, LMP1 but not CD40 can 
upregulate bfl-1 mRNA stability Also, although both LMP1 and CD40 have been shown 
to bind several o f the same TRAF molecules (namely TRAF-2,-3 and -5 ), TRAF6 binds 
to CD40 but not to LMP1 and TRAF1 and TRADD have been reported to bind to LMP-1 
but do not bind CD40 directly (reviewed in Busch and Bishop, 1999)
At the steady state mRNA level, dual signaling from CD40 and LMP1 in DG75tTALMP- 
1 cells appeared to lead to an upregulation o f bfl-1 mRNA levels, the extent o f which 
appeared to be greater than that expected o f an additive effect o f the independent signals 
(Figure 3 54) At the promoter level, CD40 activation and LMP1 expression individually 
transactivated the b fl-l promoter in an NF-icB-dependent manner in DG75 cells and 
although dual signaling from the two molecules had a greater effect on b fl-l promoter 
transactivation than each o f the individual signals the overall effect was less than that 
expected o f an additive effect o f the individual signals (Figure 3 56) The discrepancy 
between the results o f the studies at the promoter level and at steady-state mRNA level 
may be a reflection o f the fact that the parental cell line DG75 was used in the case o f  the 
former, while a subclone DG75tTALM Pl was used in the case o f the latter In fact, 
uninduced DG75tTALM P-l cells have much lower levels o f CD40 expression than 
DG75 arguing the case for the possibility o f clonal variation accounting for the 
discrepancy Alternatively, there may be elements outside o f the -1374/+81 region o f bfl- 
1, that may also be involved in transactivation o f the promoter by LMP1 and CD40 and 
hence the promoter studies conducted in this thesis using the -1374/+81 region o f bfl-1 
may not be a complete reflection o f the effect o f these molecules on the endogenous bfl-1 
promoter Arriving at a firm conclusion about the question o f cooperativity between 
LMP-1 and CD40 in upregulating bfl-1 expression is further complicated by the fact that 
LM P1 can upregulate CD40 expression in BL lines and that in the case o f interpreting the 
results o f  Northern analysis, LMP-1 may increase the stability o f the CD40-induced bfl-l 
mRNA The results o f the promoter studies are easier to interpret in this regard If  LMP 1
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and CD40 utilise different signaling pathways to transactivate the bfl-1 promoter then at 
least an additive effect would be expected The finding o f a less than additive effect but 
greater than an individual effect o f signaling from the two membrane molecules on bfl-1 
transactivation can be interpreted to mean that both LMP1 and CD40 are using the same 
signaling pathway in this effect Furthermore, although the signaling components would 
appear to be non-limiting even after engagement by either LMP1 or CD40 individually, 
they do become limiting when both molecules are activated to less than the capacity 
required o f an additive signal
LMP1 and CD40 have been shown to cooperate in an additive or synergistic manner in 
upregulating cell surface molecules such as B7 1 as well as in inducing IL6 secretion in 
mouse B cell lines in which LMP-1 does not affect endogenous CD40 levels (Busch and 
Bishop, 1999) However, this does not apply to all o f the effects on gene/protein 
expression that these molecules share For example, although both CD40 and LMP-1 
could individually induce ICAM-1 and LFA-1 expression a clear cooperative effect was 
not demonstrated The studies o f Busch and Bishop were conducted at the protein level 
and hence the possibility that CD40 and LMP-1 may exert a cooperative effect in 
upregulating bfl-1 expression at the post-transcriptional/translational level cannot be 
excluded In BL cell lines, dual signaling from CD40 and LMP1 failed to result in a 
cooperative effect on induction o f an NF-kB reporter construct in transient transfection 
assays (Floettmann et al, 1998) Thus, cooperativity between CD40 and LMP-1 in 
regulating gene/protein expression may not be a global phenomenon
It is well documented that BL lines express CD40 endogenously and LMP1 upregulates 
CD40 expression m BL lines (reviewed in Gregory, 1995) Hence, it would be expected 
that when LMP1 and CD40 signals are given concurrently, the B cell responds more 
robustly than it does to either signal alone In vivo, latently infected B cells expressing 
LMP1 can be stimulated through both CD40 and LMP1, perhaps resulting in a 
superactivated state predisposing the cell to a second event resulting in transformation 
However, there may also be circumstances where cooperativity in signaling by LMP1 
and CD40 leading to overexpression o f particular proteins may be deleterious to the cell
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such as in the upregulation o f Fas. There may also be yet other circumstances where 
cells are defective in CD40 activation but are responsive to the LMP1 expression. This 
may be relevant in vivo, in that since reception o f a CD40-mediated signal by B cells in 
the absence o f cognate antigen can lead to cell elimination (reviewed in Busch and 
Bishop, 1999), then the selection o f cells with a defect in the CD40 pathway may in some 
cases be a contributory step in BL pathogenesis. The finding that Rael, which is a type I 
BL line, is defective in responding to CD40 activation with upregulation o f bfl-1 mRNA 
is in accordance with the findings o f others that this cell line is non-responsive to CD40 
activation with respect to other parameters as well (Henriquez et al., 1999). In fact, Rael 
is one amongst a group o f BL lines that are non-responsive to CD40 activation but 
respond to LMP1 expression (in terms o f upregulation o f ICAM-1 expression as well as 
NF-kB activation). Furthermore, ectopic expression o f functional CD40 into Rael cells 
did not confer responsiveness to CD40 ligand, thereby excluding that the lack o f 
responsiveness to CD40-mediated effects in this cell line may be due to a defective 
endogenous CD40 receptor itself (Henriquez et al., 1999). These observations would 
indicate the use o f different signaling pathways or different components o f the same 
signaling pathway by CD40 and LMP1, which usually converge to effect similar 
downstream functions. Therefore, in this case if one subscribes to the view that LMP1 
mimics CD40 this would give LMP1 the advantage to remain fully functional in cellular 
backgrounds in which CD40 signaling is impaired.
4.9 MECHANISM UNDERLYING LMP-1-MEDIATED UPREGULATION OF 
BCL-2 EXPRESSION
The results presented in this thesis support the findings o f others that LMP1 upregulates 
Bcl-2 expression in BL cells (Henderson et al., 1991; Rowe et al., 1994; Wang et al.,
1996). In several o f the cell systems used in these studies, even though upregulation o f 
Bcl-2 protein was detected by 24 -4 8  h post-induction o f LMP-1 expression, maximum 
upregulation was not detected until after 72h, suggesting that the induction o f Bcl-2 
protein expression by LMP1 is a delayed response. The results presented in this thesis 
are in agreement with the induction o f bcl-2 expression by LMP1 as being a delayed
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response particularly at the steady-state mRNA level and to a lesser extent at the protein 
level There appeared to be some discordance between extents o f upregulation o f bcl-2 
expression at the mRNA and protein levels by LMP1 in DG75tTALM Pl cells 
particularly at 24 h post induction o f LM P1, suggesting that the control on upregulation 
o f bcl-2 expression by LMP-1 occurs at both the transcriptional and translational levels 
with the latter exerting a stronger effect (by 24 h post-induction o f LMP1) It is possible 
that this effect on induction o f bcl-2 expression by LMP1 may be specific to DG75 
tTA LM Pl cells However, there is evidence for the action o f both o f these mechanisms in 
the control o f bcl-2 expression during normal B-cell development and differentiation 
Changes in the rate o f transcription have been found to regulate bcl-2 mRNA levels 
during B-cell development (Seto et a l , 1988, Young and Korsmeyer, 1993) Also, m 
hemopoietic tissue in vivo, although Bcl-2 protein can be detected in the mantle zone but 
not in the germinal centre, its mRNA can be detected in both o f these regions, implying 
that translational mechanisms can also contribute to the regulation o f bcl-2 expression 
(Akagi et a l , 1994, Chleq-Deschamps et a l , 1993) In addition a cis-acting element 
within the 5’ untranslated region o f the bcl-2 gene has been shown to be necessary for 
regulating bcl-2 expression at the level o f translation (Hangai et a l , 1996)
A cAMP responsive element (CRE) has been shown to play a positive role in constitutive 
activity o f the bcl-2 promoter in mature B cells and also in mediating PMA-induced 
activation o f the bcl-2 promoter in immature and mature B cells (W ilson et a l , 1996) 
Unfortunately, studies presented in thesis suggested the lack o f a demonstrable effect o f 
LMP1 induction on activation o f a bcl-2 promoter-luciferase construct in which the 
promoter region included the CRE site by transient transfection assays It was expected 
that since LMP-1 has been shown to activate a calcium/calmodulin-dependent kinase 
(Mosialos et a l , 1994) and that these enzymes can in turn activate CRE binding proteins 
(CREBs), LMP-1 may activate the bcl-2 promoter via the CRE site Nevertheless, if 
LMP-1 does affect bcl-2 promoter activity it is likely not to involve elements within the -  
3934 to -8  region upstream o f the translation start site
Phosphorylation represents a further level o f control o f Bcl-2 function. Bcl-2 
phosphorylation can be induced by various agents including IL-3, erythropoietin, the
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PKC activator bryostatin, the phosphatase inhibitor okadaic acid, the chemotherapeutic 
agent taxol and the microtubule agent vincristine (Haidar et a l , 1995, Ito et a l , 1997, 
Snvastava et a l ,  1998) While Bcl-2 phosphorylation is associated with apoptosis in 
some cell lines (Haidar et a l , 1995, Snvastava et a l , 1998), it is associated with an anti- 
apoptotic function in others (Ito et a l , 1997) Phosphorylation o f Bcl-2 occurs on serine 
residues and there are 17 such residues in the protein that serve as candidate sites for 
phosphorylation (Ito et a l ,  1997) In the case o f some but not all stimuli, the serine 
residues whose phosphorylation is critical to Bcl-2 function have been identified (Ito et 
a l , 1997) Thus, phosphorylation o f serine 70 by bryostatin-1 has been shown to be the 
critical residue required for the anti-apoptotic function o f Bcl-2 (Ito et a l , 1997) In 
several lymphoid cell lines phosphorylation o f Bcl-2 by the serme phosphatase inhibitor, 
okadaic acid (OA), is associated with cell death (Haidar et a l , 1995) However, in an 
EBV-immortalised cell line examined in this study by Haidar et a l , OA treatment did not 
induce apoptosis or phosphorylation o f Bcl-2 This result was interpreted to mean that the 
putative kinase responsible for phosphorylation o f Bcl-2 is not activated in this cell line 
However, the possibility that OA may not have been able to permeate this cell line was 
not considered m this study The finding in this thesis that a large fraction o f the Bcl-2 
protein induced by LMP-1 in DG75tTA-LM Pl cells appears to be unphosphorylated but 
that the potential for phosphorylation does exist would suggest that the cells may be 
primed for apoptosis However, at least for the duration o f the experiment (6h), there 
appeared to be no increase in the number o f trypan-blue stained cells after treatment with 
OA either in the absence or presence o f LMP 1 expression (result not shown) Although 
this might question the importance o f Bcl-2 phosphorylation in controlling apoptosis in 
this cell context, it is possible that cell death may have occurred on prolonged treatment 
This needs to be examined in future experiments and perhaps using methods that detect 
early markers o f apoptosis such as measuring cytochrome c release (in response to an 
apoptotic stimulus cytochrome c is released from mitochondria into the cytoplasm where 
it activates dormant killer proteases) (Wetzel and Green, 2000a) or annexin V labeling 
[annexin V (fluorescein-labeled) binds phosphatidyl serine that translocates from the 
cytoplasmic face o f the membrane to the cell surface in response to an apoptotic 
stimulus] (Wetzel and Green, 2000b)
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4.10 FUTURE WORK
A few o f the conclusions arrived at in this thesis would be strengthened by additional 
experiments and these have been pointed out either in the results chapter or in earlier 
sections o f this chapter Some o f the unanswered questions include a) Does LMP-1 
upregulate bfl-1 mRNA in T -lymphocyte and epithelial cell contexts7 This is 
particularly relevant to the T cell context since induction o f LM P1 expression in Jurkat 
tTALM Pl did not lead to bfl-1 mRNA upregulation but LMP1 expression did result in 
transactivation o f the bfl-1 promoter m the parental Jurkat T cells b) Does Bfl-1 
expression confer protection against other apoptotic stimuli relevant to BL lines such as 
calcium lonophore and anti-fi antibody9 How does Bfl-1 compare with other anti- 
apoptotic proteins such as Bcl-2 and A20 in protecting BL cells against apoptosis9 c) 
Does JAK3 activation contribute to upregulation o f bfl-1 promoter activity and mRNA by 
LMP l 9 If  so, does this effect map solely to CTAR3 or is there an additional requirement 
for CTAR1 and/or CTAR2 function9 d) Is the lack o f responsiveness o f the NF-kB site 
at position -833  to LMP1 signalling a lymphocyte-specific effect9 e) Does LMP-1- 
mediated activation o f the PI3-kinase-Akt pathway contribute to activation o f the bfl-l 
promoter9
The major findings o f the investigations detailed in this report suggest a number o f 
potentially useful further experiments As already mentioned it will be important to 
elucidate the mechanism o f bfl-1 mRNA stabilisation by LMP1 As a first step it would 
be interesting to investigate if  inhibition o f de novo protein synthesis, by using inhibitors 
such as cycloheximide, can stabilise bfl-1 mRNA The mouse A1 mRNA can be rapidly 
induced by cycloheximide treatment o f bone marrow macrophages as would be expected 
o f an early-response gene (Lm et a l , 1993) Cycloheximide can also induce bfl-1 mRNA 
in endothelial cells (Hu et a l , 1998) Two mechanisms have been proposed to explain 
how inhibition o f protein synthesis can stabilise mRNAs (reyiewed in Ragheb et a l , 
1999a) The first is that mRNA degradation is coupled to translation and thus blocking 
translation prolongs mRNA half-life The second is that degradation is dependent on a
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labile protein whose synthesis is blocked by the translation inhibitor In addition some 
translational inhibitors such as cycloheximide, cause ribosomes to stall on the mRNA 
potentially shielding it from degradation by cytoplasmic RNases
Owing to the difficulties encountered with EMSA it may be better to initially approach 
the investigation o f the role o f candidate elements in LMP-1-mediated activation o f the 
bfl-1 promoter by mutation/deletion analysis This will allow the identification o f the 
role o f these elements in the context o f  the full-length promoter This approach should 
apply to not only the NF-kB site in the -129/+81 region o f the promoter in BL cells and 
LCLs but also the four NF-kB elements (excluding the site at -833) in the -1240/-367 
region in Jurkat cells Although NF-kB activation is required for several o f the 
stimulatory effects o f LMP-1 on gene (IL6, A20, ICAM -1 , MMP-9) and protein 
expression (LFA-1, CD40) (Eliopoulos et a l , 1997, Laherty et a l , 1992, Liljeholm et a l , 
1998, Yoshizaki et a l , 1998, Devergne et a l , 1998), these effects may also be mediated 
by other LMP-1-activated transcription factors including AP-1 (Eliopoulos and Young,
1998) Indeed, it has been demonstrated that both AP-1 and NF-kB mediate the 
activation o f the MMP-9 promoter by LMP-1 (Yoshizaki et a l , 1998) The presence o f 
several potential AP-1 sites in the b fl-l promoter, two o f which he in the -129/+81 region 
o f bfl-1 (Figure 3 44), makes the investigation o f a potential role for AP-1 activation in 
LMP-1 mediated activation o f bfl-l feasible, perhaps by using a dominant negative 
approach (for instance using dominant negative SEKK1 that is targeted by LMP-1 to 
activate the JNK pathway)
The absence o f suitable antibodies to Bfl-1 has made it difficult to extend the 
observations made in this study at the mRNA level to the protein level Antibodies that 
detect Bfl-1 protein either by Western blotting or immunohistochemistry would also 
prove useful in examining normal and tumour tissue material In the case o f  normal 
tissue material it would be interesting to correlate the pattern o f expression o f bfl-1 in the 
germinal centers as determined by in situ hybridisation studies (Jung-Ha et a l , 1998) 
with immunohistochemical analysis o f Bfl-1 protein expression In the case o f tumour 
material it will be useful to correlate expression o f Bfl-1 with expression o f LMP1 in
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those EBV-associated cancers such as PTLD and NPC which are known to have a high 
association with LMP-1 expression (Young et a l , 1989, Thomas et a l , 1990)
It will be useful to map the domains o f CD40 required for upregulating bfl-1 mRNA 
levels by using various CD40 mutants that effect known signaling functions o f the 
molecule Like LMP-1, CD40-mediated signaling results in activation o f NF-kB, JNK 
and p38 and several o f these effects are mediated by TRAF interactions with two regions 
within the cytoplasmic tail o f the CD40 receptor (Pullen et a l , 1999) The membrane 
proximal TRAF-binding region o f CD40 binds TRAF6 whilst the membrane distal 
TRAF-binding region binds TRAF1, TRAF2 and TRAF3 Mutational analysis has 
shown that both o f the TRAF binding sites are required for optimal NF-kB and JNK 
activation, while activation o f p38 is dependent solely on TRAF6 binding (Pullen et a l ,
1999) This analysis could be supported by identification o f the regions o f the bfl-1 
promoter targeted by CD40 and the identification o f target promoter elements mediating 
b fl-l transactivation
An understanding o f the translational mechanisms underlying the LMP-1 induced 
upregulation o f Bcl-2 is also worthy o f future investigation, in particular, the potential 
role o f LMP-1 m modulating the negative regulatory element (NRE) in the 5’ UTR of 
bcl-2 (Hangai el a l , 1996) This NRE is located at -119/-84 bp upstream o f the 
translation start site The functional significance o f this element was established by 
performing transient transfection assays in cell lines using Bcl2-CAT reporter constructs 
containing the 5’ region o f bcl-2 [region -1649/-1 containing the major promoter (PI), 
the 5 ’UTR (containing the NRE) and minor promoter (P2)] either in a wild-type format 
or with point/deletion mutations o f  the NRE in transfection assays followed by measuring 
CAT mRNA levels and CAT activity It was found that whilst the CAT mRNA levels m 
the transfectants were similar, the CAT activity was elevated when the NRE was 
mutated Thus, by transfecting a series o f similar constructs as that used in the study o f 
H angai et al in transfection studies o f DG75tTALM P-l cells before and after induction 
o f LMP-1 (perhaps 24h post-induction o f LMP-1 to avoid the effect on bcl-2
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transcription) it should be possible to determine if  this NRE is the control point in the 
LMP-1-mediated upregulation o f Bcl-2 protein
Although resting B cells already express a high level o f Bcl-2, which is only slightly 
elevated following infection with EBV (Martin et a l , 1993), the Bfl-1 status o f these 
cells before and after infection remains unknown and therefore merits investigation 
Since mitogemc activation o f lymphocytes in vitro results in decreased Bcl-2 protein 
expression (Aiello et a l , 1992) it is possible that depending on the type o f B cell that the 
virus infects, the expression o f LMP-1 may serve to transiently upregulate or maintain 
Bfl-1 and Bcl-2 levels during the EBV-associated mitogemc stimulation that cells 
undergo upon infection and during the critical period prior to entry o f the virus-infected 
cell into the long-lived memory B cell pool
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CHAPTER 5
SUMMARY
SUMM ARY
Control over apoptosis is an important feature o f the life cycle o f EBV in both the latent 
and lytic phases (reviewed by Allday, 1995) In vitro, latent infection o f B-lymphocytes 
involving the expression o f all o f the EBV latent proteins is accompanied by an 
increased resistance to apoptosis In this thesis, an investigation was carried out to 
identify EBV-associated changes in the level o f  expression o f apoptosis-related genes 
Using a multiprobe set specific for a subset o f apoptosis-related genes (both pro- and 
anti- apoptotic genes) in ribonuclease protection assays, the steady-state levels of 
mRNA transcripts o f each o f these genes was assessed m the context o f a range o f 
EBV-related cell lines O f the genes under study, which included bclxus, bfl-1, bik, bak, 
bax, bcl-2 and m cl-I, the most significant change was observed in the level o f bfl-1 
mRNA which was markedly upregulated on transition from EBV latency type I to type 
III m EBV-positive BL cells EBV-negative BL cells like type I BL cells were found to 
express negligible or very low levels o f b fl-l mRNA, while EBV-immortahsed LCL 
lines exhibited elevated levels o f expression o f bfl-1 mRNA Functional assessment o f 
ectopic expression o f Bfl-1 m the context o f an EBV-positive type I BL line revealed 
that Bfl-1 expression can confer resistance to apoptosis induced by serum-deprivation 
and also exert a proliferative effect under such growth conditions
Using a tetracycline-regulated gene expression system in an EBV-negative BL line, 
DG75tTALM P-l, in which LMP-1 is expressed as the sole EBV latent protein, it was 
possible to show that LMP-1 can contribute to the upregulation o f bfl-l mRNA Levels 
o f bfl-1 mRNA were barely detectable in a T cell line, Jurkat-tTA-LMP-1, or an 
epithelial cell line, C33A, and expression o f LMP1 in either cellular context had no 
apparent effect on bfl-1 mRNA levels Although these results would suggest that 
LMP1-mediated upregulation o f bfl-1 mRNA levels is a B-cell effect, the absence o f a 
similar effect in the T and epithelial cell lines may be the result o f clonal variation
Further investigations into the mechanism o f upregulation revealed that stabilisation o f
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bfl-1 mRNA contributed to the observed LMP1-mediated effect An LMP1-induced 
increase in activity o f the bfl-1 promoter could also be demonstrated in transient 
transfection reporter assays m two EBV-negative BL lines (DG75 and BL41) and a T 
cell line (Jurkat) with the CTAR2 domain o f LMP1 exerting the predominant effect 
However, the regions o f the promoter targeted for activation by LM P1 differed between 
DG75 and Jurkat T cells Thus it was found that whereas elements in the proximal 
region (bp -129 to +81 relative to the transcription start site) o f the promoter appeared 
to play a greater role in the LMP 1-mediated effect in DG75 cells, elements in the -  
1240/-367 region o f the promoter were targeted for activation o f the bfl-l promoter by 
LMP1 in Jurkat cells However, in both cell types NF-kB was demonstrated to play an 
important role in the LMP 1-mediated effect on the b fl-l promoter and that too in a 
TRAF-2-dependent mechanism This was based on observations o f the inhibitory 
effects o f a dominant negative IkBo, mutant or a dominant negative TRAF2 or a TRAF- 
mteracting protein A20 on the LMP 1-mediated effect Ectopic expression o f p65 or 
PMA treatment could also activate the bfl-l promoter in transient transfection reporter 
assays with DG75 and Jurkat cells thereby demonstrating the NF-KB-responsiveness o f 
the promoter Despite the importance o f NF-kB in mediating the activation o f the -  
129/+81 region o f bfl-1, it was not possible to demonstrate binding o f NF-kB to this 
region
In LCLs, the -129/+81 region o f the promoter was found to be optimal for constitutive 
activation o f the gene Furthermore, by using a dominant negative mutant o f LMP 1 that 
is defective in NF-KB-signahng from both CTAR1 and CTAR2, it was possible to show 
that this EBV latent protein contributes to the constitutive level o f activation o f the 
promoter in LCLs However, NF-kB may not be the only mechanism responsible for 
activating the bfl-l promoter in different LCLs as revealed, by transient transfection 
studies with a dominant negative IkBcx mutant
Activation o f CD40 was also found upregulate bfl-l mRNA levels in BL cells, however 
although both CD40 and LMP1 are members o f the TNFR superfamily, the effect o f
268
CD40 was transient and unlike LMP1, CD40 activation did not result in an increased 
stabilisation o f bfl-1 mRNA Like LMP1, CD40-induced activation o f the bfl-1 
promoter was also found to be mediated by NF-kB Coactivation o f CD40 and LMP1 in 
DG75 cells resulted in a greater effect on the bfl-1 promoter than coactivation o f either 
molecule alone, however the effect was less than additive suggesting that both 
molecules must engage common components o f the same signaling pathway to activate 
the bfl-l promoter
A perhaps minor but significant finding o f the results presented in this thesis is the 
involvement o f both transcriptional and translational mechanisms in the LMP-1- 
mediated effect on Bcl-2 expression in DG75tTALM P-l cells with the effect on 
translation appearing to be more significant Furthermore, it was possible to 
demonstrate that autocrine/paracrine factors are not involved m this effect o f LMP1
The induction o f bfl-1 expression by LMP1 in B lymphocytes has implications for the 
biology o f EBV LMP1-mediated upregulation o f bfl-1 may contribute to the survival 
o f EBV-infected B cells, since cells similar to LCLs are present in the circulation during 
primary infection by EBV (Qu and Rowe, 1992, Tierney et a l , 1994) Additionally, the 
effect on bfl-1 may contribute to the development o f EBV-associated B-cell 
malignancies such as posttransplant lymphoproliferative disorders and BL tumour 
metastases in which LMP1 is expressed Mechanistic studies o f the contribution o f Bfl- 
1 to cell survival will provide important information about normal B-cell development 
and potential routes to B-cell and non-B-cell malignancy
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APPENDIX
SOLUTIONS FOR DNA MANIPULATION
TE buffer
10 mM Tris-Cl
1 mM EDTA pH 8  0
Solutions for mini-preparation of plasmid DNA  
Solution I
50 mM Glucose
25 mM  Tris Hcl (pH 8  0)
10 mM EDTA (pH 8  0)
Solution II (Prepared fresh)
0 2 M NaOH
1 % (w/v) SDS
Solution III
60 ml 5 M potassium acetate
11 5 ml Glacial acetic acid
28 5 ml Distilled water
The resulting solution is 3 M with respect to potassium and 5 M with respect to acetate
DNase-free RNase
RNase A (1 m g /m l) in sterile water
Heat to 100°C for 30 min Cool slowly and store -20°C
Solutions for Maxipreparations o f DNA -  Qiagen Buffers
Buffer PI (Resuspension buffer)
50 mM T ns-c l, pH 8  0
b
10 mM EDTA
100 |ag RNase A
Store at 4°C after the addition o f RNase A
Buffer P2 (Lysis buffer)
200 mM Sodium Hydroxide
1% (w/v) SDS
Prepared fresh and stored at room temperature
Buffer P3 (Neutraliziation buffer)
3 0 M Potassium acetate pH 5 5
Stored at 4°C
Buffer QBT (Equilibriation buffer)
750 mM  NaCl
50 mM  MOPS pH 7 0
15% (v/v) Isopropanol
0 15% (v/v) Titon X -100
Stored at room temeprature
Buffer QC (Wash buffer)
1 0 M NaCl
50 mM MOPS pH 7 0
15% (v/v) Isopropanol
Stored at room temperature
50% (v/v) Glycerol 
25 ml Distilled
25 ml Glycerol
Autoclaved and stored at room temperature
c
0.5 M EDTA
186 1 g EDTA
800 ml Distilled water
6  g NaOH pelletes
pH to 8  0 with 5 M NaOH Volume was adjusted to 1 L with water
50X TAE
242 g 
57 1 ml 
1 0 0  ml 
Adjusted to
10X TBE
108 g Tns
50 g Boric acid
40 ml 0 5 M EDTA pH 8  0
Adjusted to IL with water
Ethidium bromide
0  1 g/ 1 0  ml water ( 1 0  mg/ml)
Stored in dark at room temperature
Agarose gel loading dye
40% (w/v) sucrose 
0 25% (w/v) bromophenol blue
BACTERIAL GROW TH MEDIA  
LB agar
10 g Tryptone
5 g Yeast extract
5 g NaCl
Tns
Acetic acid 
0 5 M EDTA pH 8  0 
1 L with water
d
15 g Agar technical
Autoclaved and plates stored at 4°C
LB agar plus ampicillin
Ampicillin was added to a final concentration o f 100 |ag/ml to LB agar (50°C)
Plates were stored at 4°C
LB broth (per L)
10 g Bacto-tryptone
5 g Yeast extract
5 g NaCl
Autoclaved and stored at 4°C
LB Ampicillin broth
Ampicillin was added to LB broth to a final concentration o f 100 |ig/ml from stock 
solutions (100 mg/ml in dL^O, stored at -20°C) Stored at 4°C
SOB medium (per L)
20 g Trytpone
5 g Yeast extract
0 5 g NaCl
10 ml KC1 (250 mM)
Adjusted pH to 7 0 with 5 M NaOH 
Autoclaved, cooled to -5°C  and added 
10 ml 1 M MgcL2 
Stored at 4°C
SOC medium (per L)
1 L SOB
7 5 ml 50% glucose (filter sterilised)
Stored at 4°C
e
Ampicillin stock solution (50 mg/ml)
50 mg o f ampicillin per ml o f sterile H2 O 
Filter sterilised and stored at -20°C
CELL CULTURE MEDIA/SOLUTIONS 
Supplemented RPMI (200 ml)
176 ml RPMI 1640
20 ml Foetal calf Serum (Decomplemented -50°C  for 30 mm)
2 ml 200 mM L-glutamine
2 ml Penicillin/Streptomycin ( 1000 U /m l-1000 (ig/ml)
Supplemented DM EM  High Glucose
178 ml DMEM high glucose with L-glutamine
20 ml Foetal calf Serum (Decomplemented, 50°C for 30 mm)
2 ml Penicillin/Streptomycin ( 1000 U /m l-1000 |ag/ml)
10X Phosphate Buffered Saline (PBS)
14 24 g Na2H P 0 4 2H20  ( 8  mM)
2 04 g KH2PO4 (1 5 mM)
80 Og NaCl (137 mM)
2 0 g KCI (2 7 mM)
pH 7 5 and make up to 1 litre
Diluted 1 in 10 in sterile distilled water and used at a 1 X working concentration 
Thiol supplements
The following were added to 200 ml o f supplemented media 
200 |_il a-Thiolglycerol
2 ml Sodium pyruvate
2 ml HEPES
f
Bathocuproine disulfonic acid (BCS -  10 mM stock solution)
36 4 mg BCS
10 ml I X  PBS
Dissolved by vortexing, filter sterilised using a 0 2 micron filter 
Aliquoted and stored at -20°C
a-Thiolglycerol
A stock solution o f 50 mM in PBS containing 20 |jM  BCS was prepared 
20 jj.1 10 mM BCS
10 ml I X  PBS
43 3 jj.1 100% a-thiolglycerol
Filter sterilised using a 0 3 micron filter, aliquoted and stored at -20°C 
Sodium pyruvate
100 mM stock solution in 1 X PBS (Gibco BRL) Stores at 4°C 
HEPES
1 M stock pH 7 5 (Gibco BRL) Stored at room temperature
Geneticin G418 (stock solution 50 mg/ml) for tetracycline inducible cell lines
0 1 g Geneticin
2 ml RPM I1640
Filter sterilised using a 0 2 micron filter, aliquoted and stored at -20°C  20 jal o f the
stock solution was added per ml o f  media to give a final concentration o f  1 mg/ml
Hygromycin B (stock solution 50 mg/ml supplied)
Ten micro litres o f the stock solution was added per ml o f media to give a final
concentration o f 500 jj,g per ml Stored at 4°C
g
Tetracycline (stock 5 mg/ml)
5 mg Tetracycline
1 ml 100% Ethanol
Stored at -20°C, 1 (J,l o f tetracycline was added t o5 ml o f media to give a final 
concentration o f 1 fig per ml
Geneticin G418 (stock solution 600 mg/ml) for transfected ephithelial cell lines 
C33A Neo and LMP1
0 6 g Geneticin
1 ml 1 M Hepes pH 7 5
Filter sterilised using a 0 2 micron filter, ahquoted and stored at -20°C One (J.1 o f the 
stock solution was added per ml o f media to give a final concentration o f 600 p,g per ml
Okadaic acid (stock solution)
0 4 m M i n  10% DMSO 
Stored in aliquots at -20°C
Sodium orthovanadate (stock solution)
1M in dH20  Boiled until translucent and pH readjusted to 10 0 
Stored in aliquots at -20°C
PMA (phorbol 12-mynstate 13-acetate) (stock solution)
0 1 mg/ml in ethanol 
Stored in aliquots at -20°C
Ionomycin (stock solution)
2mM in DMSO 
Stored in aliquots at -20°C
h
Solutions for modified DEAE-Dextran Transfection Protocol 
T.E.
l OmM Tns (pH 7 4)
1 mM EDTA
Prepared fresh on the day o f use using autoclaved o f Tns and EDTA It is important to 
ensure that the pH o f the Tris is at 7 4 room temperature prior to use
TBS
25 mM Tns (pH 7 4)
137 mM NaCl
5 mM KC1
0 7 mM CaCl2
0 5 mM MgCl2
0 6 mM Na2H P 0 4
Prepared from autoclaved stocks, ahquoted and filtered before use Again the pH o f the 
Tns is critical
DEAE Dextran
lm g/m l m TBS, prepared fresh and filter sterilised 
p-galactosidase assay
100 x Mg solution
0 1 M Mg cl2
4 5 M 2-mercaptoethanol 
Stored at -20°C
1 x ONPG substrate (o-nitrophenyl P-D-galactopyranoside)
4mg/ml m 0 1M sodium phosphate buffer pH7 5 
Stored at -20°C
l
SOLUTIONS FOR PROTEIN ISOLATION
Suspension buffer
0 1 M NaCl
0 01 M Tns-Cl (pH 7 6)
0 001 M EDTA (pH 8 0)
1 jag/ml leupeptin
100(J.g/ml PMSF
Stored at 4°C
2X SDS gel loading buffer
100 mM  Tns-cl
10% 2-mercaptoethanol
4% (w/v) SDS
0 2% (w/v) Bromophenol blue
20% (v/v) Glycerol
Two times loading buffer was prepared without 2-mercaptoethanol and stored at room 
temperature 2-mercaptoethanol was added just prior to use from a 14 4M (100%) stock
Protease Inhibitors (stock solutions)
2 mg/ml Leupeptin in water
0 1 M PMSF (phenylmethylsulfonyl fluoride) in isopropanol 
Stored at -20°C (PMSF was stored away from light)
SOLUTIONS FOR SDS PAGE/W ESTERN BLOTTING
1 M Tns-Cl pH 6 8
1 5 M Tns-Cl pH 8 8
10% (w/v) SDS
10% (w/v) Ammonium persulphate (APS)
J
Acrylagel
Bis-acrylagel
TEMED
10X Tris glycine running buffer (500 ml)
15 138 g Tris
71 125 g Glycine
5 0 g SDS
Made up to 500 ml with distilled water
Destain
1 0 0  ml 
400 ml 
500 ml
Coomassie blue stain
1 g Coomassie blue R
200 ml Destain
Transfer Buffer (10X stock solution)
30 3g Tris
144 2g Glycine
Adjusted to pH 8  3, made up to 1 L with distilled water, stored at room temperature
Transfer Buffer (IX  working Solution)
100 ml 1 OX Stock Solution
200 ml Methanol
700 ml Distilled H20
Stored at 4°C
Acetic acid 
Methanol 
Distilled water
TBS (IX)
k
6 1 g 
8 8 g
Tris
NaCl
Made up to 1 L with distilled water and adjusted to pH 7 5 with HC1 
Autoclaved and stored at room temperature
TBST (0.1% , v/v)
Blotto
IX  TBS (as above)
0 05% (v/v)Tween 20
5% (w/v) non-fat dry milk (Marvel)
0 02% NaN 3
Sodium azide (10%) (w/v)
lg  NaN 3
10ml Distilled water
REAGENTS FOR RNA ANALYSIS 
RNA sample buffer
50 % (v/v) Deionized formamide
8  3 % (v/v) Formaldehyde
0 027 M MOPS pH 7 0
6  7 mM Sodium acetate
RNA loading buffer (containing ethidium bromide)
50% (v/v) High grade glycerol
1 mM EDTA (pH 8  0)
0 4 %  (w/v) Bromophenol blue
I ml
1 L TBS (as above) 
Tween 20
1
0 1 (ig/ml Ethidium bromide
Aliquoted and stored at -20°C
5 X MOPS Buffer (Formaldehyde gel running buffer)
0 1 M MOPS (pH 7 0)
40 mM Sodium Acetate 
5 mM EDTA (pH 8  0)
20 6 g o f 3 -(Af-morpholino) propanesulfomc acid (MOPS) was dissolved in 800 ml o f 
DEPC treated 50 mM  sodium acetate The pH o f the solution was adjusted to 7 0 using 2 
M NaOH 10 ml o f DEPC-treated 0 5 M EDTA (pH 8  0) was added and the volume of 
the solution was adjusted to 1L using DEPC-treated H2O The 5X solution was filter 
sterilised through a 0  2  micron filter prior to use
Formaldehyde gel
1 part Formaldehyde
3 5 parts agarose in DEPC H2O
0 6 8  g Agarose
35ml DEPC H20
The agarose solution was boiled until fully dissolved and allowed to cool to 60°C The 
following were then added 
11 ml 5X MOPS buffer
10 ml Formaldehyde
56 ml Final volume
The gel was cast in a fume hood and allowed to set for approximately 45 mm The gel 
was electrophoresed in IX  formaldehyde gel running buffer
RNA loading buffer
50% (v/v) High grade glycerol
1 mM EDTA (pH 8  0)
0 25% (w/v) Bromophenol blue
m
0 25% (w/v) Xylene cyanol FF
DEPC-treated overnight, autoclaved and stored at room temperature
20XSSC
175 3g NaCl
8 8  2g NaCitrate
pH to 7 0 using a few drops o f 10M NaOH and made up to 1 litre using up H20  DEPC 
treated and autoclaved Stored at room temperature
Hybridization Buffer
50% (v/v) Deionized formamide
6 X SSC
1% (w/v) SDS
0 1% (v/v) Tween 20
100|ig/ml tRNA
Prepared fresh prior to use stored at room temperature
REAGENTS FOR RIBONUCLEASE PROTECTION ASSAY  
Five percent denaturing polyacrylamide gel
A five percent denaturing polyacrylamide gel was prepared for resolution o f labelled 
riboprobes and analysis o f protected RNA fragments The following formula was 
employed to determine the amount o f acrylamide and bis-acrylamide required
Va = volume o f acrylamide
Vb = volume o f bis-acrylamide
Vt = total volume o f gel mix (150 ml)
C = %  crosslmking
A = %  gel
Vb = ACVt
2 0 0
n
Va = 5*150/30 = 2 5  ml Vb = 5*5 2*150/200 = 19 5 ml
5 % Denaturing PAGE
63 g 
25 ml 
19 5 ml 
15 ml
Urea
Acrylamide
Bisacrylamide
10X TBE
Made up to 150 ml with up H2 O
Ninehundred |ll1 o f 10% (w/v) APS and 150 \i\ TEMED were added, and mixed briefly, 
before pouring
10X TBE (per 500 ml)
One X concentration was used for polyacrylamide gel preparation
10% (w/v) Ammonium persulphate
0 1 g APS/ml ultra pure H2O
Elution Buffer
0 5M ammonium acetate 
10 0 mM M agnesium acetate 
Im M  EDTA pH 8  0 
0 1% SDS
made up in DEPC-treated upH 2 0
54 g 
27 5 g 
2 0  ml
Tris base
Boric acid
0 5 M EDTA (pH 8  0)
Developer (5 L)
1 50 L H20
o
c2 25 L
1 25 L Developer
H20
Stirred for 2 min
Fixer (5 125 L)
3 625 L 
1 250 L 
0 250 L B fixer
H20  
A fixer
Stirred for 2 min
REAGENTS FOR EMSA  
Nuclear Protein Extraction buffers
Buffer A
1 OmM Hepes pH7 9 
1 5 mM Mgcl2 
lOmM Kcl 
0 5mM PMSF
0 5mM DTT
Buffer C
20mM Hepes pH 7 9 
420 mM NaCl
1 5mM M gCl2 
0 2mM EDTA 
25% glycerol
0 5 mM PMSF
0.5mM DTT
P
Buffer D
lOmM Hepes pH7 9 
50mM Kcl 
0 2mM EDTA 
2 0 % glycerol 
0 5mM PMSF 
0 5mM DTT
Buffer A, C and D were stored at 4°C for no more than 1 week PMSF and DTT were 
added to the buffers just before use
Poly (dl-dC).Poly (dl-dC) (stock)
Dissolve 10 U in 393 5 jal ultrapure H20 
Store in aliquots at -20°C
Binding buffer (10 x)
Glycerol 40%
EDTA 10 mM
Tris pH 7 5 lOOmM
NaCl 1 M
BSA 1 mg/ml
DTT 50 mM
Bandshift polyacrylamide gel
The formula used to calculate the volume o f Accugel [40% (29 1)
Acrylamide Bisacrylamide solution] used to prepare a gel o f a given percentage is as 
follows
Va = volume o f accugel to be used (ml)
Vt = Total volume o f gel casting solution required (ml)
q
X = % gel desired
V a - lY tiQ Q
40
For a 4% or 5% gel o f 50 mi volume
Solution (stock)
4%
Volume (ml) 
5% 8 %
Accugel 5 0 6 2 1 0 0
lOxTBE 5 0 5 0 5 0
W ater (ultrapure) 39 9 38 7 34 9
Then, 5 (4.1 o f 1M DTT was added to the gel mixture followed by 50mg o f APS and 15(il 
o f TEMED and the gel mixture swirled briefly and poured into the gel mould The comb 
was then inserted and the gel allowed to set for at least 45 mm
r
